

**(12) STANDARD PATENT  
(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2013258849 B2**

(54) Title  
**Rotavirus-like particle production in plants**

(51) International Patent Classification(s)  
**C12N 7/04** (2006.01)      **C07K 14/14** (2006.01)  
**A61K 39/15** (2006.01)      **C12N 7/01** (2006.01)  
**A61P 31/14** (2006.01)      **C12N 15/46** (2006.01)  
**A61P 37/04** (2006.01)      **C12N 15/82** (2006.01)

(21) Application No: **2013258849**      (22) Date of Filing: **2013.05.10**

(87) WIPO No: **WO13/166609**

(30) Priority Data

(31) Number      (32) Date      (33) Country  
**61/646,058**      **2012.05.11**      **US**

(43) Publication Date: **2013.11.14**  
(44) Accepted Journal Date: **2018.12.13**

(71) Applicant(s)  
**Mitsubishi Tanabe Pharma Corporation;Medicago Inc.**

(72) Inventor(s)  
**D'aoust, Marc-Andre;Landry, Nathalie;Lavoie, Pierre-Olivier;Arai, Masaaki;Asahara, Naomi;Mutepfa, David Levi Rutendo;Hitzeroth, Inga Isabel;Rybicki, Edward Peter**

(74) Agent / Attorney  
**Adams Pluck, PO BOX 905, Hornsby, NSW, 2077, AU**

(56) Related Art  
**YANG, Y. M. ET AL., "Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants", SCIENCE CHINA LIFE SCIENCES., (2011-01), vol. 54, no. 1, pages 82 - 89**



## (51) International Patent Classification:

*C12N 7/04* (2006.01)      *C07K 14/14* (2006.01)  
*A61K 39/15* (2006.01)      *C12N 15/46* (2006.01)  
*A61P 31/14* (2006.01)      *C12N 15/82* (2006.01)  
*A61P 37/04* (2006.01)      *C12N 7/01* (2006.01)

(72) **Inventors:** **D'AOUST, Marc-Andre**; 3925 rue Louise-Fiset, Quebec, Quebec G1X 4N4 (CA). **LANDRY, Nathalie**; 1060, rue de La Voie Ouest, St-Jean-Chrysostome, Quebec G6Z 1K1 (CA). **LAVOIE, Pierre-Olivier**; 621 Franklin, Quebec, Quebec G1N 2L7 (CA). **ARAI, Masaaki**; c/o Mitsubishi Tanabe Pharma Corporation, 2-6-18, Kitahama, Chuo-ku, Osaka-shi, Osaka 541-8505 (JP). **ASAHARA, Naomi**; c/o Mitsubishi Tanabe Pharma Corporation, 2 - 6 - 18, Kitahama, Chuo-ku, Osaka-shi, Osaka 541-8505 (JP). **MUTEPFA, David Levi Rutendo**; 26 Bonnington Crescent, Sherwood Nottingham N5G 3EY (GB). **HITZEROTH, Inga Isabel**; 11 Clifford Avenue, Vrededorp, Cape Town (ZA). **RYBICKI, Edward Peter**; 34 Uitvlugt Road, Pinelands, 7405 Cape Town (ZA).

## (21) International Application Number:

PCT/CA2013/050364

## (22) International Filing Date:

10 May 2013 (10.05.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/646,058      11 May 2012 (11.05.2012)      US


(71) **Applicants:** **MEDICAGO INC.** [CA/CA]; 600 -1020 Route de l'Eglise, Quebec, Quebec G1V 3V9 (CA). **MITSUBISHI TANABE PHARMA CORPORATION** [JP/JP]; 2 - 6 - 18, Kitahama, Chuo-ku, Osaka-shi, Osaka 541-8505 (JP).

(74) **Agents:** **SECHLEY, Konrad A.** et al.; 2300 - 550 Burrard Street, Vancouver, British Columbia V6C 2B5 (CA).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,

*[Continued on next page]*

## (54) Title: ROTAVIRUS-LIKE PARTICLE PRODUCTION IN PLANTS

**Figure 47**

VP2/VP4/VP6 /VP7 RLPs

(57) **Abstract:** A method of producing a virus-like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid into the plant, or portion of the plant. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein for example but not limited to rotavirus protein VP2. The nucleotide sequence may further comprise one or more than one amplification element and/or a compartment targeting sequence. A second nucleic acid might be introduced into the plant, or portion of the plant. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, for example but not limited to rotavirus protein VP6. Optionally, a third nucleic acid and/or fourth nucleic acid might be introduced into the plant, or portion of the plant. The third nucleic acid comprises a third regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, for example but not limited to rotavirus protein VP4. The fourth nucleic acid comprises a fourth regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, for example but not limited to rotavirus protein VP7. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.



KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*); ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

## ROTAVIRUS-LIKE PARTICLE PRODUCTION IN PLANTS

### FIELD OF INVENTION

5 [0001] This invention relates to producing rotavirus structural proteins in plants. More specifically, the present invention relates to producing virus-like particles comprising rotavirus structural protein in plants.

### BACKGROUND OF THE INVENTION

10 [0002] Rotavirus infection is a global problem mainly affecting children under the age of five. It results in severe gastroenteritis and in worst cases death.

15 [0003] Rotaviruses are members of the Reoviridae family of viruses (genus Rotavirus) that affect the gastrointestinal system and respiratory tract. The name is derived from the wheel like appearance of virions when viewed by negative contrast electron microscopy (Figure 1a; prior art). The rotavirus is usually globular shape and is named after the outer and inner shells or double-shelled capsid structure of the same. The outer capsid is about 70 nm, and inner capsid is about 55 nm in diameter, respectively. The double-shelled capsid of the rotavirus surrounds the core including the inner protein shell and genome. The genome of the rotavirus consists of double 20 stranded RNA segments encoding at least 11 rotavirus proteins.

25 [0004] The dsRNA codes for six structural proteins (VP) and six non-structural proteins (NSP) (Figure 1c; prior art). The structural proteins comprise VP1, VP2, VP3, VP4, VP6 and VP7 (Figure 1b; prior art). Three concentric layers are formed by the assembly of VP2, VP6 and VP7 respectively, with VP4 forming “spikes” on the surface of the virus structure. The NSPs are synthesized in infected cells and function in various parts of the replication cycle or interact with some of the host proteins to influence pathogenesis or the immune response to infection (Greenberg and Estes, 2009).

30 [0005] VP2 is a 102 kDa protein and is the most abundant protein of the viral core. It forms the inner-most structural protein layer and provides a scaffold for the correct

assembly of the components and transcription enzymes of the viral core (Lawton, 2000). VP1, the largest viral protein at 125 kDa, acts as an RNA-dependent polymerase for rotavirus, creating a core replication intermediate, and associates with VP2 at its icosahedral vertices (Varani and Allain, 2002; Vende et al., 2002). VP3, a 5 98 kDa protein, is also directly associated with the viral genome, acting as an mRNA capping enzyme that adds a 5' cap structure to viral mRNAs. Together, VP1 and VP3 form a complex that is attached to the outer 5-fold vertices of the VP2 capsid layer (Angel, 2007). VP6 is a 42 kDa protein which forms the middle shell of the viral core, 10 is the major capsid protein and accounts for more than 50% of the total protein mass of the virion (González et al., 2004; Estes, 1996). It is required for gene transcription and may have a role in encapsulation of the rotavirus RNA by anchoring VP1 to VP2 in the core, as seen in bluetongue virus, another member of the Reoviridae family. It 15 also determines the classification of rotaviruses into five groups (A to E) with group A most commonly affecting humans (Palombo, 1999). VP6 in rotavirus group A has at least four subgroups (SG), which depend on the presence or absence of SG specific epitopes: SG I, SG II, SG (I+II) and SG non-(I+II). Groups B and C lack a common group A antigen but are also known to infect humans, while group D only affects 20 animals e.g chickens and cows (Thongprachum, 2010).

15 [0006] The two outer capsid proteins VP7, a 37 kDa glycoprotein (G) and the 87 kDa protease sensitive VP4 (P), define the virus' serotypes. These two proteins induce neutralizing antibody responses and are thus used to classify rotavirus serotypes into a dual nomenclature system, depending on the G-P antigen combination (e.g. G1 P[8] or G2 P[4]) (Sanchez-Padilla et al., 2009). The VP4 protein dimerizes to form 60 spikes on the outer shell of the virus, which are directly involved in the initial stages 25 of host cell entry. The spike protein contains a cleavage site at amino acid (aa) position 248. Upon infection, it is cleaved by the protease trypsin to produce VP5 (529 aa, 60 kDa) and VP8 (246 aa, 28 kDa) (Denisova et al., 1999). This process enhances virus infectivity (cell attachment and invasion of host cell) and stabilizes the spike structure (Glass, 2006). The VP7 glycoprotein forms the third or outside layer 30 of the virus. At present, 27 G and 35 P genotypes are known (Greenberg and Estes, 2009). VP4 and VP7 are the major antigens involved in virus neutralization and are important targets for vaccine development (Dennehy, 2007).

[0007] In infected mammalian cells, rotaviruses undergo a unique mode of morphogenesis to form the complete triple-layered VP2/6/4/7 viral particles (Lopez et al., 2005). The triple-layer capsid is a very stable complex which enables faecal-oral transmission and delivery of the virus into the small intestine where it infects non-dividing differentiated enterocytes near the tips of the villi (Greenberg and Estes, 2009). Firstly, the intact virus attaches to sialic acid-independent receptors via 60 VP4 dimer spikes on the surface of the virus (Lundgren and Svensson, 2001). The 60 VP4 dimer spikes on the surface of the virus allow the virus to attach to these cell receptors. VP4 is susceptible to proteolytic cleavage by trypsin which results in a conformational change that exposes additional attachment sites on the surface of the glycoprotein for interaction with a series of co-receptors.

[0008] The multi-step attachment and entry process is, however, not clearly understood but the virus is delivered across the host's plasma membrane. The VP7 outer capsid shell which is also involved in the entry process, is removed in the process and double-layered particles (DLP) are delivered into the cell cytoplasm in vesicles (Figure 2; prior art). The DLP escapes from the vesicle and goes into non-membrane bound cytoplasmic inclusions. Early transcription of the genome by VP1 begins in particles so that dsRNA is never exposed to the cytoplasm. RNA replication and core formation takes place in these non-membrane-bound cytoplasmic inclusions. The nascent (+) RNAs are then transported into the cytoplasm and serve as templates for viral protein synthesis. VP4 is produced in the cytosol and transported to the rough endoplasmic reticulum (RER), and VP7 is secreted into the RER. VP2 and VP6 are produced and assemble in the cytosol in virosomes and subsequently bud into the RER compartments, receiving a transient membrane envelope in the process (Lopez et al., 2005; Tian et al., 1996). In the RER, the transient envelopes of the viral particles are removed and replaced by VP4 and VP7 protein monomers, with critical involvement of rotaviral glycoprotein NSP4 (Tian et al., 1996; Lopez et al., 2005; Gonzalez et al., 2000). NSP4 functions as an intracellular receptor in the ER membrane and binds newly made subviral particles and probably also the spike protein VP4 (Tian et al., 1996). NSP4 is also toxic to humans and is the causative agent of the diarrhea. The complete, mature particles are subsequently transferred from the RER through the Golgi apparatus to the plasma membrane for secretion (Lopez et al., 2005).

[0009] A variety of different approaches have been taken to generate a rotavirus vaccine suitable to protect human populations from the various serotypes of rotavirus. These approaches include various Jennerian approaches, use of live attenuated viruses, use of virus-like particles, nucleic acid vaccines and viral sub-units as immunogens. At present there are two oral vaccines available on the market, however, these have low efficacy in some developing countries due to strain variation and presence of other pathogens.

[0010] U.S. Pat. Nos. 4,624,850, 4,636,385, 4,704,275, 4,751,080, 4,927,628, 5,474,773, and 5,695,767, each describe a variety of rotavirus vaccines and/or methods of preparing the same. A commonality shared by the members of this group is that each of these vaccines relies on the use of whole viral particles to create the ultimate rotavirus vaccines. Given the long standing need for an effective, multivalent vaccine, it is clear that this body of work has been only partially successful in addressing the need for such a vaccine.

[0011] Departing from traditional methods of vaccine generation, advances in the field of molecular biology have permitted the expression of individual rotavirus proteins. Crawford et al. (J Virol. 1994 September; 68(9): 5945-5952) cloned VP2, VP4, VP6, and VP7 coding for the major capsid protein into the baculovirus expression system and expressed each protein in insect cells. Co-expression of different combinations of the rotavirus major structural proteins resulted in the formation of stable virus-like particles (VLPs). The co-expression of VP2 and VP6 alone or with VP4 resulted in the production of VP2/6 or VP2/4/6 VLPs, which were similar to double-layered rotavirus particles. Co-expression of VP2, VP6, and VP7, with or without VP4, produced triple-layered VP2/6/7 or VP2/4/6/7 VLPs, which were similar to native infectious rotavirus particles. The VLPs maintained the structural and functional characteristics of native particles, as determined by electron microscopic examination of the particles, the presence of non-neutralizing and neutralizing epitopes on VP4 and VP7, and hemagglutination activity of the VP2/4/6/7 VLPs.

[0012] Vaccine candidates generated from virus-like particles of different protein compositions have shown potential as subunit vaccines. O'Neal et al. ("Rotavirus Virus-like Particles Administered Mucosally Induce Protective Immunity," J. Virology, 71(11):8707-8717 (1997)) showed that VLPs containing VPs 2 and 6 or

VPs 2, 6, and 7 when administered to mice with and without the addition of cholera toxin induced protective immunity in immunized mice, although protection was more effective when the VLPs were administered with cholera toxin (CT).

[0013] Core-like particles (CLP) and VLPs have also been used to immunize cows Fernandez, et al., ("Passive Immunity to Bovine Rotavirus in Newborn Calves Fed Colostrum Supplements From Cows Immunized with Recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines," Vaccine, 16(5):507-516 (1998)). In this study the ability of CLPs and VLPs to create passive immunity was studied. This group concluded that VLPs were more effective than CLPs in inducing passive immunity.

[0014] Plants are increasingly being used for large-scale production of recombinant proteins. For example US 2003/0175303 discloses the expression of recombinant rotavirus structural protein VP6, VP2, VP4 or VP7 in stable transformed tomato plants.

[0015] Saldana et al. expressed VP2 and VP6 in the cytoplasm of tomato plants using a cauliflower mosaic virus (CaMV) 35S promoter and recombinant *A. tumefaciens* (Saldana et al., 2006). Electron microscopy studies showed that a small proportion of the particles had assembled into 2/6 VLPs. A protective immune response was detected in mice and this may have to some extent been contributed by the non-assembled VPs. Individual proteins have been shown to elicit immune responses in mice, as in the case of VP8 and VP6 (Zhou et al., 2010).

[0016] Matsumura et al., (2002) were first to report bovine rotavirus A VP6 expression and assembly in transgenic potato plants. In their study, they used transgenic potato plants regulated by a cauliflower mosaic virus (CaMV) 35S promoter and recombinant *Agrobacterium tumefaciens* carrying the VP6 gene. The protein was expressed, purified and immunogenic studies performed. Immune-response in adult mice showed presence of VP6 antibodies in the sera. However, they did not show evidence of assembled VP6 proteins. It may have been simple monomers or trimers that could elicit an immune response in mice. Another group's work showed VP6 assembly in *Nicotiana benthamiana* using a potato virus X (PVX) vector (O'Brien et al., 2000). When the VP6 protein was expressed in plants, it was discovered that it only assembled when fused to the PVX protein rods. Once cleavage

occurred, VP6 assembled into icosahedral VLPs as seen in a similar study of HIV-PVX by Marusic et al., (2001). This result probably suggests that rotavirus proteins may require an additional factor or enhancement in order to form VLPs.

[0017] Production of VLP is a challenging task, as both the synthesis and assembly of one or more recombinant proteins are required. This is the case for VLP of rotavirus which is an RNA virus with a capsid formed by 1860 monomers of four different proteins. For VLP production the simultaneous expression and assembly of two to three recombinant proteins is necessary. These comprise 120 molecules of VP2 (inner layer), 780 molecules of VP6 (middle layer) and 780 molecules of the glycoprotein VP7 (outer layer), ultimately forming a double or triple-layered particle. In addition, the production of most VLP requires the simultaneous expression and assembly of several recombinant proteins, which – for the case of rotavirus like particle (RLP) – needs to occur in a single host cell.

[0018] A more recent study showed the successful expression of codon-optimized human rotavirus VP6 in *Chenopodium amaranticolor* using a Beet black scorch virus (BBSV) mediated expression system. The protein was engineered as a replacement to the coat protein open reading frame of BBSV. Oral immunization of female BALB/c mice with the plant based VP6 protein induced high titers of anti-VP6 mucosal IgA and serum IgG (Zhou et al., 2010). The group, however, did not mention whether the VP6 proteins assembled into VLPs or particles.

[0019] Rotavirus VP7 has also been successfully expressed in tobacco plants and was shown to maintain its neutralizing immune response in mice (Yu and Langridge, 2001). Another study using transgenic potato plants to express VP7 showed that the VP7 gene was stable over 50 generations in the transformed plants. VP7 protein from the 50th generation induced both protective and neutralizing antibodies in adult mice (Li et al., 2006).

[0020] Yang et al. (Yang Y M, Li X, Yang H, et al. 2011) co-expressed three rotavirus capsid proteins VP2, VP6 and VP7 of group A RV (P[8]G1) in tobacco plants and expression levels of these proteins, as well as formation of rotavirus-like particles and immunogenicity were studied. VLPs were purified from transgenic tobacco plants and analyzed by electron microscopy and Western blot. Yang et al.

results indicate that the plant derived VP2, VP6 and VP7 protein self-assembled into 2/6 or 2/6/7 rotavirus like particle with a diameter of 60-80 nm.

## SUMMARY OF THE INVENTION

5 [0021] The present invention relates to producing rotavirus structural proteins in plants. More specifically, the present invention also relates to producing virus-like particles comprising rotavirus structural protein in plants.

[0022] Firstly, there is described herein a method (A) of producing a rotavirus-like particle (RLP) in a plant comprising:

10 a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein into the plant, portion of a plant or plant cell,

15 b) incubating the plant, portion of a plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP.

20 [0023] Furthermore a fourth nucleic acid comprising a fourth regulatory region active in the plant and operatively linked to a fourth nucleotide sequence encoding a fourth rotavirus structural protein may be introduced into the plant, portion of a plant or plant cell in step a), and is expressed when incubating the plant, portion of a plant or plant cell in step b).

[0024] In the method (A) as described above the first rotavirus structural protein may be VP2, the second rotavirus structural protein may be VP6 and the third rotavirus structural protein may be VP4 or VP7. Furthermore, the fourth rotavirus structural protein may be VP7 or VP4. The VP4 may be processed or cleaved to produce VP5 and VP8. Cleavage of VP4 may be performed using a protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, or a subtilisin. The protease may be co-expressed within the plant.

[0025] There is also provided herein a method (B) of producing a rotavirus-like particle (RLP) comprising:

a) introducing a nucleic acid comprising a regulatory region active in the plant operatively linked to a first nucleotide sequence encoding one or more rotavirus structural protein, into

5 the plant, portion of a plant or plant cell,

b) incubating the plant, portion of a plant or plant cell under conditions that permit the transient expression of the first nucleic acid, thereby producing the RLP.

[0026] The method (B) as described above may further comprise introducing in (step a) a second nucleic acid comprising a second regulatory region active in the plant and

10 operatively linked to a second nucleotide sequence encoding one or more rotavirus structural protein and expressing the a second nucleic acid when incubating the plant, portion of a plant or plant cell in step b).

[0027] The method (B) as described above may further comprise introducing in (step a) a third nucleic acid comprising a third regulatory region active in the plant and operatively

15 linked to a third nucleotide sequence encoding one or more rotavirus structural protein is introduced into the plant, portion of a plant or plant cell in step a), and expressing the third nucleic acid when incubating the plant, portion of a plant or plant cell in step b).

[0028] Furthermore, in method (A) or (B) an additional nucleic acid may be expressed in the plant, portion of a plant or plant cell, and wherein the additional nucleic acid

20 comprises a regulatory region active in the plant operatively linked to a nucleotide sequence encoding a suppressor of silencing.

[0029] The codon usage of the nucleotide sequence may be adjusted to preferred human codon usage, increased GC content or a combination thereof.

[0030] The rotavirus structural protein may comprise a truncated, native or a non-

25 native signal peptide. The non-native signal peptide may be a protein disulfide isomerase signal (PDI) peptide.

[0031] The first, second, third or fourth nucleotide sequence or a combination thereof may be operatively linked to a Cowpea Mosaic Virus (CPMV) regulatory region.

[0032] The method (A) or (B) as described above may further comprise the steps of:

30 c) harvesting the plant, portion of a plant or plant cell, and

d) purifying the RLPs from the plant, portion of a plant or plant cell.

[0033] During the step of harvesting or purifying in method (A) or (B), VP4 may be processed or cleaved to produce VP5 and VP8 using trypsin, a trypsin-like protease, a 5 serine protease, a chymotrypsin-like protease, subtilisin.

[0034] The RLPs may range size from 70-100 nm and may purified in the presence of calcium.

[0035] There is further provided a RLP produced by a method as described herein, e.g., the methods (A) or (B) as described above. The RLP produced may comprise at least a VP4 10 rotavirus structural protein. The VP4 may be cleaved into VP5 and VP8 using a protease for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. The protease may be co-expressed within the plant or added during harvesting, purification, or both. Furthermore the RLP produced by the method (A) or (B) may be a double layered RLP and/or a triple layered RLP.

[0036] Furthermore, nucleotide sequences are provided. The nucleotide sequence encoding VP2 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 45. The nucleotide sequence encoding VP6 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:46. The nucleotide sequence encoding VP7 15 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 19, 20, 48, 49, 52, 53, 54 or 57. And the nucleotide sequence encoding VP4 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 15, 16, 47, 50, or 51. In addition VP2 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID 20 NO:1 or SEQ ID NO: 25. VP6 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID NO:3 or SEQ ID NO: 31. VP7 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID NO: 4, 39, 43 or 59. VP4 25 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID NO: 2 or SEQ ID NO: 36. 33. The one or more rotavirus structural protein may be VP2, VP4, VP6 and/or VP7. The VP4 may be processed to VP5 and VP8. The one or more rotavirus structural protein may be selected 30

from rotavirus strain G9 P[6], rotavirus A WA strain, rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain, and rotavirus SA11 strain.

[0037] In method (A) as described above the first, second or third nucleic acid sequence or a combination thereof may comprise a regulatory region active in the plant operatively

5 linked to one or more than one comovirus enhancer, to one or more than one amplification element and to a nucleotide sequence encoding a rotavirus structural protein, and wherein a fourth nucleic acid encoding a replicase may be introduced into the plant, portion of a plant or plant cell.

[0038] In method (B) as described above the first, second, third or fourth nucleic acid

10 sequence or a combination thereof may comprise a regulatory region active in the plant operatively linked to one or more than one comovirus enhancer, to one or more than one amplification element and to a nucleotide sequence encoding a rotavirus structural protein, and wherein a fifth nucleic acid encoding a replicase may be introduced into the plant, portion of a plant or plant cell.

15 [0039] In addition, there is provided herein a method (C) of producing a rotavirus-like particle (RLP) in a plant comprising:

a) introducing a nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, into the plant, or portion of the plant,

20 b) incubating the plant, portion of the plant under conditions that permit the transient expression of the first nucleic acid, thereby producing the RLP.

[0040] Furthermore, a second nucleic acid may be introduced into the plant or portion of the plant, the second nucleic acid comprises a second regulatory region that is active in the plant and operatively linked to a second nucleotide sequence encoding one or more

25 rotavirus structural protein and wherein the second nucleic acid is expressed when incubating the plant or portion of the plant in step b).

[0041] Furthermore a third nucleotide sequence may be introduced into the plant or portion of the plant, the third nucleic acid comprises a third regulatory region that is active in the plant and operatively linked to a third nucleotide sequence encoding one or more

30 rotavirus structural protein and wherein the third nucleic acid is expressed when incubating the plant or portion of the plant in step b).

[0042] The method (C) as described above may further comprising a step of harvesting the plant and extracting the RLPs.

[0043] The one or more rotavirus structural protein of method (C) may be rotavirus protein VP2, VP4 or VP6. The one or more rotavirus structural protein encoded by the first or second nucleotides sequence may be VP2 or VP6. The one or more rotavirus structural protein encoded by the third nucleotides sequence may be VP4. The VP4 may be cleaved to produce VP5 and VP8.

[0044] The first, second or third nucleotide sequence may further encode, comprise, or encode and comprise, one or more than one compartment targeting sequence and/or an amplification element. The one or more compartment targeting sequence directs the one or more rotavirus structural protein to the endoplasmatic reticulum (ER), chloroplast, plastid or apoplast of the plant cell.

[0045] In addition, there is provided herein a method (D) of producing a rotavirus-likeparticle (RLP) comprising,

a) providing a plant or portion of a plant comprising a nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein;

b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the nucleic acid, thereby producing the RLP.

[0046] Furthermore the plant or portion of the plant of method (D) may further comprise;

i) a second nucleic acid comprising a second regulatory region active in the plant and operatively linked to a second nucleotide sequence encoding one or more rotavirus structural protein or,

ii) a second and third nucleic acid, wherein the second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a second nucleotide sequence encoding one or more rotavirus structural protein and the third nucleic acid comprises a third regulatory region active in the plant and operatively linked to a third nucleotide

sequence encoding one or more rotavirus structural protein, wherein the second or the second and third nucleic acids are expressed when incubating the plant or portion of the plant in step b).

[0047] The one or more structural protein in method (D) may be rotavirus protein VP2, VP4 or VP6. The one or more rotavirus structural protein encoded by the first or second nucleotides sequence may be VP2 or VP6. The one or more rotavirus structural protein encoded by the third nucleotides sequence may be VP4. The VP4 may be cleaved into VP5 and VP8 using a protease for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. The protease may be co-expressed within the plant or added during harvesting, purification, or both.

5 [0048] There is further provided a RLP produced by a method as described herein, e.g., method (A), method (B), method (C), method (D), or a combination thereof, as described 10 above. The RLP may comprise one or more rotavirus structural protein that may comprises comprise plant-specific N-glycans, or modified N-glycans.

15 [0049] There is further provided a composition comprising an effective dose of the RLP made by a method as described herein, e.g., method (A), method (B), method (C), method (D), or a combination thereof as just described, for inducing an immune response, and a pharmaceutically acceptable carrier.

[0050] There is also provided a method of inducing immunity to a rotavirus infection in a subject, comprising administering an RLP as described herein, to the subject. The RLP may be administered to a subject orally, intradermally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

20 [0051] In addition, there is provided plant matter comprising a RLP produced by a method as described herein, e.g., method (A), method (B), method (C), method (D), or a combination thereof, as described above. The plant matter may be used in inducing immunity to a rotavirus virus infection in a subject. The plant matter may also be admixed as a food supplement.

25 [0052] In the methods as described herein (e.g., methods A, B, C or D) the plant or portion of the plant may further be administered with, or may further comprise, another nucleic acid sequence encoding a suppressor of silencing.

[0053] Furthermore, there is provided herein a method (E) of producing rotavirus structural protein in plant comprising

30 a) introducing a nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, into the plant, or portion of the plant;

b) incubating the plant or portion of the plant under conditions that permit the transient expression of the nucleic acid, thereby producing the one or more rotavirus structural protein.

[0053a] In particular, in an aspect of the present invention there is provided a method of 5 producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:

a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second 10 regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein selected from one of VP2, VP6 and VP7, into the plant, portion of the plant or plant cell,

15 wherein the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated native signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, 20 the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell, and

d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of calcium and purifying the RLPs in the presence of calcium.

[0053b] In another aspect of the present invention there is provided a method of 25 producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell comprising:

a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid 30 comprising a second regulatory region active in the plant operatively linked to a second

nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and

wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

5 b) incubating the plant, portion of the plant or plant cell under conditions that permit the  
10 transient expression of the first, second and third nucleic acid, thereby producing the RLP,  
the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell, and

d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of  
calcium and purifying the RLPs in the presence of calcium.

15 [0053c] In another aspect of the invention there is provided a method of producing a  
rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:

20 a) introducing a first nucleic acid comprising a first regulatory region active in the plant  
operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein  
selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second  
regulatory region active in the plant operatively linked to a second nucleotide sequence  
encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and  
25 a third nucleic acid comprising a third regulatory region active in the plant operatively  
linked to a third nucleotide sequence encoding a third rotavirus structural protein selected  
from one of VP2, VP6 and VP7, into the plant, portion of a the plant or plant cell, wherein  
the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide  
sequence encoding a truncated signal peptide, or comprises a nucleotide sequence  
encoding a non-native signal peptide, or

30 a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid  
comprising a first regulatory region active in the plant operatively linked to a first  
nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid

comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

5 b) incubating the plant, portion of a the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,

10 c) harvesting the plant, portion of the plant or plant cell.

[0053d] In another aspect there is provided a rotavirus like particle (RLP) produced by a method embodied by the invention. Typically, the RLP is of a size from 70-100nm and 15 generally wherein the RLP comprises one or more rotavirus structural protein that comprises plant-specific N-glycans, or plant-specific modified N-glycans.

[0053e] In another aspect there is provided a composition comprising an effective dose of a rotavirus like particle (RLP) embodied by the invention for inducing an immune response in a subject, and a pharmaceutically acceptable carrier.

20 [0053f] In another aspect there is provided a method of inducing immunity to a rotavirus infection in a subject, comprising administering a composition embodied by the invention comprising a rotavirus like particle (RLP).

[0053g] In another aspect there is provided the use of a composition embodied by the invention comprising a rotavirus like particle (RLP) in the manufacture of a medicament for 25 inducing immunity to a rotavirus infection in a subject.

[0054] This summary of the invention does not necessarily describe all features of the invention.

[0054a] Throughout this specification, the word “comprise”, or variations thereof such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, 30 integer or step, or group of elements integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0054b] Any discussion of documents, acts, materials, devices, articles or the like which has been included in this specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters 5 form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or elsewhere before the priority date of this application.

## BRIEF DESCRIPTION OF THE DRAWINGS

10 [0055] These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

[0056] **FIGURE 1** shows rotavirus structure and gene-protein assignment . (A) Transmission electron microscopy of rotavirus particles (bar represents 100nm). (B) Organization of the virus capsid proteins comprising inner, intermediate and outer. (C) 15 Rotavirus dsRNA segments arranged as per size and function. The dsRNA can be separated polyacrylamide gel electrophoresis (D). Proteins in (C) are indicated by dsRNA segments in (D). Images from Crawford et al.,1997 (A), Swiss Institute of Bioinformatics, 2008 (B) and Greenberg and Estes, 2009 (D).

[0057] **Figure 2** shows rotavirus cell entry and replication. When rotavirus enters a cell, 20 VP4 and VP7 are lost, forming a double layered particle (DLP). Transcription of the dsRNA commences resulting in translation of VP2, VP4, VP6 and VP7. Progeny cores with replicase activity are produced in virus factories (also called viroplasms). Late transcription occurs in these progeny cores. At the periphery of virus factories, these core are coated with VP6, forming immature DLPs that bud across the membrane of the 25 endoplasmic reticulum, acquiring a transient lipid membrane which is modified with the ER resident viral glycoproteins NSP4 and VP7; these enveloped particles also contain VP4. As the particles move towards the interior of the ER cisternae, the transient lipid membrane and the nonstructural protein NSP4 are lost, while the virus surface proteins VP4 and VP7 rearrange to form the outermost virus protein layer, yielding mature infectious triple- 30 layered particles (see Swiss Institute of

Bioinformatics (ViralZone): [viralzone.expasy.org/viralzone/all\\_by\\_species/107.html](http://viralzone.expasy.org/viralzone/all_by_species/107.html)

[0058] **FIGURE 3** shows Agrobacterium vectors pTRAc, pTRAk-crbcs1-cTP and pTRAk-ERH. P35SS, CaMV 35S promoter with duplicated transcriptional enhancer;; CHS, chalcone synthase 5' untranslated region; pA35S, CaMV 35S polyadenylation signal; SAR, scaffold attachment region of the tobacco Rb7 gene; LB and RB, the left and right borders for T-DNA integration; ColE1ori, origin of replication for *E. coli*; RK2ori, origin of replication for Agrobacterium; bla, ampicillin/carbenicillin-resistance bla gene; LPH, signal-peptide sequence from the murine mAb24 heavy chain; his6, 6 × His tag sequence; SEKDEL, ER-retention signal sequence; rbcs1-cTP, chloroplast-transit peptide sequence of a Rubisco small-subunit gene (rbcs1) from *Solanum tuberosum*; npt II, kanamycin resistance npt II gene; Pnos and pAnos, promoter and polyadenylation signal of the nopaline synthase gene (Maclean et al., 2007).

[0059] **Figure 4** shows an overview of rotavirus cloning and infiltration procedure

[0060] **Figure 5** shows an apoplast protein extraction procedure. (A) Illustration of the plant cell and location of the apoplast. VP proteins are expressed in the cytosol and targeted to the apoplast (red arrow). (B) - After time trial, plant leaf is vacuum infiltrated with PBS (1) and placed in a perforated spin column (2) then centrifuged in a 2ml Eppendorf tube to collect sap (3).

[0061] **Figure 6** shows a western blots of expression of rotavirus VP6 protein in plant leaf cell compartments over 7 days. Mouse anti-rotavirus VP6 antibody (1:5000) was used to probe the membranes. (+) and (-) indicates expression with or without silencing suppressor respectively. The red lines indicate the position of VP6 proteins in the various samples analysed (~ 40 kDa). Expression and extraction efficiency of VP6 was best in the cytoplasm.

[0062] **Figure 7** shows a western blot showing the individual expression of his-tagged rotavirus proteins at day 3 in the cytoplasm of *N. benthamiana* plant leaves. +ve – bacterial expressed rotavirus VP2; M – molecular weight marker; VP – rotavirus capsid protein. VP7 infiltration resulted in yellowing of leaves (b).

[0063] **Figure 8** shows expression of rotavirus VP2 (a) and VP4 (b) targeted to various *N. benthamiana* plant leaf cell compartments at day 3. The respective chicken

anti-rotavirus serum (1:2000) for VP2 and VP4 were used for probing the proteins. cTp - chloroplasts; ER – endoplasmic reticulum; pTRAc – cytoplasm; A – apoplast; Negative control (-ve) – plants infiltrated with silencing suppressor only; Positive control (+ve) in (a) – bacterial expressed VP2, (b) – bacterial expressed VP4; (- and +) with or without silencing suppressor; M – molecular weight marker. The arrows indicate the position of the protein bands in question.

5 [0064] **Figure 9** shows western blot analysis of day 3 extracts of co-expressed VP2/6/4 in the cytoplasm of *N. benthamiana* leaves. Proteins were probed with a mixture of chicken anti-rotavirus serum (anti-VP2 (1/5000) and anti-VP4 (1/5000)) and mouse anti-VP6 antibody (1:5000). Infiltration of recombinant Agrobacterium was done with silencing suppressor. Negative control (-ve) – whole plants infiltrated with silencing suppressor only; M – molecular weight marker.

10 [0065] **Figure 10** shows electron micrographs of day 3 cytoplasm extracted rotavirus proteins stained with uranyl acetate. (a) Negative protein sample extract with silencing suppressor; (b) VP6 protein extract; (c) VP2/6 protein extract and (d) VP2/6/4 protein extract. Bars = 200 nm. All RLPs detected were between 70 - 100 nm in diameter. Arrow in (b) indicates VP6 sheath/mat. Arrow in (c) indicates an example of aRLP. All proteins were expressed in the presence of a silencing suppressor. All were captured with mouse-anti VP6 antibody (1:2000).

15 [0066] **Figure 11** shows sucrose gradient purification of co-expressed VP2/6 and VP2/6/4 (a). Dot blots of sucrose gradient purified VP2/6 (b) and VP2/6/4 (c). Protein extracts were loaded on a sucrose gradient (10 – 60 %) and ultracentrifuged. Fractions were analysed by probing with (b) mouse anti-VP6 antibody (1:5000) and (c) chicken anti-VP2 and VP4 serum (1:5000).

20 [0067] **Figure 12** shows western blot analysis of VP2/6 fractions (a), SDS-PAGE coomassie stained gel photograph of fractions VP2/6 fractions 16 and 17 (b), and western blot analysis of fractions 16 and 17 (c). Mouse anti-VP6 (1:5000) and chicken anti-VP2 serum (1:5000) was used in the western blot (a) and only mouse anti-VP6 (1:5000) in (c). Negative control (- ve) in (a) and (c) – bacterial expressed VP4, and in (b) – plants infiltrated with silencing suppressor and sucrose gradient purified; crude – non-purified VP2/6 extract; Positive control (+ve) in (a) – bacterial expressed VP2,

(b) and (c) – plant expressed VP6; VP6-SF9 – VP6 protein of known concentration expressed in SF9 insect cells. Arrows indicate protein bands of interest.

[0068] **Figure 13** shows total soluble protein assay on fractions of sucrose density gradient purified VP2/6. (a) – IgG standard curve, (b) - absorbance readings of fractions taken at 750 nm. Points of interest: fractions 16 to 19.

[0069] **Figure 14** shows sucrose density gradient analysis of cytoplasm co-expressed VP2/6/4 fractions. Raw absorbance readings at 750nm were taken to verify the protein peaks previously detected on the dot blot of VP2/6/4.

[0070] **Figure 15** shows transmission electron micrographs of sucrose density gradient purified VP2/6 particles. Both (a) and (b) show two different sections viewed on the copper grid. All RLPs detected were between 70 - 100 nm in diameter. Samples were captured with mouse-anti VP6 antibody (1:2000). Bars represent 200 nm.

[0071] **Figure 16a** shows amino acid sequence (SEQ ID NO:1) and nucleotide sequences of Rotavirus VP2 (SEQ ID NO:13 and 14). **Figure 16b** shows amino acid sequence (SEQ ID NO:2) and nucleotide sequences of Rotavirus VP4 (SEQ ID No: 15 and 16). **Figure 16c** shows amino acid sequence (SEQ ID NO: 3) and nucleotide sequences of Rotavirus VP6 (SEQ ID NO: 17 and 18). **Figure 16d** shows amino acid sequence (SEQ ID NO:4) and nucleotide sequences of Rotavirus VP7 (SEQ ID NO: 19 and 20).

[0072] **Figure 17A** shows nucleotide sequence of primer IF-WA\_VP2(opt).s1+3c (SEQ ID NO: 21). **Figure 17B** shows nucleotide sequence of primer IF-WA\_VP2(opt).s1-4r (SEQ ID NO: 22). **Figure 17C** shows a schematic representation of construct 1191. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation.

[0073] **Figure 18** shows nucleotide sequence (SEQ ID NO: 23) of construct 1191 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette.

[0074] **Figure 19** shows nucleotide sequence encoding VP2(opt) from Rotavirus A WA strain (SEQ ID NO:45).

[0075] **Figure 20** shows amino acid sequence of VP2 from Rotavirus A WA strain (SEQ ID NO: 25).

[0076] **Figure 21** shows a schematic representation of construct number 1710.

[0077] **Figure 22A** shows a schematic representation of construct 193. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation. **Figure 22B** shows nucleotide sequence of construct 193 (SEQ ID NO: 26). Construct 193 is shown from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS into BeYDV(m)+Replicase amplification system with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette.

[0078] **Figure 23** shows nucleotide sequence of expression cassette 1710 (SEQ ID NO: 27). Expression cassette number 1710 is shown from 2X35S promoter to NOS terminator. VP2(opt) from Rotavirus A WA strain is underlined.

[0079] **Figure 24** shows a schematic representation of construct number 1711.

[0080] **Figure 25A** shows nucleotide sequence of primer IF-WA\_VP6(opt).s1+3c (SEQ ID NO:28). **Figure 25B** shows nucleotide sequence of primer IF-WA\_VP6(opt).s1-4r (SEQ ID NO: 29). **Figure 25c** shows expression cassette number 1713 from 2X35S promoter to NOS terminator (SEQ ID NO: 30). VP6(opt) from Rotavirus A WA strain is underlined. Figure 25d shows nucleotide sequence encoding VP6(opt) from Rotavirus A WA strain (SEQ ID NO: 46)

[0081] **Figure 26** shows the amino acid sequence of VP6 from Rotavirus A WA strain (SEQ ID NO: 31).

[0082] **Figure 27** shows the schematic representation of construct number 1713.

[0083] Figure 28 shows the nucleotide sequence of expression cassette number 1714 from 2X35S promoter to NOS terminator (SEQ ID NO:32). VP6(opt) from Rotavirus A WA strain is underlined.

[0084] **Figure 29** shows a schematic representation of construct number 1714.

[0085] **Figure 30A** shows the nucleotide sequence of primer IF-Rtx\_VP4(opt).s1+3c (SEQ ID NO: 33). Figure 30B shows the nucleotide sequence of primer IF-Rtx\_VP4(opt).s1-4r (SEQ ID NO: 34).

[0086] **Figure 31A** shows the nucleotide sequence of expression cassette number 1731 from 2X35S promoter to NOS terminator (SEQ ID NO: 35). VP4(opt) from Rotavirus A Rotarix strain is underlined. **Figure 31B** shows optimized coding sequence of Rotavirus A VP4 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO: 47). **Figure 31C** shows the nucleotide sequence of expression cassette number 1730 from 2X35S promoter to NOS terminator (SEQ ID NO: 44). VP4(opt) from Rotavirus A Rotarix strain is underlined.

[0087] **Figure 32** shows amino acid sequence of VP4 from Rotavirus A Rotarix strain (SEQ ID NO: 36).

10 [0088] **Figure 33A** shows a schematic representation of construct number 1730. Figure 33B shows a schematic representation of construct number 1731.

15 [0089] **Figure 34A** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s1+3c (SEQ ID NO: 37). **Figure 34B** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s1-4r (SEQ ID NO: 38). **Figure 34C** shows the nucleotide sequence of expression cassette number 1733 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined (SEQ ID NO: 24). **Figure 34D** shows nucleotide sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 48). Figure 34E shows the optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO 54).

20 [0090] **Figure 35** shows the amino acid sequence of VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 39).

[0091] **Figure 36** shows a schematic representation of construct number 1733.

25 [0092] **Figure 37** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s2+4c (SEQ ID NO: 40).

[0093] **Figure 38** shows a schematic representation of construct 1192. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation.

30 [0094] **Figure 39** shows the nucleotide sequence of construct 1192 from left to right t-DNA borders (underlined) (SEQ ID NO: 41). 2X35S/CPMV-HT/PDISP/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette are shown.

[0095] **Figure 40A** shows the nucleotide sequence of expression cassette number 1735 from 2X35S promoter to NOS terminator (SEQ ID NO: 42). PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined. **Figure 40B** Nucleotide sequence encoding PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 49).

[0096] **Figure 41** shows amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 43).

[0097] **Figure 42** shows a schematic representation of construct number 1735.

[0098] **Figure 43A** shows the coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO: 50). **Figure 43B** shows the optimized coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 51). **Figure 43C** shows the coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 52). **Figure 43D** shows optimized coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO :53).

[0099] **Figure 44A** shows the nucleotide sequence of primer IF-TrSP+Rtx\_VP7(opt).s1+3c (SEQ ID NP: 55). **Figure 44B** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s1-4r (SEQ ID NO: 56). **Figure 44C** shows the nucleotide sequence of optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO: 57). **Figure 44D** shows the nucleotide sequence of expression cassette number 1734 from 2X35S promoter to NOS terminator (SEQ ID NO 58). VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined. **Figure 44E** shows the amino acid sequence of TrSp-VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 59). **Figure 44F** shows the schematic representation of construct number 1734.

[00100] **Figure 45** shows purification of rotavirus-like particles comprising VP2 and VP6 by iodixanol density gradient centrifugation. **Figure 45A** Coomassie-stained SDS-PAGE analysis of the load prior to centrifugation and fractions 1 to 10 (fraction 1 being at the bottom of the tube). Position of the rotavirus antigens are

shown by arrows. **Figure 45B** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-rotavirus antibody. **Figure 45C** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-VP2 antibody.

[00101] **Figure 46** shows purification of rotavirus-like particles comprising VP2, VP6 and VP7 by iodixanol density gradient centrifugation. **Figure 46A** Coomassie-stained SDS-PAGE analysis of the load prior to centrifugation and fractions 1 to 10 (fraction 1 being at the bottom of the tube). Position of the rotavirus antigens are shown by arrows. **Figure 46B** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-rotavirus antibody. **Figure 46C** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-VP7 antibody.

[00102] **Figure 47** shows purification of rotavirus-like particles comprising VP2, VP4, VP6 and VP7 by iodixanol density gradient centrifugation. **Figure 47A** Coomassie-stained SDS-PAGE analysis of the load prior to centrifugation and fractions 1 to 10 (fraction 1 being at the bottom of the tube). Position of the rotavirus antigens are shown by arrows. **Figure 47B** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-rotavirus antibody. **Figure 47C** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-VP7 antibody.

[00103] **Figure 48** shows assessment of VP4 content in purified rotavirus-like particles comprising VP2, VP4, VP6 and VP7 by anti-VP4 specific ELISA.

[00104] **Figure 49** shows cryo-electron microscopy image of purified rotavirus-like particles comprising VP2 and VP6 (left panel) and VP2, VP4, VP6 and VP7 (right panel).

## DETAILED DESCRIPTION

[00105] The following description is of a preferred embodiment.

[00106] The present invention relates to virus-like particles (VLPs) comprising one or more rotavirus structural protein (i.e. a rotavirus like particle, rotavirus VLP or RLP), and methods of producing rotavirus-like particle (RLPs) in plants. The rotavirus like particle (RLP) may therefore comprise one or more rotavirus structural protein. The RLP may be double layered or triple layered.

[00107] The present invention in part provides a method of producing a rotavirus-like particle (RLP) in a plant. The method may comprise introducing one or

more nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein into the plant, or portion of the plant. Followed by incubating the plant or portion of the plant under conditions that permit the transient expression of the nucleic acids, thereby producing the RLP.

5 [00108] Furthermore, the present invention in part provides a method of producing a rotavirus-like particle (RLP) vaccine candidate in a plant. The method may comprise introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first 10 rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein into the plant, portion of the plant or plant cell. Followed by incubating the plant, portion of the plant or plant cell under 15 conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP. The RLP may be single, double or triple layered.

10 [00109] The “rotavirus structural protein” may refer to all or a portion of a rotavirus structural protein sequence isolated from rotavirus, present in any naturally occurring or variant rotavirus strain or isolate. Thus, the term rotavirus structural 20 protein and the like include naturally occurring rotavirus structural protein sequence variants produced by mutation during the virus life-cycle or produced in response to selective pressure (e.g., drug therapy, expansion of host cell tropism or infectivity, etc.). As one of skill in the art appreciates, such rotavirus structural protein sequences 25 and variants thereof may be also produced using recombinant techniques.

[00110] Furthermore, structural proteins may include capsid proteins such for example VP2 and VP6 and/or surface proteins such for example VP4. The structural protein may further include for example VP7.

30 [00111] Non-limiting examples of rotavirus structural protein are rotavirus protein VP2, VP4, VP6 and VP7, and a fragment of VP2, VP4, VP6 and VP7. Non-limiting examples of VP2, VP4, VP6 and VP7, or fragments of VP2, VP4, VP6 and VP7 protein that may be used according to the present invention include those VP2,

VP4 VP6 and VP7 protein from rotavirus strain G9 P[6], rotavirus A WA strain, rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain and rotavirus SA11 strain.

[00112] An example of a VP2 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO:25. Furthermore, the VP2 structural protein may comprise the sequence set forth in SEQ ID NO: 1, SEQ ID NO:25, or a sequence having at least about 90-100% sequence similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP2 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO:13, 14, 25, or 45 or a sequence having at least about 80-100% sequence similarity thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00113] An example of a VP4 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 2 and SEQ ID NO: 36. Furthermore, the VP4 structural protein may comprise the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 36 or a sequence having at least about 90-100% sequence similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP4 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO: 15, 16, 47, 50 or 51 or a sequence having at least about 80-100% sequence similarity thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00114] An example of a VP6 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 3 and SEQ ID NO: 31. Furthermore, the VP6 structural protein may comprise the sequence set forth in SEQ ID NO: 3, SEQ ID NO: 31 or a sequence having at least about 90-100% sequence similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP6 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO:17, 18, or 46 or a sequence having at least about 80-100% sequence similarity

thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00115] An example of a VP7 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 39, SEQ ID NO: 43, and SEQ ID NO: 47. Furthermore, the VP7 structural protein may comprise the sequence set forth in SEQ ID NO: 4, SEQ ID NO: 39 and SEQ ID NO: 43, or a sequence having at least about 90-100% similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP7 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO:19, 20, 48, 49, 52, 53 or 54 or a sequence having at least about 80-100% sequence similarity thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00116] Amino acid sequence similarity or identity may be computed by using the BLASTP and TBLASTN programs which employ the BLAST (basic local alignment search tool) 2.0 algorithm. Techniques for computing amino acid sequence similarity or identity are well known to those skilled in the art, and the use of the BLAST algorithm is described in ALTSCHUL et al. (1990, J Mol. Biol. 215: 403-410) and ALTSCHUL et al. (1997, Nucleic Acids Res. 25: 3389-3402).

[00117] The term "virus-like particle" (VLP), or "virus-like particles" or "VLPs" refers to structures that self-assemble and comprise one or more structural proteins such as for example rotavirus structural protein, for example but not limited to VP2, VP4, VP6 and/or VP7 structural protein. VLPs comprising rotavirus structural protein maybe also be referred to "rotavirus VLP", "rotavirus -like particle (RVLP)", "rotavirus -like particle (RLP)" , "rotavirus -like particle", "RVLP" or "RLP" . VLPs or RLPs are generally morphologically and antigenically similar to virions produced in an infection, but lack genetic information sufficient to replicate and thus are non-infectious. VLPs may be produced in suitable host cells including plant host cells. Following extraction from the host cell and upon isolation and further purification under suitable conditions, VLPs may be purified as intact structures. The RLP may be a single-, double or triple-layered RLP. Single-layered RLPs may be obtained by expressing one rotavirus structural protein, such as VP2 or VP6. Double-layered RLPs may be obtained by expressing two rotavirus structural proteins, such as

for example by co-expressing both VP2 and VP6, with or without VP4. Triple-layered RLPs may be obtained by the simultaneous expression of at least three rotavirus structural proteins for example the co-expression of VP2, VP6 and VP7, with or without VP4. Co-expression of VP4 results in a particle with spikes that resembles native rotavirus. VP4 may be processed or cleaved to produce VP5 and VP8. This processing may take place within the host using endogenous proteases, or by co-expressing a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed to produce VP5 and VP8 by adding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin during any step of the RLP extraction procedure, or after RLP purification.

[00118] Each of the rotavirus structural proteins has different characteristics and size, and is required in different amounts for assembly into RLP. The term "rotavirus VLP", "rotavirus virus-like particle (RVLP)", "rotavirus virus-like particle (RLP)" , "rotavirus virus-like particle", "RVLP" or "RLP" refers to a virus-like particle (VLP) comprising one or more rotavirus structural proteins. Example of rotavirus structural proteins may include, but are not limited to VP2, VP4 (or VP5 and VP8) VP6 and VP7 structural protein.

[00119] The present invention also provides for a method of producing RLPs in a plant, wherein a first nucleic acid (a first nucleic acid) encoding a first rotavirus structural protein, for example a VP2 or VP6 protein, is co-expressed with a second nucleic acid encoding a second rotavirus structural protein, for example a VP6 or VP2 protein. Furthermore, a third nucleic acid encoding a third rotavirus structural protein, for example VP4 or VP7 may be co-expressed with the first and second nucleic acid so that the first, the second nucleic acids and third nucleic acids are co-expressed in the plant. The first nucleic acid, second nucleic acid and third nucleic acid, may be introduced into the plant in the same step, or may be introduced to the plant sequentially. The VP4 may be processed or cleaved to produce VP5 and VP8 within the host by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[00120] Furthermore, a plant that expresses a first nucleic acid encoding a first rotavirus structural protein, a second nucleic acid encoding a second rotavirus structural protein and a third nucleic acid encoding a third rotavirus structural protein may be further transformed with a fourth nucleic acid encoding a fourth rotavirus structural protein, for example a VP7 or VP4 protein, so that the first, the second nucleic acids, third and fourth nucleic acids are co-expressed in the plant. The VP4 may be processed or cleaved to produce VP5 and VP8 within the host by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a satiable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[00121] Furthermore, a first plant expressing the first nucleic acid encoding one or more rotavirus structural protein, for example a VP2 or VP6 protein, may be crossed with a second plant expressing the second nucleic acid encoding one or more rotavirus structural protein for example but not limited to VP6 or VP2 protein, to produce a progeny plant (third plant) that co-expresses the first and second nucleic acids encoding VP2 and VP6 or VP6 and VP2, respectively. Furthermore, the third plant expressing the first and second nucleic acids encoding VP2 and VP6 or VP6 and VP2, respectively, may be crossed with a fourth plant expressing the third nucleic acid encoding one or more rotavirus structural protein for example but not limited to VP4 or VP7, to produce a further progeny plant (fifth plant) that co-expresses the first, second and third nucleic acids encoding VP2, VP6, and VP4 or VP7 respectively. The VP4 may be processed or cleaved to produce VP5 and VP8 within the plant using host a protease, or by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin within one of the first, second, third or fourth plants. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a satiable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[00122] As described in more detail below, RLPs may be produced in a plant by expressing a nucleic acid (a first nucleic acid) encoding one or more rotavirus structural protein, for example but not limited to VP2, VP6 or VP7. A second nucleic

acid encoding a second rotavirus structural protein, for example but not limited to VP7, VP6 or VP2 might be co-expressed in the plant. Furthermore, a third nucleic acid encoding a third rotavirus structural protein, for example but not limited to VP6, VP7 or VP2 might be co-expressed in the plant. The nucleic acid, second nucleic acid and third nucleic acid may be introduced to the plant in the same step, or they may be introduced to the plant sequentially. The nucleic acid, second nucleic acid and third nucleic acid may be introduced in the plant in a transient manner, or in a stable manner.

5 [00123] Furthermore, a plant that expresses a first nucleic acid encoding a first rotavirus structural protein, for example a VP2 protein, may be transformed with a second nucleic acid encoding a second rotavirus structural protein, for example but not limited to VP6 or VP7 so that both the first and the second nucleic acids are co-expressed in the plant. The plant might be further transformed with a third nucleic acid encoding a third rotavirus structural protein, for example but not limited to VP7 or VP6.

10 [00124] Alternatively, a plant that expresses a VP6 or VP7 protein, (second nucleic acid) may be transformed with the first nucleic acid encoding the VP2 protein, so that both the first and the second nucleic acids are co-expressed in the plant. The plant might be further transformed with a third nucleic acid encoding a third rotavirus structural protein, for example but not limited to VP7 or VP6.

15 [00125] In addition, a plant expressing a first and second nucleic acid encoding a first and second rotavirus structural protein for example a VP2 and VP6 protein, may be transformed with a third nucleic acid encoding a third rotavirus structural protein example VP4 or VP7. The VP4 may be processed or cleaved to produce VP5 and VP8 by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a satiable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

20 [00126] The present invention also provides a method of producing RLPs in a plant that involves introducing one or more nucleic acid encoding one or more rotavirus structural protein operatively linked to a regulatory region active in the

plant, and one or more than one compartment targeting sequence and/or an amplification elements, into the plant, portion of the plant or plant cell. The plant, portion of the plant or plant cell is then incubated under conditions that permit the expression of the one or more nucleic acid, thereby producing the RLPs. The one or more rotavirus structural protein may be VP2, VP4 (or VP5 and VP8), VP6, VP7 a fragment of the VP2, VP4 (or VP5 and VP8), VP6, VP7 or a combination thereof.

5 [00127] The present invention further provides for a RLP comprising one or more rotavirus structural protein for example but not limited to VP2, VP4 (or VP5 and VP8), VP6, VP7 or a combination thereof. The RLP may be produced by one or more of the methods as provided by the present invention.

10 [00128] The occurrence of RLPs may be detected using any suitable method for example density gradient centrifugation or size exclusion chromatography. RLPs may be assessed for structure and size by, for example electron microscopy, or by size exclusion chromatography.

15 [00129] For size exclusion chromatography, total soluble proteins may be extracted from plant tissue by homogenizing (Polytron) sample of frozen-crushed plant material in extraction buffer, and insoluble material removed by centrifugation. Precipitation with ice cold acetone or PEG may also be of benefit. The soluble protein is quantified, and the extract passed through a SephacrylTM column, for example a SephacrylTM S500 column. Blue Dextran 2000 may be used as a calibration standard. Following chromatography, fractions may be further analyzed by immunoblot to determine the protein complement of the fraction.

20 [00130] The separated fraction may be for example a supernatant (if centrifuged, sedimented, or precipitated), or a filtrate (if filtered), and is enriched for proteins, or suprastructure proteins, such as for example nanotubes, nanospheres or higher-order, higher molecular weight, particles such as single-layered (sl), double-layered (dl) or triple-layered (tl) RLPs.

25 [00131] The separated fraction may be further processed to isolate, purify, concentrate or a combination thereof, the proteins, suprastructure proteins or higher-order particles by, for example, additional centrifugation steps, precipitation, chromatographic steps (e.g. size exclusion, ion exchange, affinity chromatography), tangential flow filtration, or a combination thereof. The presence of purified proteins,

suprastructure proteins or higher-order particles such as RLPs, may be confirmed by, for example, native or SDS-PAGE, Western analysis using an appropriate detection antibody, capillary electrophoresis, electron microscopy, or any other method as would be evident to one of skill in the art.

5 [00132] The RLP's produced according to the present invention may be purified, partially purified from a plant, portion of a plant or plant matter, or may be administered as an oral vaccine, using methods as known to one of skill in the art.

10 [00133] RLP purification may involve gradient centrifugation, for example sucrose, iodixanol, OptiPrep™ or cesium chloride (CsCl) density gradients may be used to purify or partially purify the RLPs from transformed plant biomass. As shown for example in Figure 45, an iodixanol step gradient or iodixanol continuous gradient might be used to purify the RLP and/or expressed rotavirus structural proteins.

15 [00134] Calcium (Ca<sup>2+</sup>) concentration has been shown to be important for the triple-layer particle (TLP) to double layer particle (DLP) transformation and is strain dependent (see for example Martin et al. *Journal of Virology*, Jan 2002, which is incorporated herein by reference). Complete loss of the outer-capsid proteins from TLPs (TLP decapsidation) takes place in the nanomolar range of [Ca<sup>2+</sup>]. Therefore the purification and/or extraction of RLP may be performed in the presence of calcium, and the step of gradient centrifugation may be performed in the presence of calcium, for example in the present of CaCl<sub>2</sub>. The concentration of CaCl<sub>2</sub> maybe between for example, 1 mM and 1000 mM, or any amount there between, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 50, 600, 650, 700, 750, 800, 850, 900, 950 mM or any amount therebetween.

25 [00135] The plants, or plant fragments may be minimally processed. By the term "minimal processing" it is meant plant matter, for example, a plant or portion thereof comprising a protein of interest and /or the RLP which is partially purified to yield a plant extract, homogenate, fraction of plant homogenate or the like (i.e. minimally processed). Partial purification may comprise, but is not limited to disrupting plant cellular structures thereby creating a composition comprising soluble plant components, and insoluble plant components which may be separated for example, but not limited to, by centrifugation, filtration or a combination thereof. In

5 this regard, proteins secreted within the extracellular space of leaf or other tissues could be readily obtained using vacuum or centrifugal extraction, or tissues could be extracted under pressure by passage through rollers or grinding or the like to squeeze or liberate the protein free from within the extracellular space. Minimal processing could also involve preparation of crude extracts of soluble proteins, since these preparations would have negligible contamination from secondary plant products. Further, minimal processing may involve aqueous extraction of soluble protein from leaves, followed by precipitation with any suitable salt. Other methods may include 10 large scale maceration and juice extraction in order to permit the direct use of the extract. The RLPs may be purified or extracted using any suitable method for example mechanical or biochemical extraction.

15 [00136] The one or more rotavirus structural protein may be synthesized at an amount up to 2 g per kilogram of plant fresh weight. For example, the amount of synthesized structural protein maybe between 1 and 2 g per kilogram of fresh weight, or any amount there between, such as 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2 g per kilogram of fresh weight or any amount therebetween. For example, the structural protein may be synthesized at an amount up to 1.54 g per kilogram of plant fresh weight.

20 [00137] Furthermore, the RLP may be synthesized at an amount up to 1.5 g per kilogram of plant fresh weight. For example, the amount of synthesized RLP maybe between 0.5 and 1.5 g per kilogram of fresh weight, or any amount there between, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 g per kilogram of fresh weight. For example, the RLP may be synthesized at an amount of up to 1.1g per kilogram of plant fresh weight.

25 [00138] The size (i.e. the diameter) of the above-defined RLPs, maybe measures for example by dynamic light scattering (DLS) or electron microscope (EM) techniques, is usually between 50 to 110 nm, or any size therebetween. For example, the size of the intact RLP structure may range from about 70 nm to about 110 nm, or any size therebetween, such as 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm 30 or any size therebetween.

[00139] The present invention further provides a nucleic acid comprising a nucleotide sequence encoding one or more rotavirus structural protein operatively

linked to a regulatory region active in a plant. The nucleotide sequence may be optimized for example for human codon usage or plant codon usage. Furthermore one or more rotavirus structural protein may be operatively linked to one or more than one amplification elements. In addition one or more rotavirus structural protein may be operatively linked to one or more than one compartment targeting sequence. The one or more rotavirus structural protein encoded by the nucleotide sequence may be for example VP2, VP4, VP6 or VP7. Furthermore the one or more rotavirus structural protein encoded by the nucleotide sequence may be for example from any rotavirus group A to G, but more preferably from rotavirus group A. Furthermore, the one or more rotavirus structural protein encoded by the nucleotide sequence maybe from any rotavirus strain having a genotype of any combinations of G- and P- types from G1 to G27 and from P1 to P34, and more preferably from G1 to G19 and from P1 to P27, including, but not limited to G1P[8], G2P[4], G2P[8], G3P[8], G4P[8], G9P[6], G9P[8], rotavirus A WA strain, rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain or rotavirus SA11 strain.

[00140] A nucleic acid sequence referred to in the present invention, may be “substantially homologous”, “substantially similar” or “substantially identical” to a sequence, or a compliment of the sequence if the nucleic acid sequence hybridise to one or more than one nucleotide sequence or a compliment of the nucleic acid sequence as defined herein under stringent hybridisation conditions. Sequences are “substantially homologous” “substantially similar” “substantially identical” when at least about 70%, or between 70 to 100%, or any amount therebetween, for example 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100%, or any amount therebetween, of the nucleotides match over a defined length of the nucleotide sequence providing that such homologous sequences exhibit one or more than one of the properties of the sequence, or the encoded product as described herein.

[00141] For example the present invention provides an isolated polynucleotide comprising a nucleic acid which encodes one or more rotavirus structural protein that is at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% 100% or any amount therebetween identical to sequences as defines for example in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 45, 46, 47, 49, 50, 51, 52, 53, 54. The polynucleotide may be human codon optimized by any of the methods known in the art.

[00142] Furthermore, the present invention provides RLPS that comprise rotavirus structural proteins that are for example encoded by nucleic acids that are at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% 100% or any amount therebetween identical to sequences as defines for

5 example in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 45, 46, 47, 49, 50, 51, 52, 53, 54.

[00143] Such a sequence similarity or identity may be determined using a nucleotide sequence comparison program, such as that provided within DNASIS (using, for example but not limited to, the following parameters: GAP penalty 5, #of top diagonals 5, fixed

GAP penalty 10, k tuple 2, floating gap 10, and window size 5). However, other methods

10 of alignment of sequences for comparison are well-known in the art for example the

algorithms of Smith & Waterman (1981, *Adv. Appl. Math.* 2:482), Needleman & Wunsch

(*J. Mol. Biol.* 48:443, 1970), Pearson & Lipman (1988, *Proc. Nat'l. Acad. Sci. USA*

85:2444), and by computerized implementations of these algorithms (GAP, BESTFIT,

FASTA, and BLAST, available through the NIH.), or by manual alignment and visual

15 inspection (see, e.g., *Current Protocols in Molecular Biology*, Ausubel et al., eds. 1995

supplement), or using Southern or Northern hybridization under stringent conditions (see

Maniatis et al., in *Molecular Cloning (A Laboratory Manual)*, Cold Spring Harbor

Laboratory, 1982). Preferably, sequences that are substantially homologous exhibit at least

about 80% and most preferably at least about 90% sequence similarity over a defined

20 length of the molecule.

[00144] An example of one such stringent hybridization conditions may be overnight

(from about 16-20 hours) hybridization in 4 X SSC at 65°C, followed by washing in 0.1 X

SSC at 65°C for an hour, or 2 washes in 0.1 X SSC at 65°C each for 20 or 30 minutes.

Alternatively an exemplary stringent hybridization condition could be overnight (16-20

25 hours) in 50% formamide, 4 X SSC at 42°C, followed by washing in 0.1 X SSC at 65°C for

an hour, or 2 washes in 0.1 X SSC at 65°C each for 20 or 30 minutes, or overnight (16-20

hours), or hybridization in Church aqueous phosphate buffer (7% SDS; 0.5M NaPO4 buffer

pH 7.2; 10 mM EDTA) at 65°C, with 2 washes either at 50°C in 0.1 X SSC, 0.1% SDS for

20 or 30 minutes each, or 2 washes at 65°C in 2 X SSC, 0.1% SDS for 20 or 30 minutes

30 each for unique sequence regions.

[00145] A nucleic acid encoding a rotavirus structural polypeptide may be described as a "rotavirus nucleic acid", a "rotavirus nucleotide sequence", a "rotavirus nucleic acid", or a "rotavirus nucleotide sequence". For example, which is not to be considered limiting, a virus-like particle comprising one or more rotavirus structural protein or rotavirus structural polypeptide, may be described as a "rotavirus VLP", "RVLP" or "RLP".

[00146] Many organisms display a bias for use of particular codons to code for insertion of a particular amino acid in a growing peptide chain. Codon preference or codon bias, differences in codon usage between organisms, is afforded by degeneracy of the genetic code, and is well documented among many organisms. Codon bias often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, *inter alia*, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. The process of optimizing the nucleotide sequence coding for a heterologously expressed protein can be an important step for improving expression yields. The optimization requirements may include steps to improve the ability of the host to produce the foreign protein.

[00147] "Codon optimization" is defined as modifying a nucleic acid sequence for enhanced expression in cells of interest by replacing at least one, more than one, or a significant number, of codons of the native sequence with codons that may be more frequently or most frequently used in the genes of another organism or species. Various species exhibit particular bias for certain codons of a particular amino acid.

[00148] The present invention includes synthetic polynucleotide sequences that have been codon optimized for example the sequences have been optimized for human codon usage or plant codon usage. The codon optimized polynucleotide sequences may then be expressed in plants. More specifically the sequences optimized for human codon usage or plant codon usage may be expressed in plants. Without wishing to be bound by theory, it is believed that the sequences optimized for human codon increases the guanine-cytosine content (GC content) of the sequence and improves expression yields in plants.

[00149] There are different codon-optimisation techniques known in the art for improving, the translational kinetics of translationally inefficient protein coding regions. These techniques mainly rely on identifying the codon usage for a certain host organism. If a certain gene or sequence should be expressed in this organism, the coding sequence of such genes and sequences will then be modified such that one will replace codons of the sequence of interest by more frequently used codons of the host organism.

5 [00150] The rotavirus structural protein or polypeptide may be expressed in an expression system comprising a viral based, DNA or RNA, expression system, for example but not limited to, a comovirus-based expression cassette and geminivirus-based amplification element.

10 [00151] The expression system as described herein may comprise an expression cassette based on a bipartite virus, or a virus with a bipartite genome. For example, the bipartite viruses may be of the Comoviridae family. Genera of the 15 Comoviridae family include Comovirus, Nepovirus, Fabavirus, Cheravirus and Sadwavirus. Comoviruses include Cowpea mosaic virus (CPMV), Cowpea severe mosaic virus (CPSMV), Squash mosaic virus (SqMV), Red clover mottle virus (RCMV), Bean pod mottle virus (BPMV), Turnip ringspot virus (TuRSV), Broad bean true mosaic virus (BBtMV), Broad bean stain virus (BBSV), Radish mosaic 20 virus (RaMV). Examples of comovirus RNA-2 sequences comprising enhancer elements that may be useful for various aspects of the invention include, but are not limited to: CPMV RNA-2 (GenBank Accession No. NC\_003550), RCMV RNA-2 (GenBank Accession No. NC\_003738), BPMV RNA-2 (GenBank Accession No. NC\_003495), CPSMV RNA-2 (GenBank Accession No. NC\_003544), SqMV RNA-2 (GenBank Accession No. NC\_003800), TuRSV RNA-2 (GenBank Accession No. NC\_013219.1), BBtMV RNA-2 (GenBank Accession No. GU810904), BBSV RNA2 (GenBank Accession No. FJ028650), RaMV (GenBank Accession No. NC\_003800).

25 [00152] Segments of the bipartite comoviral RNA genome are referred to as RNA-1 and RNA-2. RNA-1 encodes the proteins involved in replication while RNA-30 2 encodes the proteins necessary for cell-to-cell movement and the two capsid proteins. Any suitable comovirus-based cassette may be used including CPMV, CPSMV, SqMV, RCMV, or BPMV, for example, the expression cassette may be based on CPMV.

[00153] “Expression cassette” refers to a nucleotide sequence comprising a nucleic acid of interest under the control of, and operably (or operatively) linked to, an appropriate promoter or other regulatory elements for transcription of the nucleic acid of interest in a host cell.

5 [00154] The expression systems may also comprise amplification elements from a geminivirus for example, an amplification element from the bean yellow dwarf virus (BeYDV). BeYDV belongs to the Mastreviruses genus adapted to dicotyledonous plants. BeYDV is monopartite having a single-strand circular DNA genome and can replicate to very high copy numbers by a rolling circle mechanism. 10 BeYDV-derived DNA replicon vector systems have been used for rapid high-yield protein production in plants.

15 [00155] As used herein, the phrase “amplification elements” refers to a nucleic acid segment comprising at least a portion of one or more long intergenic regions or long intergenic repeat (LIR) of a geminivirus genome. As used herein, “long intergenic region” or “long intergenic repeat” refers to a region of a long intergenic region that contains a rep binding site capable of mediating excision and replication by a geminivirus Rep protein. In some aspects, the nucleic acid segment comprising one or more LIRs, may further comprises a short intergenic region or small intergenic region (SIR) of a geminivirus genome. As used herein, “short intergenic region” or 20 “small intergenic region” refers to the complementary strand (the short IR (SIR) of a Mastreviruses). Any suitable geminivirus-derived amplification element may be used herein. See, for example, WO2000/20557; WO2010/025285; Zhang X. et al. (2005, Biotechnology and Bioengineering, Vol. 93, 271-279), Huang Z. et al. (2009, Biotechnology and Bioengineering, Vol. 103, 706-714), Huang Z. et al.(2009, Biotechnology and Bioengineering, Vol. 106, 9-17); which are herein incorporated by 25 reference). If more than one LIR is used in the construct, for example two LIRs, then the promoter, CMPV-HT regions and the nucleic acid sequence of interest and the terminator are bracketed by each of the two LIRs. Furthermore, the amplification element might for example originate from the sequence as disclosed in Halley-Stott et al. (2007) Archives of Virology 152: 1237-1240, deposited under Gen Bank accession number DQ458791, which are herein incorporated by reference. The nucleic acid segment comprising LIRs are joined nucleotides 2401 to 2566 and 1 to 30 128. The nucleic acid segment comprising SIRs are nucleotides 1154 to 1212.

[00156] As described herein, co-delivery of bean yellow dwarf virus (BeYDV)-derived vector and a Rep/RepA-supplying vector, by agroinfiltration of *Nicotiana benthamiana* leaves results in efficient replicon amplification and robust protein production.

5 [00157] A comovirus-based expression cassette and a geminivirus-derived amplification element may be comprised on separate vectors, or the component parts may be included in one vector. If two vectors are used, the first and second vectors may be introduced into a plant cell simultaneously, or separately.

10 [00158] A viral replicase may also be included in the expression system as described herein to increase expression of the nucleic acid of interest. An non-limiting example of a replicase is a BeYDV replicase (pREP110) encoding BeYDV Rep and RepA (C2/C1; Huang et al., 2009, *Biotechnol. Bioeng.* 103, 706-714; which is incorporated herein by reference). Another non-limiting example of a replicase is disclosed in Halley-Stott et al. (2007) *Archives of Virology* 152: 1237-1240, deposited under Gen Bank accession number DQ458791, which are herein incorporated by reference. The nucleic acid segment comprising C1:C2 gene are nucleotides 1310 to 2400.

15 [00159] By “co-expressed” it is meant that two or more than two nucleotide sequences are expressed at about the same time within the plant, and within the same tissue of the plant. However, the nucleotide sequences need not be expressed at exactly the same time. Rather, the two or more nucleotide sequences are expressed in a manner such that the encoded products have a chance to interact. The two or more than two nucleotide sequences can be co-expressed using a transient expression system, where the two or more sequences are introduced within the plant at about the same time under conditions that both sequences are expressed. Alternatively, a platform plant comprising one of the nucleotide sequences may be transformed in a stable manner, with an additional sequence encoding the protein of interest for example one or more rotavirus structural protein, introduced into the platform plant in a transient manner.

20 [00160] Correct folding of the protein may be important for stability of the protein, formation of multimers, formation of RLPs and function. Folding of a protein may be influenced by one or more factors, including, but not limited to, the

sequence of the protein, the relative abundance of the protein, the degree of intracellular crowding, the availability of cofactors that may bind or be transiently associated with the folded, partially folded or unfolded protein. Furthermore the compartment or sub-compartment within the plant where the protein is expressed may influence the expression levels and folding of the protein.

5

[00161] The expression of the one or more rotavirus structural protein may be targeted to specific plant cell compartment and/or sub-compartments by agroinfiltration in transgenic plants. The compartment or sub-compartments may be for example plastids, endoplasmic reticule (ER), chloroplast or apoplast. Without wishing to be bound by theory, compartment or sub-compartments targeting may increased protein accumulation into the targeted compartment or sub-compartments over cytoplasmic accumulation. Compartment or sub-compartment accumulation may protect protein from degradation by proteases present in the cytoplasm and/or allow it to accumulate to higher concentration without affecting the function of the plant cell.

10

[00162] Therefore, the expression cassette or vector may be adapted to direct the vector or rotavirus structural protein or polypeptide expressed from the vector to the desired compartment or sub-compartment in the plant.

15

[00163] For example the expression cassette or vector may be adapted to target plastids by causing an expressed rotavirus structural protein or polypeptide to include a portion capable of interacting with the thylakoid membranes of the plastids, in particular the transfer mechanism of the thylakoid membranes. This interaction may cause the rotavirus structural protein or polypeptide to be imported into the plastid from the cytoplasm where it is expressed. Without wishing to be bound by theory, the mechanism of importation from the cytoplasm may be important for proper folding of the proteins. It will be appreciated that the expression cassette or vector may be adapted to target the plastids themselves to become transformed and expression of the rotavirus structural protein or polypeptide may occur wholly within the plastid.

20

[00164] By the term "targeting sequence" it is meant that the targeting sequences may be included in the vector or expression cassette. Such targeting sequences may be translated into a peptide which directs the vector or product thereof to the desired compartment or sub-compartment in the plant, such as a plastid. For example, plastid signal peptides (also referred to as "plastid transit peptides" in the

25

art) for targeting proteins into plastids are known in the art. A non limiting example of a plastid transit peptide that may be used is that of rbcS1-cTP. As suitable example of a chloroplast-transit peptide sequence is the Rubisco small-subunit gene (rbcS1), for example, from Solanum tuberosum .

5 [00165] Therefore, the rotavirus structural protein or polypeptide may include a signal peptide that is the same as, or heterologous with, the remainder of the polypeptide or protein. The term "signal peptide" is well known in the art and refers generally to a short (about 5-30 amino acids) sequence of amino acids, found generally at the N-terminus of a polypeptide that may direct translocation of the 10 newly-translated polypeptide to a particular organelle, or aid in positioning of specific domains of the polypeptide chain relative to others. As a non-limiting example, the signal peptide may target the translocation of the protein into the endoplasmic reticulum and/or aid in positioning of the N-terminus proximal domain relative to a membrane-anchor domain of the nascent polypeptide to aid in cleavage and folding of 15 the mature protein, for example which is not to be considered limiting, a rotavirus structural protein.

20 [00166] A signal peptide (SP) may be native to the protein or virus protein, or a signal peptide may be heterologous with respect to the primary sequence of the protein or virus protein being expressed. For example the native signal peptide of rotavirus structural protein may be used to express the rotavirus structural protein in a plant system.

25 [00167] A signal peptide may also be non-native, for example, from a protein, viral protein or native structural protein of a virus other than rotavirus protein, or from a plant, animal or bacterial polypeptide. A non limiting example of a signal peptide that may be used is that of alfalfa protein disulfide isomerase (PDISP) (nucleotides 32-103 of Accession No. Z11499). Furthermore, the signal peptide may be completely deleted or truncated. By truncation or truncated it is meant that 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or any amount therebetween of amino acid residues are 30 deleted from the signal peptide. Preferably, the truncated amino acid residues are continuous, and the truncation occurs from the second methionine onward

[00168] The present invention therefore provides for a rotavirus structural protein, such as for example VP2, VP4, VP6 and/or VP7, comprising a native, a non-native signal peptide or truncated signal peptide, and nucleic acids encoding such rotavirus structural proteins.

5 [00169] The one or more than one genetic constructs of the present invention may be expressed in any suitable plant host that is transformed by the nucleotide sequence, or constructs, or vectors of the present invention. Examples of suitable hosts include, but are not limited to, agricultural crops including alfalfa, canola, Brassica spp., maize, Nicotiana spp., potato, ginseng, pea, oat, rice, soybean, wheat, 10 barley, sunflower, cotton and the like.

[00170] The nucleotide sequences encoding for the rotavirus structural proteins may be transferred into the plant host using 1, 2, 3, 4 or 5 binary plasmid vectors. Each binary plasmid vector may therefore contain 1, 2, 3, 4 or 5 nucleotide sequences encoding for a rotavirus structural protein.

15 [00171] The one or more genetic constructs of the present invention can further comprise a 3' untranslated region. A 3' untranslated region refers to that portion of a gene comprising a DNA segment that contains a polyadenylation signal and any other regulatory signals capable of effecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by effecting the addition of polyadenylic acid tracks to the 3' end of the mRNA precursor. Polyadenylation signals are commonly recognized by the presence of homology to the canonical form 5' 20 AATAAA-3' although variations are not uncommon. Non-limiting examples of suitable 3' regions are the 3' transcribed nontranslated regions containing a polyadenylation signal of Agrobacterium tumor inducing (Ti) plasmid genes, such as the nopaline synthase (NOS) gene, plant genes such as the soybean storage protein genes, the small subunit of the ribulose-I, 5-bisphosphate carboxylase gene (ssRUBISCO; US 4,962,028; which is incorporated herein by reference), the promoter used in regulating plastocyanin expression, described in US 7,125,978 25 (which is incorporated herein by reference).

30 [00172] One or more of the genetic constructs of the present invention may also include further enhancers, either translation or transcription enhancers, as may be required. Enhancers may be located 5' or 3' to the sequence being transcribed.

Enhancer regions are well known to persons skilled in the art, and may include an ATG initiation codon, adjacent sequences or the like. The initiation codon, if present, may be in phase with the reading frame ("in frame") of the coding sequence to provide for correct translation of the transcribed sequence.

5 [00173] The constructs of the present invention can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, micro-injection, electroporation, etc. For reviews of such techniques see for example Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, New York VIII, pp. 421-463 (1988); Geierson and Corey, *Plant Molecular Biology*, 10 2d Ed. (1988); and Miki and Iyer, *Fundamentals of Gene Transfer in Plants*. In *Plant Metabolism*, 2d Ed. DT. Dennis, DH Turpin, DD Lefebvre, DB Layzell (eds), Addison Wesley, Langmans Ltd. London, pp. 561-579 (1997). Other methods include direct DNA uptake, the use of liposomes, electroporation, for example using protoplasts, micro-injection, microprojectiles or whiskers, and vacuum infiltration. 15 See, for example, Bilang, et al. (*Gene* 100: 247-250 (1991), Scheid et al. (*Mol. Gen. Genet.* 228: 104-112, 1991), Guerche et al. (*Plant Science* 52: 111-116, 1987), Neuhause et al. (*Theor. Appl. Genet.* 75: 30-36, 1987), Klein et al., *Nature* 327: 70-73 20 (1987); Howell et al. (*Science* 208: 1265, 1980), Horsch et al. (*Science* 227: 1229-1231, 1985), DeBlock et al., *Plant Physiology* 91: 694-701, 1989), *Methods for Plant Molecular Biology* (Weissbach and Weissbach, eds., Academic Press Inc., 1988), 25 *Methods in Plant Molecular Biology* (Schuler and Zielinski, eds., Academic Press Inc., 1989), Liu and Lomonossoff (*J Virol Meth*, 105:343-348, 2002,), U.S. Pat. Nos. 4,945,050; 5,036,006; and 5,100,792, U.S. patent application Ser. Nos. 08/438,666, filed May 10, 1995, and 07/951,715, filed Sep. 25, 1992, (all of which are hereby incorporated by reference).

#### Transient expression

30 [00174] Without wishing to be bound by theory, the protein concentration and ratio of the different rotavirus structural proteins may be important for the assembly efficiency of RLPs. Therefore multiplicity and time of infection, may be important to manipulate protein concentration and the overall assembly efficiency of RLPs in plants.

[00175] The construct of the present invention may be transiently expressed in a plants or portion of a plant. A transient expression system relying on the epichromosomal expression of recombinant *Agrobacterium tumefaciens* in a plant, portion of a plant or plant cell may be used to express the rotavirus structural protein, targeted to various cell compartments or sub-compartments. A transient expression system allows for a high production speed. Furthermore, large amounts of protein can be attained within a few days after infiltration of recombinant *Agrobacterium* in plants (Rybicki, 2010; Fischer et al., 1999). It is also possible to express long gene sequences and have more than one gene simultaneously expressed in the same cell, allowing for efficient assembly of multimeric proteins (Lombardi et al., 2009).

[00176] The nucleotide sequences encoding for the rotavirus structural proteins may be transferred into the plant host into 1, 2, 3, 4 or 5 transformed *Agrobacterium tumefaciens* strain.

[00177] However, during transient expression post-transcriptional gene silencing may limit the expression of the heterologous proteins in plants. The co-expression of a suppressor of silencing, for example, but not limited to *Nss* from Tomato spotted wilt virus may be used to counteract the specific degradation of transgene mRNAs (Brigneti et al., 1998). Alternate suppressors of silencing are well known in the art and may be used as described herein (Chiba et al., 2006, *Virology* 346:7-14; which is incorporated herein by reference), for example but not limited to *HcPro*, *TEV* -p1/*HC-Pro* (Tobacco etch virus-p1/*HC-Pro*), *BYV* -p21, p19 of Tomato bushy stunt virus (*TBSV* p19), capsid protein of Tomato crinkle virus (*TCV* -CP), 2b of Cucumber mosaic virus; *CMV*-2b), p25 of Potato virus X (*PVX*-p25), p11 of Potato virus M (*PVM*-p11), p11 of Potato virus S (*PVS*-p11), p16 of Blueberry scorch virus, (*BScV* -p16), p23 of Citrus tristeza virus (*CTV*-p23), p24 of Grapevine leafroll-associated virus-2, (*GLRaV*-2 p24), p10 of Grapevine virus A, (*GVA*-p10), p14 of Grapevine virus B (*GVB*-p14), p10 of Heracleum latent virus (*HLV*-p10), or p16 of Garlic common latent virus (*GCLV*-p16). Therefore, a suppressor of silencing, for example *HcPro*, *TEV* -p1/*HC-Pro*, *BYV*-p21, *TBSV* p19, *TCV*-CP, *CMV*-2b, *PVX*-p25, *PVM*-p11, *PVS*-p11, *BScV*-p16, *CTV*-p23, *GLRaV*-2 p24, *GBV*-p14, *HLV*-p10, *GCLV*-p16 or *GVA*-p10, may be co-expressed along with one or more rotavirus structural protein for example VP2, VP4, VP6, or a combination

thereof, to further ensure high levels of protein production within a plant or portion of a plant.

[00178] The present invention also provides a methods as described above, wherein an additional (second, third, fourth, or fifth ) nucleotide sequence is expressed within the plant, the additional (second, third, fourth, or fifth) nucleotide sequence encoding a suppressor of silencing is operatively linked with an additional (second, third, fourth, or fifth) regulatory region that is active in the plant. The nucleotide sequence encoding a suppressor of silencing may be, for example NSS, HcPro, TEV -p1/HC-Pro, BYV-p21, TBSV p19, TCV-CP, CMV-2b, PVX-p25, PVM-p11, PVS-p11, BScV-p16, CTV-p23, GLRaV-2 p24, GBV-p14, HLV-p10, GCLV-p16 or GVA-p10.

[00179] As described below, transient expression methods may be used to express the constructs of the present invention (see Liu and Lomonossoff, 2002, Journal of Virological Methods, 105:343-348; which is incorporated herein by reference). Alternatively, a vacuum-based transient expression method, as described by Kapila et al., 1997, which is incorporated herein by reference) may be used. These methods may include, for example, but are not limited to, a method of Agro-inoculation or Agro-infiltration, syringe infiltration, however, other transient methods may also be used as noted above. With Agro-inoculation, Agro-infiltration, or syringe infiltration, a mixture of Agrobacteria comprising the desired nucleic acid enter the intercellular spaces of a tissue, for example the leaves, aerial portion of the plant (including stem, leaves and flower), other portion of the plant (stem, root, flower), or the whole plant. After crossing the epidermis the Agrobacteria infect and transfer t-DNA copies into the cells. The t-DNA is episomally transcribed and the mRNA translated, leading to the production of the protein of interest in infected cells, however, the passage of t-DNA inside the nucleus is transient.

[00180] To aid in identification of transformed plant cells, the constructs of this invention may be further manipulated to include plant selectable markers. Useful selectable markers include enzymes that provide for resistance to chemicals such as an antibiotic for example, gentamycin, hygromycin, kanamycin, or herbicides such as phosphinothycin, glyphosate, chlorosulfuron, and the like. Similarly, enzymes providing for production of a compound identifiable by colour change such as GUS (beta-glucuronidase), or luminescence, such as luciferase or GFP, may be used.

5 [00181] Also considered part of this invention are transgenic plants, plant cells or seeds containing the gene construct of the present invention. Methods of regenerating whole plants from plant cells are also known in the art. In general, transformed plant cells are cultured in an appropriate medium, which may contain selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be used to establish repetitive generations, either from seeds or using 10 vegetative propagation techniques. Transgenic plants can also be generated without using tissue cultures.

10 [00182] The use of the terms "regulatory region", "regulatory element" or "promoter" in the present application is meant to reflect a portion of nucleic acid typically, but not always, upstream of the protein coding region of a gene, which may be comprised of either DNA or RNA, or both DNA and RNA. When a regulatory 15 region is active, and in operative association, or operatively linked, with a gene of interest, this may result in expression of the gene of interest. A regulatory element may be capable of mediating organ specificity, or controlling developmental or temporal gene activation. A "regulatory region" may include promoter elements, core promoter elements exhibiting a basal promoter activity, elements that are inducible in response to an external stimulus, elements that mediate promoter activity such as negative regulatory elements or transcriptional enhancers. "Regulatory region", as used herein, may also include elements that are active following transcription, for example, regulatory elements that modulate gene expression such as translational and 20 transcriptional enhancers, translational and transcriptional repressors, upstream activating sequences, and mRNA instability determinants. Several of these latter elements may be located proximal to the coding region.

25 [00183] In the context of this disclosure, the term "regulatory element" or "regulatory region" typically refers to a sequence of DNA, usually, but not always, upstream (5') to the coding sequence of a structural gene, which controls the expression of the coding region by providing the recognition for RNA polymerase and/or other factors required for transcription to start at a particular site. However, it is to be understood that other nucleotide sequences, located within introns, or 3' of the 30

sequence may also contribute to the regulation of expression of a coding region of interest. An example of a regulatory element that provides for the recognition for RNA polymerase or other transcriptional factors to ensure initiation at a particular site is a promoter element. Most, but not all, eukaryotic promoter elements contain a 5 TATA box, a conserved nucleic acid sequence comprised of adenosine and thymidine nucleotide base pairs usually situated approximately 25 base pairs upstream of a transcriptional start site. A promoter element comprises a basal promoter element, responsible for the initiation of transcription, as well as other regulatory elements (as listed above) that modify gene expression.

10 [00184] There are several types of regulatory regions, including those that are developmentally regulated, inducible or constitutive. A regulatory region that is developmentally regulated, or controls the differential expression of a gene under its control, is activated within certain organs or tissues of an organ at specific times during the development of that organ or tissue. However, some regulatory regions that 15 are developmentally regulated may preferentially be active within certain organs or tissues at specific developmental stages, they may also be active in a developmentally regulated manner, or at a basal level in other organs or tissues within the plant as well. Examples of tissue-specific regulatory regions, for example see-specific a regulatory region, include the napin promoter, and the cruciferin promoter (Rask et al., 1998, J. Plant Physiol. 152: 595-599; Bilodeau et al., 1994, Plant Cell 14: 125-130). An 20 example of a leaf-specific promoter includes the plastocyanin promoter (see US 7,125,978, which is incorporated herein by reference).

25 [00185] An inducible regulatory region is one that is capable of directly or indirectly activating transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer the DNA sequences or genes will not be transcribed. Typically the protein factor that binds specifically to an inducible regulatory region to activate transcription may be present in an inactive form, which is then directly or indirectly converted to the active form by the inducer. However, the 30 protein factor may also be absent. The inducer can be a chemical agent such as a protein, metabolite, growth regulator, herbicide or phenolic compound or a physiological stress imposed directly by heat, cold, salt, or toxic elements or indirectly through the action of a pathogen or disease agent such as a virus. A plant cell containing an inducible regulatory region may be exposed to an inducer by

externally applying the inducer to the cell or plant such as by spraying, watering, heating or similar methods. Inducible regulatory elements may be derived from either plant or non-plant genes (e.g. Gatz, C. and Lenk, L.R.P., 1998, Trends Plant Sci. 3, 352-358; which is incorporated by reference). Examples, of potential inducible promoters include, but not limited to, tetracycline-inducible promoter (Gatz, C., 1997, Ann. Rev. Plant Physiol. Plant Mol. Biol. 48, 89-108; which is incorporated by reference), steroid inducible promoter (Aoyama, T. and Chua, N.H., 1997, Plant 1, 2, 397-404; which is incorporated by reference) and ethanol-inducible promoter (Salter, M.G., et al., 1998, Plant Journal 16, 127-132; Caddick, M.X., et al., 1998, Nature Biotech. 16, 177-180, which are incorporated by reference) cytokinin inducible IB6 and CKI 1 genes (Brandstatter, I. and Kieber, 1.1., 1998, Plant Cell 10, 1009-1019; Kakimoto, T., 1996, Science 274, 982-985; which are incorporated by reference) and the auxin inducible element, DR5 (Ulmasov, T., et al., 1997, Plant Cell 9, 1963-1971; which is incorporated by reference).

[00186] A constitutive regulatory region directs the expression of a gene throughout the various parts of a plant and continuously throughout plant development. Examples of known constitutive regulatory elements include promoters associated with the CaMV 35S transcript (Odell et al., 1985, Nature, 313: 810-812), the rice actin 1 (Zhang et al., 1991, Plant Cell, 3: 1155-1165), actin 2 (An et al., 1996, Plant J., 10: 107-121), or tms 2 (U.S. 5,428,147, which is incorporated herein by reference), and triosephosphate isomerase 1 (Xu et al., 1994, Plant Physiol. 106: 459-467) genes, the maize ubiquitin 1 gene (Cornejo et al., 1993, Plant Mol. Biol. 29: 637-646), the Arabidopsis ubiquitin 1 and 6 genes (Holtorf et al., 1995, Plant Mol. Biol. 29: 637-646), and the tobacco translational initiation factor 4A gene (Mandel et al., 1995, Plant Mol. Biol. 29: 995-1004).

[00187] The term "constitutive" as used herein does not necessarily indicate that a gene under control of the constitutive regulatory region is expressed at the same level in all cell types, but that the gene is expressed in a wide range of cell types even though variation in abundance is often observed. Constitutive regulatory elements may be coupled with other sequences to further enhance the transcription and/or translation of the nucleotide sequence to which they are operatively linked. For example, the CPMV-HT system is derived from the untranslated regions of the Cowpea mosaic virus (CPMV) and demonstrates enhanced translation of the

associated coding sequence. By "native" it is meant that the nucleic acid or amino acid sequence is naturally occurring, or "wild type". By "operatively linked" it is meant that the particular sequences, for example a regulatory element and a coding region of interest, interact either directly or indirectly to carry out an intended function, such as mediation or modulation of gene expression. The interaction of operatively linked sequences may, for example, be mediated by proteins that interact with the operatively linked sequences.

5 [00188] The RLP produced within a plant may induce a rotavirus VP7 structural protein comprising plant-specific N-glycans. Therefore, this invention also provides for a RLP comprising VP7 having plant specific N-glycans.

10 [00189] Furthermore, modification of N-glycan in plants is known (see for example U.S. 60/944,344; which is incorporated herein by reference) and VP7 having modified N-glycans may be produced. VP7 comprising a modified glycosylation pattern, for example with reduced fucosylated, xylosylated, or both, fucosylated and xylosylated, N-glycans may be obtained, or VP7 having a modified glycosylation pattern may be obtained, wherein the protein lacks fucosylation, xylosylation, or both, and comprises increased galactosylation. Furthermore, modulation of post-translational modifications, for example, the addition of terminal galactose may result in a reduction of fucosylation and xylosylation of the expressed VP7 when compared 15 to a wild-type plant expressing VP7.

20 [00190] For example, which is not to be considered limiting, the synthesis of VP7 having a modified glycosylation pattern may be achieved by co-expressing VP7 along with a nucleotide sequence encoding beta-1,4 galactosyltransferase (GalT), for example, but not limited to mammalian GalT, or human GalT however GalT from another sources may also be used. The catalytic domain of GalT may also be fused to 25 a CTS domain (i.e. the cytoplasmic tail, transmembrane domain, stem region) of N-acetylglucosaminyl transferase (GNT1), to produce a GNT1-GalT hybrid enzyme, and the hybrid enzyme may be co-expressed with VP7. The VP7 may also be co-expressed along with a nucleotide sequence encoding N-acetylglucosaminyl transferase III (GnT-III), for example but not limited to mammalian GnT-III or human 30 GnT-III, GnT-III from other sources may also be used. Additionally, a GNT1-GnT-III hybrid enzyme, comprising the CTS of GNT1 fused to GnT-III may also be used .

[00191] Therefore the present invention also provides RLPs comprising VP7 having modified N-glycans.

[00192] Without wishing to be bound by theory, the presence of plant N-glycans on VP7 may stimulate the immune response by promoting the binding of VP7 by antigen presenting cells. Stimulation of the immune response using plant N-glycan has been proposed by Saint-Jore-Dupas et al. (2007).

[00193] The present invention will be further illustrated in the following examples.

### Examples

#### Example 1

##### **Expression of rotavirus proteins and production of VLPs in *N. benthamiana* plant leaves**

[00194] The following analysis utilized rotavirus capsid proteins from the G9 P[6] rotavirus strain, and assessed whether rotavirus-like particles were formed in the various compartments of tobacco *N. benthamiana* leaf cells. Co-expression of VP2 and VP6 as well as various combinations of VP2, VP6, VP7 and VP4 in tobacco plant leaves were investigated.

#### Materials and Methods

##### Plasmid construction

[00195] Plant codon optimized rotavirus cDNAs for VP2, VP4, VP6 and VP7 were supplied by Geneart, Germany. The plasmid DNA was transformed into DH5- $\alpha$  chemically competent *E. coli* cells (*E. coli* cloni<sup>TM</sup>, Lucigen) as per the manufacturer's instructions. Novel binary Agrobacterium vectors pTRAc (cytoplasm), pTRAkcrbcs1-cTP (chloroplast targeting) and pTRAk-ERH (endoplasmic reticulum targeting) supplied by Rainer Fischer (Fraunhofer Institute for Molecular Biology and Applied Ecology, IME, Germany) were used in this study. An additional vector, pTRAk-A (apoplast), was derived from the modification of pTRAk-ERH by restriction enzyme (RE) digestion at sites NcoI and XhoI in the multiple cloning site (Figure 3). This removes the histidine tag and KDEL sequence which retain proteins in the ER. The proteins are instead targeted to the apoplast.

[00196] VP2, VP4 and VP6 cDNA was restriction enzyme (RE) digested with NcoI/XhoI while VP7 was cut with AflIII/XhoI. Restriction enzymes AflIII, NcoI and MluI have compatible sticky ends. For direct cloning of the DNA into pTRAc, pTRAk-c-rbcs-cTP and pTRAk-c-A, the vectors were each RE digested at sites AflIII/XhoI, MluI/XhoI and NcoI/XhoI, respectively. Cloning of DNA in the vectors was carried out as per standard protocol followed by transformation into chemically competent *E. coli* DH5- $\alpha$  cells (*E. cloni*<sup>TM</sup>, Lucigen). Selected recombinant colonies were verified by colony PCR. For cloning in pTRAk-ERH, a NotI restriction enzyme site was added to replace the stop codon of each the four rotavirus cDNA by PCR amplification. The cDNA was amplified with primers as detailed in Table 1. The PCR reaction conditions included denaturation at 95°C for 5 min, followed by five cycles of denaturation at 95°C for 30 sec, annealing at 52°C for 1 min, and elongation at 72°C for 1.5 min. A further 20 cycles were done as follows; 95°C for 30 sec, 57°C for 1 min, 72°C for 1.5 min and 72°C for 5 min. The amplified fragments were then cloned into pGEM-T-Easy (Promega) as per the manufacturer's instructions. Transformation was carried out in chemically competent *E. coli* DH5- $\alpha$  (*E. cloni*<sup>TM</sup>, Lucigen). Colony PCR was then carried out on selected colonies as done for the other three constructs.

Table 1: Rotavirus cDNA primers for ER vector cloning

20

Primer	Sequence	R.E site added	Orientation
VP2F	5'-TTCCATGGCTTACCGTAAAGG-3'	-	SEQ ID NO: 5 Forward
VP2R	5'- <u>ATGCGGCCGCAAGCTCGTTCATATCCTCATG</u> -3'	NotI	SEQ ID NO: 6 Reverse
VP4F	5'-TTCCATGGCTTCCCTCATCTAC-3'	-	SEQ ID NO: 7 Forward
VP4R	5'-ATGCGGCCGCAAGACGGCACTGGAGAATGAG-3'	NotI	SEQ ID NO: 8 Reverse
VP6F	5'-TTCCATGGATGTGCTCTACTC-3'	-	SEQ ID NO: 9 Forward
VP6R	5'-ATGCGGCCGCTTCACGAGCATGGAACG-3'	NotI	SEQ ID NO: 10 Reverse
VP7F	5'-GTACATGTACGGAATCGAGTAC-3'	-	SEQ ID NO: 11 Forward
VP7R	5'-ATGCGGCCGCCACACGGTAGTAGAAAGCAGC-3'	NotI	SEQ ID NO: 12 Reverse

25

30

[00197] The pGEM-VP DNAs from positive colonies were sequenced to verify fidelity of the PCR. DNA was digested with NcoI/NotI and the appropriate DNA fragment cloned into pTRAk-ERH at sites NcoI and NotI to form pTRAk-ERH-VP. Transformation was then carried out into *E. coli* DH5- $\alpha$  cells as previously done. Colony PCR was also performed to check for rotavirus DNA in selected colonies.

### **Agrobacterium transformation**

[00198] Agrobacterium tumefaciens GV3101 strain was provided by Professor Rainer Fischer (Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany) and made electrocompetent as previously described (Shen and Forde, 1989). Three hundred nanograms of isolated rotavirus pTRA-VP constructs were mixed with 100  $\mu$ l of electrocompetent GV3101 cells in a 0.1 cm electroporation cuvette (BioRadTM) then electroporated in a GenePulser (BioRad) under the following settings: 1.8 kV, 25  $\mu$ F and 200  $\Omega$ . Incubation was allowed for 1 hr at 27°C in 900  $\mu$ l of LB before plating on LA plates containing 50  $\mu$ g/ml carbenicillin (carb), 30  $\mu$ g/ml kanamycin (kan) and 50  $\mu$ g/ml rifampicin (rif). The plates were incubated at 27°C for 3 days. To check for positive transformants, plasmid DNA was isolated from the recombinant Agrobacterium colonies and back-transformed into E. coli competent DH5- $\alpha$  cells. These were then selected on 100  $\mu$ g/ml ampicillin (amp) LA. Colony PCR and restriction enzyme digests on cDNA were done to verify successful transformants. Glycerol stocks of relevant recombinant Agrobacterium were made and stored at -70 °C.

### **Recombinant Agrobacterium infiltration**

[00199] A. tumefaciens LBA 4404 (pBIN-NSs) used in this study was obtained from Marcel Prins (Laboratory of Virology, Wageningen University, Binnenhaven, Netherlands). It contains the NSs silencing suppressor found in Tomato spotted wilt virus (TSWV). Recombinant Agrobacterium (pTRA-VPs) from glycerol stocks were grown at 27 °C overnight in LB with 50  $\mu$ g/ml carb, 30  $\mu$ g/ml kan and 50  $\mu$ g/ml rif. The recombinant Agrobacterium and LBA4404 (pBIN-NSs) were then each inoculated in induction medium (LB, 10 mM 2-(N-morpholino) ethanesulphonic acid MES, 2 mM MgSO<sub>4</sub>, 20  $\mu$ M acetosyringone, 50  $\mu$ g/ml carb, 30  $\mu$ g/ml kan and 50  $\mu$ g/ml rif, and pH 5.6).

[00200] Cultures were incubated at 27°C overnight. Agrobacterium cells were collected by centrifugation at 4000 rpm for 5 min at 4°C and then resuspended in 2 ml infiltration medium (10 mM MES, 10 mM MgCl<sub>2</sub>, 3 % sucrose, pH 5.6, 200  $\mu$ M acetosyringone and sterile water). Optical density (OD600) of the cells was verified and diluted with infiltration medium to obtain an OD600 of 0.25. For each pTRA-VP construct, LBA4404 was mixed with recombinant Agrobacterium to final OD600 of

0.5. For co-expression studies, each construct was added to total an OD600 of 0.5, for example; VP2 – 0.25 and VP6 – 0.25, until the OD600 for mixture equalled 0.5. Acetosyringone used in the induction and infiltration medium helps in activation of vir genes in Agrobacterium.

5 [00201] Wounded plant cells release phenolic compounds which are detected by Vir A and Vir G genes in Agrobacterium subsequently leading to induction of protein expression in the host cells (Zupan, J. et al., 2000). The cells were then incubated at room temperature for 1 h to allow acetosyringone to induce vir genes. 10 Three week old wild type *N. benthamiana* plants were infiltrated with recombinant Agrobacterium expressing the VP proteins. This involved either vacuum infiltration of whole plants or injection of recombinant Agrobacterium (pTRA-VP) into the abaxial air spaces on the ventral side of plant leaves. Recombinant agrobacterium was infiltrated either with or without the silencing suppressor LBA 4404 (pBIN-NSs).

15 [00202] Initially, 2 ml of Agrobacterium infiltration medium suspension was injected into each plant using a syringe per construct. One plant was used per construct over a seven day time trial. Co-expression of rotavirus proteins was also carried out in which VP2, VP6 and VP4 were simultaneously expressed in the cytoplasm of *N. benthamiana* plant leaves. Combinations investigated were VP2/6 and VP2/6/4. VP4 “spike” protein may bind to VP6, and thus there is a possibility that 20 they could add to RLP structures. VP7 cloning was attempted but toxicity issues to host cells proved to be a problem. Recombinant VP7 Agrobacterium killed leaf cells within a day after infiltration. Several methods were tried to evade this such as infiltrating plants at a low temperature of 17° C and infiltrating after day 3 and/or day 5 of the time trials. As such, VP7 was omitted in the co-expression studies due to its 25 toxic nature in the tobacco plants.

### **Protein Extraction**

30 [00203] Whole leaves or two leaf discs per construct were harvested and ground in liquid nitrogen. Ground leaf matter was resuspended in sterile PBS containing Complete Protease Inhibitor (EDTA-free; Roche). This was then centrifuged for 5 min at 13000 rpm and the pellets (plant leaf matter) discarded. 100 µl of each construct were then mixed with 5X SDS-PAGE loading buffer and boiled for 2 min at 95 °C, ready for further analysis on SDS-PAGE gels and western blots.

The rest of the samples were stored at -20 °C for future use. Figure 4 shows an overview of the cloning and infiltration procedure for the rotavirus cDNA.

### **Apoplast protein extraction**

[00204] An additional extraction procedure was carried out on the pTRAkc-A, 5 apoplast constructs. The apoplast is the free diffusional space between the plasma membrane and cell walls of plant cells (Figure 5a). Proteins expressed in the cytoplasm have an export sequence that targets them to the apoplast hence they accumulate here. In the extraction procedure that followed, whole leaves from each extraction day were either vacuum or injection infiltrated with sterile PBS containing 10 Complete Protease Inhibitor. For vacuum infiltration, individual plant leaves were suspended in PBS and put under a vacuum at 100 mbar for 10 min in a vacuum tank. The leaves were then rolled and gently placed in spin columns (similar to Qiagen spin 15 columns) with a hole at the bottom (Figure 5b2). The holes allow easy passage of fluid from the leaves without allowing solid leaf matter to pass through. The spin columns were placed in 2 ml Eppendorf tubes and centrifugation carried out at 4000 rpm for 15 min (Figure 5 b3). The filtrate was collected and protein loading dye for SDS-PAGE gels and western blot analysis was added to 100 µl of each filtrate sample.

### **Western Blots and Coomassie stains**

[00205] Western blots and Coomassie blue stained SDS-PAGE gels were used 20 as previously described. Mouse anti-rotavirus VP6 antibody (US Biologicals) (1:5000), anti-mouse histidine tag antibody (Sigma®) (1:2000), chicken anti-VP2 and chicken anti-VP4 serum (1:2000) were used to probe each of the respective proteins in western blots. Coomassie blue stained SDS-PAGE gels were used to quantify 25 proteins by density scanning of bands using a Syngene Gel Documentation System.

### **Electron Microscopy**

[00206] To determine whether expressed proteins assembled into RLPs, 30 transmission electron microscopy (TEM) of immuno-trapped particles was performed on day 3 of expression of cytoplasm expressed VP6, VP2/6 and VP2/6/4, all in the presence of a silencing suppressor Nss. Glow discharged carbon/copper grids were placed on 20 µl of mouse anti-rotavirus VP6 antibody (1:5000) for 5 min and then washed 3 times with sterile distilled water. The grids were then placed on 10 µl of the

protein extracts and left for 2 min before being washed 3 times again with sterile distilled water. Finally, the grids were floated on 20  $\mu$ l of 2 % uranyl acetate for 1 min before viewing under a TEM (Zeiss 912 OMEGA Energy Filter Transmission Electron Microscope, University of Cape Town).

5 [00207] For samples isolated from sucrose gradients, the sucrose first had to be removed by dialysis before immune-trapping on the copper grids. If not removed, sucrose crystals inhibit definitive viewing of samples under the TEM as it forms crystals on the grids, disrupting the structure of bound carbon and material. The sucrose fractions were placed in 10 000 MW dialysis cassettes and dialyzed in sterile 10 PBS containing 0.4 M NaCl for 4 hr before exchanging the buffer and leaving it overnight at 4 °C with stirring. Since volume increases with dialysis, the protein samples required concentrating. The samples were vacuum freeze dried for 3 hours and resuspended in 2 ml of sterile PBS, ready for further analysis.

### **Sucrose gradient purification of RLPs**

15 [00208] Plant protein extracts were initially filtered through miracloth to remove solid plant matter. Sucrose gradients from 10 to 60 % sucrose were set up in 40ml tubes each by creating six layers of 5 ml of sucrose dissolved in sterile PBS (pH 7.4). Clarified protein samples in 5 to 10 ml volumes were then loaded on top of each gradient column.

20 [00209] Ultracentrifugation at 150 000 g (SWTi28 swinging bucket rotor, Beckman Coulter) was carried out at 4 °C for 1 h 30 min. At the end of the centrifugation, 2 ml fractions were collected from the bottom of each column by tube puncture. Dot blots were then performed to determine fractions with proteins of interest. For each fraction, 1  $\mu$ l of sample was loaded in a grid on a nitrocellulose 25 membrane, which was then blocked with BSA blocking buffer. Western blot analysis was then performed as usual. Proteins were probed with mouse anti-VP6 antibody (1:5000) for VP6 or chicken anti-VP2 and VP4 serum (1:5000) for the other two proteins.

### **Total Soluble Protein Assay**

30 [00210] Total soluble protein (TSP) was determined by Bradford assays. This was carried out to compare the levels of accumulated proteins in cytoplasm co-expressed VP2/6. The protein IgG (1.43mg/ml stock) was used in a dilution series as a

standard. 5 µl of standard and samples were each added to a clean dry microtitre plate. Total Soluble Protein Reagents A and B were added as per manufacturer's instructions (Bio-Rad Dc Protein Assay). All experiments were done in triplicate. Absorbance readings were recorded at 750 nm using a microplate reader (Bio-tek PowerWave XS).

5

## Results

### Expression of VP6 in plant leaf cell compartments

[00211] VP6 was expressed and targeted to all cellular compartments (Figure 6; (the line marks VP6, at ~42 kDa)), with and without the silencing suppressor. In the cytoplasm, protein was expressed from day one of the time trial, with increasing protein accumulation in the cytoplasm during the week-long trial (Figure 6a). In the ER, protein accumulation was clearly seen at day 3 only (Figure 6b). The protein ran at a higher band size (approximately 11 kDa more) than the other proteins. This may be a result of the 6 histidine-tag added to the C-terminal end of the protein, as well as the cleavage site (refer to pProEx vector sequence)

[00212] Protein accumulation in the chloroplasts occurred between days 1 and 3 (Figure 6 "chloroplasts"). The silencing suppressor had an effect on the proteins as no proteins were detected in its absence. There was no protein expression at days 5 and 7. The apoplast, just as in the ER, had the best protein accumulation between days 3 and 5 of the time trial (Figure 6 "apoplast") and none at all at day 1 and day 7. The silencing suppressor had a positive effect especially on day 3, resulting in higher protein detection levels compared to when it was left out. It can also be seen that two bands are visible at the ~40 kDa mark probably as a result of cleavage of the signaling tag on the VP6 protein.

20  
25 [00213] The ER, chloroplasts and apoplast all exhibited the highest protein expression on day 3, with the most protein accumulating in the presence of the silencing suppressor. The cytoplasm was the best in terms of protein accumulation as it exhibited high and increasing protein expression throughout the time-trial.

### Expression of histidine-tagged rotavirus proteins in the cytoplasm

30 [00214] The four rotavirus VPs were cloned into an additional vector, pTRAc-HT. This vector includes a 6-histidine tag to proteins targeted to the cytoplasm and makes detection easy by use of an anti-histidine tag antibody if the antibodies for the

proteins of interest are unavailable. In our case, only VP6 has a commercially available antibody and hence we tried this procedure for early detection of all proteins while awaiting serum. The cytoplasm also worked well for VP6 expression and motivated us to try the other proteins.

5 [00215] Western blot results of day 3 extracts from a 7 day time trial showed successful expression of VP2, VP4 and VP6 (Figure 7a). In order to obtain expression of VP7 in plants, various techniques were tried. However, plants infiltrated with VP7 exhibited yellowing leaves from day 1 and proceeded to wilt during the course of the time trial (Figure 7b). No expression of protein was detected under these conditions,  
10 even after day 1 of infiltration when the plant still looked reasonably good.

#### **Expression of VP2 and VP4 in plants**

15 [00216] VP2 and VP4 were infiltrated in *N. benthamiana* plant leaves and targeted to the ER, chloroplast, cytoplasm and apoplast. We were unable to express VP2 targeted to the apoplast vector as we could not get any positive clones in *E. coli*. However, the protein was successfully expressed and targeted to all other 3 compartments (Figure 8a). Chicken anti-VP2 and anti-VP4 serum (1:2000) was used in western blot analysis of extracts. VP2 and VP4 bands were visible just below the 20 100 kDa mark (protein band indicated by arrow) as seen in Figure 8a and 8b respectively. Expression appeared to be best in the cytoplasm and ER for VP2 while for VP4, in the cytoplasm and apoplast. The silencing suppressor did not have a significant effect on the expression of the proteins. It only slightly increased expression in the VP2 ER construct and not so much in the rest, as can be seen from the western blot. VP4 constructs were all expressed in the presence of the silencing suppressor.

25 **Co-expression of VP2/6 and VP2/6/4 in the cytoplasm**

[00217] The cytoplasm appeared to be best for rotavirus capsid protein expression and exhibited the highest extraction efficiencies. All further expression work was therefore done with proteins targeted to the cytoplasm.

30 [00218] VP2 and VP6 have been shown to form RLPs with protective immunogenic responses in mice and therefore co-expression of VP2/6 and VP2/6/4 in the cytoplasm was investigated. Day 3 extracts of co-expressed VP2/6/4 were detected by western blot with anti-VP2 and VP4 serum (1/5000) and mouse anti-VP6

5 antibody (1:5000) (Figure 9). VP6 expression was very high as previously determined, but expression of VP2 and VP4 was very low as can be seen from the very faint band at the 100 kDa mark. This may have been attributed by the co-expression which resulted in more host cell resources being utilized in the over-expression of VP6, leaving less for VP2 and/or VP4. It was also not easy to determine if the detected band was both VP2 and VP4 or either of the 2 proteins. The very visible band running above 130 kDa may be dimerized VP6 proteins. The band visible at the 55 kDa mark is most likely the abundant plant enzyme Rubisco.

10 [00219] Transmission electron microscopic analysis on the cytoplasm-expressed VP6 as well as on co-expressed VP2/6 and VP2/6/4, were carried out to check for protein particles and assembled RLPs (Figure 10). This also determined if VP2 and/or VP4 were indeed co-expressed successfully. VP6 when expressed alone assembled to form sheaths of protein as indicated by the arrow in Figure 10b. On addition of VP2, the particles assembled to form RLPs (Figure 10c). VP2 acts as 15 scaffolding protein that enables other proteins to assemble and ultimately form a complete rotavirus structure. VP6 as such bound to VP2 but it was still not easy to determine VP4 structures in co-expressed VP2/6/4. The electron micrograph in Figure 10d may be purely assembled VP2/6 particles. It has been shown however that VP4 binds to VP6 during protein assembly, and this occurs before VP7 binds. It is likely 20 that these VP4 structures are not stable and may fall off the RLP structure during preparation procedures for electronic microscopy.

#### **Sucrose gradient purification of VP2/6 and VP2/6/4**

25 [00220] VP2/6 and VP2/6/4 were purified on a sucrose gradient ranging from 10 to 60 % sucrose (Figure 11a). 2 ml fractions were collected from the bottom of each of the tubes and probed with mouse anti-VP6 antibody and/or chicken anti-VP2 and VP4 serum to determine which fractions contained the proteins. For VP2/6, proteins were found in fractions 16 and 17 as these were positive for VP6 protein on the blot (Figure 11b). VP2/6/4 blot analysis with chicken anti-VP2 and VP4 serum showed positive results throughout all the fractions. This may have been as a result of 30 the high levels of background protein detection by the chicken serum. However, intensity of dots was highest in fractions 17 and 18 as seen in Figure 11c, possibly due to higher concentration of the proteins of interest in these fractions.

[00221] Putting these results together (Figure 11b and 11c), the rotavirus proteins were in fractions ranging from 16 to 20.

#### **Western Blot and Coomassie stains of fractions**

[00222] A western blot and SDS-PAGE of co-expressed VP2/6 were done to verify presence of VP2 and VP6 proteins in fractions 13 to 20. Western blot analysis for VP6 protein probed with mouse anti-VP6 antibody was positive in fractions 16 right through to 20 (Figure 12a, bottom arrow and Figure 12c). VP2 protein probed with chicken anti-VP2 serum was detected in fractions 17 to 20 (Figure 12a, top arrow). VP2 has been shown to express less than VP6 in past co-expression studies and this was also shown here Figure 12a in which VP2 protein bands have a lower intensity in comparison to VP6.

[00223] Fractions 16 and 17 of co-expressed VP2/6 previously determined to contain VP6 protein by dot blots (Figure 11b) were electrophoresed on an SDS-PAGE gel. A protein of known concentration, SF9 insect cell expressed VP6 (0.91 µg/µl) was included so as to determine the concentration of VP2/6 crude proteins (Figure 11b and c). This was done by density scanning of the crude protein band (lane labeled crude) using a Syngene Gel Documentation System and consequently allowed us to determine the amount of VP2/6 per kilogram of leaf matter. Protein yield was found to be approximately 1.54 g/kg fresh weight (FW). 1.1 mg of purified RLPs were obtained from 1 gram of plant material (1.1g/kg).

#### **Total Soluble Protein Assay of VP2/6**

[00224] Total soluble protein (TSP) was determined on co-expressed VP2/6 fractions to determine the relative amounts of VP2/6 protein (Figure 13). Protein concentrations were calculated as 0.538 mg/ml and 1.012 mg/ml for fractions 17 and 18 respectively with the use of an IgG standard (Figure 13a). The protein bands corresponding to VP2/6 in these fractions were calculated by density scanning on a Syngene Gel Documentation System and found to be approximately 0.108 mg/ml and 0.202 mg/ml, respectively.

[00225] Thus, the TSP for VP2/6 in fractions 17 and 18 were both approximately 20 % TSP Most of the RLPs in the sucrose column were found to be between 15 and 25 % sucrose, corresponding with fractions 15 to approximately 20, where the graph is noted to suddenly peak and then subside. The differences in

density of the various materials in the extract allowed me to separate and thereby purify the proteins of interest. SDS-PAGE gels stained with Coomassie blue showed only one prominent band indicating that the proteins are relatively pure (Figure 12b).

#### **TEM of purified VP2/6**

5 [00226] Purified VP2/6 fractions were pooled together and dialyzed in high salt PBS to remove sucrose before viewing on a transmission electron microscope. The TEM was done to determine purity and check if RLPs remained intact after the purification procedure. As can be seen in Figure 15, most of the background material which mainly consisted of the host cell's products (Figure 10b, c and d) was removed, leaving behind RLPs. Most of the RLPs remained intact but some appeared to have lost shape probably as a result of deformation due to the conditions on the EM grid.

10

#### **Preliminary analysis of expression of rotavirus structural proteins in *N. benthamiana* leaves**

15 [00227] This preliminary analysis focused on the expression of rotavirus structural proteins VP2 (SEQ ID NO:1), VP4 (SEQ ID NO:2), VP6 (SEQ ID NO:3) and VP7 (SEQ ID NO:4) in *N. benthamiana* leaves as an example host expression system. The strain of rotavirus selected here was a G9 P[6] strain which circulates predominantly in South Africa and other sub-Saharan regions. A RLP vaccine targeting this strain would help in alleviating the burden of disease in sub-Saharan 20 Africa.

25 [00228] A transient expression system mediated by Agrobacterium was used in this analysis. Transient expression, as opposed to transgenic expression, permits rapid expression of proteins in a relatively short time, without integration of the rotavirus capsid protein genes in the host's chromosome. Most proteins were expressed and accumulated to detectable amounts by day 3 of recombinant Agrobacterium infiltration in *N. benthamiana* leaves. As shown below successful expression of several rotavirus structural proteins was observed including VP2, VP4 and VP6 in plant leaf cell compartments as detailed in table 2:

**Table 2: Expression of rotavirus VP proteins in various leaf cell compartments**

Capid Protein	Leaf Cell Compartment			
	Apoplast	Chloroplast	Cytoplasm	ER
VP2	0	1	1	1
VP4	1	0	1	1
VP6	1	1	1	1
VP7	0	0	0	0

0 = no expression  
1 = expressed

[00229] Expression of the glycoprotein VP7 was not observed possibly due to its toxic effects on plant cells. It is worth noting that for this preliminary study, a VP7 containing its native signal peptide had been used. Infiltrating at day 3 during co-expression trials was also tried. This was attempted to see if the protein was expressed and soon after assembled with VP2 and VP6 to form RLPs. The toxic nature of recombinant VP7 as observed in this study has been previously described (Williams et al., 1995; McCorquodale, 1987; Arias et al., 1986).

[00230] Past VP7 expression studies in transgenic potatoes has been reported (Li et al., 2006; Choi et al., 2005; Wu et al., 2003). Choi et. al. (2005) used a simian rotavirus VP7, and Li et. al. and Wu et. al. (Li et al., 2006; Wu et al., 2003) used human group A G1 VP7. The result described herein used human rotavirus G9 VP7.

[00231] VP2 was expressed and targeted to all compartments except the apoplast as we were unable to clone the appropriate cDNA, and time constraints only allowed us a few attempts before proceeding with the other constructs. Expression levels of VP2 were noted to be significantly low in all the compartments. In a past study quoted by Saldana et al. 2006, it was concluded that a VP2 having its sequence optimized for expression in the plant was impossible to express, despite mRNA being detected in the plant cells. They however managed to express it in tomato plant cells using synthetic DNA. The reason for the difficulty in VP2 expression is most likely as result of improper mRNA translation or that the mRNA contains some sequence motifs that destabilize the plant cells (Kawaguchi and Bailey-Serres, 2002). Evidence of low expression levels of VP2 in comparison to VP6 have been seen in both plant

and insect-cell expression studies by Mena et al. (2006), Saldana et al. (2006), Vieira et al. (2005), and Labb   et al. (1991).

[00232] The outer capsid protein, VP4, which forms spikes on the surface of the virion structure, was expressed and targeted for accumulation in the cytoplasm, ER and apoplast. No protein accumulation was detected in chloroplasts. As observed for VP2, protein expression levels for VP4 were lower than seen for VP6 on western blots. The protein has a trypsin cleavage site which results in two proteins, VP5 and VP8. It may be possible that local trypsin in *N. benthamiana* leaves cleaves some of the proteins as they are produced resulting in lower concentration levels of accumulated, intact VP4 in the designated compartments. The protein has been shown to be a major neutralizing antigen but there have been a few attempts to clone the whole protein for vaccine development (Khodabandehloo et al., 2009; Mahajan et al., 1995; Nishikawa et al., 1989). There have been, however, several studies in the insect-cell and yeast expression system showing expression of either the VP5 or VP8 subunits of VP4 (Andr  s et al., 2006; Favacho et al., 2006; Kovacs-Nolan et al., 2001). To date, the present study represents the first study showing expression of the whole protein in a plant expression system.

[00233] VP6 was expressed in all compartments with over-expression being observed in the cytoplasm with protein accumulation observed from day 1 to day 7 in this compartment. This is contrary to some literature which suggests that protease activity and gene silencing reduce or hinder the accumulation of foreign protein in the cytoplasm (Fischer et al., 2004). In addition, given the right pH conditions, VP6 is known to self-assemble into tubular or helical particles, much like the particles seen in our study (Figure 9b) (Estes et al., 1987). VP6 makes up about 50 % of the viral core and therefore is a major antigen in the development of a rotavirus vaccine. The result attained above enabled us to further investigate the co-expression of VP2, VP6 and VP4 in the cytoplasm.

[00234] When co-expressed in the cytoplasm, VP2 and VP6 assembled to form RLPs. Very high protein yields from transient expression system of between 1.27 – 1.54 g/kg FW were observed. When purified on a sucrose column, the amount of VPs retained was 1.1 g/kg FW. This yield is comparable to that obtained for the production of an antibody, IgG, using a transient expression system in *N. benthamiana*, with a yield of up to 1.5 g/kg FW (V  zina et al., 2009). Saldana et al. (2006) were until now

the only group known to have successfully co-expressed rotavirus VP2 and VP6 in transgenic tomato plants and to levels of approximately 1 % total soluble protein. The assembly of VP2/6 in the insect-cell expression system has been well documented (Vieira et al., 2005;; O'Brien et al., 2000). These VP2/6 RLPs have also been shown 5 to provide protective immunity against rotavirus infection (Zhou et al., 2011, Saldana et al., 2006). Thus the VP2/6 RLPs we produced in the plant expression system are suitable candidates for the development a subunit rotavirus vaccine.

[00235] VP2/6/4 were also co-expressed and detected. The first peak visible (Figure 14, fraction 16) in the total protein absorbance reading of the co-expressed 10 proteins might be assembled VP2/6/4, but on examination of this fraction under a TEM, no RLPs were detected. The protein peak observed may result from an accumulation of VP4 monomers or its respective VP5 and VP8 subunits. The second peak (fraction 18), when examined under a TEM showed RLP structures very much similar to the ones seen in the VP2/6 sample. However, Crawford et al have 15 previously reported that VP4 could not be seen under TEM, and that VP2/6/4 and VP2/6/4/7 particles had similar structure and diameter under TEM (Crawford 1994). We made the same observation for VP2/6/7 RLPs, VP 2/6/4/7 RLPs and VP2/6 RLPs, which all look similar under regular TEM.

## Example 2

### Constructs

#### A-2X35S/CPMV-HT/ RVA(WA) VP2(opt)/ NOS (Construct number 1710)

[00236] An optimized sequence encoding VP2 from Rotavirus A WA strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. 25 A fragment containing the VP2 coding sequence was amplified using primers IF-WA\_VP2(opt).s1+3c (Figure 17A, SEQ ID NO: 21) and IF-WA\_VP2(opt).s1-4r (Figure 17B, SEQ ID NO: 22), using optimized VP2 gene sequence (Figure 19, SEQ ID NO: 45) as template. For sequence optimization, VP2 protein sequence (Genbank accession number CAA33074) was backtranslated and optimized for human codon 30 usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17C) was digested

with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1710 (Figure 23, SEQ ID NO: 27). The amino acid sequence of VP2 from Rotavirus A strain WA is presented in Figure 20 (SEQ ID NO: 25). A representation of plasmid 1710 is presented in Figure 21.

B-2X35S/CPMV-HT/RVA(WA) VP2(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1711)

[00237] An optimized sequence encoding VP2 from Rotavirus A WA strain was cloned into 2X35S/CPMV-HT/NOS comprising the BeYDV(m)+replicase amplification system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP2 coding sequence was amplified using primers IF-WA\_VP2(opt).s1+3c (Figure 17A, SEQ ID NO: 21) and IF-WA\_VP2(opt).s1-4r (Figure 17B, SEQ ID NO: 22), using optimized VP2 gene sequence (SEQ ID NO: 45) as template. For sequence optimization, VP2 protein sequence (Genbank accession number CAA33074) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette into the BeYDV(m) amplification system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 193 (Figure 22A) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 193 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette into the BeYDV(m) amplification system. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 22B (SEQ ID NO: 26). The resulting construct was given number 1711 (Figure 23, SEQ ID NO: 27).

The amino acid sequence of VP2 from Rotavirus A strain WA is presented in Figure 20 (SEQ ID NO: 25). A representation of plasmid 1711 is presented in Figure 24.

C-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS (Construct number 1713)

[00238] An optimized sequence encoding VP6 from Rotavirus A WA strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP6 coding sequence was amplified using primers IF-WA\_VP6(opt).s1+3c (Figure 25a, SEQ ID NO: 28) and IF-WA\_VP6(opt).s1-4r (Figure 25b, SEQ ID NO: 29), using optimized VP6 gene sequence (SEQ ID NO: 46) as template. For sequence optimization, VP6 protein sequence (Genbank accession number AAA47311) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17c) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1713 (Figure 25c, SEQ ID NO: 30). The amino acid sequence of VP6 from Rotavirus A strain WA is presented in Figure 26 (SEQ ID NO: 31). A representation of plasmid 1713 is presented in Figure 27.

D-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1714)

[00239] An optimized sequence encoding VP6 from Rotavirus A WA strain was cloned into 2X35S/CPMV-HT/NOS comprising the BeYDV(m)+replicase amplification system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP6 coding sequence was amplified using primers IF-WA\_VP6(opt).s1+3c (Figure 25a, SEQ ID NO: 28) and IF-WA\_VP6(opt).s1-4r (Figure 25b, SEQ ID NO: 29), using

optimized VP6 gene sequence (SEQ ID NO: 46) as template. For sequence optimization, VP6 protein sequence (Genbank accession number AAA47311) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette into the BeYDV(m) amplification system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 193 (Figure 22A) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 193 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette into the BeYDV(m) amplification system. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 22B (SEQ ID NO: 26). The resulting construct was given number 1714 (Figure 28, SEQ ID NO: 32). The amino acid sequence of VP6 from Rotavirus A strain WA is presented in Figure 26 (SEQ ID NO: 31). A representation of plasmid 1714 is presented in Figure 29.

#### C-2X35S/CPMV-HT/RVA(Rtx) VP4(opt)/NOS (Construct number 1730)

[00240] An optimized sequence encoding VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S/CPMV-HT/NOS in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP4 coding sequence was amplified using primers IF-Rtx\_VP4(opt).s1+3c (Figure 30A, SEQ ID NO: 33) and IF-Rtx\_VP4(opt).s1-4r (Figure 30B, SEQ ID NO: 34), using optimized VP4 gene sequence (Figure 31B, (SEQ ID NO: 47) as template. For sequence optimization, VP4 protein sequence (Genbank accession number AEX30660) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 18, SEQ ID NO: 23) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin

gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in (Figure 18, SEQ ID NO: 23). The resulting construct was given number 1730 (Figure 31C, SEQ ID NO: 50). The amino acid sequence of VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] is presented in Figure 32 (SEQ ID NO: 36). A representation of plasmid 1730 is presented in Figure 33A.

E-2X35S/CPMV-HT/RVA(Rtx) VP4(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1731)

[00241] An optimized sequence encoding VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S/CPMV-HT/NOS comprising the BeYDV(m)+replicase amplification system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP4 coding sequence was amplified using primers IF-Rtx\_VP4(opt).s1+3c (Figure 30A, SEQ ID NO: 33) and IF-Rtx\_VP4(opt).s1-4r (Figure 30B, SEQ ID NO: 34), using optimized VP4 gene sequence (SEQ ID NO: 47) as template. For sequence optimization, VP4 protein sequence (Genbank accession number AEX30660) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette into the BeYDV(m) amplification system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 193 (Figure 22A) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 193 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette into the BeYDV(m) amplification system. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 22B (SEQ ID NO: 26). The resulting construct was given number 1731 (Figure 31, SEQ ID NO: 35). The amino acid sequence of VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] is presented in Figure 32 (SEQ ID NO: 36). A representation of plasmid 1731 is presented in Figure 33B.

F-2X35S/CPMV-HT/RVA(Rtx) VP7(opt)/NOS (Construct number 1733)

[00242] An optimized sequence encoding VP7 with is native signal peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A 5 fragment containing the VP7 coding sequence was amplified using primers IF-Rtx\_VP7(opt).s1+3c (Figure 34A, SEQ ID NO: 37) and IF-Rtx\_VP7(opt).s1-4r (Figure 34B, SEQ ID NO: 38), using optimized VP7 gene sequence (SEQ ID NO: 54) as template. For sequence optimization, VP7 protein sequence (Genbank accession number AEX30682) was backtranslated and optimized for human codon usage, GC content and mRNA 10 structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17C) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression 15 cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1733 (Figure 34C, SEQ ID NO: 24). The amino acid sequence of VP7 with is native signal 20 peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is presented in Figure 35 (SEQ ID NO: 39). A representation of plasmid 1733 is presented in Figure 36.

D-2X35S/CPMV-HT/TrSp-RVA(Rtx) VP7(opt)/NOS (Construct number 1734)

[00243] An optimized sequence encoding VP7 with a truncated version of the native 25 signal peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP7 coding sequence was amplified using primers IF-TrSP+Rtx\_VP7(opt).s1+3c (Figure 44A, SEQ ID NO: 55) and IF-Rtx\_VP7(opt).s1-4r (Figure 44B, SEQ ID NO: 56), using optimized VP7 gene sequence (corresponding to nt 30 88-981 from Figure 44C, SEQ ID NO: 57) as template. For sequence optimization, VP7 protein sequence

(Genbank accession number AEX30682) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17C) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1734 (Figure 44D, SEQ ID NO: 58). The amino acid sequence of VP7 with truncated signal peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is presented in Figure 44E (SEQ ID NO: 59). A representation of plasmid 1734 is presented in Figure 44F.

G-2X35S/CPMV-HT/PDISP/RVA(WA) VP7(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1735)

[00244] A sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S-CPMV-HT-PDISP-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP7 coding sequence without his wild type signal peptide was amplified using primers IF-Rtx\_VP7(opt).s2+4c (Figure 37A, SEQ ID NO: 40) and IF-Rtx\_VP7(opt).s1-4r (Figure 34B, SEQ ID NO: 38), using optimized VP7 gene sequence (SEQ ID NO: 54). For sequence optimization, VP7 protein sequence (Genbank accession number AEX30682) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in-frame with alfalfa PDI signal peptide in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 1192 (Figure 38) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1192 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in frame with an alfalfa PDI signal peptide in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-

expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 39 (SEQ ID NO: 41). The resulting construct was given number 1735 (Figure 40, SEQ ID NO: 42). The amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is presented in Figure 41 (SEQ ID NO: 43). A representation of plasmid 1735 is presented in Figure 42.

Table 3. Description of synthesized genes for the production of RLPs.

SEQ ID No	Antigen	Strain of origin	Sequence type*	Figure in disclosure
45	VP2	WA	Optimized	19B
46	VP6	WA	Optimized	25D
47	VP4	Rotarix	Optimized	31B
50	VP4	SA11	Wild-type	43A
51	VP4	SA11	Optimized	43B
54	VP7	Rotarix	Optimized	34E
53	VP7	SA11	Wild-type	43D
52	VP7	SA11	Optimized	43C

\* Optimized sequences were modified to favor the use of preferred human codons and increase GC content

Table 4. Description of assembled and tested construct for the production of RLPs.

Expression system	Amplification system	Signal peptide <sup>†</sup>	Antigen (strain) <sup>*,‡</sup>	Gene SEQ ID used for PCR	Construct number
CPMV HT	-	-	RVA(WA) VP2 [optimized]	SEQ ID NO: 45	1710
CPMV HT	BeYDV(m)+rep	-	RVA(WA) VP2 [optimized]	SEQ ID NO: 45	1711
CPMV HT	-	-	RVA(WA) VP6 [optimized]	SEQ ID NO: 46	1713
CPMV HT	BeYDV(m)+rep	-	RVA(WA) VP6 [optimized]	SEQ ID NO: 46	1714
CPMV HT	-	-	RVA(Rtx) VP4 [optimized]	SEQ ID NO: 47	1730
CPMV HT	BeYDV(m)+rep	-	RVA(Rtx) VP4 [optimized]	SEQ ID NO: 47	1731

CPMV HT	-	WtSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1733
CPMV HT	-	TrSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1734
CPMV HT	-	SpPDI	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1735
CPMV HT	BeYDV(m)+rep	WtSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1736
CPMV HT	BeYDV(m)+rep	TrSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1737
CPMV HT	BeYDV(m)+rep	SpPDI	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1738
CPMV HT	-	-	RVA(SA11) VP4	SEQ ID NO: 50	1760
CPMV HT	BeYDV(m)+rep	-	RVA(SA11) VP4	SEQ ID NO: 50	1761
CPMV HT	-	-	RVA(SA11) VP4 [optimized]	SEQ ID NO: 51	1770
CPMV HT	BeYDV(m)+rep	-	RVA(SA11) VP4 [optimized]	SEQ ID NO: 51	1771
CPMV HT	-	WtSp	RVA(SA11) VP7	SEQ ID NO: 53	1763
CPMV HT	-	TrSp	RVA(SA11) VP7	SEQ ID NO: 53	1764
CPMV HT	-	SpPDI	RVA(SA11) VP7	SEQ ID NO: 53	1765
CPMV HT	BeYDV(m)+rep	WtSp	RVA(SA11) VP7	SEQ ID NO: 53	1766
CPMV HT	BeYDV(m)+rep	TrSp	RVA(SA11) VP7	SEQ ID NO: 53	1767
CPMV HT	BeYDV(m)+rep	SpPDI	RVA(SA11) VP7	SEQ ID NO: 53	1768
CPMV HT	-	WtSp	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1773
CPMV HT	-	TrSp	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1774
CPMV HT	-	SpPDI	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1775
CPMV HT	BeYDV(m)+rep	WtSp	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1776
CPMV HT	BeYDV(m)+rep	TrSp	RVA(SA11) VP7[optimized]	SEQ ID NO: 52	1777
CPMV HT	BeYDV(m)+rep	SpPDI	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1778

† WtSp: Wild type signal peptide, SpPDI: Signal peptide of plant origin, cloned form alfalfa protein disulfide isomerase gene, TrSp: truncated wild type signal peptide, TrSp start at 2nd Met in WtSp (M30).

\* [optimized] means that the sequence has been optimized based on codon usage, GC content and RNA structure.

### Example 3

#### Assembly of gene constructs and Agrobacterium transformation

5 [00245] All plasmids, including plasmids 1710, 1713, 1730 and 1734, were used to transform *Agrobacterium tumefaciens* (AGL1; ATCC, Manassas, VA 20108, USA) by electroporation (Mattanovich et al., 1989, Nucleic Acid Res. 17:6747) alternatively, heat shock using CaCl<sub>2</sub>-prepared competent cells (XU et al., 2008, Plant Methods 4) may be used. The integrity of the plasmids in the *A. tumefaciens* strains created was confirmed by restriction mapping. The *A. tumefaciens* strain transformed with a given binary plasmid is named AGL1/"plasmid number". For example, the *A. tumefaciens* strain transformed with construct number 1710 is termed "AGL1/1710".

10

#### Preparation of plant biomass, inoculum, agroinfiltration, and harvesting

15 [00246] *Nicotiana benthamiana* plants were grown from seeds in flats filled with a commercial peat moss substrate. The plants were allowed to grow in the greenhouse under a 16/8 photoperiod and a temperature regime of 25°C day/20°C night. Three weeks after seeding, individual plantlets were picked out, transplanted in pots and left to grow in the greenhouse for three additional weeks under the same environmental conditions.

20 [00247] Agrobacteria transfected with each construct were grown in a LB medium from vegetal origin and supplemented with 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) and 50 µg/ml kanamycin pH5.6 until they reached an OD<sub>600</sub> between 0.6 and 2.5. Agrobacterium suspensions were mixed to reach appropriate ratio for each construct and brought to 2.5X OD<sub>600</sub> with infiltration medium (10 mM MgCl<sub>2</sub> and 10 mM MES pH 5.6). *A. tumefaciens* suspensions were stored overnight at 4°C. On the day of infiltration, culture batches were diluted with infiltration medium in 2.5 suspension volumes and allowed to warm before use. Whole plants of *N. benthamiana* were placed upside down in the bacterial suspension in an air-tight stainless steel tank under a vacuum of 20-40 Torr for 2-min. Following infiltration, plants were returned to the greenhouse for a 3-12 day incubation period until harvest. Harvested biomass was kept frozen (-80°C) until use for purification of particles.

25

30

### Extraction and purification of rotavirus-like particles

[00248] Proteins were extracted from frozen biomass by mechanical extraction in a blender with 3 volumes of extraction buffer (TNC: 10 mM Tris pH 7.4, 140 mM NaCl, 10 mM CaCl<sub>2</sub>). The slurry was filtered through a large pore nylon filter to remove large debris and centrifuged 5000 g for 5 min at 4°C. The supernatant was collected and centrifuged again at 5000 g for 30 min (4°C) to remove additional debris. The supernatant was depth-filtered and ultra-filtered and the filtrate was centrifuged at 75 000 g for 20 min (4°C) to concentrate the rotavirus-like particles. The pellet containing the particles was resuspended in 1/12 volume of TNC and the insoluble were remove with a centrifugation at 5000 g for 5 minutes. The supernatant was filtered on Miracloth before being loaded on iodixanol density gradients.

[00249] Density gradient centrifugation was performed as follows. Tubes containing step gradients from 5% to 45% of iodixanol were prepared and overlaid with the filtered extracts containing the rotavirus-like particles. The gradients were centrifuged at 120 000 g for 4 hours (4°C). After centrifugation, 1 ml fractions were collected from the bottom to the top and analysed by Coomassie-stained SDS-PAGE and Western blot. To remove iodixanol for the fractions selected for further analysis, selected fractions were centrifuged 75 000 g for 20 min (4°C) and the pelleted particles were resuspended in fresh TNC buffer.

### SDS-PAGE and immunoblotting

[00250] Protein concentrations were determined by the BCA protein assay (Pierce Biochemicals, Rockport IL). Proteins were separated by SDS-PAGE under reducing or non-reducing conditions and stained with Coomassie Blue. Stained gels were scanned and densitometry analysis performed using ImageJ Software (NIH).

[00251] For immunoblotting, electrophoresed proteins were electrotransferred onto polyvinylene difluoride (PVDF) membranes (Roche Diagnostics Corporation, Indianapolis, IN). Prior to immunoblotting, the membranes were blocked with 5% skim milk and 0.1% Tween-20 in Tris-buffered saline (TBS-T) for 16-18h at 4°C.

[00252] Immunoblotting was performed by incubation with a suitable antibody (Table 5), in 2 µg/ml in 2% skim milk in TBS-Tween 20 0.1%. Secondary antibodies used for chemiluminescence detection were as indicated in Table 5, diluted as indicated in 2% skim milk in TBS-Tween 20 0.1%. Immunoreactive complexes were

detected by chemiluminescence using luminol as the substrate (Roche Diagnostics Corporation). Horseradish peroxidase–enzyme conjugation of human IgG antibody was carried out by using the EZ-Link Plus® Activated Peroxidase conjugation kit (Pierce, Rockford, IL).

5 Table 5: Electrophoresis conditions, antibodies, and dilutions for immunoblotting of rotavirus antigens.

Rotavirus antigen	Electrophoresis condition	Primary antibody	Dilution	Secondary antibody	Dilution
VP2	Reducing	Rabbit polyclonal anti-VP2 (kindly provided by professor Koki Taniguchi)	1 µg/ml	Goat anti-rabbit (JIR 111-035-144)	1:10 000
VP6	Reducing	ABIN 308233	1:20000	Goat anti-rabbit (JIR 111-035-144)	1:10 000
VP7	Non-Reducing	Rabbit polyclonal anti-VP7 (kindly provided by professor Koki Taniguchi)	1:2000	Goat anti-rabbit (JIR 111-035-144)	1:10 000

#### Anti-VP4 Enzyme-linked immuno sorbent assay (ELISA)

U-bottom 96-well microtiter plates were coated with a mouse monoclonal anti-VP4

10 (kindly provided by Professor Koki Taniguchi) diluted 1:100000 in 10 mM PBS pH7.4 (phosphate-buffered saline), 150 mM NaCl for 16-18 hours at 4°C. After incubation, plates were washed three times with 10 mM PBS pH7.4, 1 M NaCl containing 0.1% Tween-20 and blocked with 5% BSA in 10 mM PBS pH7.4, 150 mM NaCl containing 0.1% Tween-20 for 1 hour at 37°C. After the blocking step, plates were washed three times with 10 mM PBS pH7.4, 1 M NaCl containing 0.1% Tween-20. Samples were added and plates were incubated for 1 hour at 37°C. Plate were then washed 3 times with 10 mM PBS pH7.4, 1 M NaCl, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub> containing 0.1% Tween-20. For all remaining wash steps, washing buffer remain the same and during the third wash, plates were incubated 10 minutes at room temperature before completely removing washing solution. Rabbit polyclonal

15

20

antibody raised against Rotavirus (kindly provided by Professor Koki Taniguchi) diluted 1:10000 with 3% BSA in 10 mM PBS pH7.4, 150 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub> containing 0.1% Tween-20 was added and plates were incubated for 1 hour at 37°C. Plates were then washed 3 times and horseradish peroxidase-conjugated goat anti-rabbit antibody (111-035-144, Jackson Immunoresearch, West Grove, PA) diluted 1:5000 with 3% BSA in 10 mM PBS pH7.4, 150 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub> containing 0.1% Tween-20 was added and plates were incubated for 1 hour at 37°C. Plates were washed 3 times. After final washes, plates were incubated with SureBlue TMB peroxidase substrate (KPL, Gaithersburg, MD) for 20 minutes at room temperature. Reaction was stopped by the addition of 1N HCl and A450 values were measured using a Multiskan Ascent plate reader (Thermo Scientific, Waltham, MA).

10 Production of rotavirus-like particles comprising VP2 and VP6.

15 [00253] Rotavirus-like particles comprising VP2 and VP6 were produced by transient expression in *Nicotiana benthamiana*. Plants were agro-infiltrated with an inoculum of Agrobacteria containing a mixture of AGL1/1710 and AGL1/1713 in a 1:1 proportion and incubated for 7 days before harvest. Rotavirus-like particles were purified from the biomass using the methodology described in the materials and methods section. After centrifugation of the clarified extracts on iodixanol density 20 gradient, the first ten fractions from the bottom of the tube were analyzed by Coomassie-stained SDS-PAGE. As shown in Figure 45A, the rotavirus antigens (VP2 and VP6) were mainly found in fractions 2 and 3 of the density gradient where the concentration of iodixanol is approximately 35%, a concentration where rotavirus-like particles are expected to be found. Very little contamination by plant proteins was 25 found in these fractions. Western blot analysis of the fractions with anti-rotavirus hyperimmune rabbit serum and polyclonal rabbit anti-VP2 antibodies confirmed the identity of VP2 and VP6 in the density gradient fractions (Figures 45B and 45C). Fractions 2 and 3 were pooled and iodixanol was removed by high speed centrifugation and resuspension, and the purified particles were sent for cryo-electron 30 microscopy analysis (NanoImaging Services Inc., La Jolla, CA) to confirm the assembly of the VP2 and VP6 into particles resembling the rotavirus particle. As shown in Figure 49 (left panel) the cryoEM images of VP2/VP6 particles confirmed the correct assembly of the antigens into rotavirus-like particles.

Production of rotavirus-like particles comprising VP2, VP6 and VP7.

[00254] Rotavirus-like particles comprising VP2, VP6 and VP7 were produced by transient expression in *Nicotiana benthamiana*. Plants were agro-infiltrated with an inoculum of Agrobacteria containing a mixture of AGL1/1710, AGL1/1713, AGL1/1734 in a 1:1:1 proportion and incubated for 7 days before harvest. Rotavirus-like particles were purified from the biomass using the methodology described in the materials and methods section. After centrifugation of the clarified extracts on iodixanol density gradient, the first ten fractions from the bottom of the tube were analyzed by Coomassie-stained SDS-PAGE. As shown in Figure 46A, the rotavirus antigens (VP2, VP6 and VP7) were mainly found in fractions 2 and 3 of the density gradient where the concentration of iodixanol is approximately 35%, a concentration where rotavirus-like particles are expected to be found. Very little contamination by plant proteins was found in these fractions. Western blot analysis of the fractions with anti-rotavirus hyperimmune rabbit serum and polyclonal rabbit anti-VP7 antibodies confirmed the identity of VP6 and VP7 in the density gradient fractions (Figures 46B and 46C).

Production of rotavirus-like particles comprising VP2, VP4, VP6 and VP7.

[00255] Rotavirus-like particles comprising VP2, VP4, VP6 and VP7 were produced by transient expression in *Nicotiana benthamiana*. Plants were agro-infiltrated with an inoculum of Agrobacteria containing a mixture of AGL1/1710, AGL1/1730, AGL1/1713, AGL1/1734 in a 1:1:1:1 proportion and incubated for 7 days before harvest. Rotavirus-like particles were purified from the biomass using the methodology described in the materials and methods section. After centrifugation of the clarified extracts on iodixanol density gradient, the first ten fractions from the bottom of the tube were analyzed by Coomassie-stained SDS-PAGE. As shown in figure 47A, 3 of the 4 rotavirus antigens (VP2, VP6 and VP7) were visible and mainly found in fractions 3 of the density gradient where the concentration of iodixanol is approximately 35%, a concentration where rotavirus-like particles are expected to be found. Very little contamination by plant proteins was found in these fractions. The absence of detectable level of VP4 in the Coomassie-stained gel was expected since VP4 cannot be observed when the same analysis is performed on purified human rotavirus virion. Western blot analysis of the fractions with anti-rotavirus hyperimmune rabbit serum and polyclonal rabbit anti-VP7 antibodies confirmed the

identity of VP6 and VP7 in the density gradient fractions (Figures 47B and 47C). Iodixanol was removed from fraction 3 by high speed centrifugation and resuspension and the purified particles were analyzed by ELISA to confirm the presence of VP4. The results presented in Figure 48 clearly show that the ELISA specifically recognizes VP4 as the negative control particles comprising VP2/VP6 and VP7 only resulted in background signal level. In contrast, the analysis of 3 different lots of purified particles comprising VP2, VP4, VP6 and VP7 antigens showed strong and uniform signals when assayed under the same conditions. Purified VP2/VP4/VP6/VP7 RLPs were sent for cryo-electron microscopy analysis (NanoImaging Services Inc., La Jolla, CA) to confirm the assembly of the four antigens into particles resembling the rotavirus particle. As shown in Figure 49 (right panel) the cryoEM images of VP2/VP4/VP6/VP7 particles confirmed the correct assembly of the antigens into rotavirus-like particles.

15 [00256] Table 6 lists sequences provided in various embodiments of the invention.

Table 6: Sequence description for sequence identifiers.

SEQ ID NO	Description	Page/Figure
1	Amino acid sequence of optimized G9P6_VP2	Figure 16A
2	Amino acid sequence of optimized G9P6_VP4	Figure 16B
3	Amino acid sequence of optimized G9P6_VP6	Figure 16C
4	Amino acid of optimized G9P6_VP7	Figure 16D
5	Primer VP2F	Table 1
6	Primer VP2R	Table 1
7	Primer VP4F	Table 1
8	Primer VP4R	Table 1
9	Primer VP6F	Table 1
10	Primer VP6R	Table 1
11	Primer VP7F	Table 1
12	Primer VP7R	Table 1
13	Nucleotide sequence of G9P6_VP2	Figure 16A
14	Nucleotide sequence of optimized G9P6_VP2	Figure 16A
15	Nucleotide sequence of G9P6_VP4	Figure 16B
16	Nucleotide sequence of G9P6_VP4	Figure 16B
17	Nucleotide sequence of G9P6_VP6	Figure 16C
18	Nucleotide sequence of optimized G9P6_VP6	Figure 16C
19	Nucleotide sequence of G9P6_VP7	Figure 16D
20	Nucleotide sequence of G9P6_VP7	Figure 16D

21	Primer IF-WA_VP2(opt).s1+3c	Figure 17A
22	Primer IF-WA_VP2(opt).s1-4r	Figure 17B
23	Construct 1191 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette	Figure 18
24	Expression cassette number 1733 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.	Figure 34C
25	Amino acid sequence of VP2 from Rotavirus A WA strain	Figure 20
26	Construct 193 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS into BeYDV(m)+Replicase amplification system with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette	Figure 22B
27	Expression cassette number 1710 from 2X35S promoter to NOS terminator. VP2(opt) from Rotavirus A WA strain is underlined.	Figure 23
28	Primer IF-WA_VP6(opt).s1+3c	Figure 25a
29	Primer IF-WA_VP6(opt).s1-4r	Figure 25b
30	Expression cassette number 1713 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.	Figure 25c
31	Amino acid sequence of VP6 from Rotavirus A WA strain	Figure 26
32	Expression cassette number 1714 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.	Figure 28
33	Primer IF-Rtx_VP4(opt).s1+3c	Figure 30A
34	Primer IF-Rtx_VP4(opt).s1-4r	Figure 30B
35	Expression cassette number 1731 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.	Figure 31A
36	Amino acid sequence of VP4 from rotavirus A Rotarix strain	Figure 32
37	Primer IF-Rtx_VP7(opt).s1+3c	Figure 34A
38	Primer IF-Rtx_VP7(opt).s1-4r	Figure 34B
39	Amino acid sequence of VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Fig 35
40	Primer IF-Rtx_VP7(opt).s2+4c	Figure 37A
41	Construct 1192 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/PDISP/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette	Figure 39
42	Expression cassette number 1735 from 2X35S promoter to NOS terminator. PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.	Figure 40A
43	Amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	41

44	Expression cassette number 1730 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.	Figure 31C
45	Nucleotide sequence encoding VP2(opt) from Rotavirus A WA strain	Figure 19
46	Nucleotide sequence encoding VP6(opt) from Rotavirus A WA strain	Figure 25d
47	Optimized coding sequence of Rotavirus A VP4 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]	Figure 31B
48	Nucleotide sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Figure 34D
49	Nucleotide sequence encoding PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Figure 40B
50	Coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43A
51	Optimized coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43B
52	Optimized coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43C
53	Coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43D
54	Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]	Figure 34E
55	Primer IF-TrSP+Rtx VP7(opt).s1+3c	Figure 44A
56	Primer IF-Rtx VP7(opt).s1-4r	Figure 44B
57	Nucleotide sequence of Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]	Figure 44C
58	Expression cassette number 1734 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.	Figure 44D
59	Amino acid sequence of TrSp-VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Figure 44E

## References

Yang Y M, Li X, Yang H, et al. Immunogenicity and virus-like particle formation of rotavirus capsid produced in transgenic plants. *Sci China Life Sci*, 2011, 54: 82-89

Angel, J., Franco, M.A. and Greenberg, H.B. (2007). Rotavirus vaccines: recent developments and future considerations. *Nature reviews: Microbiology* 5, 529-539

Araujo, I.T., Ferreira, M.S.R. and Failho, A.M. (2001). Rotavirus genotypes [4]G9, P[6]G9, and P[8]G9 in hospitalized children with acute gastroenteritis in Rio de Janeiro, Brazil. *J Clin Microbiol* 39 1999–2001.

5 Arias, C.F., Ballado, T. and Plebafiski, M. (1986). Synthesis of the outer-capsid glycoprotein of the simian rotavirus SA11 in *Escherichia coli*. *Gene* 47, 211-219

Au K.S., Mattion N.M., Estes M.K., (1993). A Subviral Particle Binding Domain on the Rotavirus Nonstructural Glycoprotein NS28. *Virology* 194, 665-67

Balen B, Krsnik-Rasol M, (2007). N-glycosylation of recombinant therapeutic glycoproteins in plant systems. *Food Technology and Biotechnology* 45 1-10.

10 Bardor, M., Faveeuw, C., Fitchette, A.C., Gilbert,D., Galas, L., Trottein, F., Faye, L. and Lerouge P. (2003). Immunoreactivity in mammals of two typical plant glycoepitopes, core alpha (1,3)-fucose and core xylose. *Glycobiology* 13 427-434

Berois, M., Sapin, C., Erk, I., Poncet, D. and Cohen, J. (2003). Rotavirus Nonstructural Protein NSP5 Interacts with Major Core Protein VP2. *Journal of virology* 77, 1757

15 Bertolotti-Ciarlet, A., Ciarlet, M., Crawford, S.E., Conner, M.E. and Estes, M.K. (2003). Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. *Vaccine* 21, 3885-3900

20 Chen, J.Z., Settembre, E.C., Aoki, A.T., Zhang, X., Bellamy, A.R., Dormitzer, P.R., Harrison, S.C. and Grigorieff, N. (2009). Molecular interactions in rotavirus assembly and uncoating seen by high-resolution cryo-EM. *PNAS* 106, 10644-10648

25 Crawford, S.E., Estes, M.K., Ciarlet, M., Barone, C., O'Neal, C.M., Cohen, J. and Conner, M.E. (1999). Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. *Journal of Virology* 73, 4813- 4822

Crawford, S.E., Labbe, M., Cohen, J., Burroughs, M.H., Zhou, Y.J. and Estes, M.K. (1994). Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. *Journal of virology* 68, 5945-5952

30 Denisova, E.R., Dowling, W., LaMonica, R., Shaw, R., Scarlata, S., Ruggeri, F. and Mackow, E.R. (1999). Rotavirus Capsid Protein VP5\* Permeabilizes Membranes. *Journal of Virology* 73 3147-3153

Dennehy, P.H. (2007). Rotavirus vaccines - An update. *Vaccine* 25, 3137-3141

Estes M.K (1996). Rotavirus and their replication. *Fields Virology* 2, 1625-1655

Fabbretti, E., Afrikanova, I., Vascotto, F. and Burrone, O.R. (1999). Two nonstructural rotavirus proteins, NSP2 and NSP5, form viroplasm-like structures in vivo. *J Gen Virol* 80 333-9.

Favacho, A.R., Kurtenbach, E., Sardi, S.I. and Gouvea, V.S. (2006). Cloning, expression, and purification of recombinant bovine rotavirus hemagglutinin, VP8\*, in *Escherichia coli*. *Protein Expression and Purification* 46, 196-203

Gentsch, J.R., Laird, A.R., Bielfelt, B., Griffin, D.D., Bányai, K., Ramachandran, M., Jain, V., Cunliffe, N.A., Nakagomi, O., Kirkwood, C.D., Fischer, T.K., Parashar, U.D., Bresee, J.S., Jiang, B. and Glass, R.I. (2005). Serotype Diversity and Reassortment between Human and Animal Rotavirus Strains: Implications for Rotavirus Vaccine Programs *J Infect Dis.* 192 , S146-59

Glass, R.I., Parashar, U.D., Bresee, J.S., Turcios, R., Fischer, T.K., Widdowson, MA., Jiang, B. and Gentsch, J.R. (2006). Rotavirus vaccines: current prospects and future challenges. *Lancet* 368, 323-32

González, A.M., Nguyen, T.V., Azevedo, M.S. P., Jeong, K., Agarib, F., Iosef, C., Chang, K., Lovgren-Bengtsson, K., Morein, B. and Saif, L.J. (2004). Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. *Clinical & Experimental Immunology* 135 361-372

González, R.A., Espinosa, R., Romero, P., López, S. and Arias C.F. (2000). Relative localization of viroplasmic and endoplasmic reticulum-resident rotavirus proteins in infected cells. *Archives of Virology* 145, 1963-1973

Greenberg, H.B. and Estes, M.K. (2009). Rotaviruses: From Pathogenesis to Vaccination. *Gastroenterology* 136, 1939-1951

Hoshino, Y., Jones, R.W. and Kapikian, A.Z. (1998). Serotypic characterization of outer capsid spike protein VP4 of vervet monkey rotavirus SA11 strain. *Archives of Virology* 143, 1233-1244

Istrate, C., Hinkula, J., Charpilienne, A., Poncet, D., Cohen, J., Svensson, L. and Johansen, K. (2008). Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. *Vaccine* 26, 4594-4601

5 Khodabandehloo, M., Shamsi, S.M., Shahrabadi, Keyvani, H. and Bambai, B. (2009). Cloning and Expression of Simian Rotavirus Spike Protein (VP4) in Insect Cells by Baculovirus Expression System. *Iranian Biomedical Journal* 13 9-18

10 Kim, Y., Nielsen, P.R., Hodgins, D., Chang, K.O. and Saif, L.J. (2002). Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines. *Vaccine* 20, 1248-1258

Kovacs-Nolan J., Erika Sasaki, Dongwan Yoo, Yoshinori Mine, Cloning and Expression of Human Rotavirus Spike Protein, VP8\*, in Escherichia coli. *Biochemical and Biophysical Research Communications*, 282, 1183-1188

15 Lawton, J.A., Estes, M.K. and Venkataram, P.B.V. (2000). Mechanism of genome transcription in segmented dsRNA viruses. *Advances in Virus Research* 55, 185-214

Lopez, T., Camacho M., Zayas M., Najera R., Sanchez R., Arias C. F. and Lopez S. (2005). Silencing the Morphogenesis of Rotavirus. *Journal of Virology* 79, 184-92

Lundgren, O. and Svensson, L. (2001). Pathogenesis of Rotavirus diarrhoea. *Microbes and Infection* 3 1145-1156

20 Madore, H.P., Estes, M.K., Zarley, C.D., Hu, B., Parsons, S., Digravio, D., Greiner, S., Smith, R., Jiang, B., Corsaro, B., Barniak, V., Crawford, S. and Conner, M.E. (1999). Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. *Vaccine* 17, 2461-2471

25 Marusic, C., Rizza, P., Lattanzi, L., Mancini, C., Spada, M., Belardelli, F., Benvenuto, E. and Capone, I. (2001). Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. *Journal of Virology* 75, 8434-8439.

30 Matsumura, T., Itchoda, N. and Tsunemitsu, H. (2002). Production of immunogenic VP6 protein of bovine group A rotavirus in transgenic potato plants. *Archives of Virology* 147, 1263-1270

Mena, J.A., Ramírez, O.T. and Palomares, L.A. (2006). Intracellular distribution of rotavirus structural proteins and virus-like particles expressed in the insect cellbaculovirus system. *Journal of Biotechnology* 122, 443-452

5 Meyer, J.C., Bergmann, C.C. and Bellamy, A.R. (1989). Interaction of rotavirus cores with the nonstructural glycoprotein NS28. *Virology* 171, 98-107

Molinari, P., Peralta, A. and Taboga, O. (2008). Production of rotavirus-like particles in *Spodoptera frugiperda* larvae. *Journal of Virological Methods* 147, 364-367

10 Nilsson, M., von Bonsdorff, C.H., Wecliewicz, K., Cohen, J. and Svensson, L. (1998). Assembly of viroplasm and virus-like particles of rotavirus by a Semliki Forest virus replicon. *Virology* 242, 255-265

Nishikawa, K., Fukuhara, N., Liprandi, F., Green, K., Kapikian, A., Chanock, R. and Gorziglia, M. (1989). VP4 protein of porcine rotavirus strain OSU expressed by a baculovirus recombinant induces neutralizing antibodies. *Virology* 173, 631-637

15 O'Brien, G.J., Bryant, C.J., Voogd, C., Greenberg, H.B., Gardner, R.C. and Bellamy, A.R. (2000). Rotavirus VP6 expressed by PVX vectors in *Nicotiana benthamiana* coats PVX rods and also assembles into virus-like particles. *Virology* 270, 444-453

Palombo, E.A. (1999). Genetic and antigenic diversity of human rotaviruses: potential impact on the success of candidate vaccines. *FEMS Microbiology Letters* 181, 1-8

20 Palomares, L.A. and Ramirez, O.T. (2009). Challenges for the production of virus-like particles in insect cells: The case of rotavirus-like particles. *BiochemicalEngineering Journal* 45(3), 158-167

Peralta, A., Molinari, P. and Taboga, O. (2009). Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes. *Virology Journal* 6, 192

25 Ramachandran, M., Kirkwood, C.D., Unicomb, L., Cunliffe, N.A., Ward, R.L., Bhan, M.K., Clark, H.F., Glass, R.I. and Gentsch, J.R. (2000). Molecular characterization of serotype G9 rotavirus strains from a global collection. *Virology* 278, 436-444

Ribes, J.M., Ortego, J., Ceriani, J., Montava, R., Enjuanes, L. and Buesa, J. (2011). Transmissible gastroenteritis virus (TGEV)-based vectors with engineered murine tropism express the rotavirus VP7 protein and immunize mice against rotavirus. *Virology* 410 107-118

Rodríguez-Limas, W.A., Tyo, K.E.J., Nielsen, J., Ramírez, O.T. and Palomares, L.A. (2011). Molecular and process design for rotavirus-like particle production in *Saccharomyces cerevisiae*. *Microb Cell Fact*. 10, 33

5 Saldana, S., Esquivel Guadarrama, F., Olivera Flores Tde, J., Arias, N., Lopez, S., Arias, C., Ruiz-Medrano, R., Mason, H., Mor, T., Richter, L., Arntzen, C.J. and Gomez Lim, M.A. (2006). Production of rotavirus-like particles in tomato (*Lycopersicon esculentum* L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies. *Viral Immunology* 19, 42-53

10 Sanchez-Padilla, E., Grais, R.F., Guerin, P.J., Steele, A.D., Burny, M.E. and Luquero, F.J. (2009). Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. *Lancet Infectious Diseases* 9, 567-576.

15 Steele, A.D., Ivanoff, B. and African Rotavirus Network (2003). Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. *Vaccine* 21, 361-367

Tian, P., Ball, J.M., Zeng, C.Q.Y. and Estes, M.K. (1996). The Rotavirus Nonstructural Glycoprotein NSP4 Possesses Membrane Destabilization Activity. *Journal of Virology* 70, 6973-6981

20 Thongprachum, A., Chaimongkol, N., Khamrin, P., Pantip, C., Mizuguchi, M., Ushijima, H. and Maneekarn, N. (2010). A novel multiplex RT-PCR for identification of VP6 subgroups of human and porcine rotaviruses, *Journal of Virological Methods*, 168, 191-196

25 Trabelsi, A., Peenze, I., Pager, C., Jiddi, M. and Steele, D. (2000). Distribution of Rotavirus VP7 Serotypes and VP4 Genotypes Circulating in Sousse, Tunisia, from 1995 to 1999: Emergence of Natural Human Reassortants. *Journal of Clinical Microbiology* 38, 3415-3419

Varani, G. and Allain, F.H-T. (2002). How a rotavirus hijacks the human protein synthesis machinery. *Nature Structural Biology* 9, 158 – 160.

30 Vende, P., Taraporewala, Z.F. and Patton, J.T. (2002). RNA-Binding Activity of the Rotavirus Phosphoprotein NSP5 Includes Affinity for Double-Stranded RNA. *Journal of Virology* 76, 5291-5299.

Vesikari, T., Karvonen, A., Korhonen, T., Espo, M., Lebacq, E., Forster, J., Zepp, F., Delem, A. and De Vos, B. (2004). Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. *Vaccine* 22, 2836-2842

5 Vézina, L.-P., Faye, L., Lerouge, P., D'Aoust, M.-A., Marquet-Blouin, E., Burel, C., Lavoie, P.-O., Bardor, M. and Gomord, V. (2009). Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. *Plant Biotechnology Journal* 7, 442-455.

10 Zhou, B., Zhang, Y., Wang, X., Dong, J., Wang, B., Han, C., Yu, J., Li, D. (2010). Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. *Vaccine* 28, 6021-6027

15 Zhou, H., Guo, L., Wang, M., Qu, J., Zhao, Z., Wang, J. and Hung, T. (2011). Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. *Virology Journal* 8, 3

[00257] All citations are hereby incorporated by reference.

20 [00258] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.

## CLAIMS

1. A method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:

a) introducing a first nucleic acid comprising a first regulatory region active in the plant

5 operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and a third nucleic acid comprising a third regulatory region active in the  
10 plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein selected from one of VP2, VP6 and VP7, into the plant, portion of the plant or plant cell,

wherein the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated native signal peptide, or comprises a  
15 nucleotide sequence encoding a non-native signal peptide,

b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell, and

20 d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of calcium and purifying the RLPs in the presence of calcium.

2. The method of claim 1, wherein a fourth nucleic acid comprising a fourth regulatory region active in the plant and operatively linked to a fourth nucleotide sequence encoding a fourth rotavirus structural protein is introduced into the plant, portion of the plant or plant cell in step a), and is expressed when incubating the plant, portion of a plant or plant cell in step b), wherein the fourth rotavirus structural protein is VP4.

3. The method of claim 1, wherein the first, second, and third nucleic acid are introduced into the plant, portion of the plant or plant cell in a ratio of 1:1:1.
4. The method of claim 2, wherein the first, second, third and fourth nucleic acid are introduced into the plant, portion of the plant or plant cell in a ratio of 1:1:1:1.
5. 5. The method of claim 1 or 2, wherein the codon usage of the nucleotide sequence is adjusted to preferred human codon usage, increased GC content, or a combination thereof.
6. The method of claim 1, wherein the non-native signal peptide is a protein disulfide isomerase signal peptide.
- 10 7. The method of claim 1, wherein the first, second and third nucleotide sequence is operatively linked to a translation enhancer element.
8. The method of claim 7, wherein the translation enhancer element comprises a Cowpea Mosaic Virus (CPMV) regulatory region.
9. The method of claim 1, wherein the first, second or third nucleotide sequence or a 15 combination thereof is operatively linked to a Cowpea Mosaic Virus (CPMV) regulatory region.
10. The method of claim 2, wherein the first, second, third or fourth nucleotide sequence or a combination thereof is operatively linked to a Cowpea Mosaic Virus (CPMV) regulatory region.
- 20 11. An RLP produced by the method of any one of claims 1 to 10, wherein the RLP is of a size from 70-100.
12. A composition comprising an effective dose of the RLP of claim 11 for inducing an immune response in a subject, and a pharmaceutically acceptable carrier.
13. The method of claim 1 wherein the nucleotide sequence encoding VP2 comprises 25 from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 45, the nucleotide sequence encoding VP6 comprises

from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:46, and the nucleotide sequence encoding VP7 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 19, 20, 48, 49, 52, 53, 54 or 57.

5 14. The method of claim 2 wherein the nucleotide sequence encoding VP2 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 45, the nucleotide sequence encoding VP6 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:46, the nucleotide sequence encoding VP7 comprises  
10 from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 19, 20, 48, 49, 52, 53, 54 or 57, and the nucleotide sequence encoding VP4 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 15, 16, 47, 50, or 51.

15 15. A method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell comprising:

a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and  
20  
25 wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,  
b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the  
30 RLP, the RLP comprising VP2, VP6 and VP7,

- c) harvesting the plant, portion of the plant or plant cell, and
- d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of calcium and purifying the RLPs in the presence of calcium.

5 16. The method of claim 15, wherein the plant, portion of the plant or plant cell is provided with a fourth nucleic acid comprising a fourth regulatory region active in the plant and operatively linked to a fourth nucleotide sequence encoding a fourth rotavirus structural protein and the fourth rotavirus structural protein is expressed when incubating the plant, portion of the plant or plant cell in step b), wherein the fourth

10 10 rotavirus structural protein is VP4.

17. The method of claim 15, wherein the non-native signal peptide is a protein disulfide isomerase signal peptide.

18. An RLP produced by the method of claim 15 or 16, wherein the RLP is of a size from 70-100.

15 19. A composition comprising an effective dose of the RLP of claim 18 for inducing an immune response in a subject, and a pharmaceutically acceptable carrier.

20. A method of inducing immunity to a rotavirus infection in a subject, comprising administering the composition of claim 19.

21. A method of inducing immunity to a rotavirus infection in a subject, comprising

20 administering the composition of claim 12.

22. Use of the composition of claim 19 in the manufacture of a medicament for inducing immunity to a rotavirus infection in a subject.

23. Use of the composition of claim 12 in the manufacture of a medicament for inducing immunity to a rotavirus infection in a subject.

24. A method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:

a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural

5 protein selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus

10 structural protein selected from one of VP2, VP6 and VP7, into the plant, portion of a the plant or plant cell, wherein the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide, or

a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid

15 comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third

20 nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

25 b) incubating the plant, portion of a the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell.







Figure 1




**Figure 2**




**Figure 3**




**Figure 4**




**Figure 5**




**Figure 6**



**Figure 7**



**Figure 8**



**Figure 9**




Figure 10





Figure 11



**Figure 12**




Figure 13





Figure 14



**Figure 15**

**Figure 16A -1****Rotavirus VP2**Gene Name: **G9P6\_VP2**

Gene length: 2700 bp

Optimized for expression in:

*Nicotiana tabacum*

```

1      GGTACCGAATTGGACCGCGTTCGTTCCATGGCTTACCGTAAAAGGGGTGCTAGGCGTGAA
-----+-----+-----+-----+-----+-----+-----+
CCATGGCTTAAGCCTGCGCAAGCAAGGTACCGAATGGCATTTCcccACGATCCGCACTT
SEQ ID NO:1 G_R_V_R_S_M_A_Y_R_K_R_G_A_R_R_E_
-----+-----+-----+-----+-----+-----+-----+
GCTAACCTCAACAACGATAGGATGCAAGAGAAGATCGATGAGAAGCAGGATTCCAAC
61     -----+-----+-----+-----+-----+-----+-----+
CGATTGGAGTTGTTGCTATCCTACGTTCTTCTAGCTACTCTCGTCTAAGGTTG
A_N_L_N_N_N_D_R_M_Q_E_K_I_D_E_K_Q_D_S_N_
-----+-----+-----+-----+-----+-----+-----+
AAGATCCAGCTCTCCGATAAGGTGCTCTCCAAGAAAGAAGAGATCGTTACTGATTCCCAC
121    -----+-----+-----+-----+-----+-----+-----+
TTCTAGGTCGAGAGGCTATTCCACGAGAGGTTCTTCTCTAGCAATGACTAAGGTTG
K_I_Q_L_S_D_K_V_L_S_K_K_E_E_I_V_T_D_S_H_
-----+-----+-----+-----+-----+-----+-----+
GAAGAGGTGAAGGTGACAGATGAGCTTAAGAAGTCCACAAAGAAGAGTCCAAGCAGCTC
181    -----+-----+-----+-----+-----+-----+-----+
CTTCTCCACTTCCACTGTCTACTCGAATTCTCAGGTGTTCTCAGGTTCGTCAG
E_E_V_K_V_T_D_E_L_K_K_S_T_K_E_E_S_K_Q_L_
-----+-----+-----+-----+-----+-----+-----+
CTTGAGGTGCTCAAGACAAAAGAGGAACACCAAGAAAGAGATCCAGTACGAGATCCTCAA
241    -----+-----+-----+-----+-----+-----+-----+
GAACCTCCACGAGTTCTGTTCTCCTGTGGTCTTCTAGGTATGCTCTAGGAGGTT
L_E_V_L_K_T_K_E_E_H_Q_K_E_I_Q_Y_E_I_L_Q_

```

Figure 16A -2

301 AAGACTATCCAACTTCGAGCCAAAGAGACTATCCTCAGGAAGCTTGAGGATATCCAG  
 K\_T\_I\_P\_T\_F\_E\_P\_K\_E\_T\_I\_L\_R\_K\_L\_E\_D\_I\_Q\_

361 CCAGAGCTTGTAAAGAACAGACTAAGCTTCAAGGATCTCGAGCCAAAGCAGCTCCA  
 GGTCTCGAACGATTCTCGTCTGATTGAGAAGTCCTAGAACGCTCGGTTCGTCGAGGGT  
 P\_E\_L\_A\_K\_K\_Q\_T\_K\_L\_F\_R\_I\_F\_E\_P\_K\_Q\_L\_P\_

421 ATCTACCGTGCTAACGGTAAAGGGAACTTAGAACAGGTGGTACTGGAAGCTCAAGAAC  
 TAGATGGCACGATTGCCACTTCCCTGAATCCTGTCCACCATGACCTCGAGTTCTC  
 I\_Y\_R\_A\_N\_G\_E\_R\_E\_L\_R\_N\_R\_W\_Y\_W\_K\_L\_K\_K\_

481 GATACTCTCCAGACGGTGAATACGATGTGAGAGAGTACTCCTCAACCTCTACGATCAG  
 CTATGAGAGGGTCTGCCACTAATGCTACACTCTCATGAAGGAGTTGGAGATGCTAGTC  
 D\_T\_L\_P\_D\_G\_D\_Y\_D\_V\_R\_E\_Y\_F\_L\_N\_L\_Y\_D\_Q\_

541 GTGCTCACTGAGATGCCAGATTACCTCCTCAAGGATATGGCTGTGGAGAACAGAAC  
 CACGAGTGACTCTACGGTCTAACGGAGTTCTATACCGACACCTCTGTTCTTG  
 V\_L\_T\_E\_M\_P\_D\_Y\_L\_L\_L\_K\_D\_M\_A\_V\_E\_N\_K\_N\_

601 TCCAGGGATGCTGAAAGGTGGATTCCGAGACTGCTTCCATCTGTGATGCTATCTC  
 AGGTCCCTACGACCTTCCACCACCTAACGGCTCTGACGAAGGTAGACACTACGATAGAAC  
 S\_R\_D\_A\_G\_K\_V\_V\_D\_S\_E\_T\_A\_S\_I\_C\_D\_A\_I\_F\_

661 CAGGATGAAGAGACTGAGGGTGTGAGGCCTTCATTGCTGAGATGAGGAGGGTT  
 GTCCTACTCTCTGACTCCCACGACACTCCGCAAAGTAACGACTCTACTCCGTCTCCAA  
 Q\_D\_E\_E\_T\_E\_G\_A\_V\_R\_R\_F\_I\_A\_E\_M\_R\_Q\_R\_V\_

721 CAGGCTGATAGGAACGTGGTAACCTACCCATCCATCCTCACCCAAATCGATTACGCTTC  
 GTCCGACTATCCTTGACCACTTGATGGTAGGTAGGAGGTGGTTAGCTAATGCGAAAG  
 Q\_A\_D\_R\_N\_V\_V\_N\_Y\_P\_S\_I\_L\_H\_P\_I\_D\_Y\_A\_F\_

781 AACGAGTACTTCCTCAGCACCAAGCTTGTGGAGGCCACTAACACGATATCATCTCAAC  
 TTGCTCATGAAGGAAGTCGTGGTCGAACACCTCGGTGAGTTGCTATAGTAGAAGTTG  
 N\_E\_Y\_F\_L\_Q\_H\_Q\_L\_V\_E\_P\_L\_N\_N\_D\_I\_I\_F\_N\_

**Figure 16A -3**

TACATCCCAGAGAGGATTAGGAACGACGTTAACATACCTCAACATGGATAGGAACCTC  
 841 -----+-----+-----+-----+-----+-----+  
 ATGTAGGGTCTCTCCTAACATCCTTGCTGCAATTGATGATGGAGTTGTACCTATCCTGGAG  
Y\_I\_P\_E\_R\_I\_R\_N\_D\_V\_N\_Y\_I\_L\_N\_M\_D\_R\_N\_L

CCATCCACTGCTCGTTACATCAGGCCAACCTCCTCCAGGATAGGCTAACCTCCACGAT  
 901 -----+-----+-----+-----+-----+-----+  
 GGTAGGTGACGAGCAATGTAGTCCGGTTGGAGGAGGTCTATCCGAGTTGGAGGTGCTA  
P\_S\_T\_A\_R\_Y\_I\_R\_P\_N\_L\_L\_Q\_D\_R\_L\_N\_L\_H\_D

AACTTCGAGTCCCTCTGGGATACAATCACTACTTCAAACACTATTCTCGCTCGTCCGTG  
 961 -----+-----+-----+-----+-----+-----+  
 TTGAAGCTCAGGGAGACCCTATGTTAGTGTAGAAGGGTGTAGTAAGAGCGAGCAAGGCAC  
N\_F\_E\_S\_L\_W\_D\_T\_I\_T\_T\_S\_N\_Y\_I\_L\_A\_R\_S\_V

GTGCCAGATCTCAAAGAACTCGTGTCCACTGAGGCTCAGATCCAGAAGATGTCCCAGGAT  
 1021 -----+-----+-----+-----+-----+-----+  
 CACGGTCTAGAGTTCTTGAGCACAGGTGACTCCGAGTCAGGTCTTCTACAGGGTCTA  
V\_P\_D\_L\_K\_E\_L\_V\_S\_T\_E\_A\_Q\_I\_Q\_K\_M\_S\_Q\_D

CTCCAGCTTGAGGCTCTCACTATCCAGTCCGAGACTCAGTTCTCACTGGTATCAACTCC  
 1081 -----+-----+-----+-----+-----+-----+  
 GAGGTCGAACTCCGAGAGTGATAGGTCAAGGCTCTGAGTCAGGAGTGACCATAGTTGAGG  
L\_Q\_L\_E\_A\_L\_T\_I\_Q\_S\_E\_T\_Q\_F\_L\_T\_G\_I\_N\_S

CAGGCTGCTAACGATTGCTCAAGACTCTCATTGCTGCTATGCTCTCCAGAGGACTATG  
 1141 -----+-----+-----+-----+-----+-----+  
 GTCCGACGATTGCTAACGAAGTTCTGAGAGTAACGACGATAAGGAGGGCTCCTGATAC  
Q\_A\_A\_N\_D\_C\_F\_K\_T\_L\_I\_A\_A\_M\_L\_S\_Q\_R\_T\_M

TCCCTCGATTCTGACTACTAACTATATGTCCTCATCTCCGAATGTGGCTCTGACT  
 1201 -----+-----+-----+-----+-----+-----+  
 AGGGAGCTAACGACTGATGATTGATATACAGGGAGTAGAGGCTTACACCGAGAACACTGA  
S\_L\_D\_F\_V\_T\_T\_N\_Y\_M\_S\_L\_I\_S\_G\_M\_W\_L\_L\_T

GTGGTGCCAAACGATATGTCATCCGTGAGTCCCTTGCGCTTGCCAGCTCGCTATCGTG  
 1261 -----+-----+-----+-----+-----+-----+  
 CACCAAGGTTGCTATACAAGTAGGCACTCAGGGAAACACCGAACGGTCGAGCGATAGCAC  
V\_V\_P\_N\_D\_M\_F\_I\_R\_E\_S\_L\_V\_A\_C\_Q\_L\_A\_I\_V

AACACTATCATCTACCCAGCTTCGGAATGCAAAGGATGCACTACCGTAACGGTGATCCA  
 1321 -----+-----+-----+-----+-----+-----+  
 TTGTGATAGTAGATGGGTCGAAAGCCTACGTTCTACGTGATGGCATGCCACTAGGT  
N\_T\_I\_I\_Y\_P\_A\_F\_G\_M\_Q\_R\_M\_H\_Y\_R\_N\_G\_D\_P

Figure 16A -4

1381 CAGACTCCATTCCAGATCGCAGAGCAGCAGATCCAGAACTTCCAGGTGGCAAACCTGGCTC  
 GTCTGAGGTAAGGTCTAGCGTCTCGTCTAGGTCTTGAAGGTCCACCGTTGACCGAG  
Q\_T\_P\_F\_Q\_I\_A\_E\_Q\_Q\_I\_Q\_N\_F\_Q\_V\_A\_N\_W\_L

1441 CACTCGTGAACAAACAAACAGGTCAGGCAGGCTGTGATCGATGGTGTGTTGAACCAGGTG  
 GTGAAGCACTTGTGTTGGTCAAGTCCGTCCGACACTAGCTACCAACACAACCTGGTCCAC  
H\_F\_V\_N\_N\_N\_Q\_F\_R\_Q\_A\_V\_I\_D\_G\_V\_L\_N\_Q\_V

1501 CTCAACGATAACATCCGTAACGGTCACGTGATCAACCAGCTCATGGAAGCTCTCATGCAA  
 GAGTTGCTATTGTAGGCATTGCCAGTGCACTAGTTGGTCGAGTACCTTCGAGAGTACGTT  
L\_N\_D\_N\_I\_R\_N\_G\_H\_V\_I\_N\_Q\_L\_M\_E\_A\_L\_M\_Q

1561 CTCTCCAGGCAGCAGTTCCAACTATGCCCTATCGATTACAAGCGTTCCATCCAGAGGGGA  
 GAGAGGTCCGTCAAGGGTTGATACGGATAGCTAATGTTGCAAGGTAGGTCTCCCT  
L\_S\_R\_Q\_Q\_F\_P\_T\_M\_P\_I\_D\_Y\_K\_R\_S\_I\_Q\_R\_G

1621 ATCCTCCTCCTTCCAACAGGCTTGGACAGCTCGTGGATCTCACTAGGCTCCTCGCTTAC  
 TAGGAGGAGGAAAGGTTGTCGAAACCTGTCGAGCACCTAGAGTGATCCGAGGAGCGAATG  
I\_L\_L\_L\_S\_N\_R\_L\_G\_Q\_L\_V\_D\_L\_T\_R\_L\_L\_A\_Y

1681 AACTACGAGACTCTCATGGCTTGCATCACTATGAACATGCAGCACGTTAGACTCTCACT  
 TTGATGCTCTGAGAGTACCGAACGTAGTGATACTTGTACGTCGTCAAGTCTGAGAGTGA  
N\_Y\_E\_T\_L\_M\_A\_C\_I\_T\_M\_N\_M\_Q\_H\_V\_Q\_T\_L\_T

1741 ACTGAGAAGCTCCAGCCTACTTCCGTGACTTCCCTCTGCATGCTCATCGGAAACGCTACT  
 TGACTCTCGAGGTCGAGTGAAGGCACTGAAGGGAGACGTACGAGTAGCCTTGCATGTA  
T\_E\_K\_L\_Q\_L\_T\_S\_V\_T\_S\_L\_C\_M\_L\_I\_G\_N\_A\_T

1801 GTGATCCCATTCCCCACAGACACTCTTCCACTACTACAACGTGAACGTGAACCTCCACTCC  
 CACTAGGGTAGGGGTGTCGTGAGAAGGTGATGATGTTGCACTTGCACCTGAAGGTGAGG  
V\_I\_P\_S\_P\_Q\_T\_L\_F\_H\_Y\_Y\_N\_V\_N\_V\_N\_F\_H\_S

1861 AACTACAACGAGAGGATCAACGATGCTGTGGCTATCATCACTGCTGCTAACAGGCTTAAC  
 TTGATGTTGCTCTCCTAGTTGCTACGGACACCGATAGTAGTGACGACGATTGTCCGAATTG  
N\_Y\_N\_E\_R\_I\_N\_D\_A\_V\_A\_I\_I\_T\_A\_A\_N\_R\_L\_N

**Figure 16A -5**

1921 CTCTACCAAAAGAAGATGAAGGCTATCGTTGAGGATTCCCTCAAGAGGCTCTACATCTTC  
 -----+-----+-----+-----+-----+-----+  
 GAGATGGTTTCTTCTACTTCCGATAGCAACTCCTAAAGGAGTCTCGAGATGTAGAAG  
L Y Q K K M K A I V E D F L K R L Y I F    
 -----+-----+-----+-----+-----+  
 1981 GATGTGTCCAGGGTGCCAGATGATCAGATGTACCGTCTAGGGATAGGCTTAGGCTCCTC  
 -----+-----+-----+-----+-----+  
 CTACACAGGTCCCACGGTCTACTAGTCTACATGGCAGAATCCCTATCCGAATCCGAGGAG  
D V S R V P D D Q M Y R L R D R L R L L    
 -----+-----+-----+-----+-----+  
 2041 CCAGTGGAGATCAGAAGGCTCGATATCTCAACCTCATCCTTATGAACATGGATCAGATC  
 -----+-----+-----+-----+-----+  
 GGTACACTCTAGTCTTCCGAGCTATAGAAGTTGGAGTAGGAATACTTGTACCTAGTCTAG  
P V E I R R L D I F N L I L M N M D Q I    
 -----+-----+-----+-----+-----+  
 2101 GAGAGGGCTCCGATAAGATCGCTCAGGGTGTATTATCGTTACCGTATGCACCTT  
 -----+-----+-----+-----+-----+-----+  
 CTCTCCCAGGGCTATTCTAGCGAGTCCCACAATAATAGCGAATGGCACTATACGTGGAA  
E R A S D K I A Q G V I I A Y R D M H L    
 -----+-----+-----+-----+-----+-----+  
 2161 GAGAGGGATGAGATGTACGGATACTGAAACATTGCTAGGAACCTTGAGGGATTCCAGCAG  
 -----+-----+-----+-----+-----+-----+  
 CTCTCCCTACTCTACATGCCTATGCACTTGTAACGATCCTGGAACTCCCTAAGGTCGTC  
E R D E M Y G Y V N I A R N L E G F Q Q    
 -----+-----+-----+-----+-----+-----+  
 2221 ATCAACCTTGAAGAGCTTATCGTTCCGGTATTACGCTCAGATCACTAACATGTCCTC  
 -----+-----+-----+-----+-----+-----+  
 TAGTTGGAACTCTCGAACAGCAAGGCCACTAATGCGAGTCTAGTGATTGTACGAGGAG  
I N L E E L M R S G D Y A Q I T N M L L    
 -----+-----+-----+-----+-----+-----+  
 2281 AACAAACCAGCCAGTGGCTTGTGGCTCTCCATTCACTGATTCCCTCCGTGATC  
 -----+-----+-----+-----+-----+-----+  
 TTGGTGGTCGGTCACCGAGAACACACAGAGAGGGTAAGTAGTGACTAAGGAGGCACTAG  
N N Q P V A L V G A L P F I T D S S V I    
 -----+-----+-----+-----+-----+-----+  
 2341 TCCCTCATTGCTAAGTTGGATGCTACTGTGTTCGCTCAGATCGTAAGCTCAGGAAAGTG  
 -----+-----+-----+-----+-----+-----+  
 AGGGAGTAACGATTCAACCTACGATGACACAAGCGAGTCTAGCACTTCGAGTCCTTCAC  
S L I A K L D A T V F A Q I V K L R K V    
 -----+-----+-----+-----+-----+-----+  
 2401 GATACTCTCAAGCCAATCCTCTACAAGATCAACTCCGATTCCAACGATTCTACCTCGTG  
 -----+-----+-----+-----+-----+-----+  
 CTATGAGAGTTGGTTAGGAGATGTTCTAGTTGAGGCTAAGGTTGCTAAAGATGGAGCAC  
D T L K P I L Y K I N S D S N D F Y L V

**Figure 16A -6**

2461 GCTAACTACGATTGGGTGCCAACTTCCACTACAAAGGTGTACAAGCAGGTGCCACAGCAG  
 CGATTGATGCTAACCCACGGTTGAAGGTGATGTTCCACATGTTCGTCCACGGTGTGTC  
A\_N\_Y\_D\_W\_V\_P\_T\_S\_T\_T\_K\_V\_Y\_K\_Q\_V\_P\_Q\_Q

2521 TTGATTCCGTAACCCATGCACATGCTCACTTCCAACCTCACTTCACTGTGTACTCC  
 AAGCTAAAGGCATTGAGGTACGTGTACGAGTGAAGGTTGGAGTGAAAGTGACACATGAGG  
F\_D\_F\_R\_N\_S\_M\_H\_M\_L\_T\_S\_N\_L\_T\_F\_T\_V\_Y\_S

2581 GATCTCCTCGCTTCTGTCGCTGATACTGTGGAGCCTATCAACGCTGTGGCTTCGAT  
 CTAGAGGAGCGAAAGCACAGGCAGTATGACACCTCGGATAGTTGCGACACCGAAAGCTA  
D\_L\_L\_A\_F\_V\_S\_A\_D\_T\_V\_E\_P\_I\_N\_A\_V\_A\_F\_D

2641 AACATGAGGATTATGAACCGAGCTTGATGACTCGAGGGATCCTCTAGAGAA  
 TTGTACTCCTAATACTTGCTCGAAACTACTGAGCTCCCTAGGAGATCTCTT  
N\_M\_R\_I\_M\_N\_E\_L\_\*\_\*\_ SEQ ID NO: 1

TTCGAGCTC SEQ ID NO: 13  
 -----+  
 AAGCTCGAG SEQ ID NO: 14

**Figure 16B -1****Rotavirus VP4**

Gene name: **G9P6\_VP4**

Gene length: 2388 bp

Optimized for expression in: **Nicotiana tabacum**

GGTACCGAATTGGACCGCGTTCGTTCCATGGCTTCCCTCATCTACCGTCAGTTGCTCACT  
 1 -----+-----+-----+-----+-----+-----+  
 CCATGGCTTAAGCCTGCGCAAGCAAGGTACCGAAGGGAGTAGATGGCAGTCAACGAGTGA  
 SEQ ID NO 2 G\_R\_V\_R\_S\_M\_A\_S\_L\_I\_Y\_R\_Q\_L\_L\_T\_

AACTCCTACACTGTGGAGCTTCCGATGAGATCAACACTATCGGTTCCGAGAAAGTCCCAG  
 61 -----+-----+-----+-----+-----+-----+  
 TTGAGGATGTGACACCTCGAAAGGCTACTCTAGTTGTGATAGCCAAGGCTTCAGGGTC  
 N\_S\_Y\_T\_V\_E\_L\_S\_D\_E\_I\_N\_T\_I\_G\_S\_E\_K\_S\_Q\_

AACGTGACTATCAACCCAGGACCATTGCTCAGACTAACTACGCTCCAGTGACTTGGTCA  
 121 -----+-----+-----+-----+-----+-----+  
 TTGCACTGATAGTTGGTCTGGTAAGCGAGTCTGATTGATGCGAGGTCACTGAACAGT  
 N\_V\_T\_I\_N\_P\_G\_P\_F\_A\_Q\_T\_N\_Y\_A\_P\_V\_T\_W\_S\_

CACGGTGAAGTGAACGATTCCACTACTATCGAGCCAGTGCTCGATGGACCATACCAGCCA  
 181 -----+-----+-----+-----+-----+-----+  
 GTGCCACTTCACTTGCTAAGGTGATGATAGCTCGGTACGAGCTACCTGGTATGGTCGGT  
 H\_G\_E\_V\_N\_D\_S\_T\_T\_I\_E\_P\_V\_L\_D\_G\_P\_Y\_Q\_P\_

ACTAACTTCAAGCCACCAAACGATTACTGGATTCTCCTCAACCCAACAACTAACAGCAGGTG  
 241 -----+-----+-----+-----+-----+  
 TGATTGAAGTTCGGTGGTTGCTAATGACCTAACAGGGAGTTGGGTTGATTGGTCGTCCAC  
 T\_N\_F\_K\_P\_P\_N\_D\_Y\_W\_I\_L\_L\_N\_P\_T\_N\_Q\_Q\_V\_

GTGCTTGAGGGAACAAACAGACTGATATCTGGTGGCACTCCTTCTGTGGAGCCAAAC  
 301 -----+-----+-----+-----+-----+  
 CACGAACCTCCCTGATTGTTCTGACTATAGACCCACCGTGAGGAAGAACACCTCGGTTG  
 V\_L\_E\_G\_T\_N\_K\_T\_D\_I\_W\_V\_A\_L\_L\_V\_E\_P\_N\_

G TGACTAACCAAGTCCAGGCAGTACACTCTTCGGAGAGACTAACAGATCACTGTGGAG  
 361 -----+-----+-----+-----+-----+  
 CACTGATTGGTCAGGTCCGTATGTGAGAGAGAGCCTCTGATTGCTAGTGACACCTC  
 V\_T\_N\_Q\_S\_R\_Q\_Y\_T\_L\_F\_G\_E\_T\_K\_Q\_I\_T\_V\_E\_

**Figure 16B -2**

AACAAACACTAACAAAGTGGAAAGTTCTCGAGATGTTAGGTCCAACGTGAACGCTGAGTTC  
 421 -----+-----+-----+-----+-----+-----+  
 TTGTTGTGATTGTTCACCTCAAGAAGCTCTACAAGTCCAGGTTGCACTTGCGACTCAAG  
 N\_N\_T\_N\_K\_W\_K\_F\_F\_E\_M\_F\_R\_S\_N\_V\_N\_A\_E\_F\_  
  
 CAGCACACAAGAGGACTCTCACTTCCGATACAAAGCTCGCTGGTTTATGAAGTTCTACAAC  
 481 -----+-----+-----+-----+-----+-----+  
 GTCGTGTTCTCCTGAGAGTGAAGGCTATGTTCGAGCGACCAAAATACTCAAGATGTTG  
 Q\_H\_K\_R\_T\_L\_T\_S\_D\_T\_K\_L\_A\_G\_F\_M\_K\_F\_Y\_N\_  
  
 TCTGTGTGGACTTCCACGGTGAAACTCCACACGCTACTACTGATTACTCCCTCCACTTCC  
 541 -----+-----+-----+-----+-----+-----+  
 AGACACACCTGAAAGGTGCCACTTGGAGGTGTGCGATGATGACTAATGAGGAGGTGAAGG  
 S\_V\_W\_T\_F\_H\_G\_E\_T\_P\_H\_A\_T\_T\_D\_Y\_S\_S\_T\_S\_  
  
 AACCTTCCGAGGTGGAGACTGTGATCCACGTGGAGTTCTACATCATCCAAAGGTCCAA  
 601 -----+-----+-----+-----+-----+-----+  
 TTGGAAAGGCTCCACCTCTGACACTAGGTGCACCTCAAGATGTAGTAGGGTCCAGGGTT  
 N\_L\_S\_E\_V\_E\_T\_V\_I\_H\_V\_E\_F\_Y\_I\_I\_P\_R\_S\_Q\_  
  
 GAGTCTAACGTGCTCCGAGTACATCAACACTGGACTCCCACCAATGCAAACACTAGGAAC  
 661 -----+-----+-----+-----+-----+-----+  
 CTCAGATTACGAGGCTCATGTAGTTGTGACCTGAGGGTGGTTACGTTTGATCCTTG  
 E\_S\_K\_C\_S\_E\_Y\_I\_N\_T\_G\_L\_P\_P\_M\_Q\_N\_T\_R\_N\_  
  
 ATCGTGCCAGTGGCTTGTCTCGTCCGTGACTTACCAAGGGCTCAGGTGAACGAG  
 721 -----+-----+-----+-----+-----+-----+  
 TAGCACGGTCACCGAACAGGAGAGCAAGGCACTGAATGGCTCCGAGTCCACCTGCTC  
 I\_V\_P\_V\_A\_L\_S\_S\_R\_S\_V\_T\_Y\_Q\_R\_A\_Q\_V\_N\_E\_  
  
 GATATCATCATCTCCAAGACTCCCTCTGGAAAGAGATGCAGTACAACAGGGATATTATC  
 781 -----+-----+-----+-----+-----+-----+  
 CTATAGTAGTAGAGGTTCTGAAGGGAGACCTTCTACGTCATGTTGTCCTATAATAG  
 D\_I\_I\_I\_S\_K\_T\_S\_L\_W\_K\_E\_M\_Q\_Y\_N\_R\_D\_I\_I\_  
  
 ATCAGGTTCAAGTTCAACAACTCCATCGTGAAGCTCGGAGGACTCGGATACAAGTGGAGT  
 841 -----+-----+-----+-----+-----+-----+  
 TAGTCCAAGTTCAAGTTGAGGTAGCATTGAGGCTACCTGAGCCTCCTGAGCCTATGTTCACCTCA  
 I\_R\_F\_K\_F\_N\_N\_S\_I\_V\_K\_L\_G\_G\_L\_G\_Y\_K\_W\_S\_  
  
 GAGATCTCCTCAAGGCTGCTAACTACCAGTACTCCTACCTCAGGGATGGTGAACAGGTG  
 901 -----+-----+-----+-----+-----+-----+  
 CTCTAGAGGAAGTTCCGACGATTGATGGTCATGAGGATGGAGTCCCTACCACTGTCCAC  
 E\_I\_S\_F\_K\_A\_A\_N\_Y\_Q\_Y\_S\_Y\_L\_R\_D\_G\_E\_Q\_V\_

**Figure 16B-3**

ACAGCTCACACTACTTGCTCCGTGAACGGTGTAAACAACCTCTCCTACAACGGTGGTTCC  
 961 -----+-----+-----+-----+-----+-----+  
 TGTCGAGTGTGATGAACGAGGCACTTGCCACAATTGTTGAAGAGGGATGTTGCCACCAAGG  
 T\_A\_H\_T\_T\_C\_S\_V\_N\_G\_V\_N\_N\_F\_S\_Y\_N\_G\_G\_S\_

CTCCCAACTGATTCTCCGTGTCCCGTTACGAGGTGATCAAAGAGAACTCCTACGTTAC  
 1021 -----+-----+-----+-----+-----+-----+  
 GAGGGTTGACTAAAGAGGCACAGGGCAATGCTCCACTAGTTCTCTTGAGGATGCAAATG  
 L\_P\_T\_D\_F\_S\_V\_S\_R\_Y\_E\_V\_I\_K\_E\_N\_S\_Y\_V\_Y

GTGGATTACTGGGATGATTCCCAGGCTTCAGGAACATGGTGTATGTTAGATCCCTCGCT  
 1081 -----+-----+-----+-----+-----+-----+  
 CACCTAATGACCCTACTAAAGGGTCCGAAAGTCCTGTACACATACAATCTAGGGAGCGA  
 V\_D\_Y\_W\_D\_D\_S\_Q\_A\_F\_R\_N\_M\_V\_Y\_V\_R\_S\_L\_A

GCTAACCTCAACTCCGTGAAGTGCTCCGGTGGAAACTACAACCTCCAGATCCCAGTGGGA  
 1141 -----+-----+-----+-----+-----+-----+  
 CGATTGGAGTTGAGGCACCTCACGAGGCCACCTTGATGTTGAAGGTCTAGGGTCACCCCT  
 A\_N\_L\_N\_S\_V\_K\_C\_S\_G\_G\_N\_Y\_N\_F\_Q\_I\_P\_V\_G

GCTTGGCCAGTGATGTCCTGGTGAGCTGTCTCTCCACTTCGCTGGTGTACACTCTCC  
 1201 -----+-----+-----+-----+-----+  
 CGAACCGGGTCACTACAGACCACCTCGACACAGAGAGGTGAAGCGACCACAATGTGAGAGG  
 A\_W\_P\_V\_M\_S\_G\_G\_A\_V\_S\_L\_H\_F\_A\_G\_V\_T\_L\_S

ACTCAGTTCACTGATTCGTGTCCTCAACTCCCTCAGGTTCACTGCTGGTGTACACTCTCC  
 1261 -----+-----+-----+-----+-----+  
 TGAGTCAGTGACTAAAGCACAGGGAGTTGAGGGAGTCCAAGTCCAAGAGGGAGTGACAC  
 T\_Q\_F\_T\_D\_F\_V\_S\_L\_N\_S\_L\_R\_F\_R\_F\_S\_L\_T\_V

GAAGAGCCACCATTCTCCATCCTCAGGACTAGGGTGTCCGACTTACGGACTCCCAGCT  
 1321 -----+-----+-----+-----+-----+-----+  
 CTTCTCGGGTGAAGAGGTAGGAGTCCTGATCCCACAGGCCTGAAATGCCTGAGGGTCGA  
 E\_E\_P\_P\_F\_S\_I\_L\_R\_T\_R\_V\_S\_G\_L\_Y\_G\_L\_P\_A

TTCAACCCAAACAACGGACACGAGTACTACGAGATCGCTGGACGTTCTCCCTATCTCC  
 1381 -----+-----+-----+-----+-----+-----+  
 AAGTTGGGTTGTTGCCCTGCTCATGATGCTCTAGCGACCTGCAAAGAGGGAAATAGAGG  
 F\_N\_P\_N\_N\_G\_H\_E\_Y\_Y\_E\_I\_A\_G\_R\_F\_S\_L\_I\_S

CTCGTGCACCAACGATGATTACAGACTCCAATTATGAACTCCGTGACTGTGAGGCAG  
 1441 -----+-----+-----+-----+-----+-----+  
 GAGCACGGTAGGTTGCTACTAATGGCTGAGGTTAAACTTGAGGCACGTGACACTCCGTC  
 L\_V\_P\_S\_N\_D\_D\_Y\_Q\_T\_P\_I\_M\_N\_S\_V\_T\_V\_R\_Q

Figure 16B-4

GATCTTGAGAGGCAGCTCGGAGATCTCAGGAAAGAGTCAACTCCCTCTCCAAAGAGATC  
 1501 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 CTAGAACTCTCCGTCGAGCCTCTAGAGTCCCTCTCAAGTTGAGGGAGAGGGTCTCTAG  
D\_L\_E\_R\_Q\_L\_G\_D\_L\_R\_E\_E\_F\_N\_S\_L\_S\_Q\_E\_I

GCTATGACTCAGCTCATCGATCTCGCTCTCCCTCCACTCGATATGTTCTCCATGTTCTCT  
 1561 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 CGATACTGAGTCGAGTAGCTAGAGCGAGAGGAGGGTAGCTATACAAGAGGTACAAGAGA  
A\_M\_T\_Q\_L\_I\_D\_L\_A\_L\_L\_P\_L\_D\_M\_F\_S\_M\_F\_S

GGTATCAAGTCCACTATCGATGTGGCTAAGTCTATGGTACTAAGGTGATGAAGAAAGTTC  
 1621 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 CCATAGTTCAAGGTGATAGCTACACCGATTCAAGATACCACTGATTCCACTACTTCTCAAG  
G\_I\_K\_S\_T\_I\_D\_V\_A\_K\_S\_M\_V\_T\_K\_V\_M\_K\_K\_F

AAGAAGTCCGGACTCGCTACTTCCATCTCCGAGCTTACTGGATCTCTCCAACGCTGCT  
 1681 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 TTCTTCAGGCCTGAGCGATGAAGGTAGAGGCTCGAATGACCTAGAGAGAGGTGCGACGA  
K\_K\_S\_G\_L\_A\_T\_S\_I\_S\_E\_L\_T\_G\_S\_L\_S\_N\_A\_A

TCTTCTGTGTCTAGGTCCCTCCATCAGGTCCAACATCTCCTCCATCTCAGTGTGGACT  
 1741 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 AGAAGACACAGATCCAGGAGGAGGTAGTCCAGGTTGTAGAGGAGGTAGAGTCACACCTGA  
S\_S\_V\_S\_R\_S\_S\_S\_I\_R\_S\_N\_I\_S\_S\_I\_S\_V\_W\_T

GATGTGTCCGAGCAGATCGCTGGATCTCCGATTCCGTGCGTAACATCTCCACTCAGACT  
 1801 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 CTACACAGGCTCGTCTAGCGACCTAGAAGGCTAAGGCACGCATTGTAGAGGTGAGTCTGA  
D\_V\_S\_E\_Q\_I\_A\_G\_S\_S\_D\_S\_V\_R\_N\_I\_S\_T\_Q\_T

TCCGCTATCTCCAAGAGGCTTAGGCTCAGAGAGATCACTCAGACTGAGGAATGAAC  
 1861 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 AGGCAGATAGAGGTTCTCGAATCCGAGTCTCTAGTGTAGAGTCTGACTCCCTACTTG  
S\_A\_I\_S\_K\_R\_L\_R\_E\_I\_T\_T\_Q\_T\_E\_G\_M\_N

TTCGATGATATCTCCGCTGCTGTGCTCAAGACTAAGATCGTAGGTCCACTCACATCTCC  
 1921 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 AAGCTACTATAGAGGCGACGACAGAGTTCTGATTCTAGCTATCCAGGTGAGTGTAGAGG  
F\_D\_D\_I\_S\_A\_A\_V\_L\_K\_T\_K\_I\_D\_R\_S\_T\_H\_I\_S

CCAGATACTCTCCAGATATCATCACTGAGTCCTCCGAGAAGTTCATCCAAAGCGTGCT  
 1981 ~~-----+-----+-----+-----+-----+-----+-----+~~  
 GGTCTATGAGAGGGTCTATAGTAGTGTACTCAGGAGGCTTCAAGTAGGGTTCGCACGA  
P\_D\_T\_L\_P\_D\_I\_I\_T\_E\_S\_S\_E\_K\_F\_I\_P\_K\_R\_A

**Figure 16B-5**

2041 TACCGTGTCTCAAGGATGATGAGGTGATGGAAGCTGATGTGGATGGAAAGTTCTCGCT  
 Y R V L K D D E V M E A D V D G K F F A

2101 TACAAAGTGGAACTTCTGAAGAGGTGCCATTGATGTGGATAAGTTCTGGATCTCGTG  
 Y K V G T F E E V P F D V D K F V D L V

2161 ACTGATTCCCCAGTGATCTCGCTATCGATTTCAAGACTCTCAAGAACCTAACGAT  
 T D S P V I S A I I D F K T L K N L N D

2221 AACTACGGAATCACTAGGTCCCAGGCTCTCGATCTCATCCGTTCCGATCCAAGGGTGCTC  
 TTGATGCCTTAGTGATCCAGGGTCCGAGAGCTAGAGTAGGCAAGGCTAGGTTCCCACGAG  
 N Y G I T R S Q A L D L I R S D P R V L

2281 AGGGATTCATCAACCAGAACACCAATCATCAAGAACAGGGATCGAGCAGCTCATTCTC  
 TCCCTAAAGTAGTTGGCTTGGTTAGTAGTTCTTGTCTAGCTCGTCGAGTAAGAG  
 R D F I N Q N N P I I K N R I E Q L I L

2341 CAGTGCCGTCTTGATGACTCGAGGGATCCTCTAGAGAACGAGCTC SEQ ID NO: 15  
 GTCACGGCAGAAACTACTGAGCTCCCTAGGAGATCTTAAGCTCGAG SEQ ID NO: 16  
 Q C R L \* \*   SEQ ID NO: 2

**Figure 16C -1**  
**Rotavirus VP6**

Gene name: **G9P6\_VP6**

Gene length: 1254 bp

Optimized for expression in: **Nicotiana tabacum**

GGTACCGAATTGGACGCGTTCGTCATGGATGTGCTCTACTCCCTCTCCAAGACTCTC  
1 -----+-----+-----+-----+-----+-----+  
CCATGGCTTAAGCCTGCGCAAGCAAGGTACCTACAGGAGATGAGGGAGAGGTTCTGAGAG  
G\_R\_V\_R\_S\_M\_D\_V\_L\_Y\_S\_L\_S\_K\_T\_L

AAGGATGCTAGGGATAAGATCGTGGAGGAACTCTACTCCAACGTTCCGATCTCATC  
61 -----+-----+-----+-----+-----+-----+  
TTCCTACGATCCCTATTCTAGCACCTCCCTTGAGAGATGAGGTTGCAAAGGCTAGAGTAG  
K\_D\_A\_R\_D\_K\_I\_V\_E\_G\_T\_L\_Y\_S\_N\_V\_S\_D\_L\_I

CAGCAGTTCAACCAGATGATCATCACTATGAACGGAAACGAGTTCCAGACTGGTGGAATC  
121 -----+-----+-----+-----+-----+-----+  
GTCGTCAAGTTGGTCTACTAGTAGTGTACTGCCTTGCTCAAGGTCTGACCACCTAG  
Q\_Q\_F\_N\_Q\_M\_I\_I\_T\_M\_N\_G\_N\_E\_F\_Q\_T\_G\_G\_I

GGAAACCTCCAATCAGGAACCTGGAACTTCGATTTGGACTCCTCGGAACTACTCTCCTC  
181 -----+-----+-----+-----+-----+-----+  
CCTTGAGGGTTAGTCCTTGACCTTGAAAGCTAAAGCCTGAGGAGCCTTGATGAGAGGAG  
G\_N\_L\_P\_I\_R\_N\_W\_N\_F\_D\_F\_G\_L\_L\_G\_T\_T\_L\_L

AACCTCGATGCTAACTACGTGGAGACTGCTAGGAACACTATCGATTACTCGTTGATTTC  
241 -----+-----+-----+-----+-----+-----+  
TTGGAGCTACGATTGATGCACCTCTGACGATCCTTGATAGCTAAATGAAGCAACTAAAG  
N\_L\_D\_A\_N\_Y\_V\_E\_T\_A\_R\_N\_T\_I\_D\_Y\_F\_V\_D\_F

GTTGATAATGTGTGCATGGATGAGATGGTCTGTGAGTCCCAGAGGAACGGAATTGCTCCA  
301 -----+-----+-----+-----+-----+-----+  
CACCTATTACACACGTACCTACTCTACCAAGCACTCAGGGTCTCCTGCCTTAACGAGGT  
V\_D\_N\_V\_C\_M\_D\_E\_M\_V\_R\_E\_S\_Q\_R\_N\_G\_I\_A\_P

CAGTCCGATTCCCTCAGGAAGCTCTCCGATCAAGTTCAAGAGGATCAACTTCGATAAC  
361 -----+-----+-----+-----+-----+-----+  
GTCAGGGCTAAGGGAGTCCTCGAGAGGCCATAGTTCAAGTTCTCCTAGTTGAAGCTATTG  
Q\_S\_D\_S\_L\_R\_K\_L\_S\_G\_I\_K\_F\_K\_R\_I\_N\_F\_D\_N

TCCTCCGAGTACATCGAGAACCTGGACCTCCAGAACAGAACAGAGGACTGGATTCACT  
421 -----+-----+-----+-----+-----+-----+  
AGGAGGGCTCATGTAGCTCTGACCTTGGAGGTCTGTCTTCCGTCCTGACCTAAGTGA  
S\_S\_E\_Y\_I\_E\_N\_W\_N\_L\_Q\_N\_R\_R\_Q\_R\_T\_G\_F\_T

**Figure 16C -2**

TTCCACAAGCCAAACATCTTCCCATACTCCGCTTCCTTCACTCTCAACAGGTCCCAGCCA  
 481 -----+-----+-----+-----+-----+-----+  
 AAGGTGTTGGTTGTAGAAGGGTATGAGGCAGAGGAAGTGGAGAGTTGTCCAGGGTCGGT  
 F\_H\_K\_P\_N\_I\_F\_P\_Y\_S\_A\_S\_F\_T\_L\_N\_R\_S\_Q\_P\_

GCTCACGATAACCTCATGGGAACTATGTGGCTAACGCTGGTTCTGAGATCCAGGTGGCA  
 541 -----+-----+-----+-----+-----+  
 CGAGTGCCTATTGGAGTACCCCTGATACACCGAGTTGCGACCAAGACTCTAGGTCCACCGT  
 A\_H\_D\_N\_L\_M\_G\_T\_M\_W\_L\_N\_A\_G\_S\_E\_I\_Q\_V\_A\_

GGATTGATTACTCCTGCGCTATCAACGCTCCAGCTAACACTCAGCAGTTGAGCACATC  
 601 -----+-----+-----+-----+-----+  
 CCTAAGCTAATGAGGACGCGATAGTTGCGAGGTGATTGTGAGTCGTCAAGCTCGTAG  
 G\_F\_D\_Y\_S\_C\_A\_I\_N\_A\_P\_A\_N\_T\_Q\_Q\_F\_E\_H\_I\_

GTTCAGCTCAGAAGGGTGCTCACTGCTACTATCACTCTCCTCCCAGATGCTGAGAGG  
 661 -----+-----+-----+-----+-----+  
 CAAGTCGAGTCTTCCCACGAGTGATGACGATGATAGTGAGAGGAGGGTCTACGACTCTCC  
 V\_Q\_L\_R\_R\_V\_L\_T\_T\_A\_T\_I\_T\_L\_L\_P\_D\_A\_E\_R\_

TTCTCCTTCCCAAGGGTGTCAACTCCGCTGATGGTGCTACTACTTGGTACTTCAACCCA  
 721 -----+-----+-----+-----+-----+  
 AAGAGGAAGGGTTCCCACTAGTTGAGGCAGTACACAGATGATGAACCATGAAGTTGGGT  
 F\_S\_F\_P\_R\_V\_I\_N\_S\_A\_D\_G\_A\_T\_T\_W\_Y\_F\_N\_P\_

G TGATCCTCAGGCCAAACAAACGTGGAGGTGGAGTTCTTCAACGGACAGATCATCAAC  
 781 -----+-----+-----+-----+-----+  
 CACTAGGAGTCCGGTTGTTGACCTCCACCTCAAGGAAGAGTTGCCTGCTAGTAGTTG  
 V\_I\_L\_R\_P\_N\_N\_V\_E\_V\_E\_F\_L\_L\_N\_G\_Q\_I\_I\_N\_

ACTTACCAAGGCTCGTTCGGAACTATCGTGGCTAGGAACCTCGATAACAATCAGGCTCTCC  
 841 -----+-----+-----+-----+-----+  
 TGAATGGTCCGAGCAAAGCCTGATAGCACCAGATCCTGAAGCTATGTTAGTCCGAGAGG  
 T\_Y\_Q\_A\_R\_F\_G\_T\_I\_V\_A\_R\_N\_F\_D\_T\_I\_R\_L\_S\_

TTCCAGCTTATGAGGCCACAAACATGACTCCATCCGTGGCTGCACCTTCCAAACGCA  
 901 -----+-----+-----+-----+-----+  
 AAGGTGAAATACTCCGGTGGTTGTACTGAGGTAGGCACCGACGTGAGAAGGGTTGCGT  
 F\_Q\_L\_M\_R\_P\_P\_N\_M\_T\_P\_S\_V\_A\_A\_L\_F\_P\_N\_A\_

CAGCCATTGAGCACACGCTACTGTGGACTCACTCTCAAGATCGAGTCCGCTGTGTC  
 961 -----+-----+-----+-----+-----+  
 GTCGGTAAGCTCGTGGTGCATGACACCCCTGAGTGAGAGTTCTAGCTCAGGCACACAG  
 Q\_P\_F\_E\_H\_H\_A\_T\_V\_G\_L\_T\_L\_K\_I\_E\_S\_A\_V\_C\_

**Figure 16C -3**

1021 GAGTCTGTGCTCGCTGATGCTTCCGAGACTATGCTCGCTAACGTGACTTCTGTGAGGCAA  
 CTCAGACACGAGCGACTACGAAGGCTCTGATACGAGCGATTGCACTGAAGACACTCCGTT  
E\_S\_V\_L\_A\_D\_A\_S\_E\_T\_M\_L\_A\_N\_V\_T\_S\_V\_R\_Q

1081 GAGTACGCTATCCCAGTGGGACCAGTGTTCCACCAAGGAATGAACTGGACTGATCTCATC  
 CTCATGCGATAGGGTCACCCCTGGTCACAAAGGTGGTCCTTACTTGACCTGACTAGAGTAG  
E\_Y\_A\_I\_P\_V\_G\_P\_V\_F\_P\_P\_G\_M\_N\_W\_T\_D\_L\_I

1141 ACTAACTACTCCCCATCCAGAGAGGATAACCTCCAGAGGGTGTTCACTGTGGCTTCCATC  
 TGATTGATGAGGGGTAGGTCTCTCCTATTGGAGGTCTCCCACAAGTGACACCGAAGGTAG  
T\_N\_Y\_S\_P\_S\_R\_E\_D\_N\_L\_Q\_R\_V\_F\_T\_V\_A\_S\_I

1201 CGTTCCATGCTCGTAAGTGATGACTCGAGGGATCCTCTAGAGAA  
 GCAAGGTACGAGCACTTCACTACTGAGCTCCCTAGGAGATCTCTT  
R\_S\_M\_L\_V\_K\_\* SEQ ID NO: 3

TTCGAGCTC SEQ ID NO: 17  
 AAGCTCGAG SEQ ID NO: 18

**Figure 16D -1**  
**Rotavirus VP 7**

Gene name: **G9P6\_VP7**

Gene length: 1041 bp

Optimized for expression in:

*Nicotiana tabacum*

GGTACCGAATT CGGAC CGCGT CGTGC ATGTAC GGAAT CGAGTAC ACTACTAT CCTCACT  
1 -----+-----+-----+-----+-----+-----+  
CCATGGCTTAAGCCTGCGCAAGCAACGTACATGCCTAGCTCATGTGATGATAGGAGTGA  
**SEQ ID NO: 4 G\_R\_V\_R\_C\_M\_Y\_G\_I\_E\_Y\_T\_T\_I\_L\_T\_**

TTCCCTCATCTCCATCGTGCTCCTCAACTACATCCTCAAGTCCCTCACTTCCGCTATGGAT  
61 -----+-----+-----+-----+-----+-----+  
AAGGAGTAGAGGTAGCACGAGGAGTTGATGTAGGAGTTCAAGGAGTGAAGGCGATACCTA  
**F\_L\_I\_S\_I\_V\_L\_L\_N\_Y\_I\_L\_K\_S\_L\_T\_S\_A\_M\_D\_**

TTCATCATCTACCGTTCCCTCCTCATCGTGATCGCTCCCCATTGTTAACAGACTCAG  
121 -----+-----+-----+-----+-----+-----+  
AAGTAGTAGATGGCAAAGGAGGAGTAGCACTAGCGAAGGGTAAGCAATTCTGAGTC  
**F\_I\_I\_Y\_R\_F\_L\_L\_L\_I\_V\_I\_A\_S\_P\_F\_V\_K\_T\_Q\_**

AACTACGGTATCAACCTCCAATCACTGGATCTATGGATACTGCTTACGCTAACCTCC  
181 -----+-----+-----+-----+-----+  
TTGATGCCATAGTTGGAGGGTTAGTGACCTAGATACTATGACGAATGCGATTGAGGAGG  
**N\_Y\_G\_I\_N\_L\_P\_I\_T\_G\_S\_M\_D\_T\_A\_Y\_A\_N\_S\_S\_**

CAGCAAGAGACTTCCTCACTCCACACTCTGCCTCTACTACCCAAGTGGCATCCACA  
241 -----+-----+-----+-----+-----+  
GTCGTTCTGAAAGGAGTGAAGGTGTGAGACGGAGATGATGGGTTGACTCCGTAGGTGT  
**Q\_Q\_E\_T\_F\_L\_T\_S\_T\_L\_C\_L\_Y\_Y\_P\_T\_E\_A\_S\_T\_**

CAGATCGGAGATA CAGAGTGGAGGATACTCTCTCCAGCTTCCACTAACGGATGG  
301 -----+-----+-----+-----+-----+  
GTCTAGCCTCTATGTCTCACCTCCTATGAGAGAGGGTCGAGAAGGAGTGATTCCCTACC  
**Q\_I\_G\_D\_T\_E\_W\_K\_D\_T\_L\_S\_Q\_L\_F\_L\_T\_K\_G\_W\_**

CCAAC TGGTCCGTGTACTCAAAGAGTACACTGATATCGCTTCCATCGATCCA  
361 -----+-----+-----+-----+-----+  
GGTTGACCAAGGCACATGAAGTTCTCATGTGACTATAGCGAAGGAAGAGGTAGCTAGGT  
**P\_T\_G\_S\_V\_Y\_F\_K\_E\_Y\_T\_D\_I\_A\_S\_F\_S\_I\_D\_P\_**

**Figure 16D -2**

CAGCTCTACTGCGATTACAACGTGGTGCTTATGAAGTACGATTCCACTCTTGAGCTTGAT  
 421 -----+-----+-----+-----+-----+-----+  
 GTCGAGATGACGCTAATGTTGACCACGAATACTTCATGCTAAGGTGAGAACTCGAACTA  
Q\_L\_Y\_C\_D\_Y\_N\_V\_V\_L\_M\_K\_Y\_D\_S\_T\_L\_E\_L\_D\_  
  
 ATGTCCGAGCTTGCTGATCTCATCCTCAACGAGTGGCTCTGCAACCCAATGGATATCACT  
 481 -----+-----+-----+-----+-----+-----+  
 TACAGGCTCGAACGACTAGAGTAGGAGTTGCTCACCGAGACGTTGGGTTACCTATAGTA  
M\_S\_E\_L\_A\_D\_L\_I\_L\_N\_E\_W\_L\_C\_N\_P\_M\_D\_I\_T\_  
  
 CTCTACTACTACCAGCAGACTGATGAGGCTAACAAAGTGGATCTCTATGGGACAGTCCTGC  
 541 -----+-----+-----+-----+-----+-----+  
 GAGATGATGATGGTCGTCTGACTACTCCGATTGTTCACCTAGAGATAACCTGTCAGGACG  
L\_Y\_Y\_Y\_Q\_Q\_T\_D\_E\_A\_N\_K\_W\_I\_S\_M\_G\_Q\_S\_C\_  
  
 ACTATCAAAGTGTGCCCACTAACACTCAGACTCTCGGAATCGGATGCATCACTACTAAC  
 601 -----+-----+-----+-----+-----+-----+  
 TGATAGTTCACACGGGTGAGTTGAGTCTGAGAGCCTTAGCCTACGTAGTGTGATTG  
T\_I\_K\_V\_C\_P\_L\_N\_T\_Q\_T\_L\_G\_I\_G\_C\_I\_T\_T\_N\_  
  
 ACTGCTACTTCGAGGAAGTGGCTACTTCCGAGAAGCTCGTGTGATCACTGATGTGGTGGAT  
 661 -----+-----+-----+-----+-----+  
 TGACGATGAAAGCTCCTTCACCGATGAAGGCTTCGAGCACTAGTGAACACACCACCA  
T\_A\_T\_F\_E\_E\_V\_A\_T\_S\_E\_K\_L\_V\_I\_T\_D\_V\_V\_D\_  
  
 GGTGTTAACCAAGACTCGATGTGACTACTAACACATGCACAATCAGGAACGTGCAAGAAG  
 721 -----+-----+-----+-----+-----+  
 CCACAATTGGTGTGAGCTACACTGATGATTGTTAGCCTGACGTTCTC  
G\_V\_N\_H\_K\_L\_D\_V\_T\_T\_N\_T\_C\_T\_I\_R\_N\_C\_K\_K\_  
  
 CTCGGACCAAGGGAAAACGTGGCTATCATCCAAGTGGAGGTTCCGATGTGCTCGATATC  
 781 -----+-----+-----+-----+-----+  
 GAGCCTGGTCCCTTGCACCGATAGTAGGTTCACCTCCAAGGCTACACGAGCTATAG  
L\_G\_P\_R\_E\_N\_V\_A\_I\_I\_Q\_V\_G\_G\_S\_D\_V\_L\_D\_I\_  
  
 ACTGCTGATCCAACTAAGTGTCCACAGACTGAGAGGATGATGAGGGTGAACGTGGAAGAAG  
 841 -----+-----+-----+-----+-----+  
 TGACGACTAGGTTGATGACGAGGTGCTGACTCTCTACTACTCCCACCTGACCTTCTC  
T\_A\_D\_P\_T\_T\_A\_P\_Q\_T\_E\_R\_M\_M\_R\_V\_N\_W\_K\_K\_  
  
 TGGTGGCAGGTTCTACACTGTGGTGGATTACATCAACCAGATCGTTAGGTGATGTCC  
 901 -----+-----+-----+-----+-----+  
 ACCACCGTCCAAAGATGTGACACCACCTAATGTAGTTGGTCTAGCAAGTCCACTACAGG  
W\_W\_Q\_V\_F\_Y\_T\_V\_V\_D\_Y\_I\_N\_Q\_I\_V\_Q\_V\_M\_S\_

**Figure 16D -3**

AAGAGGTCCCGTTCTCTCAACTCCGCTGCTTCTACTACCGTGTGATGACTCGAGGGA  
961 -----+-----+-----+-----+-----+-----+  
TTCTCCAGGGCAAGAGAGTTGAGGCGACGAAAGATGATGGCACACACTACTGAGCTCCCT  
**K\_R\_S\_R\_S\_L\_N\_S\_A\_A\_F\_Y\_Y\_R\_V\_\*\_\*\_ SEQ ID NO: 4**

TCCTCTAGAGAATTGAGCTC SEQ ID NO: 19

1021 -----+-----+  
AGGAGATCTCTTAAGCTCGAG SEQ ID NO: 20

**Figure 17**

A-2X35S/CPMV-HT/ RVA(WA) VP2(opt)/ NOS (Construct number 1710)

**Figure 17A, SEQ ID NO: 21**

IF-WA VP2(opt).s1+3c


AAATTGTCGGGCCATGGCATACCGGAAGAGAGGGAGCAAAGCGCGAA

**Figure 17B, SEQ ID NO: 22**

IF-WA\_VP2(opt).s1-4r

ACTAAAGAAAAATAGGCCTTAAAGCTCGTTCATTATTCGCATATTGTCGA

**Figure 17C**



**Figure 18, SEQ ID NO: 23**

Construct 1191 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette

TGGCAGGATATTGTGGTAAACAAATTGACGCTTAGACAACTTAATAACACATTGCGGACGTTT  
 TTAATGTACTGAATTACCGCAATCCGGCTGGTATATTATATGTTGTCAAATAACTCAAAAACC  
 ATAAAAGTTAAGTTAGCAAGTGTACATTTTACTGAAACAAAATATTCAACCTACTACTGTTATA  
 AATCATTATTAAACATTAGAGTAAAGAAATATGGATGATAAGAACAAAGAGTAGTGTATTTGACAA  
 CAATTGTCACATTGAGAAAATTGTTGTTCTCTCTTCAATTGGTCAAAACAAATAGAGAG  
 AGAAAAAGGAAGAGGGAGAATAAAACATAATGTGAGTATGAGAGAGAAAGTTGACAAAAGTTG  
 TACCAAAATAGTTGACAAATATCATTGAGGAATTGACAAAAGCTACACAAATAAGGGTTAATTG  
 TGTAATAAAATAGGTGACGCAATTAGAGAGATGTACCAATTAGAGAATTGGCAAGTCATTAAA  
 AGAAAAGAATAAAATTATTTAAATTAAAGTTGAGTCATTGATTAAACATGTGATTATTAATGAA  
 TTGATGAAAGAGAGTTGATTAAAGTTGATTAGTAATTAGAATTGGTCAAAATTGACATT  
 GATCTTCCATATAATTGCCCATAGAGTCAGTAACTCATTATTCATAGATCAAATAAGA  
 GAAATAACGGTATATAATCCCTCAAAAAAAACGGTATATTACTAAAAAATCTAACGCCAG  
 TAGGAGGATAACAGGATCCCCTAGGAGGATAACATCCAATCCAACATCACACAACTCTGATG  
 AGATAACCCACTTAAAGCCCACGCATCTGTGGCACATCTACATTCTAAACACACATTCCAC  
 CATCTGAGCCACACAAAAACCAATCCACATCTTATCACCATTCTATAAAAATCACACTTGTGAG  
 TCTACACTTGTATTCCCTTAAACACATAAAAGAGAAGAGACTAATTAAATTAAATCATCTGAG  
 AGAAAATGGAACGAGCTATACAAGGAAACGACGCTAGGGAAACAAGCTAACAGTGAACGTTGGATG  
 GAGGATCAGGAGGTACCACTCTCCCTCAAACCTCCTGACGAAAGTCCGAGTTGGACTGAGTGGCG  
 GCTACATAACGATGAGACGAATTGAATCAAGATAATCCCTGGTTCAAGGAAAGCTGGGGTTTC  
 GGGAAAGTTGATTAAAGAGATATCTCAGATACGACAGGAGCGGAAGCTTCACTGCACAGAGTCCTG  
 GATCTGGACGGGAGATTGGTTAACTATGCAGCATCTGATTTCGGTTTCGACCGAGATCGGATGT  
 ACCTATAGTATTGGTTTCGAGGAGTTAGTACCGGTTCTGGAGGGTGCAGACTCTCAGCATCT  
 CTGAGATGGCAATTCTCGCTAAAGCAAGAACTGCTACAGCTTCCCAATCGAAGTGGAAAGTAAT  
 GTATCAAGAGGATGCCCTGAAGGACTCAAACCTTCGAAAAAGAAAGCGAGTAAGTAAATGCTT  
 CTTCGTCTCTATTATAATGGTTGTTATTGTAATTGGTCAAGGAGCTTAATTATCG  
 TTGTTGTTATGAAATACTATTGTATGAGATGAACCTGGTGTATGTAATTCAATTACATAAGTGGAGT  
 CAGAACATGAGCTTCCATAACTAACATGACATGAAGACCTGCCGTACAATTGCTTATATT  
 TGAACAACAAATTGAACATCTTGCACAAACTTATAAGGTTAATATAGCTCAAATAATGGT  
 CAAGTTCAATAGATAAAATGGAATATCAGTTATCGAAATTCAACATCAACTAACGTTATT  
 AACTACTAATTTATATCATCCCTTGATAAAATGATAGTACACCAATTAGGAAGGAGCATGTCGCC  
 TAGGAGATTGTCGTTCCCGCTTCAGTTGCAAGCTGCTTAGCCGTAGCAATACGCAAACCGC  
 CTCTCCCGCGCGTTGGAAATTACTAGCGCGTGTGACAAGCTTGCATGCCGTCAACATGGTGGAG  
 CACGACACACTGTCTACTCCAAAATATCAAAGATAACAGTCTCAGAAGACCAAAGGGCAATTGAG  
 ACTTTCAACAAAGGTAATATCCGAAACCTCTCGGATTCCATTGCCAGCTATCTGTCACTTAT  
 TGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATTGCGATAAAAGGAAGGCCAT  
 CGTTGAAGATGCCCTGCCGACAGTGGTCCCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACG  
 ACACCTGTCTACTCCAAAATATCAAAGATAACAGTCTCAGAAGACCAAAGGGCAATTGAGACTTTC  
 AACAAAGGTAATATCCGAAACCTCTCGGATTCCATTGCCAGCTATCTGTCACTTATTGAGAGGTAT  
 ATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATTGCGATAAAAGGAAGGCCATGTTGAA  
 GATGCCCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAAAGAA  
 GACGTTCCAACCACGCTTCAAAGCAAGTGGATTGATGTGATACTCCACTGACGTAAGGGATGACG  
 CACAATCCCACATCCTCGCAAGACCCCTCTATATAAGGAAGTTCATTCAATTGGAGAGGTAT  
 TAAAATCTTAATAGGTTGATAAAAGCAACGTGGGAAACCGAACCAAACCTCTTCTAAACTC  
 TCTCTCATCTCTTAAAGCAAACCTCTCTTGTCTTCTGCTGAGCGATCTCAACGTTGTCAGA  
 TCGTGTCTCGGCCACCAGTACAACGTTCTTCACTGAAGCGAAATCAAAGATCTTGTGGACACG  
 TAGTGCAGCGCATTAAATAACGTTGACTTGTCTTCTTGTGGTCTTGGGAAAAGAAAGC  
 TTGCTGGAGGCTGCTTCAAGGCCACATTAATTGTCAGCTTCTTCTTCTTGTGACTTCTGGCGGGTGAA  
 TATCTCTACTCTGCTTCAAGGAGTTGTCAGCTTCTTCTTCTTGTGATTGGTCTTGGTCTTGGTCT  
 ATAAGAAATCTAGTATTCTTCTTGTGAAACAGAGTTTCCGTTGTTCTGAAACTTGGAGAAAGATTGTT  
 AAGCTCTGTATATTCTGCCAAATTGTCGGGCCCGGATGGCAAAACGTTGCGATTTCGGCT  
 TATTGTTTCTCTTCTGTTGTTCTCTCAGATCTGCCCTGCAAGCTGCCACCCGGCAGCAGCACCAAGGTGA  
 CCCCCATCTGCTATCCACTGGCCCTGGATCTGCTGCCAAACTAACCTGACCTGGTACCCCTGGGATG  
 CCTGGTCAAGGGCTATTCCCTGAGCCAGTGAACAGTGAACCTGGAACTCTGGATCCCTGTCAGCGGT  
 GTGCACACCTTCCAGCTGCTCTGCACTGAGCAGCTCAGTGAACGACTGTCACCTCTGAGCAGCTCAGTGA  
 CAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCCACCCGGCAGCAGCACCAAGGTGA  
 CAAGAAAATTGTGCCAGGGATTGTTGTAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCT  
 GTCTTCATCTCCCCCAAAGCCAAGGATGTGTCACCATTACTCTGACTCTTAAGGTACAGTGTGAGGT  
 TGTGGTAGACATCAGCAAGGATGATCCGAGGTCCAGTTCAAGCTGGTTGAGATGTGAGGT

CACACAGCTCAGACGCAACCCGGGAGGAGCAGTTCAACAGCACTTCCGCTCAGTCAGTGAACCTTC  
CCATCATGCACCAGGACTGGCTCAATGGCAAGGAGCGATCGCTACCACATACCACATACCACAT  
CACCATTAAAGGCCTATTTCTTACTGGATTACTGTTATTCGGTGTGCATTCTATGTTGGTGA  
GCGGTTTCTGTGCTCAGAGTGTGTTATTTATGTAATTAAATTCTTGTGAGCTCCTGTTAGCAG  
GTCGTCCTTCAGCAAGGACACAAAAAGATTAAATTATTAATTAAAGTTCTTAAGATTG  
GAATTCGATATCAAGCTTATCGACCTGCAGATCGTCAAACATTGGCAATAAAGTTCTTAAGATTG  
AATCCTGTTGCCGTCTCGATGATTATCATATAATTCTGTTGAATTACGTTAACGATGTAATAAT  
TAACATGTAATGCATGACGTTATTTAGAGATGGGTTTATGATTAGAGTCCCAGCAATTATACATT  
AATACCGCATAGAAAACAAAATATAGCGCGAAACTAGGATAAATTATCGCGCCGGTGTCTAT  
GTTACTAGATCTCTAGAGTCTCAAGCTGGCGCCCACGTGACTAGTGGCACTGGCGTCGTTAC  
AACGTCGTGACTGGAAAACCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTCGCC  
AGCTGGCGTAATAGCGAAGAGGCCGCACCGATGCCCTCCAAACAGTTGCGCAGCCTGAATGGCG  
AATGCTAGAGCAGCTGAGCTGGATCAGATTGCGTTCCGCTTCAGTTAAACTATCAGTGTGTT  
GACAGGATATATTGGCGGGTAAACCTAAGAGAAAAGAGCGTTA

**Figure 19** nucleotide sequence encoding VP2(opt) from Rotavirus A WA strain (SEQ ID NO: 45).

ATGGCATAACCGGAAGAGAGGAGCAAAGCGCGAAAACCTGCCGCAACAGAACGAGAGA  
CTGCAAGAAAAAGAGATAGAGAAAGATGTCGACGTAACAATGGAAAACAAGAATAAC  
AATAGGAAACAACAGCTGTCCGACAAAGTTCTGTCCCAGAAGGGAGGAAATTACTACT  
GACGCCAGGAGCAGTATTAAAATTGCCGGAGAAATAAGAAGAGCTCGAAAGAAGAA  
TCTAACAGCTGCTCGAAATTCTGAAAACAAAAGAACGACATCAGAAAGAGATTCAA  
TATGAAATTTCGAAAAAACATACTACATTGAGTCAAAGAAAGTATCCTCAAG  
AAGCTTGAAGACATAAGACCGGAGCAGGCCAAAAACAGATGAAACTCTTCGCATT  
TTCGAGC AAAACAGCTCCCTATATATCGCGCAATGGCGAGAAGGGAGCTACGCAAC  
CGGTGGTACTGGAAGTTGAAAAAGACACCCCTGCCAGATGGAGATTATGACGTCCGG  
GAGTATTTCCTCAATCTATGATCAGATCCTCATCGAAATGCCGGACTATCTGCTC  
CTCAAGGACATGCCGTGGAGAACAAAATAGCAGAGACGCCGGCAAAGTTGTCGAC  
TCTGAGACTGCCAATATTGTGATGCCATCTCCAGGATGAGGAGACCGAGGGAGTC  
GTCCGTAGATTATCGCTGATATGCCAACAGGCCAGGTGATCGTAACATTGTC  
AATTACCCCTCCATCCTCACCCATTGATCATGCAATTGAGTATTTCCTTAAC  
CACCAAGTTGGTGGAGCCGCTGAACAATGAGATAATTCAATTACATACCAGAGAG  
ATAAGGAATGACGTGAATTACATCCTGAACATGGATATGAATCTGCCATCTACAGCC  
AGGTATATCAGGCCAAACTTGTGCAAGGATAGACTGAATCTCAGATAATTGAG  
TCCCTGTGGGATACCATCACAAACATCCAACATTCTGCCAGGTCCGTGTTCCC  
GATTGAAGGAGAACGGAGCTGGCTCCACCGAACAGACAGTCCAGAAAATGAGCCAG  
GACCTGCAGCTGGAGGCCCTCACTATTCAAGAGCAGACACAGATTAGCCGGATT  
AACAGTCAGGCTGCCAATGATTGTTCAAGACCCCTCATAGCCGCAATGCTGTCAA  
AGAACCATGTCTTGACTTGTGACCACGAACATATGAGCCTAACATCCGGAAATG  
TGGCTACTTACAGTGAATTCCCAACGATATGTTCCCGGGAGTCAGTAGTGGCCTGT  
GAGCTGGCGATCATCAACACCATCGTGTATCCAGCATTGGAATGCAGAGAATGCA  
TACCGGAATGGCGACCCTCAGACACCCCTCCAGATCGCAGAACAGCAGATCCAGAAT  
TTCCAGGTGGCAACTGGCTCCATTAAACAATAACAGATTCAAGGCAAGTTGT  
ATTGATGGAGTTCTGAATCAGACTCTGAACGACAATAACGGAATGGACAGGTCA  
AACAGCTGATGGAAGCATTGATGCAACTCAGCAGACAGCAGTTCCCCACGATGCCT  
GTGGATTACAAACGGAGCATCCAACGGGCATTCTGCTTCTCCAATAGGCTGGG  
CAGCTTGTGACTTAACCGACTGGTCTCCTATAACTACGAGACGCTAACGGCT  
GTGACCATGAACATGCAGCACGTGCAAACCCCTGACAACGAGATGGCAGCTCA  
TCTGTGACTTCGTTGTATGTTAATTGGTAACACAACCGTGATTCCGTCCCCACAG  
ACACTGTTCAACTACTACAACATCAACGTGAATTCCACTCCAATTATAATGAGCGG  
ATCAACGACGCCGTGCCATAATTACCGCAGCAAATAGGCTGAATCTTATCAGAAA  
AAAATGAAGTCCATAGTGGAAAGACTTCTGAAACGGCTCCAGATTTCGACGTACCA  
CGAGTGCCTGACGACCAAATGTACAGGCTGAGGGATGCCCTCGGCTTACCGTT  
GAACGGAGACGGCTTGACATATTCAACTTGATCCTGATGAATATGGAGCAGATCGAA  
CGCGCTTCTGATAAGATTGCTCAGGGGTTATCATCGCATACCGAGATATGCA  
GAACGCGACGGAGATGTACGGATATGTTAATTGACGGAAATCTGATGGCTACCA  
CAAATTAACTTGGAGGAACATCGCACCCTGATTGCGCTTACGGACTAACATG  
CTTCTCAACAAATCAACCGTTGCCCTTGTGGGTGATTGCCCTCGTACGGACTCA  
TCCGTGATCAGTCTAACGCCAAGCTCGACGCAACCGTCTCGCTCAGATAGTGAAG  
CTCAGGAAAGTTGACACACTGAAGCCCATACTGTACAAAATAACTCGGATTCAA  
GACTTTACCTTGTGGCCAACACTACGACTGGATCCCCACAAGTACAACAAAGTCTAC  
AAACAGGTGCCACAACCATTGACTTAAAGGCCAGCAGTGCACATGCTGACTTCAA  
CTTACGTTACCGTCACTCTGACCTACTGTCATTGTTAGCGGACACGGTAGAG  
CCCATTAAACGCAGTCGACAAATGCGAATAATGAACGAGCTTAA


**Figure 20**, SEQ ID NO: 25

Amino acid sequence of VP2 from Rotavirus A WA strain

MAYRKRGAKRENLPQQNLERLQEKEIEKDVDVTMENKNNNRKQQLSDKVLSQKEEIIDAQDDIKIAGEIK  
 KSSKEESKQLLEILKTKEDHQKEIQQYEILQKTIPTFESKESILKKLEDIRPEQAKKQMKLFRIFEPKQLPIYRA  
 NGEKELRNRWYWKLLKDTLPDGDYDVREYFLNLYDQILIEMPDYLLLKDMAVENKNSRDAGKVV  
 DSE TANICDAIFQDETEGVVRRFIADMRQQVQADRNIVNYPsilHpidHafNEYFLNHQLVEPLNNEIFNYIPE  
 RIRNDVNYILNMMDMNLPLSTARYIRPNLLQDRLNLHDNFESLWDTITTSNYILARSVVPDLKEKELVSTEAQ  
 IQKMSQDLQLEALTIQSETQFLAGINSQAANDCFKTLIAAMLSQRTMSLDFTTNYMSLISGMWLLTVIPN  
 DMFLRESLVACELAIINTIVYPAGMQRHRYRNGDPQTPFQIAEQQIQNFQVANWLHFINNNRFRQVVID  
 GVLNQTLNDNIRNGQVINQLMEALMQLSRQQFPTMPVDYKRSIQRGILLSNRLGQLVDLTRLVSYNYET  
 LMACVTMNMQHVQTLTTEKLQLTSVSLCMLIGHTTVPSPQTLFHYNNINVNFHSNYNERINDAVAIITA  
 ANRLNLYQKKMKSIVEDFLKRLQIFDVPRVPDDQMYRLRDRRLLPVERRLDIFNLILMNMEQIERASD  
 KIAQGVIIAYRDMQLERDEMYGYVNIARNLDGYQQINLELMRTGDYQGITNMLLNNQPVALVGALPFV  
 TDSSVISLIAKLDATVFAQIVKLRKVDTLKPILYKINSDSNDFYLVANYDWIPTSTTKVYKQVPQPDFRAS  
 MHMLTSNLTFVYSDLLSFVSADTVEPINAVAFDNMRIMNEL


**Figure 21**

Schematic representation of construct number 1710



B-2X35S/CPMV-HT/RVA(WA) VP2(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1711)

**Figure 22A**



**Figure 22B**, SEQ ID NO: 26

Construct 193 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS into BeYDV(m)+Replicase amplification system with Plastocyanine-P19-Plastocyanine silencing inhibitor cassette

TGGCAGGATATTGTGGTTAAACAAATTGACGCTTAGACAACTTAATAACACATTGCGGACGTTT  
 TTAATGTACTGAATTACCGCAATCCGGGCTGGTATATTTATGTGCAATAACTCAAAAACC  
 ATAAAAGTTAAGTGTACATTTACTTGAACAAAAAATATTCACCTACTACTGTTTATA  
 AATCATTAAACATTAGAGTAAGAAATATGGATGATAAGAACAAGAGTAGTAGTGATATTGACAA  
 CAATTGTGCAACATTGAGAAAATTGGTCTCTCTTCATTGGCAAAAACAATAGAGAG  
 AGAAAAAAGGAGAGGGAGAATAAAACATAATGTGAGTATAGAGAGAAGTTGTACAAAAGTTG  
 TACAAAATAGGTACAAATATCATTGAGGAATTGACAAAAGCTACACAAATAGGGTTATTGC  
 TGTAATAAATAAAGGTGACGCATTAGAGAGATGTGATTAGAATTTGGCAAGTCTTAA  
 AGAAAAGAAAATTATTTAAAGGTGAGTCATTGATAACATGTGATTTTAA  
 TTGATGAAAGAGTTGATTAAGGTTAGTGTTATTAGTAATTGGTCAAAATTTGACATTGAA  
 GATCTTCCCTATATATGGCCCATAGTCAGTTACTATGGTGTCAAAATTTGACATTGAA  
 GAAATAACGGTATATAACCCTCCAAAAAAAAACGGTATATAACTAAGCCACG  
 TAGAGGATACAGGATCCCCGTAGGAGGATACATCCAACCATCAACACATCTTCCACA  
 AGATAACCCACTTTAAGCCCACCGCATCTGTGGACATCTACATTCTAAATCACACATTCTTCCACA  
 CATTGAGCCACACAAAAACCAATCCACATCTTATCACCATTCTATAAAAAACATCAACACTTGTGAG  
 TCTACACTTGATTCCCTCAACACATACAAAGAGAAGAGACTATTAAATTAATCATTTGAG  
 AGAAAATGGAACGAGCTATACAAGGAAACGACGCTAGGGAAACAGCTAACAGTGAACGTGGGATG  
 GAGGATCAGGAGGTACCACTTCTCCCAAAACTCCCTGACGAAAGTCCGAGTTGGACTGAGGGCG  
 GCTACATAACGATGAGACGAATTCGAATCAAGATAATCCCTGGTTCAAGGAAAGCTGGGGTTTC  
 GGGGAAAGTGTATTTAAGAGAATCTCAGATACAGCAGGACGGAAGCTTCACTGCACAGACTCTTGG  
 GATCTGGACGGGAGATTCGGTTAACTATGCAGCATCTCGATTTTCGGTTTCACCGAGATCGGATGT  
 ACCTATAGTATCGGTTCGAGGAGTAGTGATACCCGGTTCGAGGAGTCGGAACCTTCAGCATCT  
 CTGTGAGATGGCAATTCGGCTTAAGCAAGAACTGTCTACAGCTGGCCCAATCGAAGTGGAAAGTAA  
 GTATCAAGAGGATGGCCTGAAGGTACTCAAACCTTCGAAAAGAAAGCAGTAAGTAAAAAGTCTT  
 CTCGCTCCTATTATATGTTGTTATTGTAAGAGCTGGTTAATGTATTACATAAGTGGGAT  
 TTGTTGTTATGAAACTTTGTATAGAGATGGTTAATGTATTACATAAGTGGGAT  
 CAGAATCAGAATGTTTCCCATAACTAGACATGAAAGCCTCCCGGTACATTGTCTTATT  
 TGAAACAACTAAATGAACATCTTTGCACAACTTTTAAGGTTTTAATAGCTCAAAATATGGT  
 CAAGTTAATAGATAAAATGAAATTCAGTTAATGAACTCAAAATCAACTTACAGTTTAT  
 AACTACTAATTTTATATCACCCTTTGATAATGTATAGTACCCAATAGGAAGGACATCGCC  
 TAGAGAATGTCGTTCCCCCTCAGTTTGAAGCTGCTCTAGCCGTGTAGCCAAACCCGC  
 CTCTCCCCCGCGGTGGAAATTACTAGCGCGGTTCGAAGCCCGGTTTGTGTACCCGAGGGGTTGC  
 CCTCAAACCTATCTTAACCCGGGTGGAGGCATGGAGGCAGGGGTATTTGGCTATTTAAAGAT  
 AGGTGAAAAATGACGTGGATTACTAAAGACGAAGGTCTTCGACAAGGGGGGGCCACCCGGAA  
 TTTAATATACCCGGGTGGCCCCCTATCGAGGTGTCTTTAGACAGCGGTCCAGATTTAAAGTA  
 GAAAATCCCCCCCACTAGGGTTAAAGGTTTCAACATAAAGCAATACGTGTATGGTATT  
 TGGTCGAACAGGTTCATCGCGGTCAACATGGGGAGGCACACACTGTCTACTCAAAAAAATATC  
 AAAGATAAGTCTCAGAAAAGGCAATTGGGAGACGACACACTGTCTACTCCAAAAATATCAAAGATA  
 CTCTCGGATTCCATTGCCCAGCTATGTCACTTATGTGAAGATAGTGGAAAGGAAGGTGGCT  
 CTACAAATGCCATCATTGCGATAAAAGGAAAGGCCATGTGAAGATGCCTTCGGACAGTGGCT  
 AAAGAGTGGACCCCCCACCACGAGGACATGTGGAAAAAGAAAGACGTTTCCAACCACGTCTCAAA  
 CAAGTGGATTGTGTGAAAATGTGGGAGACGACACACTGTCTACTCCAAAAATATCAAAGATA  
 CAGTCTCAGAAAAGGCAATTGGGAGACTTTCAACAAAGGGTAATACCCGAAAACCTCCCG  
 ATTCCATTGCCCAGCTATGTCACTTATGTGAAGATAGTGGAAAGGAAGGTGGCTCTACAA  
 TGCCATTCATGTGAAAAGGGAAAGGCCATGTGAAGATGCCTCTGCGAAGGTGGCCAAAGATG  
 GACCCCCACCCACGAGGACATGTGGAAAAAGGAAGACGTTTCCAACCACGTCTCAAAAGGTGG  
 ATTGATGTGAATCTCCACGTGAAGGATGCGACAATCCCATTCTGTCAAGACCCTTCC  
 TCTTAATAAAGGAAAGTCTTCATTGGAGAGGGTTTAAAGTATTGTTGTAAAGCGGAAC  
 GTGGGGAAACCCGAACCAAAACCTTCCTCTATCTCTCTATCTCTCTAAAGCAAAACTTCCTCT  
 GTCTCTCTGTCGGTAGCGATCTTCAACGGTTTGTCAGTCTGTCCGGCCACAGTAACCGTTCTTC  
 ACTGAAGCGAAATCAAAAGATCTCTTTGTGGACACGTAGGTGGCCCATTAAATACGTGTACTGT  
 CCTATTCTGTCGGTGTGGCTTTGGAAAGAAAGAGCTGTGGAGGTCTGTGGCTTTGTGGTTCCCTTC  
 ACTGTTTACGTTTCTGTGACTTTCGGGGTGAATATCTCATTCTGTCTGTGACGAGGGGTTTGTGC  
 CTGTACTTTCTCTCTCTCTGTGTATTGGTTCTTAAAAGAAATCTAGTATTTCTTTGTAAACAGAG  
 TTTTCCCGGTGGTTTCGAACTTTGGAGAAAGAGATGTTAAGCTGTTAATCTGTCCAAATTTGTCG  
 GCCCCCGGGATGGCGAAAAACGTTTGTCGATTTCGGGTTATGTTTCTCTCTGTGTGGTTCCCTTC  
 AGATCTTCCGCTGCAGGCTCCCAAGCCAAACACCCCCATCTGTCAATCCACGGCCCTGGGATC  
 TGCTCCAAACTACTCCATGGGTGACCCTGGATGCCTGTCAAGGGGTTTCCCTGTAGCCAGT  
 ACAGTGACCGTTACTGTGAACCTGGATCCCTGTCCAGCGGGGTGTGCACACCTCCAGGTTCCTGTCAGTGT

CCTCTACACTCTGAGCAGCTCAGTGA  
CTGACTGTCCCCCTCCAGCACCTGGCCAGCGAGACCGTCACCTGC  
AACGTTGCCACCCGGCAGCAGCACCAAGGGACAAGAAAATTGTGCCCAGGGATTGTGTTGTA  
AGCCTTGATATGTACAGTCCCAGAAGTATCATCTGTTCATCTTCCCCCAAGGCCAAGGATGTG  
CTCACCAATTACTCTGACTCTAACGGTCACGTGTTGTTAGACATCAGCAAGGATGATCCCGAGG  
TCCAGTTAGCTGGTTGAGATGATGTGGAGGTGCACACAGCTCAGCGAACCCCGGGAGGAGCA  
GTTCAACAGCACTTCCGCTAGTCAGTGAACCTCCATCATGCACCAGGACTGGCTCAATGGCAAG  
GAGCGATCGCTACCACCATCACCATCACCATAACGGCTATTCTTAGTTGAAT  
TTACTGTTATTCGGTGTCATTCTATGTTGGTAGCGGTTCTGTGCTCAGAGTGTGTTATT  
TGTAATTAAATTCTTGAGCTCCTGTTAGCAGTCGTCCTCAGCAAGGACACAAAAGATT  
TAATTAAAGGGAAATTGCAATAGTTCTTAAGATTGAATCCTGTTGCCGGTCTGCGATGATTATCATA  
TAATTCTGTTGAATTACGTTAACATGTAATAACATGTAATGCATGACGTTATTATGAGATG  
GGTTTATGATTAGAGTCCCAGCAATTATACATTAAACGCGATAGAAAACAAATATAGCGCGCA  
AACTAGGATAAATTATCGCGCGCGGTGTCATCTATGTTAGATCTAGCTCAAGCTTGGCGC  
GCCATAAAATGATTATTATGAATATATTTCATTGTCAGTAGAGATAAAATTACATATGTTACATA  
ACACACGAAATAACAAAAAGAACATCCAAAACAAACACCCCCAAAAAAATAATCCTTAA  
TAAACTCGTATGAGGAGAGGCACGTTAGTCAGTCGACGATTCCCAGCAAAAAAGTCTCCCGTC  
ACACATATAGGGTGACGCAATTATCTTAAAGTAATCCTTCTGTTGACTGTCATTGATAACATCC  
AGTCTCGTCAGGATTGCAAAGAATTATAGAAGGGATCCCACCTTTATTCTTCTTCCATATT  
TAGGGTTGACAGTGAATCAGACTGCAACCTTAATTGCTCCACAATGGGACGAACGTGAGGG  
GATGTCGTGATGATTAGGTGGCGTGTTCATGTTAGGGTGAATCGATGGTACCGTTCCAAT  
AGTTGTCGTCGAGACTCTAGCCAGGTGGCTTCCCTGAGCTGAGTTGGTCCGAGATGTAGAG  
GCTGGGGTGTGGATTCCATTCTCCATTGTCCTGGTAAATGGCAGACATTCAAGGTCAGATTG  
AGCTGTTGGTATGAGACAGGATGTATGTAAGTATAAGCGCTATGCTTACATGGTATAGATGGGTT  
CCCTCAGGAGTGTAGATCTCGTGGCAGCGAACATCTGATTCTGTGAAGGGCAGACACATACGGTT  
AGGTGTCGAGGAAATAATTGTTGGCTGAATATTCCAGCATTGAAAGTTTGTGCCATTGAG  
GGAATTCTCCTGATCATGTCAGAAGATATTCCCTTAGACGTTGCACTGTCAGTGTGATAATAGTTCTCCAT  
CGTCGTCAGATTGCGAGGAGAGACCTTATGATCTCGAAATCTCTCTGGTTAATATCTCCGTC  
CTTGATATGTAATCAAGGACTTGTAGAGTTCTAGCTGGCTGGATATTAGGGTGAATTCTTCAA  
AATGAAAAAGAAGGATCCCTAACAGGTTTTTCAAGCTGGAGAAGAGCATGATAAGGG  
TAGTGCCTTGTAGGAAGCTCAGAAGCAACACCAAGGAAGAAAATAAGAAAAGGTGTGAGTTCT  
CCCAGAGAAACTGGAATAATCATCTTGTAGAGATGAGCAGTGGATAGGTAAGGAAACATATT  
AGATGGAGTCTGAAGTTCTACTAGCAGAAGGCATGGAGGAGGGTATTGTCATTAAAGTAGAAAATT  
TCCCGCCACTAGGGTAAAGGTGTCACACTATAAGCATATACGATGTGATGGTATTGACTAG  
TGGCACTGGCGTGTGTTACAACGTCGTGACTGGAAAACCCCTGGCCTTACCAACTTAATGCC  
GCAGCACATCCCCCTTCGCCAGCTGGCTAACAGCAAGAGGCCGACCGATGCCCTCCAAAC  
AGTTGCGCAGCCTGAATGGCGAATGCTAGAGCAGCTTGGATCAGATTGCGTTCCCGCCTT  
CAGTTAAACTATCAGTGTGACAGGATATTGGCGGGTAAACCTAACAGAGAAAAGAGCGTTA

**Figure 23, SEQ ID NO: 27**


Expression cassette number 1710 from 2X35S promoter to NOS terminator. VP2(opt) from Rotavirus A WA strain is underlined.

GTCAACATGGTGGAGCAGCACACTTGTCTACTCCAAAAATATCAAAGATACTGTCAGAAGACC  
AAAGGGCAATTGAGACTTTCAACAAAGGGTAATATCCGGAAACCTCTCGGATTCCATTGCCAGC  
TATCTGTCACTTATTGTGAAGATAGTGGAAAAGGAAGGGCTCTACAAATGCCATCATTGCGAT  
AAAGGAAAGGCCATCGTTGAAGATGCCCTGCGACAGTGGTCCAAAGATGGACCCCCACCCACG  
AGGAGCATCGTGGAAAAGAAGACGTTCAACCACGCTCAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCAGCACACTTGTCTACTCCAAAAATATCAAAGATACTGTCAGAAGACCAAAGG  
GCAATTGAGACTTTCAACAAAGGGTAATATCCGGAAACCTCTCGGATTCCATTGCCAGCTATCTG  
TCACTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATCATTGCGATAAGGA  
AAGGCCATCGTTGAAGATGCCCTGCGACAGTGGTCCAAAGATGGACCCCCACCCACGAGGGAC  
ATCGTGGAAAAGAAGACGTTCAACCACGCTCAAGCAAGTGGATTGATGTGATACTCCACTG  
ACGTAAGGGATGACGCAACATCCACTATCCTCGCAAGACCCCTCTATATAAGGAAGGTCATT  
CATTGGAGAGGTATTAAAATCTTAATAGGTTGATAAAAGCGAACGTGGGAAACCGAACCAA  
CCTTCTCTAAACTCTCTCATCTCTTAAAGCAAACCTCTCTTGTCTTCTGCGTGGCAG  
TCAACGTGTAGATCGTGTCTGGCACCGAGTACAACGTTTCTTCACTGAAGCGAAATCAAAGATC  
TCTTGTGGACACGTTAGTGCAGGCCATTAAATAACGTTACTGTGCTTATCTTGTGGTGTGGCT  
TGGGAAAAGAAAGCTTGTGGAGGTGTGCTGAGCCACATATTACTTGTACGATTCTGCTGACT  
TTCGGCGGGTGAATATCTACTTGTGCTGAGGGTATTGTGCTGTACTTCTTCTTCTTCTC  
TTGCTGATTGGITCTATAAGAAATCTAGTATTCTTGTGAAACAGAGTTTCCGTGGTTTCTGAACT  
GGAGAAAGATTGTTAAGCTTGTATATTGTGCCAAATTGTGGGGCCATGGCATACCGAACAGAG  
AGGAGCAAAGCGAACCTGCGCAACAGAACGAGAGACTGCAAGAAAAGAGATAGAGAAAAG  
ATGTCGACGTAACAATGGAAAACAAGAATAACAATAGGAAACACAGTGTCCGACAAAGTCTG  
CCCAGAAGGAGGAATTATCACTGACGCCAGGACGATAAAAATTGCGGAGAAATAAGAAGA  
GCTCGAAAGAAGAAGAATCTAAACAGCTGCTGAAATTCTGAAAACAAAAGAACGATCAGAAAGA  
TTCAATATGAAATTGCAAAACAAATACCTACATTGAGTCAAGAAAAGATTCCTCAAGAAGCT  
TGAAGACATAGACCGGGAGCAGGCAAAACAGATGAAAACCTTCTGCAATTGAGCCAAACAA  
GCTCCCTATATTCGGCCAATGGCAGAAGGGAGCTACGCAACCGGTGTACTGGAATTGAAAAA  
AGACACCCCTGCCAGATGGAGATTAGACGTCGGAGATTCTCAATCTGAGTCAACGATCCTCA  
TCGAAATGCCGACTATCTGCTCTCAAGGACATGCCGTGGAGAACAAAAATAGCAGAGACGCC  
GAAAGTTGTCGACTCTGAGACTGCAATATTGTGATGCCATCTCCAGGATGAGGAGACCGAGGG  
AGTCGTCGAGATTCTACGCTGATATGCCAACAGGTCAGGCTGATGTAACATTGCAATTAC  
CCTTCATCCTCACCTATTGATCATGCAATTCAATGAGTATTCTTAACACCAGTGGTGGAGCC  
GCTGAACAATGAGATAATCTCAATTACATACCGAGAGGGATAAGGAATGACGTGAATTACATCTG  
AACATGGATATGAATCTGCCATCTACAGCCAGGTATATCAGGCCAACTTGTGCAAGGATAGACTGA  
ATCTTCACGATAATTGAGTCCCTGTGGGATACCATCACAACATCCAACACTACATTGCCAGGTC  
GTCGTTCCCGATTGAGGAGAAGGAGCTGGTCTCCACCGAACAGACAGATCCAGAAAATGAGCCAG  
GACCTGCAGCTGGAGGCCCTCACTATTAGAGCGAGACACAGTTTAGCCGGATTAAACAGTCAGG  
CTGCCAATGATTGTTCAAGACCCCTCATAGCCGCCATGCTGCTCAAGAACCATGTTCTGGACTTT  
GTGACCCAGAACTATAGGCTAATCTCCGGATATTGGCTACTTACAGTGGATTCCCAACGATATTG  
CCTCCGGGAGTCACTAGTGGCTGTGAGCTGGCGATCATCAACACCAGTGTATCCAGGATTCCGA  
ATGCAGAGAAATGCAATTCCGGAAATGCCAACCTCAGAACACCTTCCAGATCGCAGAACAGCAGATCC  
AGAATTCTCAGGTGGCGAACTGGCTCCATTTTATTAAACAATAACAGATTGCCAGGAAAGTGTGATTGA  
TGGAGTTCTGAATCAGACTCTGAAACGACAATATCGGAATGGACAGGTGATCAACCGACTGATGGAA  
GCATTGATGCAACTCAGCAGACAGCAGTCCCCACGATGCCGTGGATTACAACGGAGCATCCAAAC  
GGGGCATCTGCTCTCTCAATAGGCTGGGAGCTGACTTAACCCGACTGGTCTCCATTAAAC  
TACGAGACGCTAATGGCTGTGACCATGAAACATGCAAGCAGCTGCCAAACCCCTGACAACACTGAGAAGT  
TGCAGCTCACTTGTGACTTCGTTGTATTGTAACACAACCGTGATTCCGCCCCACAG  
ACACTGTTCACTACTACAACATCAACGTAATTCCACTCCAATTATAATGAGCGGATCAACGACG  
CCGTCGCCATAATTACCGCAGAAATAGGCTGAATCTTATCAGAAAAAAATGAAGTCCATAGTGG  
AGACTTCTGAACCGGCTCCAGATTTCGACGTACCGACAGTGGCTGACGACCAAATGTACAGGTG  
AGGGATCGCCTCGGCTTACCCGTTGAACGGAGACGGCTGACATATTCAACTGATCTGATG  
ATATGGAGCAGATCGAACGCCCTCTGATAAGATTGCTCAGGGGTTATCATCGCATACCGAGATAT  
GCAGCTGGAAACGCCAGCAGAGATGTACGGATACTGTTAATATTGACCGGAATCTGATGGTACCCAGCAA  
ATTAACCTGGAGGAACCTCATGCCACCGGTGATTACGGACAAATTACGAAACATGCTCTCAACAAATC  
AACCCGTTGCCCTTGTGGGTGATTGCCCTCGTACGGACTCATCCGTGATCAGTCTAATGCCAAAG  
CTCGACCGCAACCGCTTCTGCTCAGATAGTGAAGGTCAGGAAAGTGTGACACACTGAAAGCCACTACTGT  
ACAAAATAACTCCGATTCTCAATGACTTACCTTGTGGCCAACTACGACTGGATCCCCACAAAGT  
AACTAAGGTCTACAAACAGGTGCCAACCCATTGACACTTGTGATTAGAGCCAGCATGACATGTCGACTTCT  
AACCTACGTTACCGTCTACTCTGACCTACTGTGATTGTTCAAGCGGACACGGTAGAGCCATTAA  
CGCAGTCGATTGCAACATATGCAATAATGACGAGCTTAAAGGCCATTCTTCTGAGTGTGTTATTITAT  
TACTGTTATTGCGTGTGCAATTCTATGTTGGTGGAGCGGTTTCTGCTGAGTGTGTTATTITAT

GTAATTAATTCTTTGTGAGCTCCTGTTAGCAGGTCGTCCCTCAGCAAGGACACAAAAAGATTT  
AATTATTAaaaaaaaaaaaaAGACCGGGATTGATATCAAGCTTATGACCTGCAGATC  
GTTCAACATTGGCAATAAAAGTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCATGATTATCATA  
TAATTCCTGTTGAATTACGTTAACATGTAATAATTAACATGACGTTATTATGAGATG  
GGTTTTATGATTAGAGTCCGCAATTATACTTAATACCGATAGAAAACAAATAGCGCGCA  
AACTAGGATAAATTATCGCGCGCGTGTATCTATGTTACTAGAT

Figure 24

Schematic representation of construct number 1711



## C-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS (Construct number 1713)

**Figure 25a, SEQ ID NO: 28**

IF-WA VP6(opt).s1+3c

AAATTGTGGGGCCATGGAGGTCTTATAGTCTCTCCAAAACGCTGA

**Figure 25b, SEQ ID NO: 29**

## IF-WA VP6(opt).s1-4r

ACTAAAGAAAATAGGCCTCTACTGATCAACATACTCCGGATAGAGGCCA  
CA

**Figure 25c, SEQ ID NO: 30**

Expression cassette number 1713 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.

GTCAACATGGTGGAGCAGCACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTAGAACAGCC  
AAAGGGCAATTGAGACTTTCAACAAAGGTAAATATCCGAAACCTCTCGGATTCCATTGCCAGC  
TATCTGTCATTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATCATTGCGAT  
AAAGGAAAGGCCATCGTTGAAGATGCCCTGCCACAGTGGTCCAAAGATGGACCCCCACCCACG  
AGGAGCATCGGGAAAAGAAGACGTTCAACCACGTCTCAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCAGCACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTAGAACAGCAAAGG  
GCAATTGAGACTTTCAACAAAGGTAAATATCCGAAACCTCTCGGATTCCATTGCCAGCTATCTG  
TCACCTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATCATTGCGATAAAGGA  
AAGGCCATCGTTGAAGATGCCCTGCCACAGTGGTCCAAAGATGGACCCCCACCCACGAGGAGC  
ATCGTGGAAAAGAAGACGTTCAACCACGTCTCAAGCAAGTGGATTGATGTGATACTCTCAG  
ACGTAAAGGGATGACGACAATCCACTATCTTGCAGAGCCTCTCTATAAGGAAGTTCATT  
CATTGGAGAGGTATAAAATCTTAAAGGTTGATAAAAGCGAACGTGGGAAACCGAACCCAAA  
CCTTCTCTAAACTCTCTCATCTCTTAAAGCAAACCTCTCTTGTCTTCTGCGTGGCAG  
TCAACGTGTAGATCGTGTGGCACCGTACAACGTTTCTTCACTGAAGCGAACATCAAAGATC  
TCTTGTGGACACGTAGTGCAGGCCATTAAATAACGTGACTTGTCTTCTGCGTGGCT  
TGGGAAAAGAAAGCTTGTGGAGGTGTCTCAGCCCCATACATTACTTGTACGATTCTGCTGACT  
TTCGGGGGTGCAATATCTACTTGTGTTGACGAGGTATTGTTGCTGTACTTCTTCTTCTC  
TTGCTGATTGGTCTATAAGAAATCTAGTATTTCCTTGAACAGAGTTTCCGTGGTTTCAACCT  
GGAGAAAGATTGTTAAGCTTGTATATTCTGCCAAATTGTCGGGCCATGGAGGTCTTATAGT  
CTCTCCAAAACGCTGAAGGACGCTAGGGACAAGATCGTGGAGGTACACTTATAGCAATGTCAGCG  
ACCTAACAGCAGTTAACATGATCGTACAATGAATGGAATGATTCCAAACTGGCGGTAT  
TGGTAATCGCCCGTGGAGGAACCTGGACATTGAGTTCGATTCTGGCCTGCTGGCACGACTCTCTTAAATCTG  
ATGCAAATTATGTAGAAACGCCAGAACGATTATCGAGTACTTATCGATTCTGATAACGTTG  
ATGGATGAGATGGCCCGAGTCACACCGAACGGAGTTGCTCACAGTCCGAGGCCCTTGGAA  
CTCGCCGGCATTAAGTCAGCTTAAATTGCAACACTCTCCGAATATAGAACACTGGAA  
GCAGAACTGTCGACAGAGAACCGGCTCGTGTCCATAAACCTAATATCTTCCGTATAGCGCCTCAT  
TCACCCCTGAATAGGAGTCAGCCCAGTCACGACAACCTCATGGTACAATGTGGCTGAATGCGGGAG  
TGAAATACAGGTCCCGGGTTCGATTACTCTGTGCCATTAAATGCAACCGCAAACATCCAGCAGTTC  
GAACATATCGTCAACTAACGACGGCTCTCACGACCGGACAATTACACTCTGCCGACGCCGAGC  
GCTTCTCTTCCCGTAACTCAACTCAGTGTGGGCCACCACTGGTCTTCAACCTGTTATAT  
TGCCTCTAACACGTTAGAGGTGGAGTTCTTAAACGGACAGATCATCAATACCTACCAAGCCAG  
GTTCCGGACGATTATTGCAAGAAATTGACGCTATCAGGCTGCTTCCAACTGATGAGGCCCCCA  
ATATGACTCCCCTGTGAACGTTGTTCCGAGGCTCAGCCTTCCAGCACCGCCACCGTCCGG  
TTGACTCTCGAATAGAGAGCGCGGTCTCGAATCAGTGTGGCAGACGCCAACGCTGCTGG  
CAAACGTTACCGCCGTGCCAGAGTATGCCATCCAGTAGGGCTGTTCTTACCCGGCATGAA  
CTGGACTGAACTAATTACTAACATAGCCCATCCAGAGAACAACTTGCAGCGGGTCTTCACTGTG  
GCCCTATCCGGAGTATGTTGATCAAGTAGAGGCATTCTTGTGTTATTTATGTAATTAAATTCT  
GTGCAATTCTATGTTGGTGCAGCGGTTCTGCTCAGAGTGTGTTATTTATGTAATTAAATTCT  
TTGTGAGCTCTCTTGTAGCAGGTCTGCTTCTCAGCAAGGACACAAAAAGATTAAATTAAATTCT  
AATAAGTTCTAAGATTGAACTCTGTGTCAGCGGTCTGCGATGATTATCATATAATTCTGTTGAATT  
ACGTTAACGATGTAATAATTACATGTAATGCACTGAGCTTATTATGAGATGGGTTTATGATTAGA  
GTCCCGCAATTATACATTTAACGCGATAGAAAACAAAATAGCGCAGAACACTAGGATAAATTAT  
CGCGCGGTCTCATCTATGTTACTAGAT

**Figure 25d**

Nucleotide sequence encoding VP6(opt) from Rotavirus A WA strain (SEQ ID NO: 46)

```

ATGGAGGTCTTATAGTCTCTCCAAAACGCTGAAGGACGCTAGGGACAAGATCGTG
GAGGGTACACTTATAGCAATGTCAGCGACCTAATACAGCAGTTAATCAAATGATC
GTTACAATGAATGGGAATGATTCCAAACTGGCGGTATTGGAATCTGCCGTGAGG
AACTGGACATTGATTGGCCTGCTGGCACGACTCTCCTTAATCTGATGCAAAT
TATGTAGAAAACGCCAGAACGATTATCGAGTACTTTATCGATTTATTGATAACGTT
TGTATGGATGAGATGGCCCGCAGTCACAACGGAACGGAGTTGCTCACAGTCCGAG
GCCCTCGGAAACTGCCGGCATTAAGTCAAGCGTATTAATTTCGACAACCTCTCC
GAATATATAGAGAACTGGAACATTGCAAGAACATCGTCGACAGAGAACCGGCTTCGTT
CATAAACCTAATATCTTCCGTATAGCCCTCATTCACCCCTGAATAGGAGTCAGCCC
ATGCACGACAACCTCATGGGTACAATGTGGCTGAATGCCGGAGTGAATACAGGTC
GCCGGGTTGATTACTCCTGTGCCATTATGCACCCGAAACATCCAGCAGTCGAA
CATATCGTCAACTAACGACGGCTCTCACGACCGCGACAATTACACTCCTGCCGAC
GCCGAGCGCTTCTCCTTCCCCCGTAATCAACTCAGCTGATGGCGCCACCACCTGG
TTCTCAACCTGTTATATTGCGCCCTAACACGTAGAGGTGGAGTTCTCTTAAAC
GGACAGATCATCAATACTACCAAGCCAGGTTGCCAGCAGATTATTGCAAGAAATTTC
GACGCTATCAGGCTGCTTCCAACGTGAGGCCCCCAATATGACTCCGCTGTG
AACGCTTGTTCGCAGGCTCAGCCTTCCAGCACGCCACCGTCGGCTTGACT
CTTCGAATAGAGAGCGCGGTCTCGAATCAGTGTGGCAGACGCCAACGAGACGCTG
CTGGCAAACGTTACCGCCGTGCGGCAAGAGTATGCCATCCCAGTAGGGCTGTGTT
CCACCCGGCATGAACGGACTGAACTAATTACTAATAGCCCATCCAGAGAACG
AACTTGCAAGCGGGTCTTCACTGTGGCTCTATCCGGAGTATGTTGATCAAGTAG

```

**Figure 26, SEQ ID NO: 31**


Amino acid sequence of VP6 from Rotavirus A WA strain

```

MEVLYSLSKTLKDARDKIVEGTLYSNVSDLIQQFNQMIVTMNGNDFQTGGIGNLPVRNWTDFGLLGTTL
LNLDANYVENARTIEYFIDFIDNVCMDEARESQRNGVAPQSEALRKLAGIKFKRINFDNSSEYIENWNL
QNRRQRTGFVFHKPNIFPYSASFTLNRSQPMHDNLMTWLNAGSEIQQVAGFDYSCAINAPANIQQFEHI
VQLRRALTTATITLLPDAERFSFPRVINSADGATTWFFNPVILRPNNVEVEFLNQIINTYQARFGTIIARN
FDAIRLLFQLMRPPNMTPAVNALFPQAQPFQHHATVGLTLRIESAVCESVLADANETLLANVTAVRQEYA
IPVGPVFPPGMNWTELITNYSPSREDNLQRVFTVASIRMLIK

```

**Figure 27**  
Schematic representation of construct number 1713



D-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1714)

**Figure 28**, SEQ ID NO: 32

Expression cassette number 1714 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.


GTCAACATGGTGGAGCAGCACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
AAAGGGCAATTGAGACTTTCAACAAAGGGTAATATCCGAAACCTCTCGGATTCCATTGCCAGC  
TATCTGTCACTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGAT  
AAAGGAAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
AGGAGCATCGTGGAAAAAGAAGACGTTCAACCACGTCTCAAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCAGCACACTTGTCTACTCCAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG

GCAATTGAGACTTTCAACAAAGGGTAATATCCGAAACCTCTCGGATTCCATTGCCAGCTATCTG  
TCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGATAAAGGA  
AAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
ATCGTGGAAAAAGAAGACGTTCAACCACGTCTCAAAGCAAGTGGATTGATGTGATAATCTCCACTG  
ACGTAAGGGATGACGACAATCCCACTATCTCGCAAGACCCCTCCTCTATAAAGGAAGTTCATT  
CATTGGAGAGGTTAAAAATCTTAATAGGTTGATAAAAGCGAACGTGGGGAAACCCGAACCAA  
CCTCTCTAAACTCTCATCTCTTAAAGCAACACTCTCTTGTCTTCTTACTGAAGCGAAATCAAGATC  
TCAACGTTGTCAGATCGTGTCGGACCAGTACAACGTTTCTTACTGAAGCGAAATCAAGATC  
TCTTGTGGACACGTAGTGCGGCGCCATTAAATAACGTGTACTTGTCTATTCTGCGGTGTTGCT  
TGGGAAAAGAAGCTTGTGGAGGCTGCTGTTAGCCCCATACATTACTGTTACGATTCTGCTGACT  
TTCGGCGGGTGAATATCTACTTCTGCTGACGAGGTATTGTTGCCTGTACTCTTCTTCTTCTC  
TTGCTGATTGGTTCTATAAGAAATCTAGTATTCTTGAAACAGAGTTTTCCGTGGTTTCAACTT  
GGAGAAAGATTGTAAGCTTGTATATTCTGCCAATTGTCGGGCCATGGAGGTCCTTATAGT

CTCTCCAAAACGCTGAAGGACGCTAGGGACAAGATCGTGGAGGGTACACTTATAGCAATGTCAGCG  
ACCTAATACAGCAGTTAATCAAATGATCGTACAATGAATGGGAATGATTCCAAACTGGCGGTAT

TGGTAATCTGCCGTGAGGAACTGGACATTCGATTTCGGGCTGCTGGCACGACTCTCTTAATCTCG  
ATGCAAATTATGTAAGAAAAACGCCAGAACGATTATCGACTATTCGATTATGATAACGTTG  
ATGGATGAGATGGCCCGCGAGTACAACCGGAACGGAGTTGCTCCACAGTCCGAGGGCCTTCGGAAA  
CTCGCCGGCATTAAAGTCAAGCGTATTATTCGACAACTCTCCGAAATATATAGAGAACTGGAACTT  
GCAGAATCGTCGACAGAGAACCCGGCTCGTGTCCATAACCTAATATCTTCCGTATAGCGCCTCAT  
TCACCCTGAATAGGAGTCAGCCCATGCACGACAACCTCATGGGTACATGGGCTGAATGCGGGGG  
TGAAATACAGGTCGCCGGGTTCGATTACTCCTGTCCATTATGCACCCGCAACATCCCAGCGATTC  
GAACATATCGTCGCAACTAGACGGCTCTCACCGCGACAATTACACTCCCTGCCGACCCGGAGC  
GCTTCTCTTCCCCCGGTTACAACTCAGCTGATGGCGCCACCACTGGTTCTCACCCTGTTAAT  
TGCGCCCTAACAACGTAGAGGGTGGAGTTCTCTAACGGACAAGATCAATACCTACCAAGCCG  
GTTCGGCACGATTATGCAAGAATTCGACGCTATCAGGTCTGCTCTCAACTGTGAGGCCCCCA  
ATATGACTCCCGCTGTGAACGCTTTGTCCCGCAGGGTCAGCCTTTCCAGCACCACCGCCACGTCG  
TTGACTCTCGGAATAGAGAGCGCGGTCTCGGAATCACTAGGTGTGGCAAGCGCCACCGAGACGCTGTGG  
CAACGTTACCCCGGTCGGGCAAGAGGTATGCCATCCCAGGTAGGGCCGTGTTTCCACCCGGCAATGAAA  
CTGGACTGAACTAATTACTAACTATGCCCCATCCCAAGAGAAACCAACTGTGCAGCGGGGTCTTCACTGT  
GCCTCTATCCCGAGATGTGTCAAGGTAGGGCCCTATTTTCTTTAGTTGAATTTACTGTTTATTCGGT  
GTGCATTCTTATTTTGGGTGACGGGTTCTGTGTCTCAGGATGTGTTTATTTTATGTAATTAATTCT  
TTGGTGAGCTCTGTTTAGCGGTCCCTTCCAGAGGACCAAAAAGATTTTATTTTATTTAAAA  
AAAAAAAAAAAAAAAGACGGGGAAATCGATATCAAGCTTTATCGACCTGCAGATCGTTCAAAACATTTGGC  
AAAAAAGTTCTTAAGATGAATCCGTTTGTCCGGGTCTGTCGATGATTATCAATAATTCTGTGAAT  
ACGTTTAAGCGATTAAAATCAATGTTAATGCATGCGTTTATTTATGAGAATGGGGTTTTATGATTGA  
GTCCCGCAATTAACTTTAAAATCGCGATGAAAAAACAAAAATAGCGCGCAAAACTAGGGAATTATTA  
CGCGCGGGGTGTCATCATGTTTACTAG

**Figure 29**  
Schematic representation of construct number 1714



E-2X35S/CPMV-HT/ RVA(Rtx) VP4(opt)/ NOS (Construct number 1731)**Figure 30A, SEQ ID NO: 33**

IF-Rtx\_VP4(opt).s1+3c

AAATTGTCGGGCCATGGCTAGCCTGATCTACAGACAACTCTGACCAAT  
TC**Figure 30B, SEQ ID NO: 34**

IF-Rtx\_VP4(opt).s1-4r

ACTAAAGAAAATAGGCCTTCAGAGTTACATTGCAGGATTAATTGCTCAA  
TCCTA**Figure 31A, SEQ ID NO: 35**

Expression cassette number 1731 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.

GTCAACATGGTGGAGCAGCACACTTGTCTACTCCAAAATATCAAAGATACAGTCTCAGAAGACC  
AAAGGGCAATTGAGACTTTCAACAAAGGGTAATATCGGAAACCTCTCGGATTCCATTGCCAGC  
TATCTGCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGAT  
AAAGGAAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
AGGAGCATCGTGGAAAAAGAACGTTCAACCACGTCCTCAAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCAGCACACTTGTCTACTCCAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
GCAATTGAGACTTTCAACAAAGGGTAATATCGGAAACCTCTCGGATTCCATTGCCAGCTATCTG  
TCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGATAAAGGA  
AAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCGAGGAGC  
ATCGTGGAAAAGAACGAGCTTCAACCACGTCCTCAAAGCAAGTGGATTGATGTGATAATCTCCACTG  
ACGTAAGGGATGACGCAACATCCCACTATCCTCGCAAGACCCCTCCCTATATAAGGAAGTCATT  
CATTGGAGAGGATTAAAAACTTAAATAGGTTGATAAAAGCGAACGTGGGGAAACCGAACCAA  
CCTCTCTAAACTCTCTCATCTCTTAAAGCAACACTCTCTTGTCTTACTGAGCGATCT  
TCAACGTTGTCAGATCGTCTCGGCCACCAGTACAACGTTTCTTACTGAAGCGAAATCAAAGATC  
TCTTGTGGACAGTAGCGCGCATTAAATAACGTTGACTTGTCTATTCTGCGGTGGTCT  
TGGGAAAAGAAAGCTTGTGGAGGCTGCTGTCAGCCCCATACATTACTGTTACGATTCTGCTGACT  
TTCGGCGGGTGAATATCTACTTCTGTTGACGAGGTATTGTTGCTGTACTCTTCTTCTCTTC  
TTGCTGATTGGTCTATAAGAAATCTAGTATTCTTGAACAGAGTTTCCGTGGTTTCAACTT  
GGAGAAAAGATTGTAAGCTTGTATATTCTGCCAATTGTCGGGCCATGGCTAGCCTGATCTAC  
AGACAACCTTGACCAATTCTATTCTGTGGATCTTCATGACGAAATCGAGCAGATTGGGTCCGAGA  
AGACCCAGAACGTGACCATCAACCCCTGGACCTTTGTTCAGACCCGCTATGCCCTGTGAATGGGA  
TCACGGAGAAATCAACCGACGTACACGGCCGTCAACCCCCATTCGGACGGCCATACCAACCCACCC  
TTCCACCCACCTTAATGGATTTTAATCACTCCACACAACCGGAGGTGGCTACGAGTCCAC  
TAATTACTCCGATTTTGGACCCGGCTGTTAGCCCACCGTCTACCGTCGATCCCAGT  
ATATGAATTCGGCGATCCAAACAGTTACGTCCTAATCGACAACAATGGAGTTCTGGTA  
GATTTTCGGCAGTCCCTTCCAGAACGAATCTTAATAGACGGACCCTTACCTCCGATAACCCACCTCG  
TGGGATTTTTAAGTACGGCGCGGGGTGGACATTCACGGGTAAACCCCTCGAGCAACCACTGA  
CTCCAGTACGACGTCAAACCCTGAAACAATATCTTATTACCACCACAGCGGAATCTCATAATCCCA  
AGATCTCAGGAAAGTAAGGTTAACGAATATATCAACAACCGGACTTCCCCCAATTCCAGAATACCG  
AACGTTGGGTCCCTCCACTCAGTTCTCGGTCTATCCAGTAATAGAGAGCAAGGTGAATGAGGA  
TTATGTGAAGACTAGCTTGGAAAGAAATCGAGTAACACAGAGACATTAATCCGGTTAA  
GTTGGAACTTACTGTGAAGATGGCGCCCTGGGGTACAAAATGGGTCAAAATCTCATAAAAGCC  
GCCAACTATCAGTTAACTACTGTGAAGAGACGGCGAGCGAGGTTAACCCCCACACCAATGTCTGTCA  
ACGGCGTTAATAACTTAGCTTACAACGGAGGGCTCCCTCCACCGACTTCGGGTATCGCCGGATGTGA  
AGTCATCAAGGGAAATCTTAATGTGTACGTAGATTACGTGGATGTTAGCAAAGCGTTCCCGCAACATGT  
GTGTATGTGTAGGGCGCTGTCATACTCAATCTGTGAAGGTGTACGTGGATGTCATATTATCTCT  
AATTCCCGTGGGGCTGGCCAGTCTAGTGAATGGGGGGCAGTCTCCCTCATTGTGGCGGTGACGGT  
TGAGCACTAGGGTTACCGGTGTCTCTGTGAATCCCTGTGGATTTCCGGTTCCCTTACTGTCGACGT  
AGCCCCCATTCAGCATCTGTCATAAGGAACGTCAACCTCACGGGGTTACCGTCCCGGAATCCAA  
CAACGGCAATGAAATACTATGAAAATTCGGCCCTCTCTTTGATAAGGTGTACCAACTAATGA  
GACTATCAGAACCCCATCATGAACAGCGGTACGTCAGACGACAGGGACCTGGAAAGACCAACTTACAGAT  
CTCGGGGAAGAAATTCAACTCTGTCAGTCAATGGCCCAATGTGATAAGGTAGATCTGCCCTACT  
GCCTCTCGATATGTTTAGTAGTGTCTCCGGCATAATCAACTAATAGATGTGACAAAAGAGCAGTGGCTTA  
CTTCGTGTATGAAGAAGTTCAGGGAAATCAAAACCTGCCCACGGCATACAGAAAATGACAACCTCT  
GAGGTATGCAGCATCATCACGGTCACGCAACGTTCAGCAACGTGGATACCTCCTTGAACGTATTTCTACCCAGCG  
TGGACAAACGTGTCCAACGACGTCAACGTCAACGTGGATACCTCCTTGAACGTATTTCTACCCAGCG  
CAACGTCAAGTAAGAAACCTCCGTTAAGAAATGATCACCCAGACGTGGAAATGTCTTTCGACGA

CATTCCGCCGCCGTGCTAAAAACCAAAATCGATATGTCTACTCAGATCGGCAAGAACACTCTGCCG  
 GATATCGTAACCGAAGCCTCCGAAAAGTTATCCCTAAGCGCAGCTACAGAATATTGAAAGATGACG  
 AGGTCACTGGAGATCAACACAGAAGGGAAGTCTCGCTTAAAGATCAACACACCTTGACGAGGTTCC  
 GTTGCAGTCATAAGTTGCAGAGCTCGTACAGATAGTCCAGTGAATTCTGCCATCATTGACTTTA  
 AGACTTGAGAACCTGAACGACAATGGAAATAACACGGACCGAAGCGTTGAACCTCATTAAGTC  
 CAATCCAATATGTTGCATAATTCAACCAGAACATCCAATCATAAGAAATAGGATTGAGCAA  
 TTAATCCTGCAATGTAACCTGAAGGCCATTITCTTGTGAGTGTGTTATTATGTAATTAAATTCTTG  
 TTCTATGTTGTGAGCGGTTCTGTGCTCAGAGTGTGTTATTATGTAATTAAATTCTTG  
 GCTCTGTTAGCAGGCTCCCTCAGCAAGGACACAAAAGATTTAATTAAATTAAAAAAA  
 AAAAGACCGGGAAATCGATATCAAGCTTATCGACCTGCAGATCGTCAAACACATTGGCAATAA  
 AGTTCTTAAGATTGAATCCTGTTGCCGGTCTGCGATGATTATCATATAATTCTGTTGAATTACGTT  
 AAGCATGTAATAATTACATGTAATGCATGACGTTATTATGAGATGGGTTTATGATTAGAGTCCC  
 GCAATTATACATTAATACGCGATAGAAAACAAATAGCGCAGAACAGGATAAAATTATCGCGC  
 GCGGTGTCATCTATGTTACTAGAT

**Figure 31B**

Optimized coding sequence of Rotavirus A VP4 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO: 47)

ATGGCTAGCCTGATCTACAGACAACCTTGCACCAATTCAATTCTGTGGATCTCATGACGAAATCGA  
 GCAGATTGGTCCGAGAACGCCAGAACGTGACCATCAACCCCTGGACCTTTGCTCAGACCCGCTAT  
 GCCCTGTGAATTGGATCACGGAGAAATCAACGACAGTACGACCGTCAACCCATTCTGGACGGGC  
 CATACCAACCCACCACCTCACCCCCACCTAATGATTATTGATTAACTCAACTCCAACACAAACGGA  
 GTGGTCTACGAGTCCACTAATACTCGATTITGGACCGCCGTTGAGCCATGCCAGCAGCAAC  
 TCCTGTCGATGCCAGTATATGATATTGCGAGTCCAAACAGTTAACGTTCAATGACAGCAAC  
 AAATGGAAGTTCTGGAGATGTTGCGAGCTCTCAGAACGAATTCTATAATAGACGGACCTTA  
 CCTCCGATACACGACTCGTGGGTATTAAAGTACGGCGCAGGGTGTGGACATTACGGTAAAC  
 CCCTCGAGCAACCAACTGACTCCAGTAGCCTGAACAACTGAACAATATCTATTACCATCCACAGC  
 GAATCTACATAATCCAAAGATCTCAGGAAAGTAAGTGTAACTGAATATCAACAAACGGACTCCCC  
 CAATTCAAGAATACACGGAACGTGGTGCCTCTCCACTCAGTTCTCGGTCTATCCAGTATAAGAGAGC  
 ACAAGTGAATGAGGACATATTGTGAGCAAGACTAGCCTTGGAAAGAAATGCAAGTACAACAGAGA  
 CATTATCATCCGGTTAAAGTTGGAACTCTATCGTGAAGATGGGCGCCTGGGGTACAAATGGTCA  
 GAAATCTCATATAAAAGCCGCAACATCAGTAAACTACTTGTGAGAGACGGCAGCAGGTAAACGCC  
 ACACAACATGCTCTGTCACGGCGTTAATAACTTGTGAGTACGTTCAACCGAGGGCTTCCCTCCACCGACTTC  
 GGTATCAGCGGTATGAAGTCATCAAGGAAAATTCTTATGTGAGTACGTTAGATTACTGGGATGATAGCA  
 AAGCGTCCGCAACATGGTGTATGTTAGGAGCCTGGCTGCTAATCTCAATTCTGTAAGTGTACTGGT  
 GGATCATATTATTCTCAATTCCGTGGGGCTTGGCCAGTCATGAATGGCGGGCAGTCTCCCTCCA  
 TTTGCTGGCGTGACGTTGAGCACTCAGTTACCGATTCTGTCGCTCTGAACTCCCTGAGGTTCCGGTT  
 TTCCCTACTGTCGACGAGCCCCATTCACTGCAATTCTGCTACAAGAACTGTCAACCTCTACGGGTAC  
 CTGCCGGAATCCAACACGGCAATGAATACTATGAAATTCCGGCCCTCTTTGATAAGTCT  
 GGTACCAACTAATGACGACTATCAGACACCCATCATGAACAGCGTACTGTCAGACAGGACCTGGA  
 AAGACAACCTACAGATCTCGGGAAGAATTCAATTCTCTCAGTCAGGAGATTGCAATGGCCAATTG  
 ATAGATCTGCCCTACTGCCCTCTCGATATGTTAGTATGTTCTCCGGCATCAAATCAACTATAGATCT  
 GACAAAGAGCATGGCTACTCTGTGATGAAGAAGTTAGGAGATTGCAACCTTGCCACGAGCATATCA  
 GAAATGACGAACACTCTGAGTACGAGCATTCAGCGTACGCAACGTTCCATTGGTCAAC  
 TCAGCGCATCAGCAACTGGACAAACAGTGTCAACGACGTACGCAACGTTCCATTGGTCAAC  
 TATTCTACCCAGACGTCAACGATCAGTAAGAAACTCCGCTGAAAGAAATGATCACCCAGACTGAG  
 GGAATGTCTTCGACGACATTCCGCCGTGCTAAACCAAAATGATATGTCAGTCACTCAGATCG  
 GCAAGAACACTCTGCCGGATATCGTAACCGAACGCTCCGAAAGTTATCCCTAAGCGCAGCTACAG  
 AATATTGAAAGATGACGAGGTACATGGAGATCAACACAGAAGGAAAGTTCTCGCTTATAAGATCAA  
 CACCTTGACGAGGTTCCGTTGACGTCATAAGTTGAGAGCTGACAGATAGTCAGTGAATT  
 CTGCCATCATTGACTTAAGACTTTGAGAACCTGAAACGACAACATGGAATAACACGGACCGAAGC  
 GTTGAACCTCATTAAGTCAAATCCAATATGTTGCGCAATTCAACCAGAACATCCAATCATAA  
 GAAATAGGATTGAGCAATTAAATCCTGCAATGTAAACTCTGA

**Figure 31C** (SEQ ID NO: 44)

Expression cassette number 1730 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.


GTCAACATGGTGGAGCAGCACACACTTGTCTACTCCAAAAATATCAAAGATACTGTCAGAAGACC  
 AAAGGGCAATTGAGACTTTCAACAAAGGGTAATATCCGGAAACCTCTCGGATTCCATTGCCAGC  
 TATCTGTCACTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGAT  
 AAAGGAAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCAAAGATGGACCCCCACCCACG  
 AGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCTCAAAGCAAGTGGATTGATGTGATAAC  
 ATGGTGGAGCAGCACACTTGTCTACTCCAAAATATCAAAGATACTGTCAGAAGACCAAAGG  
 GCAATTGAGACTTTCAACAAAGGGTAATATCCGGAAACCTCTCGGATTCCATTGCCAGCTATCTG  
 TCACTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGATAAAGGA  
 AAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCAAAGATGGACCCCCACCCACGAGGAGC  
 ATCGTGGAAAAGAAGACGTTCCAACCACGTCTCAAAGCAAGTGGATTGATGTGATACTCCACTG  
 ACGTAAGGGATGACGCACAACTCCACTATCCTCGCAAGACCCCTCCCTATATAAGGAAGTTCATT  
 CATTGGAGAGGTATTAAATCTTAATAGGTTGATAAAAGCGAACGTGGGGAAACCGAACCAA  
 CCTCTCTAAACTCTCTCATCTCTTAAAGCAGAAACTCTCTCTTGTCTTCTGCCTGAGCGATCT  
 TCAACGTTGTCAGATGCTGCTCGGCCACCGTACAACGTTCTTCTACTGAAGCGAAATCAAAGATC  
 TCTTGTGGACACGTAGTCGGGCCATTAAATAACGTGTAATTGCTTATTCTGTGGGTGTTGCT  
 TGGGAAAAGAAGACTGCTGCTGGAGGCTGTTAGCCCTACATTACTGTTACGATTCTGCTGACT  
 TTGCGGGGTGCAATATCTACTTCTGCTGAGGTTATTGCTGACTTCTCTCTTC  
 TTGCTGATTGGTCTATAAGAAATCTAGTATTTCCTGAAACAGAGTTTCCGTGGTTTCAACTT  
 GGAGAAAGATTGTTAAGCTCTGTATATTCTGCCAATTGCTGGCCATGGCTAGCCTGATCTAC  
 AGACAACCTGACCAATTCAATTCTGTTGATCTCATGACGAAATCGAGCAGATTGGTCCGAGA  
 AGACCCAGAACGTGACCATCAACCTGGACCTTGTCAAGACCCGCTATGCCCTGTGAATTGGG  
 TCACGGAGAAATCAACGACAGTACGACCGTGAACCCATTCTGGACGGGCCATACCAACCCACC  
 TTCACCCCACCTAATGATTGGATTAAATCAACTCAACACAAACGGAGTGGTCTACGAGTCCAC  
 TAATAACTCCGATTGGACGCCGTTGAGCCATCGAGCCACACGTCATCCTGTCATGCCAGT  
 ATATGATACTCGCGAGTCAAACAGTTAACGTTCAATGACAGCAACAAATGGAAGTTCTGGA  
 GATGTTTCGCACTCTCTCAGAACGAAATTCTATAATAGACGGACCTTACCTCCGATACACGACTCG  
 TGGGTATTTTAAGTACGCGCGAGGGTGGACATTCAACGGTGAACCCCTCGAGCAACCAACTGA  
 CTCCAGTAGCAGTCAACAACTGAAATATCTATTACCATCCACACGCAATTCTACATAATCCCA  
 AGATCTCAGGAAAGTAAGTCAACGAATATCAACAAACGGACTCCCCCAATTCAAGAACACGG  
 AACGTGGTGCCTCTCCACTCAGTTCTCGGTCTACAGTATAAGAGAGCACAAAGTGAATGAGGACA  
 TTATTGTGAGCAAGACTAGCCTTGGAAAGAAATCGAGTACAACAGAGACATTATCATCGGTTAA  
 GTTGGGAACTCTATGTGAAGATGGCGCTGGGTACAAATGGTCAAGAAATCTCATATAAGCC  
 GCCAACTATCACTAAACTACTTGTACGAGGACTCCTCCACCGACTCGGTATCAGCCGTATGA  
 AGTCATCAAGGAAAATTCTTATGTGTACGTAGATTACTGGGATGATAGCAAAGCGTTCCGAAACATG  
 GTGTATGTTAGGAGCCTGGCTGCTAATCTCAATTCTGTGAAGTGTACTGGTGGATCATATTATTCTC  
 AATTCCCGTGGGGCTGCCAGTCATGAATGGCGGGCAGTCTCCCTCCATTGCTGGCGTGACGT  
 TGAGCACTCAGTTACCGATTCTGTCTGAACTCCCTGAGGTCCGTTTCCCTACTGTCAG  
 AGCCCCCATTCACTCGTACAAGAAACTGTCAACCTCTACGGTTACCTGCCAGAATCCAAA  
 CAACGGCAATGAATACTATGAAATTCCGGCCCTCTCTTGTAAACTGTCAGGTAACACTCT  
 GACTATCAGACACCCATCATGAACACGGTACTGTCAGACAGGACCTGGAAAGACAACCTACAGAT  
 CTGGGGAAAGAATCTCAATTCTCGTCACTGAGGAGATTGCAATGGGAAATTGATAGATCTGCCACT  
 GCCTCTGATATGTTAGTATGTTCTCCGGCATAAATCAACTATAGATCTGACAAAGAGCATGGCTA  
 CTTCTGTGATGAAGAAGTCAAGGAAATCAAACCTGCCACGAGCATATCAGAAATGACGAACACTCT  
 GAGTGTGATGCACTCATCGTCACGCAACGTTCCATTGGCTGAATCTCAGGCCATCAGAAC  
 TGGACAAACGTGTCCAACGACGTCAACGTGACCAACTCTGAAACGATATTCTACCCAGACGT  
 CAACGATCAGTAAGAAACTCCGTTGAAAGAAATGATCACCCAGACTGAGGGAAATGTCCTCGACGA  
 CATTCCGCCGCCGTCTAAACCAAAATCGATATGTACTCAGATCGGCAAGAACACTCTGCC  
 GATATCGTAACCGAACGCCCGAAAGTTATCCCTAAGCGCAGCTACAGAAATTGAAAGATGACG  
 AGGTATGGAGATCAACACAGAAGGGAAGTCTCGCTTATAAGATCAACACCTTGACGAGGTCC  
 GTTGTGACGTCAATAAGTTGAGAGCTGTGACAGATAGTCCAGTGATTCTGCCATATTGACTTTA  
 AGACTTGAAGAACCTGAAACGACAACATGGAATAACACGGACCGAAGCGTTGACCTCATTAAGTC  
 CAATCCCAATATGTCGCAATTCAACCGAACAAATCCAATCATAAGAAATAGGATTGAGCAA  
 TTAATCTCTGCAATGTAACCTGCAAGGGCTTCTGCTCAGAGTGTGTTATTGTAATTTCATTCTTGTGA  
 TTCTATGTTGGTGAAGCGGTTCTGCTCAGAGTGTGTTATTGTAATTTCATTCTTGTGA  
 GCTCCTGTTAGCAGGTGCTCCCTCAGCAAGGACACAAAAAGATTAAATTTCATTAAATTTA  
 AAAAAAAAGACCGGGAAATCGATATCAAGCTTATCGACCTGAGATCGTCAAACATTGGCAATAA  
 AGTTCTTAAGATTGAACTCTGTTGCCGCTTGTGATGATTATCATATAATTCTGTGAATTACGTT  
 AAGCATGTAATAATTACATGTAATGCACTGAGCTTATTGAGATGGGTTTATGATTAGAGTCCC  
 GCAATTATACATTAAATACCGCAGAGAAAACAAATAGCGCAGAACACTAGGATAAATTATCGC  
 CGGGTGTCACTATGTTACTAGAT

**Figure 32, SEQ ID NO: 36**


Amino acid sequence of VP4 from Rotavirus A Rotarix strain

MASLIYRQLLTNSYSVDLHDEIEQIGSEKTQNVТИNPGPFAQTRYAPVNWDHGEINDSTTVEPILDGPyQPT  
TFTPPNDYWILINSNTNGVYESTNNSDFWTAVVAIEPHVNVPDRQYMIFGESKQFNVSNDSNWKFLE  
MFRSSSQNEFYNRRTLTSRTLGVIFKYGGRVWTFHGETPRAATTDSSTANNNISITHSEFYIIPRSQESK  
CNEYINGLPPIQNTRNVVPLPLSSRSIQYKRAQVNEDIIVSKTSLWKEMQYNRDIIRFKFGNSIVKMGG  
GYKWSEISYKAANYQNYLRLDGEQVTAHTTCSVNGVNNFSYNGGFLPTDFGISRYEVIKENSYYVVDY  
WDDSKAFRNMVYVRSLAANLNSVKCTGGSYYFSIPVGAWPVMNGGAVSLHFAGVTLSTQFTDFVSLNS  
LRFRFSLTVDEPPFSILRTRTVNLYGLPAANPNNGNEYYEISGRFSLISLVPTNDDYQTPIMNSVTVRQDLE  
RQLTDLREEFNSLSQEIAMAMAQLIDLALLPLDMFSMFGIKSTIDLTKSMATSVMKKFRKSKLATSIEMTN  
LSDAASSASRNVSIRSNLSAISNWTNVSNDSNVNTSLNDISTQTSTISKKLRLKEMITQTEGMSFDDISAA  
VLTKTIDMSTQIGKNTLPDIVTEASEKFIPKRSYRILKDEVMEINTEGKFAYKINTFDEVPDFVNKF  
VTDSPVISAIDFKTLKNLNDNYGITRTEALNLIKSNPNMLRNFINQNNPIIRNRIEQLILQCKL

**Figure 33A**  
Schematic representation of construct number 1730



**Figure 33B**  
Schematic representation of construct number 1731



## F-2X35S/CPMV-HT/RVA(Rtx) VP7(Opt)/NOS (Construct number 1733)

Figure 34A, SEQ ID NO: 37

IF-Rtx\_VP7(opt).s1+3c

AAATTGTCGGGCCATGTACGGCATCGAGTATACAACAATTTAATTTTC

**Figure 34B, SEQ ID NO: 38**

IF-Rtx\_VP7(opt).s1-4r

ACTAAAGA~~A~~ATAGGCCTCTAACGCGATAATAGAAGGCTGCTGAGTTCA  
GGGA

**Figure 34C, SEQ ID NO: 24**

Expression cassette number 1733 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAATATCAAAGATACTGTCAGAACGAC  
AAAGGGCAATTGAGACTTTCAACAAAGGGTAATATCCGAAACCTCCTCGGATTCCATTGCCAGC  
TATCTGTCATTATTGTGAAGATAGTGGAAAAGGAAGGGTGGCTCCTACAAATGCCATCATTGCGAT  
AAAGGAAAGGCCATCGTTGAAGATGCCCTGCCGACAGTGGTCCAAAGATGGACCCCCACCCACG  
AGGAGCATCGTGGAAAAGAAGACGTTCAACCACGTCTCAAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCAGCACACTTGTCTACTCCAAAATATCAAAGATACTGTCAGAAAGACCAAAAGG  
GCAATTGAGACTTTCAACAAAGGGTAATATCCGAAACCTCCTCGGATTCCATTGCCAGCTATCTG  
TCACTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAGGA  
AAGGCCATCGTTGAAGATGCCCTGCCGACAGTGGTCCAAAGATGGACCCCCACCCACGAGGAGC  
ATCGTGGAAAAGAAGACGTTCAACCACGTCTCAAAGCAAGTGGATTGATGTGATACTCCACTG  
ACGTAAAGGGATGACGACAATCCCACTATCCTCGCAAGACCCCTCCTATAAAAGGAAGTTCATT  
CATTGGAGAGGTATAAAATCTTAATAGGTTGTATAAGGCAACGTGGGAACCCGAACCAA  
CCTCTCTAAACTCTCTCATCTCTTAAAGCAAACCTCTCTTGTCTTCTCTGTGAGCGATCT  
TCAACGTGTCAGATCGTCTCGGCCACAGTACACGTTTCTTCACTGAAGCGAAATCAAAGATC  
TCTTGTGGACACGTAGTGCAGGCCATTAAATAACGTGACTGTCTATTCTGTGGTGTGGTCT  
TGGGAAAAGAAAGCTGCTGGAGGCTGTCTCAGCCCCATACATTACTGTGACGATTCTGTGACT  
TCGGCGGGTGAATATCTACTTGTGCTGAGGAGTATTGTGCTGTACTTCTTCTCTTC  
TTGCTGATTGGTTCTATAAGAAATCTAGTATTCTTGTAAACAGAGTTCCCGTGGTTTCAACTT  
GGAGAAAGATTGTAAGCTCTGTATATTCTGCCAAATTGTGGGCCCATGTACGGCATCGAGTAT  
ACAACAATTAAATTCTCTGATTCCATATTCTGTTAAACTACATCCTAAGTCCGTGACCAGAAATT  
ATGGATTATATTATCTATCGTAGCCTCCTCATCTACGTGGCCCTTTGCCCCGACCAAGGGCCAGAA  
CTATGGCCTGAACCTACCAATACCGGTTCAATGGATAACCGTTACGCTAATCCACTCAAGAGGGG  
ATATTCGACAAGTACCCCTGTGCTGTATTATCCAACAGAAAGCCTCTACCCAGATCAATGATGGG  
AGTGGAAAGGATAGTCTCTCACAGATGTCTTAACCAAGGGCTGCCAACCGGTCTCGTACTTCAA  
GGAATACTCTAGTATTGTGACTCTCTCAGTGTGACCCCCAGCTTATTGCGACTACAACTGGTACTTA  
TGAAATACGACCAAGAACCTGGAGCTGGATAATGTCCGAGCTGGTGTGACCTGATCCTCAATGAGTGG  
GTGCAACCCCATGGACATCACATTATTAACCAACGAGTCTGGAGAATCCAACAAAGTGGATCAGT  
ATGGGCTCAAGTTGACCCGTGAAGGTGTGCTTCTGAAACACCCAAATGCTGGCATTGGTGTGAGA  
CAACTAATGTGGATCTGTTGAAATGGTAGCCGAAAACGAGAAAGCTGGCTATAGTGGACGTAGTCGA  
TGGGATTAAACCACAAGATCAATGACTACCACCACTTGTACCATCAGAAACTGTAAAAAGCTGGC  
CCCCGGGAGAACGTGCCGTGATCCAGGTGGGGGGAGCAATGTGCTGACATTACTGCCGACCCCTA  
CCACCAATCCACAGACGGAACGGATGATGAGAGTCACCTGGAAAGAAATGGTGGCAGGTCTTATA  
CCATTGTGGACTACATTAACCAAGATTGTCAAGTCATGAGTAAACGGTCCAGATCCCTGAACCTCAGC  
AGCCTCTATTATCGCTTGAAGGGCTATTCTTAGTTGAATTACTGTTATTGCGTGTGCAATT  
CTATGTTGGTGAAGCGGTTTCTGTGCTCAGAGTGTGTTTATTGTAATTAAATTCTTGTGAGC  
TCCTGTTAGCAGGTGCTCCCTCAGCAAGGACACAAAAAGATTAAATTTTATTAAAAAAA  
AAAAAAAGACGGGAATTCTGATAACAGCTTATCGACCTGAGTCACCTGGAAAGAAATGGTGGCAGTAAAG  
TTCTTAAGGATGATCCTGTTGCCGTCTGCGATGATTATCATATAATTCTGTGAAATTACGTTAA  
GCGATGTAATTAAACATGTAATGCGTACGTTATTATGAGATGGGTTTATGATTAGAGTCCCGC  
AATTATACATTAATACGCGATAGAAAACAAATAGCGCAGAACACTAGGATAAATTATCGCGC  
GGTGTCACTATGTTACTAGAT

**Figure 34D**

Nucleotide sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 48)

```
ATGTACGGCATCGAGTATAACAACAATTAACTTCTGATTCCATCATTCTGTTAAACTACATCCTT
AAGTCCTGACCGAGAATTATGGATTATATTATCTATCGTAGCCTCTCATCTACGTGGCCCTTTGC
CCTGACCAGGGCCAGAACATGGCCTGAACCTACCAATCACCGGTTCAATGGATACCGTTACGCT
AATTCCACTCAAGAGGGATATTCTGACAAGTACCTGTGCTGTATTATCCAACAGAACGCTCTAC
CCAGATCAATGATGGGAGTGGAAAGGATAGTCTCACAGATGTTCTAACCAAGGGCTGGCCACC
GGTCCGTCTACTCAAGGAATACTCTAGTATTGTCGACTTCTCAGTTGACCCCCAGCTTATTGCGA
CTACAACTGGTACTTATGAAATACGACCAGAACCTGGAGCTGGATATGTCGAGCTGGCTGACCTG
ATCCTCAATGAGTGGCTGTGCAACCCATGGACATCACATTATATTACTACCAAGCAGTCTGGAGAAT
CCAACAAGTGGATCAGTATGGCTCAAGTTGCACCGTGAAGGTGTGCTCTGAACACCCAAATGCT
GGGCATTGGTTGTAGACAACATAATGTGGATTGTTGAAATGGTAGCCAAAACGAGAACGAGCTGGCT
ATAGTGGACGTAGTCGATGGGATTAACCACAAGATCAATCTGACTACCACCTGTACCATCAGAA
ACTGTAAGGAGCTGGCCCCCGGGAGAACGTCGCCGTGATCCAGGTGGGGGGAGCAATGTGCTCG
ACATTACTGCCGACCCCTACCACCAATCCACAGACGGAACGGATGATGAGAGTCAACTGGAAGAAAT
GGTGGCAGGTCTTTATACCATTGTGGACTACATTAACCAGATTGTGCAAGTCATGAGTAACGGTC
CAGATCCCTGAACTCAGCAGCCTCTATTATCGCGTTAG
```

**Figure 34E**

Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO 54)

```
ATGTACGGCATCGAGTATAACAACAATTAACTTCTGATTCCATCATTCTGTTA
AACTACATCCTTAAGTCCGTGACCGAGAATTATGGATTATATTATCTATCGTAGCCTC
CTCATCTACGTGGCCCTTTGCCCTGACCAGGGCCAGAACATGGCCTGAACCTA
CCAATCACCGGTTCAATGGATAACGTTACGCTAATTCCACTCAAGAGGGATATT
CTGACAAGTACCTGTGCTGTATTATCCAACAGAACGCTCTACCCAGATCAATGAT
GGGGAGTGGAAAGGATAGTCTCACAGATGTTCTAACCAAGGGCTGGCCACCGGT
TCCGTCTACTCAAGGAATACTCTAGTATTGTCGACTTCTCAGTTGACCCCCAGCTT
TATTGCGACTACAACCTGGTACTTATGAAATACGACCAGAACCTGGAGCTGGATATG
TCCGAGCTGGCTGACCTGATCCTCAATGAGTGGCTGTGCAACCCATGGACATCACA
TTATATTACTACCAGCAGTCTGGAGAATCCAACAAGTGGATCAGTATGGCTCAAGT
TGCACCGTGAAGGTGTCCCTGAACACCCAAATGCTGGCATTGGTTGTAGACA
ACTAATGTGGATTGTTGAAATGGTAGCCAAAACGAGAACGCTGGCTATAGTGGAC
GTAGTCGATGGGATTAACCACAAGATCAATCTGACTACCACCACTGTACCATCAGA
AACTGTAAGGAGCTGGCCCCGGAGAACGTCGCCGTGATCCAGGTGGGGGGAGC
AAATGTGCTCGACATTACTGCCGACCCCTACCACCAATCCACAGACGGAACGGATGATG
AGAGTCAACTGGAAGAAATGGTGGCAGGTCTTTATACCATTGTGGACTACATTAAC
CAGATTGTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAACTCAGCAGCCTCTAT
TATCGCGTTAG
```


**Figure 35**, SEQ ID NO: 39

Amino acid sequence of VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain

MYGIEYTTILFLISIILLNYILKSVTRIMDYIIYRSLLIYVALFALTRAQNYGLNLPITGSMDTVYANSTQEGI  
FLTSTLCLYYPTEASTQINDGEWKDSLQMFLLKGWPTGSVYFKEYSSIVDFSVDPQLYCDYNLVLMKYD  
QNLELDMSSELADLILNEWLCNPMDITLYYYQQSGESNKWISMGSSCTVKVCPPLNTQMLGIGCQTTNVDS  
FEMVAENEKLAIVDVVDGINHKINLTTTCTIRNCKKLGPRENVAVIQVGGSNVLGITADPTTNPQTERM  
MRVNWKWWQVFYTIVDYINQIVQVMSKRSRSLNSAAFYYRV

**Figure 36**

Schematic representation of construct number 1733




G-2X35S/CPMV-HT/ RVA(Rtx) VP7(opt)/NOS (Construct number 1735)**Figure 37**, SEQ ID NO: 40

IF-Rtx\_VP7(opt).s2+4c

TCTCAGATCTCGCCCAGAACTATGGCCTGAACTTACCAATCACCGGTTCA  
ATGGATACC

**Figure 38**

Schematic representation of construct 1192. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation.



**Figure 39**, SEQ ID NO: 41

Construct 1192 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/PDISP/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette

TGGCAGGATATTGTGGTAAACAATTGACGCTAGACAACCTAATAACACATTGCGGACGTT  
 TTAATGTACTGAATTACGCCAATCCGGCTGGTATATTATGTCAAATAACTCAAAAACC  
 ATAAAAGTTAAGTAGCAAGTGTACATTACTGAAACAAAATATTACCTACTACTGTTATA  
 AATCATTATTAAACATTAGAGTAAAGAAATATGGATGATAAGAACAGAGTAGTGATATTGACAA  
 CAATTGTTGCAACATTGAGAAAATTGTTGTTCTCTTTCATTGGTCAAAAACAATAGAGAG  
 AGAAAAGAGAGGGAGAATAAAAACATAATGTGAGTAGAGAGAAAAGTTGACAAAAGTTG  
 TACCAAAATAGTTGACAAATATCATTAGGAAATTGACAAAAGCTACACAAATAAGGGTAATTGC  
 TGTAATAATAAGGATGACGATTAGAGAGATGTACCATAGAGAATTGGCAAGTCATTA  
 AGAAAGAATAAATTATTAAAATTAAAGTTGAGTCATTGATTAAACATGTGATTATTAAATGAA  
 TTGATGAAAGAGTTGGATTAAAGTTGATTAGTAATTAGAATTGGTGTCAAATTAAATTGACATT  
 GATCTTCCATATATTGCCCATAGAGTCAGTTACTCATTTATATTCAAGATCAAATAAGA  
 GAAATAACGGTATATTACCCCTCAAAAAACGGTATATTACTAAAAATCTAACGCCAG  
 TAGGAGGATAACAGGATCCCCTAGGAGGATAACATCCAATCCAACAAATCACACATTCCAC  
 AGATAACCCACTTAAGCCCACGCTCTGTGGCACATCTACATTCTAAATCACACATTCCAC  
 CATCTGAGGCCACACAAAACCAATCCACATCTTATCACCCATTCTATAAAAATCACACTTGTGAG  
 TCTACACTTGTCCCTCAACACATACAAAGAGAAGAGACTATTAAATTAAATTATCATCTTGAG  
 AGAAAATGGAACGAGCTATAAGGAAACGAGCTAGGGAAACAAGCTAACAGTGAACGTTGGATG  
 GAGGATCAGGAGGTACCCCTCCCAAACCTCCTGACGAAAGTCCGAGTTGGACTGAGTGGCG  
 GCTACATAACGATGAGAGAATCGAATCAAGATAATCCCTGGTTCAAGGAAAGCTGGGTTTC  
 GGGAAAGTTGTTAAAGAGATATCTCAGATACAGGACAGGGAAAGCTTCACTGCACAGAGCTT  
 GATCTGGACGGGAGATTGGTTAACATGCAGCATCTGATTTCGGTTCTGACAGATCGATGT  
 ACCTATAGTATTGGTTGGAGGTTAGTATCACCCTTCTGAGGAGTCGAACACTTCAGCATCT  
 CTGTGAGATGGAATTCTGGTCAAGCAAGACTGCTACAGCTGCCCAATCGAAGTGGAAAGTAAT  
 GTATCAAGAGGATGCCCTGAAGGTACTCAAACCTTCGAAAAAGAAAGCGAGTAAGTAAATGCTT  
 CTCGTCTCTATTATAATGGTTGTTATTGTTAATTGTTCTGAGAAGAGCTTAATTATCG  
 TTGTTGTTATGAAATACTATTGTATGAGATGAACTGGTGTAAATTGAAACTTACATAAGTGGAGT  
 CAGAATCAGAATGTTCCATAACTAACTAGACATGAAGACCTGCCCGTACAATTGCTTATATT  
 TGAACAACTAAATTGAACATCTTTGCCACAACTTATAAGTGGTTAATATAGCTCAAATATATGGT  
 CAAGTCAATAGATAATAATGGAATATCAGTTATGAAATTCAATTAAACATCAACTAACGTTATT  
 AACTACTAATTATATCATCCCTTGTATAATGAGTACACCAATTAGGAAGGAGCATGTCGCC  
 TAGGAGATTGCGTTCCCGCTTCAAGTGCAGCTAGCTAGCGTGTAGCCAATACGCAAACCGC  
 CTCTCCCGCGGTTGGAAATTACTAGCGCTGCGACAAGCTTGCATGCCGTCAACATGGTGGAG  
 CACGACACACTGTCTACTCCAAAATATCCGGAACACTCCTCGGATTCCATTGCCAGCTATCTGTC  
 ACTTTCAACAAAGGGTAATATCCGGAACACTCCTCGGATTCCATTGCCAGCTATCTGTC  
 ACTTTATGTAAGATGGAAAAGGAAGGTGGCTCTACAAATGCCATCTTGTGATAAAGGAAAGGCCAT  
 CGTTGAAGATGCCCTGCCGACAGTGGCTTCAAGCAAGTGGATTGATGTGATAACATGGGAGCACG  
 AACACTGTCTACTCCAAAATATCAAAGATAACGTCTCAGAAGACCAAAGGGCAATTGAGACTTTC  
 AACAAAGGGTAATATCCGGAACACTCCTCGGATTCCATTGCCAGCTATCTGTCATTGTAAG  
 ATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATCTTGTGATAAAGGAAAGGCCATCGTTGAA  
 GATGCCCTGCCGACAGTGGCTTCAAGATGGACCCCCACCGAGGAGCATCGTGGAAAAAGAA  
 GACGTTCCAACACAGTCTCAAAGCAAGTGGATTGATGTGATATCTCACTGACGTAAGGGATGACG  
 CACAATCCCACTATCTTGTGCAAGACCTCTCTATATAAGGAAGTTCATTGTTGGAGAGGTAT  
 TAAATCTTAATAGGTTGATAAAAGCGAACCTGGGGAAACCCGAACCAAACCTTCTAAACTC  
 TCTCTCATCTCTTAAAGCAAACCTCTCTTGTGTTCTGCTGAGCGATCTCAACGTTGTCAGA  
 TCGTGTCTCGGCCACAGTCAAACGTTCTCTGCTGAGCGAAATCAAAGATCTCTTGTGACACG  
 TAGTGGCGGCCATTAAATAACGTGACTTGTCTTCTGCTGAGCGTGTGGCTTGGAAAAGAAAG  
 TTGCTGGAGGCTGCTGTCAGCCCCATACATTACTGTTAGCATTCTGCTGACTTGTGCTGAG  
 TATCTCTACTCTGCTGAGGTTGCTGAGGTTGCTGAGGTTGCTGACTTCTCTCTGCTGAG  
 ATAAGAAATCTAGTATTGTTGAAACAGAGTTTCCGTGGTTTCGAACCTGGAGAAAGATTGTT  
 AAGCTTCTGTATATTCTGCCAATTGTCGGGCCATGGCGAAAACGTTGCGATTTCGGCTTATT  
 GTTTCTCTCTGTTGTTGTTGCTCTCTGAGATCTCGCCGCGCTCTCAGCCAAAACGACACCCCCA  
 TCTGTCTATCCACTGGCCCTGGATCTGCTGCCAAACTAACTCCATGGTGCACCTGGATGCC  
 CAAGGGCTATTCCCTGAGCCAGTGCACAGTGACCTGGAACTCTGGATCCCTGTCAGCGGTGTC  
 ACCTCCCAGCTGCTCTGCACTGACCTCTACACTCTGAGCAGCTCAGTGACTGCTCCCTCCAGC  
 CTGGCCAGCGAGACCGTCACCTGCAACCGTGCACCCGCCAGCAGCACCAAGGTGGACAAGAA  
 AATTGTGCCAGGGATTGTGGTTGTAAGCCTTGATATGTACAGTCCCAGAAGTATCATCTGCTTCA  
 TCTTCCCCCAAAGCCAAGGGATGTGCTCACCATTACTCTGACTCTAAGGTCAACGGTGTGTTG  
 GACATCAGCAAGGATGATCCCGAGGTCCAGTTGAGCTGGTTGAGATGATGTGAGGTCACACAG  
 CTCAGACGCAACCCGGAGGAGCAGTTCAACAGCACTTCCGCTCAGTCAGTGAACCTCCATCAT

GCACCAGGACTGGCTCAATGGCAAGGAGCGATCGCTCACCATCACCATCACCATCACCAT  
 AAAGGCCTATTCTTACTGTTAGCTTGAATTACTGTTATTCGGTGTGCATTCTATGTTGGTGAGCGGTT  
 TCTGTGCTCAGAGTGTGTTATTATGTAATTAAATTCTTGTGAGCTCTGTTAGCAGGTGTC  
 CTTCAAGCAAGGACACAAAAAGATTAAATTAAATTAAAAAAAAGACCGGAAATT  
 ATATCAAGCTTATCGACCTGCAGATCGTCAACACATTGGCAATAAAGTTCTTAAGATTGAATCCTG  
 TTGCGGCTTGCGATGATTATCATATAATTCTGTTGAATTACGTTAAGCATGTAATAATTACATG  
 TAATGCATGACGTTATTATGAGATGGGTTTATGATTAGAGTCCCGAATTATACATTAAACGC  
 GATAGAAAACAAAATATAGCGCGAAACTAGGATAATTATCGCGCCGGTGTATCTATGTTACTA  
 GATCTCTAGAGTCTCAAGCTGGCGCCACGTGACTAGTGGCACTGGCGTGTACAAACGTC  
 TGACTGGAAAACCTGGCGTACCCAACTTAATCGCCTTGAGCACATCCCCCTTCGCCAGCTGGC  
 GTAATAGCGAAGAGGCCGCACCGATGCCCTCCAACAGTTGCGCAGCCTGAATGGGAATGCTA  
 GAGCAGCTTGAGCTTGATCAGATTGCGTTCCCGCCTCAGTTAAACTATCAGTGGTACAGGA  
TATATTGGCGGTAAACCTAAGAGAAAAGAGCGTTA

**Figure 40A, SEQ ID NO:42**

Expression cassette number 1735 from 2X35S promoter to NOS terminator.  
 PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.

GTCAACATGGTGGAGCAGCACACTGTCTACTCCAAAATATCAAAGATACTGTCAGAACGACC  
 AAAGGGCAATTGAGACTTTCAACAAAGGGTAATATCGGAAACCTCTCGGATTCATTGCCAGC  
 TATCTGCACTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGAT  
AAAGGAAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCAAAGATGGACCCCCACCCACG  
 AGGAGCATCGTGGAAAAAGAACGTTCCAACCACGCTCTCAAAGCAAGTGGATTGATGTGATAAC  
 ATGGTGGAGCACGACACACTGTCTACTCCAAAATATCAAAGATACTGTCAGAACGACCAAAGG  
 GCAATTGAGACTTTCAACAAAGGGTAATATCGGAAACCTCTCGGATTCCATTGCCAGCTATCTG  
 TCACCTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCTACAAATGCCATATTGCGATAAAGGA  
 AAGGCCATCGTGAAGATGCCCTGCCGACAGTGGTCCAAAGATGGACCCCCACCGAGGGAGC  
 ATCGTGGAAAAGAACGACGTTCCAACCACGCTCTCAAAGCAAGTGGATTGATGTGATATCTCCACTG  
 ACGTAAGGGATGACGACAATCCCACTATCTTGCAGAACGACCTCCCTCTATATAAGGAAGTTCAATT  
 CATTGGAGAGGTTAAACTCTTAAAGGTTGATAAAAGCGAACGTGGGGAAACCCGAACCAA  
 CCTCTCTAAACTCTCTCATCTCTTAAAGCAACTCTCTTGTCTTGCAGCGATCT  
 TCAACGTTGTAGATCGTCTCGGACCCAGTACAACGTTTCTTCACTGAAGCGAAATCAAAGATC  
 TCTTGTGGACACGTAGTCGGCGCATTAAATAACGTGTAATTGCTCTTGTCTTGCAGCGATCT  
 TGGGAAAAGAAAGCTTGCTGGAGGCTGTTAGCAGCCCCATACATTACTGTTACGATTCTGTA  
 TTCGGCGGGTGAATATCTACTTCTGTTGACGAGGTATTGTTGCCTGTACTCTTCTTCTTCT  
 TTGCTGATTGGCTTCTATAAGAAATCTAGTATTCTTGAACAGAGTTTCCGTGGTTTCGAACCTT  
GGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCAATTGTCGGGCCATGGCGAAAACGTTGC  
GATTTCGGCTTATTGTTCTCTCTGTGTTGTTCCCTCTCAGATCTGCCAGAACTATGGCCT  
GAACCTACCAATCACCCTCAATGGATACCGTTACGCTAATTCCACTCAAGAGGGGATATTCTGA  
CAAGTACCCCTGTGCTGTATACCAACAGAACGCTTACCCAGATCAATGATGGGAGTGGAGGA  
TAGTCTCTCACAGATGTTCTCAACCAAGGGCTGCCACGGCTCCGTACTTCAAGGAATACTCTA  
GTATTGTCGACTCTCAGTTGACCCCGACTTATTGCGACTACAACCTGGTACTTATGAAATACGAC  
CAGAACCTGGAGCTGGATATGTCGAGCTGGCTGACCTGATCTCAATGAGTGGCTGTGCAACCCCA  
TGGACATCACATTATTAATTACCAACAGACTCTGGAGAATCCAACAAGTGGATCAGTATGGCTCAAG  
TTGACCGTGAAAGGTGTCCCTTGAACACCCAAATGCTGGCATTGGTTGTCAGACAACATACTG  
GATTGTTGAAATGGTAGCCGAAAAGAGAACGAGCTGGCTATAGTGGACGTTGCGATGGGATAACC  
ACAAGATCAACTGACTACCACCACTGTACCATCAGAAACTGTAAGAGCTGCCACCCGGAGAA  
CGTCCCGTGATCCAGGTGGGGGGAGCAATGTGCTGACATTACTGCCACCCCTACCAATCCA  
CAGACGGAACGGATGAGAGTCAACTGGAAGAAATGGGGCAGGTCTTTATACCAATTGGA  
ACATTAACCAGATTGTCAGTAAACGGTCCAGATCCCTGAACCTCAGCAGCCTTCTTATT  
TCGCGTTAGAGGCCTATTCTTAGTTGAATTACTGTTATTGGTGTGCATTCTATGTTGGTG  
AGCGGTTTCTGTGCTCAGAGTGTGTTATTGTAATTAAATTCTTGTGAGCTCTGTTAGCA  
GGTCTCCCTCAGCAAGGACACAAAAAGATTAAATTAAAAAAAAGACCG  
GGAAATTCGATATCAAGCTTATCGACCTGCAGATCGTCAACACATTGCAATAAAGTTCTTAAGATT  
GAATCCTGTTGCCGGCTTGCGATGATTATCATATAATTCTGTTGAATTACGTTAAGCATGTAATAA  
TTAACATGTAATGCGATGACGTTATTGAGATGGGTTTATGATTAGAGTCCCGCAATTATACATT  
TAATACGCGATAGAAAACAAATAGCGCGAAACTAGGATAAATTATCGCGCCGGTGTATCTA  
TGTTACTAGAT

**Figure 40B**

Nucleotide sequence encoding PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 62)

```
ATGGCGAAAAACGTTGCGATTTCGGCTTATTGTTTCTCTTGTGTTGGTCCTCTCAGATCTTC  
GCCAGAACTATGGCCTGAACCTACCAATCACCGTTCAATGGATACCGTTACGCTAATTCACTCA  
AGAGGGGATAATTCTGACAAGTACCTGTGCCTGTATTATCCAACAGAACGCTCTACCCAGATCAAT  
GATGGGGAGTGGAAGGATAGTCTCTCACAGATGTTCTAACCAAGGGCTGGCCCACCGGTTCCGTCT  
ACTTCAAGGAATACTCTAGTATTGTCGACTTCTCAGTTGACCCCCAGCTTATTGCGACTACAACCTG  
GTACTTATGAATACTGACAGAACCTGGAGCTGGATATGTCGAGCTGGCTGACCTGATCCTCAATG  
AGTGGCTGTGCAACCCCATGGACATCACATTATTAATTACTACCAGCAGTCTGGAGAACATCCAACAAGTG  
GATCAGTATGGGCTCAAGTTGACCGTGAGGTGTGTCCTGAACACCCAAATGCTGGGATTGGT  
TGTCAAGACAACAAATGTGGATTGACTACCAAGATCAATCTGACTACCACCATGTACCATCAGAAACTGTAAAAAA  
GCTCGGCCCCGGAGAACGTCGCCGTATCCAGGTGGGGAGCAATGTGCTGACATTACTGCC  
GACCCCTACCACCAATCCACAGACGGAACGGATGATGAGAGTCAACTGGAAGAAATGGTGGCAGGTC  
TTTATACCATTTGACTACATTAACCAGATTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAA  
CTCAGCAGCCTCTATTATCGCGTTAG
```


**Figure 41, SEQ ID NO: 43**

Amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain

```
MAKNVAIFGLLFSLLVLVPSQIFAQNYGLNLPITGSMDTVYANSTQEGIFLTSTLCLYYPTEASTQINDGE  
WKDSLSQLMFLTKGWPTGSVYFKEYSSIVDFSVDPQLYCDYNLVLMKYDQNLELDMSELADLILNEWLC  
NPMDITLYYQQSGESNKWISMGSCTVKVCPLNTQMLGIGCQTTNVDSFEMVAENEKLAIVDVVDGIN  
HKINLTTTCTIRNCKKLGPRENVAVIQVGGSNVLIDADPTTNPQTERMMRVNWKKWWQVFYIVDYI  
NQIVQVMSKRSRSLNSAAFYYYRV
```

**Figure 42**

Schematic representation of construct number 1735



**Figure 43A**

Coding sequence of Rotavirus A VP4 from strain  
RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO: 50)

ATGGCTTCGCTCATTATAGACAATTGCTCACGAATTCTTATACAGTAGATTATCC  
GATGAGATACAAGAGATTGGATCAACTAAATCACAAAATGTCACAATTAACTCCTGGA  
CCATTGCGAACACAGGTTATGCTCCAGTTAAGTGGGGACCTGGAGAAATTAAATGAT  
TCTACGACAGTTGAACCATTGCTGGATGGCCTTATCAACCAACGACATTCAATCCA  
CCAGTCGATTATTGGATGTTACTGGCTCAACGACACCTGGCGTAATTGTTGAAGGT  
ACAAATAATACAGATAGATGGTTAGCCACAATTAAATCGAGCCAATGTTCACT  
GAAAATAGAACTTACACTATATTGGTATTCAAGAACAACTAACGGTATCCAATACT  
TCACAAGACCAGTGGAAATTATTGATGTCGAAAAACAACTGCAAATGGAAGTATA  
GGACAATATGGACCATTACTATCCAGTCGAAATTATGCAAGTATGAGCATAAT  
GAAAAATTATATACATATGAAGGACAGACACCTAACGCTAGGACAGCACATTATTCA  
ACAACGAATTATGATTCTGTTAATATGACTGCTTTGTGACTTTATATAATTCC  
AGATCTGAAGAGTCTAAATGTACGGAATACATTAATAATGGATTACCAACAA  
AATACTAGAAATGTTGTAACATTACGTTGACTGCTAGAGATGTAATACACTATAGA  
GCTCAAGCTAATGAAGATATTGTGATATCCAAGACATCATTGAAAGAAATGCAA  
TATAATAGAGATATAACTATTAGATTAAATTGCAAATACAATTATAAAATCAGGA  
GGCTGGGATATAAGTGGTCAGAAATATCATTAGCCAGCGAATTATCAATACACA  
TATACTCGTATGGTGAAGAAGTTACCGCACATACTACTTGTCAGTGAATGGCGTT  
AATGACTTCAGTTAATGGAGGATATTACCAACTGATTGTTGTTATCTAAATT  
GAAGTAATTAAAGAGAATTACGTCTATATCGATTACTGGGATGATTCAAAGCA  
TTTCGTAACGTGGTATGTCGATCGTAGCAGCAAACCTGAAATTCACT  
ACTGGAGGCAGCTATAATTTCAGCTGGTGTAAACACTATCTACTCAATTACAGATT  
GGAGCAGTTCTTACATTCAAGATTAGATTAGACTAGCTGTCGAAGAACACACTTT  
AAACTGACTAGAACTAGATTAGATAGATTGTATGGCTGCCTGCTGCAGATCCAAAT  
AATGGTAAAGAATTATGAAATTGCTGGACGATTTCACTTATATCATTAGTGC  
TCAAATGATGACTATCAGACTCCTATAGCAAACCTAGTTACTGTACGACAAGATT  
GAAAGGCAGTTAGGAGAACTAAGAGAAAGAGTTAACGCTTGTCTCAAGAAATTGCA  
ATGTCGCACTTAATCGATTAGCCTCTACCAATTAGATATGTTCTCAATGTTCT  
GGCATTAAAGTACTATTGATGCTGCAAATCAATGGCTACTAATGTTATGAAAAAA  
TTCAAAAGTCAGGATTAGCGAATTCACTGAGTTAACACTGACAGATTCTTATCAGAC  
GCAGCATCATCAATATCAAGAGGTCATCTACGTTGATGGATCTCAGCATCA  
GCATGGACGGATGTATCAACACAAATAACTGATATATCGTCAGTAAGTTCA  
TCGACACAAACGTCAACTACAGTAGAAGATTGAGACTAAAGGAAATGGCAACACAA  
ACTGAGGGTATGAATTGATGATATATCAGCGGCTGTTGAAGACTAAGATAGAT  
AAATCGACTCAAATATCACCAACACAATTACGACATTGTTACTGAAGCATCGGAA  
AAATTCAACAAATAGGGCTTACCGTGTATAAACAAACGATGATGTTGAAGCT  
GGAATTGATGGAAAATTGGCTTATAAAGTGGATACATTGAGGAAATACCATT  
GATGTACAAAATTGCTGACTTAGTTACAGATTCTCCAGTAATATCCGCTATAATT  
GATTTAAACACTTAAAGATCTGACCCAAGAGTTTACGTGAATTCAATTACAGGACAAT  
TTAATCTTTAAGATCTGACCCAAGAGTTTACGTGAATTCAATTACAGGACAAT  
CCTATAATTAGAAATAGAACAACTGATTATGCAATGCAGGTTGTGA

**Figure 43B**

Optimized coding sequence of Rotavirus A VP4 from strain  
RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 51)

ATGGCTTCATTGATATATGCCAGTTGCTGACTAATAGCTATACTGTGGATTGTCA  
 GACGAAATCCAGGAAATAGGATCCACAAAGAGTCAGAACGTGACCATAACCCCCGGA  
 CCGTCGCCAGACTGGGTATGCCCGTAAACTGGGCCCCGGCGAGATTAACGAC  
 AGCACCACCGTGGAGCCACTGCTGGATGGACCTACCAACCCACTACTTTAACCT  
 CCAGTGGACTACTGGATGTTGGCTCCCACGACACCTGGTGTAAATTGTAGAGGGC  
 ACCAACAAATACCGATCGCTGGCTGGCGACAATACTGATAGAACCCAACGTGCAGTCC  
 GAGAACAGAACCTATACCATTTCGGCATCCAGGAACAGCTAACCGTGAGCAATACG  
 AGCCAGGACCAGTGGAAAGTTATCGATGTAGTAAACTACGGCAATGGATCTATC  
 GGGCAATAACGGGCCGCTGCTGTCCTCACCTAACGCTACGCCGTGTAAACACATAAT  
 GAGAAACTGTACACTTACGAGGGCAAACCCCCAATGCCAGAACTGCCCAACTACAGT  
 ACAACCAACTATGACTCGGTAAACATGACAGCGTCTGTGATTTTATATTATTCCA  
 AGATCAGAAGAATCCAAGTGTACTGAGTACATCAACAATGGACTTCCACCCATCCAG  
 AACACTCGAAATGTCGCTCCACTGTCTACTGCTCGGGATGTGATCCACTATCGC  
 GCCCAAGCTAATGAGGATATAGTCATTCAAAGACGAGCTATGGAAGGAAATGCAG  
 TATAACAGAGACATCACAATCAGGTTCAAGTTGCCAATACTATTATTAAAGTCCGGG  
 GGACTGGGGTACAAATGGAGTGAGATCAGTTAACGCCGTAACATACAGTACACC  
 TATACTCGCAGGGCGAAGAGGTAACCGCCCACACAACCTGCTCGGTTATGGCGTG  
 AACGATTTAGCTCAACGGGGCTACCTGCCTACTGATTCGTGGTGAGCAAGTTT  
 GAAGTCATCAAGGAAAATTCTACGTGTATATTGACTACTGGGATGATGCCAGGCC  
 TTCCGAAATGTTGTATGTTAGATCACTGGCGAAACCTTAATTCAAGTCATGTGC  
 ACAGGAGGTTCTTACAATTTCAGTCTTCCCGTGGCAGTGGCCAGTGCTCACAGGG  
 GGCCTGTGAGCTTGCAATTCCGGAGTCACCTGAGTACTCAGTTCACAGACTTT  
 GTGTCTCTGAATAGCCTAACGGTTCAAGGTTAGACTTGCAGTAGAAGAGCCTCACTTT  
 AAGCTCACTCGTACGAGGCTGGATCGGCTGTACGCCCTGCCGGCGCTGATCCAAT  
 AACGGCAAGGAATATTACGAGATAGCCGGAGATTTCGCTGATCAGTCTGGTGCG  
 TCAAACGATGATTACCAAGACCCAATTGCCAACAGTGTCACTGTCAGGCAAGATCTG  
 GAGAGACAATTGGCGAGCTGAGAGAGGAGTTCAACGCCCTGCTCAAGAGATCGCA  
 ATGTCAGCTCATTGACCTGGCCCTGTTACCCCTGACATGTTCTCAATGTTCTCC  
 GGCATAAAATCCACTATCGACGCTGCAAAGTCCATGCCACAAATGTGATGAAGAAG  
 TTTAAGAAGAGCGGTCTGGCAAATAGCGTGTACGCTGACCGATAGTTGTGGAT  
 GCCGCCAGTTCATTAGCCGTGGATCCAGCATAGGTCCATTGGCTTCTCCGCCCT  
 GCTTGGACTGACGTGAGTACACAGATAACTGACATTCTCTGTCTCCAGTGTG  
 AGCACACAAACTCCACGATATCAAGACGACTGAGGCTCAAAGAGATGGCAACGCAA  
 ACGGAAGGTATGAATTGATGACATCAGGCCCGAGTTGAAGACAAAGATCGAT  
 AAAAGCACTCAAATTAGCCCCAATACGATCCCTGACATTGTGACTGAGGCATCTGAA  
 AAGTCATTCCCAACCGTCTTATCGGGTCAATTAAACATGATGATGTCTCGAGGCC  
 GGCATCGATGGCAAGTTTGCTTATAAAGTGGATACCTCGAGGAGATTCCCTTC  
 GATGTACAGAAGTTGCTGACCTCGTAACGGATAGCCCAGTGATAAGGCCATTATA  
 GACTTCAAAACATTGAAAAATTGAACGATAATTATGGTATTACCAAGCAGCAGGCT  
 TTTAACTTGTAAAGATCTGACCTCGCGTGTCAAGAGAGTTATTAAACCAGGACAAC  
 CCCATCATCAGAACAGGATCGAGCAGCTGATTATGCAGTGTCGCCTGTAA

**Figure 43C**

Coding sequence of Rotavirus A VP7 from strain  
 RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 52)

ATGTATGGTATTGAATATACACAGTTCTAACCTTCTGATATCGATTATTCTACTA  
 AATTACATACTTAAATCATTAACCTAGAATAATGGACTTATAATTAGATTCTT  
 TTTATAATTGTGATATTGTCACCATTCTCAGAGCACAAATTATGGTATTAAATCTT  
 CCAATCACAGGCTCCATGGACACTGCATACGCTAACGCAAGAAGAACATTC

CTCACTTCTACACTTGCCTATATTATCGACTGAGGCTGCGACTGAAATAACGAT  
 AATTCACTGGAAAGACACACTGTCACAACATTCTTACGAAAGGGTGGCCAACCTGGA  
 TCCGTATATTAAAGAATATACTAACATTGCATCGTTCTGTTGATCCGCAGTTG  
 TATTGTGATTATAACGTAGTACTAATGAAATATGACCGCAGCTGCAATTGGATATG  
 TCAGAACTTGCAGCTAATATTAAACGAATGGTTGTGAATCCAATGGATATTACT  
 CTGTATTATTATCAGCAAACGTACGAAGCGAATAATGGATATCAATGGCCTCATCA  
 TGTACAATTAAAGTATGTCACCTAACACAAACCTCTGGAATTGGATGCTTGACA  
 ACTGATGCTACAACCTTGAAGAAGTTGCGACAGCTGAAAAGTTGGTAATTACTGAC  
 GTGGTTGATGGCGTTAACATAAGCTGGATGTACAACACAGCAACGTGACTATTAGA  
 AACTGTAAGAAATTGGGACCAAGAGAAAACGTAGCCGTTACAGTTGGTGGTCT  
 GACATCCTCGATATAACTGCTGATCCAACACTGCACACAGAACGGATGATG  
 CGAATTAACGGAAAAAATGGTGGCAAGTTTTTATACTGTAGTAGACTATGTAGAT  
 CAGATAATACAAGTTATGTCCAAAAGATCAAGATCACTAAATTCAAGCAGCATT  
 TACAGAGTGTAG

**Figure 43D**

Optimized coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO :53)

ATGTACGGAATCGAGTATACCACCGTTCTGACATTCTTATTAGTATTATCCTCTTG  
 AACTATATTCTGAAGTCACCTACCCGGATAATGGATTATTATATAGGTTCTG  
 TTCATCATTGTAATTCTGAGCCCTTCTGAGGGGCCAGAATTACGGCATAAACCTA  
 CCAATCACCGGTTCTATGGATACCGCTTATGCTAACTCTACACAAGAGGAGACATT  
 CTCACATCAACCCATGCCTGTACTATCCGACTGAAGCAGCCACAGAGATAACGAT  
 AACTCTGGAAAGATACATTGAGCCAGCTTCTGACTAAGGGATGGCCACCGGA  
 TCGGTCTACTTAAGGAGTACACAAACATCGCAAGTTCAGCGTGGATCCCCAGCTG  
 TATTGTGATTATAACGTTGTGCTGATGAAATACGACGCAACCCCTCCAGCTTGACATG  
 AGCGAGTTGGCAGACCTAACCTCAATGAGTGGCTGTAAACCAATGGATATAACA  
 CTGTACTATTATCAGCAGACCGATGAAGCAAACAAATGGATTCAATGGGAAGCAGC  
 TGTACCATCAAAGTTGTCCTCTAACACACCCAAACTCTCGGCATAGGGTGTCTGACC  
 ACAGACGCTACTACCTTGAAGAAGTTGCGACCGCGGAAAGCTGGTTATCACAGAT  
 GTGGTAGATGGCGTTAACCAAAATTGGACGTAACCACAGCAACATGCACAATTAGG  
 AACTGCAAGAAGCTAGGACCCAGGGAAACGTAGCCGTACCAAGTGGCGGCAGT  
 GACATCCTAGACATCACCGCAGACCCAAACAGCACCACAAACCGAGAGGATGATG  
 CGCATTAAATTGGAAGAAATGGTGGCAGGTGTTACACTGTCGTTGACTATGTGGAC  
 CAGATCATTAGGTGATGAGCAAGCGGAGTCGCTCATTGAATAGTGCTGCCTTTAT  
 TACAGAGTCTAA

**D-2X35S/CPMV-HT/RVA(Rtx) VP7(Opt)/NOS (Construct number 1734)****Figure 44A** (SEQ ID NO: 55)

IF-TrSP+Rtx\_VP7 (opt).s1+3c

AAATTGTCGGGCCATGGATTATATTATCGTAGCCTCCTCATCTA

**Figure 44B**, (SEQ ID NO: 56)

IF-Rtx\_VP7 (opt).s1-4r

ACTAAAGAAAATAGGCCTCTAACCGCGATAATAGAAGGCTGCTGAGTCAGGGA

**Figure 44C, (SEQ ID NO: 57)**

Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]

ATGTACGGCATCGAGTATACAACAATTTAATTTCTGATTCCATCATTCTGTTA  
 AACTACATCCTAACGTCCGTGACCAGAATTATGGATTATATTATCTATCGTAGCCTC  
 CTCATCTACGTGCCCTTTGCCCTGACCAGGGCCAGAACTATGCCCTGAACCTTA  
 CCAATCACCGGTTCAATGGATACCGTTACGCTAATTCCACTCAAGAGGGATATTT  
 CTGACAAGTACCCGTGCCTGTATTATCCAACAGAAGCCTCTACCCAGATCAATGAT  
 GGGGAGTGGAAAGGATAGTCTCACAGATGTTCTAACCAAGGGCTGCCACCGGT  
 TCCGTCTACTTCAAGGAATACTCTAGTATTGTCACCTCTCAGTTGACCCCCAGCTT  
 TATTGCGACTACAACCTGGTACTTATGAAATACGACCAGAACCTGGAGCTGGATATG  
 TCCGAGCTGGCTGACCTGATCCTCAATGAGTGGCTGTGCAACCCCATTGGACATCACA  
 TTATATTACTACCAGCAGTCTGGAGAATCCAACAAGTGGATCAGTATGGCTCAAGT  
 TGCAACCGTGAAGGTGTGTCCTGAACACCCAAATGCTGGCATTGGTTGTCAAGACA  
 ACTAATGTGGATTGCTTGAATGGTAGCCGAAACGAGAAGCTGGCTATAGTGGAC  
 GTAGTCGATGGGATTAACCACAAGATCAATCTGACTACCACCTGTACCATCAGA  
 AACTGTAAAAGCTGGCCCCGGAGAACGTCGCCGTGATCCAGGTGGGGGGAGC  
 AATGTGCTCGACATTACTGCCGACCCCTACCCACCAATCCACAGACGGAACGGATGATG  
 AGAGTCAACTGGAAGAAATGGTGGCAGGTCTTATACCATTGTGGACTACATTAAC  
 CAGATTGTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAACTCAGCAGCCTCTAT  
 TATCGCGTTAG

**Figure 44D, (SEQ ID NO: 58)**

Expression cassette number 1734 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATCAAAGATAACAGTC  
 TCAGAACGACAAAGGGCAATTGAGACTTTCAACAAAGGTAATATCCGGAAACCTC  
 CTCGGATTCCATTGCCAGCTATCTGCACTTATTGTGAAGATAGTGGAAAGGAA  
 GGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCC  
 TCTGCCGACAGTGGTCCAAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAAAAA  
 GAAGACGTTCCAACCACGTCTCAAAGCAAGTGGATTGATGTGATAACATGGTGGAG  
 CACGACACACTTGTCTACTCCAAAAATCAAAGATAACAGTCTCAGAAGACCAAAGG  
 GCAATTGAGACTTTCAACAAAGGTAATATCCGGAAACCTCCTCGGATTCCATTGC  
 CCAGCTATCTGTCACTTATTGTGAAGATAGTGGAAAGGAAGGTGGCTCCTACAAA  
 TGCCATATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCCTGCCGACAGTGGT  
 CCCAAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAAAGAAGACGTTCCAACC  
 ACGTCTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACGCA  
 CAATCCCACATCCTCGCAAGACCCCTTCTCTATATAAGGAAGTTCATTTCTATTG  
 GAGAGGTATTAATCTTAATAGGTTTGATAAAAGCGAACGTGGGGAAACCGAAC  
 CAAACCTTCTCTAAACTCTCTCATCTCTAAAGCAAACCTCTCTTGTCTT  
 TCTTGCCTGAGCGATCTCAACGTTGTCAGATCGTGCCTCGGCACCAGTACAACGTT

TTCTTCACTGAAGCGAAATCAAAGATCTTTGAGACACGTAGTGCAGCGCCATT  
 AAATAACGTGTACTTGTCTATTCTGTCGGTGTGGCTTGGGAAAGAAAGCTTGC  
 TGGAGGCTGCTGTTAGCCCCATACATTACTGTACGATTCTGCTGACTTCGGCG  
 GGTGCAATATCTACTTCTGCTGACGAGGTATTGTTGCCTGTACTTCTTCT  
 TCTTCTGCTGATTGGTTCTATAAGAAATCTAGTATTTCCTTGAAACAGAGTTTC  
 CCGTGGTTTCGAACTTGGAGAAAGATTGTTAACGTTCTGTATATTCTGCCAAATT  
 TGTCGGGCCATGGATTATATTATCTATCGTAGCCTCCTCATCTACGTGGCCCTTT  
 TGCCCTGACCAGGGCCCAGAACTATGGCCTGAACCTACCAATCACCGGTTCAATGGA  
 TACCGTTACGCTAATTCACTCAAGAGGGATATTCTGACAAGTACCCGTGCCT  
 GTATTATCCAACAGAACGCTCTACCCAGATCAATGATGGGAGTGGAAAGGATAGTCT  
 CTCACAGATGTTCTAACCAAGGGCTGGCCACGGGTTCCGTCTACTTCAAGGAATA  
 CTCTAGTATTGTCGACTTCTCAGTTGACCCCCAGCTTATTGCGACTACAACCTGGT  
 ACTTATGAAATACGACCAGAACCTGGAGCTGGATATGTCCGAGCTGGCTGACCTGAT  
 CCTCAATGAGTGGCTGTGCAACCCCATGGACATCACATTATTAACCTACAGCAGTC  
 TGGAGAATCCAACAAGTGGATCAGTATGGGCTCAAGTTGCAACCGTGAAGGTGTG  
 CTTGAACACCCAAATGCTGGCATTGGTTGTCAGACAACTAATGTGGATTGTTGA  
 AATGGTAGCCGAAAACGAGAACGCTGGCTATAGTGACGTAGTCATGGATTAAACCA  
 CAAGATCAATCTGACTACCACCACTTGTACCATCAGAAACTGTAAAAAGCTGGCC  
 CGGGAGAACGTCGCCGTGATCCAGGTGGGGGGAGCAATGTGCTGACATTACTGC  
 CGACCCCTACCACCAATCCACAGACCGAACGGATGATGAGAGTCAGCTGGAAAGAAATG  
 GTGGCAGGTCTTTATACCATTGTTGACTACATTAACCAGATTGTGCAAGTCATGAG  
 TAAACGGTCCAGATCCCTGAACTCAGCAGCCTCTATTATCGCGTTAGAGGCCTAT  
 TTTCTTAGTTGAATTACTGTTATTGGTGTGCATTCTATGTTGGTGGCG  
 TTTCTGTGCTCAGAGTGTGTTATTGTAATTAAATTCTTGTGAGCTCCTGT  
 TTAGCAGGTGTCCTCAGCAAGGACACAAAAAGATTAAATTAAATTAAAAAAA  
 AAAAAAAAAGACCGGAAATCGATATCAAGCTTATCGACCTGCAGATGTTCAAAC  
 ATTGGCAATAAAAGTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCATGATTATC  
 ATATAATTCTGTTGAATTACGTTAACGATGTAATAATTAAACATGTAATGCATGACG  
 TTATTATGAGATGGGTTTATGATTAGAGTCCCGCAATTACATTAAACGCG  
 ATAGAAAACAAAATAGCGCGCAAACCTAGGATAAATTATCGCGCGGGTGT  
 ATCTATGTTACTAGAT


**Figure 44E, SEQ ID NO: 59**


Amino acid sequence of TrSp-VP7 from Rotavirus A vaccine  
 USA/Rotarix-A41CB052A/1988/G1P1A[8] strain

MDYIIYRSLLIYVALFALTRAQNYGLNLPITGSMMDTVYANSTQEGIFLTSTLCLYY  
 PTEASTQINDGEWKDSLSQMFLTKGWPTGSVYFKEYSSIVDFSVDPQLYCDYNLVL  
 MKYDQNLELDMSSELADLILNEWLCNPMDITLYYYQQSGESNKWISMGS  
 SCTVKVCP  
 QMLGIGCQTTNVDSFEMVAENEKLAIVDVVDGINH  
 KINLTTTCTIRNCKKLGP  
 PREN  
 VAVIQVGGSNVLDITADPTTNPQTERMMRVNW  
 KWWQVFYTIVDYINQIVQVMSKRS  
 RSLNSAAFYYRV

**Figure 44F**

Schematic representation of construct number 1734



**Figure 45****VP2/VP6 RLPs**




**Figure 46**


Figure 47




**Figure 48**

**Figure 49**

**VP2/VP6**



**VP2/VP6/VP4/VP7**



pctca2013050364-seq1.txt  
SEQUENCE LISTING

<110> Medicago Inc.  
Mitsubishi Tanabe Pharma Corporation  
<120> Rotavirus-like Particle Production in Plants  
<130> V84653WO  
<150> US 61/646,058  
<151> 2012-05-11  
<160> 59  
<170> PatentIn version 3.5  
<210> 1  
<211> 884  
<212> PRT  
<213> Nicotiana tabacum  
<400> 1

Gly Arg Val Arg Ser Met Ala Tyr Arg Lys Arg Gly Ala Arg Arg Glu  
1 5 10 15

Ala Asn Leu Asn Asn Asn Asp Arg Met Gln Glu Lys Ile Asp Glu Lys  
20 25 30

Gln Asp Ser Asn Lys Ile Gln Leu Ser Asp Lys Val Leu Ser Lys Lys  
35 40 45

Glu Glu Ile Val Thr Asp Ser His Glu Glu Val Lys Val Thr Asp Glu  
50 55 60

Leu Lys Lys Ser Thr Lys Glu Glu Ser Lys Gln Leu Leu Glu Val Leu  
65 70 75 80

Lys Thr Lys Glu Glu His Gln Lys Glu Ile Gln Tyr Glu Ile Leu Gln  
85 90 95

Lys Thr Ile Pro Thr Phe Glu Pro Lys Glu Thr Ile Leu Arg Lys Leu  
100 105 110

Glu Asp Ile Gln Pro Glu Leu Ala Lys Lys Gln Thr Lys Leu Phe Arg  
115 120 125

Ile Phe Glu Pro Lys Gln Leu Pro Ile Tyr Arg Ala Asn Gly Glu Arg  
130 135 140

Glu Leu Arg Asn Arg Trp Tyr Trp Lys Leu Lys Lys Asp Thr Leu Pro  
145 150 155 160

Asp Gly Asp Tyr Asp Val Arg Glu Tyr Phe Leu Asn Leu Tyr Asp Gln  
165 170 175

Val Leu Thr Glu Met Pro Asp Tyr Leu Leu Lys Asp Met Ala Val  
Page 1

pctca2013050364-seq1.txt  
180 185 190

Glu Asn Lys Asn Ser Arg Asp Ala Gly Lys Val Val Asp Ser Glu Thr  
195 200 205

Ala Ser Ile Cys Asp Ala Ile Phe Gln Asp Glu Glu Thr Glu Gly Ala  
210 215 220

Val Arg Arg Phe Ile Ala Glu Met Arg Gln Arg Val Gln Ala Asp Arg  
225 230 235 240

Asn Val Val Asn Tyr Pro Ser Ile Leu His Pro Ile Asp Tyr Ala Phe  
245 250 255

Asn Glu Tyr Phe Leu Gln His Gln Leu Val Glu Pro Leu Asn Asn Asp  
260 265 270

Ile Ile Phe Asn Tyr Ile Pro Glu Arg Ile Arg Asn Asp Val Asn Tyr  
275 280 285

Ile Leu Asn Met Asp Arg Asn Leu Pro Ser Thr Ala Arg Tyr Ile Arg  
290 295 300

Pro Asn Leu Leu Gln Asp Arg Leu Asn Leu His Asp Asn Phe Glu Ser  
305 310 315 320

Leu Trp Asp Thr Ile Thr Thr Ser Asn Tyr Ile Leu Ala Arg Ser Val  
325 330 335

Val Pro Asp Leu Lys Glu Leu Val Ser Thr Glu Ala Gln Ile Gln Lys  
340 345 350

Met Ser Gln Asp Leu Gln Leu Glu Ala Leu Thr Ile Gln Ser Glu Thr  
355 360 365

Gln Phe Leu Thr Gly Ile Asn Ser Gln Ala Ala Asn Asp Cys Phe Lys  
370 375 380

Thr Leu Ile Ala Ala Met Leu Ser Gln Arg Thr Met Ser Leu Asp Phe  
385 390 395 400

Val Thr Thr Asn Tyr Met Ser Leu Ile Ser Gly Met Trp Leu Leu Thr  
405 410 415

Val Val Pro Asn Asp Met Phe Ile Arg Glu Ser Leu Val Ala Cys Gln  
420 425 430

Leu Ala Ile Val Asn Thr Ile Ile Tyr Pro Ala Phe Gly Met Gln Arg  
435 440 445

Met His Tyr Arg Asn Gly Asp Pro Gln Thr Pro Phe Gln Ile Ala Glu  
Page 2

450 455 460  
pctca2013050364-seq1.txt

Gln Gln Ile Gln Asn Phe Gln Val Ala Asn Trp Leu His Phe Val Asn  
465 470 475 480

Asn Asn Gln Phe Arg Gln Ala Val Ile Asp Gly Val Leu Asn Gln Val  
485 490 495

Leu Asn Asp Asn Ile Arg Asn Gly His Val Ile Asn Gln Leu Met Glu  
500 505 510

Ala Leu Met Gln Leu Ser Arg Gln Gln Phe Pro Thr Met Pro Ile Asp  
515 520 525

Tyr Lys Arg Ser Ile Gln Arg Gly Ile Leu Leu Leu Ser Asn Arg Leu  
530 535 540

Gly Gln Leu Val Asp Leu Thr Arg Leu Leu Ala Tyr Asn Tyr Glu Thr  
545 550 555 560

Leu Met Ala Cys Ile Thr Met Asn Met Gln His Val Gln Thr Leu Thr  
565 570 575

Thr Glu Lys Leu Gln Leu Thr Ser Val Thr Ser Leu Cys Met Leu Ile  
580 585 590

Gly Asn Ala Thr Val Ile Pro Ser Pro Gln Thr Leu Phe His Tyr Tyr  
595 600 605

Asn Val Asn Val Asn Phe His Ser Asn Tyr Asn Glu Arg Ile Asn Asp  
610 615 620

Ala Val Ala Ile Ile Thr Ala Ala Asn Arg Leu Asn Leu Tyr Gln Lys  
625 630 635 640

Lys Met Lys Ala Ile Val Glu Asp Phe Leu Lys Arg Leu Tyr Ile Phe  
645 650 655

Asp Val Ser Arg Val Pro Asp Asp Gln Met Tyr Arg Leu Arg Asp Arg  
660 665 670

Leu Arg Leu Leu Pro Val Glu Ile Arg Arg Leu Asp Ile Phe Asn Leu  
675 680 685

Ile Leu Met Asn Met Asp Gln Ile Glu Arg Ala Ser Asp Lys Ile Ala  
690 695 700

Gln Gly Val Ile Ile Ala Tyr Arg Asp Met His Leu Glu Arg Asp Glu  
705 710 715 720

Met Tyr Gly Tyr Val Asn Ile Ala Arg Asn Leu Glu Gly Phe Gln Gln  
Page 3

725

730

735

Ile Asn Leu Glu Glu Leu Met Arg Ser Gly Asp Tyr Ala Gln Ile Thr  
 740 745 750

Asn Met Leu Leu Asn Asn Gln Pro Val Ala Leu Val Gly Ala Leu Pro  
 755 760 765

Phe Ile Thr Asp Ser Ser Val Ile Ser Leu Ile Ala Lys Leu Asp Ala  
 770 775 780

Thr Val Phe Ala Gln Ile Val Lys Leu Arg Lys Val Asp Thr Leu Lys  
 785 790 795 800

Pro Ile Leu Tyr Lys Ile Asn Ser Asp Ser Asn Asp Phe Tyr Leu Val  
 805 810 815

Ala Asn Tyr Asp Trp Val Pro Thr Ser Thr Thr Lys Val Tyr Lys Gln  
 820 825 830

Val Pro Gln Gln Phe Asp Phe Arg Asn Ser Met His Met Leu Thr Ser  
 835 840 845

Asn Leu Thr Phe Thr Val Tyr Ser Asp Leu Leu Ala Phe Val Ser Ala  
 850 855 860

Asp Thr Val Glu Pro Ile Asn Ala Val Ala Phe Asp Asn Met Arg Ile  
 865 870 875 880

Met Asn Glu Leu

<210> 2

<211> 380

<212> PRT

<213> Nicotiana tabacum

<400> 2

Gly Arg Val Arg Ser Met Ala Ser Leu Ile Tyr Arg Gln Leu Leu Thr  
 1 5 10 15

Asn Ser Tyr Thr Val Glu Leu Ser Asp Glu Ile Asn Thr Ile Gly Ser  
 20 25 30

Glu Lys Ser Gln Asn Val Thr Ile Asn Pro Gly Pro Phe Ala Gln Thr  
 35 40 45

Asn Tyr Ala Pro Val Thr Trp Ser His Gly Glu Val Asn Asp Ser Thr  
 50 55 60

Thr Ile Glu Pro Val Leu Asp Gly Pro Tyr Gln Pro Thr Asn Phe Lys  
 65 70 75 80

pctca2013050364-seq1.txt

Pro Pro Asn Asp Tyr Trp Ile Leu Leu Asn Pro Thr Asn Gln Gln Val  
85 90 95

Val Leu Glu Gly Thr Asn Lys Thr Asp Ile Trp Val Ala Leu Leu Leu  
100 105 110

Val Glu Pro Asn Val Thr Asn Gln Ser Arg Gln Tyr Thr Leu Phe Gly  
115 120 125

Glu Thr Lys Gln Ile Thr Val Glu Leu Pro Thr Asp Phe Ser Val Ser  
130 135 140

Arg Tyr Glu Val Ile Lys Glu Asn Ser Tyr Val Tyr Val Asp Tyr Trp  
145 150 155 160

Asp Asp Ser Gln Ala Phe Arg Asn Met Val Tyr Val Arg Ser Leu Ala  
165 170 175

Ala Asn Leu Asn Ser Val Lys Cys Ser Gly Gly Asn Tyr Asn Phe Gln  
180 185 190

Ile Pro Val Gly Ala Trp Pro Val Met Ser Gly Gly Ala Val Ser Leu  
195 200 205

His Phe Ala Gly Val Thr Leu Ser Thr Gln Phe Thr Asp Phe Val Ser  
210 215 220

Leu Asn Ser Leu Arg Phe Arg Phe Ser Leu Thr Val Glu Glu Pro Pro  
225 230 235 240

Phe Ser Ile Leu Arg Thr Arg Val Ser Gly Leu Tyr Gly Leu Pro Ala  
245 250 255

Phe Asn Pro Asn Asn Gly His Glu Tyr Tyr Glu Ile Ala Gly Arg Phe  
260 265 270

Ser Leu Ile Ser Leu Val Pro Ser Asn Asp Asp Tyr Gln Thr Pro Ile  
275 280 285

Met Asn Ser Val Thr Val Arg Gln Asp Leu Glu Arg Gln Leu Gly Asp  
290 295 300

Leu Arg Glu Glu Phe Asn Ser Leu Ser Gln Glu Ile Ala Met Thr Gln  
305 310 315 320

Leu Ile Asp Leu Ala Leu Leu Pro Leu Asp Met Phe Ser Met Phe Ser  
325 330 335

Asn Tyr Gly Ile Thr Arg Ser Gln Ala Leu Asp Leu Ile Arg Ser Asp  
340 345 350

pctca2013050364-seq1.txt

Pro Arg Val Leu Arg Asp Phe Ile Asn Gln Asn Asn Pro Ile Ile Lys  
355 360 365

Asn Arg Ile Glu Gln Leu Ile Leu Gln Cys Arg Leu  
370 375 380

<210> 3  
<211> 402  
<212> PRT  
<213> Nicotiana tabacum

<400> 3

Gly Arg Val Arg Ser Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu  
1 5 10 15

Lys Asp Ala Arg Asp Lys Ile Val Glu Gly Thr Leu Tyr Ser Asn Val  
20 25 30

Ser Asp Leu Ile Gln Gln Phe Asn Gln Met Ile Ile Thr Met Asn Gly  
35 40 45

Asn Glu Phe Gln Thr Gly Ile Gly Asn Leu Pro Ile Arg Asn Trp  
50 55 60

Asn Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala  
65 70 75 80

Asn Tyr Val Glu Thr Ala Arg Asn Thr Ile Asp Tyr Phe Val Asp Phe  
85 90 95

Val Asp Asn Val Cys Met Asp Glu Met Val Arg Glu Ser Gln Arg Asn  
100 105 110

Gly Ile Ala Pro Gln Ser Asp Ser Leu Arg Lys Leu Ser Gly Ile Lys  
115 120 125

Phe Lys Arg Ile Asn Phe Asp Asn Ser Ser Glu Tyr Ile Glu Asn Trp  
130 135 140

Asn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro  
145 150 155 160

Asn Ile Phe Pro Tyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro  
165 170 175

Ala His Asp Asn Leu Met Gly Thr Met Trp Leu Asn Ala Gly Ser Glu  
180 185 190

Ile Gln Val Ala Gly Phe Asp Tyr Ser Cys Ala Ile Asn Ala Pro Ala  
195 200 205

pctca2013050364-seq1.txt

Asn Thr Gln Gln Phe Glu His Ile Val Gln Leu Arg Arg Val Leu Thr  
210 215 220

Thr Ala Thr Ile Thr Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro  
225 230 235 240

Arg Val Ile Asn Ser Ala Asp Gly Ala Thr Thr Trp Tyr Phe Asn Pro  
245 250 255

Val Ile Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly  
260 265 270

Gln Ile Ile Asn Thr Tyr Gln Ala Arg Phe Gly Thr Ile Val Ala Arg  
275 280 285

Asn Phe Asp Thr Ile Arg Leu Ser Phe Gln Leu Met Arg Pro Pro Asn  
290 295 300

Met Thr Pro Ser Val Ala Ala Leu Phe Pro Asn Ala Gln Pro Phe Glu  
305 310 315 320

His His Ala Thr Val Gly Leu Thr Leu Lys Ile Glu Ser Ala Val Cys  
325 330 335

Glu Ser Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr  
340 345 350

Ser Val Arg Gln Glu Tyr Ala Ile Pro Val Gly Pro Val Phe Pro Pro  
355 360 365

Gly Met Asn Trp Thr Asp Leu Ile Thr Asn Tyr Ser Pro Ser Arg Glu  
370 375 380 385

Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser Ile Arg Ser Met Leu  
385 390 395 400

Val Lys

<210> 4  
<211> 331  
<212> PRT  
<213> Nicotiana tabacum

<400> 4

Gly Arg Val Arg Cys Met Tyr Gly Ile Glu Tyr Thr Thr Ile Leu Thr  
1 5 10 15

Phe Leu Ile Ser Ile Val Leu Leu Asn Tyr Ile Leu Lys Ser Leu Thr  
20 25 30

Ser Ala Met Asp Phe Ile Ile Tyr Arg Phe Leu Leu Leu Ile Val Ile  
 35 40 45

Ala Ser Pro Phe Val Lys Thr Gln Asn Tyr Gly Ile Asn Leu Pro Ile  
 50 55 60

Thr Gly Ser Met Asp Thr Ala Tyr Ala Asn Ser Ser Gln Gln Glu Thr  
 65 70 75 80

Phe Leu Thr Ser Thr Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser Thr  
 85 90 95

Gln Ile Gly Asp Thr Glu Trp Lys Asp Thr Leu Ser Gln Leu Phe Leu  
 100 105 110

Thr Lys Gly Trp Pro Thr Gly Ser Val Tyr Phe Lys Glu Tyr Thr Asp  
 115 120 125

Ile Ala Ser Phe Ser Ile Asp Pro Gln Leu Tyr Cys Asp Tyr Asn Val  
 130 135 140

Val Leu Met Lys Tyr Asp Ser Thr Leu Glu Leu Asp Met Ser Glu Leu  
 145 150 155 160

Ala Asp Leu Ile Leu Asn Glu Trp Leu Cys Asn Pro Met Asp Ile Thr  
 165 170 175

Leu Tyr Tyr Tyr Gln Gln Thr Asp Glu Ala Asn Lys Trp Ile Ser Met  
 180 185 190

Gly Gln Ser Cys Thr Ile Lys Val Cys Pro Leu Asn Thr Gln Thr Leu  
 195 200 205

Gly Ile Gly Cys Ile Thr Thr Asn Thr Ala Thr Phe Glu Glu Val Ala  
 210 215 220

Thr Ser Glu Lys Leu Val Ile Thr Asp Val Val Asp Gly Val Asn His  
 225 230 235 240

Lys Leu Asp Val Thr Thr Asn Thr Cys Thr Ile Arg Asn Cys Lys Lys  
 245 250 255

Leu Gly Pro Arg Glu Asn Val Ala Ile Ile Gln Val Gly Gly Ser Asp  
 260 265 270

Val Leu Asp Ile Thr Ala Asp Pro Thr Thr Ala Pro Gln Thr Glu Arg  
 275 280 285

Met Met Arg Val Asn Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr Val  
 290 295 300

pctca2013050364-seq1.txt

Val Asp Tyr Ile Asn Gln Ile Val Gln Val Met Ser Lys Arg Ser Arg  
305 310 315 320

Ser Leu Asn Ser Ala Ala Phe Tyr Tyr Arg Val  
325 330

<210> 5  
<211> 22  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer VP2F

<400> 5  
ttccatggct taccgtaaaa gg 22

<210> 6  
<211> 32  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer VP2R

<400> 6  
atgcggccgc aagctcggtc ataatcctca tg 32

<210> 7  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer VP4F

<400> 7  
ttccatggct tccctcatct ac 22

<210> 8  
<211> 31  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer VP4R

<400> 8  
atgcggccgc aagacggcac tggagaatga g 31

<210> 9  
<211> 21  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer VP6F

<400> 9  
ttccatggat gtgctctact c 21

pctca2013050364-seq1.txt

<210> 10  
<211> 28  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer VP6R

<400> 10  
atgcggccgc cttcacgagc atggaacg 28

<210> 11  
<211> 22  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer VP7F

<400> 11  
gtacatgtac ggaatcgagt ac 22

<210> 12  
<211> 31  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer VP7R

<400> 12  
atgcggccgc cacacggtag tagaaaggcag c 31

<210> 13  
<211> 2700  
<212> DNA  
<213> Nicotiana tabacum

<400> 13  
ggtaccgaat tcggacgcgt tcgttccatg gcttaccgta aaagggggtgc taggcgtgaa 60  
gctaacctca acaacaacga taggatgcaa gagaagatcg atgagaagca ggattccaac 120  
aagatccagc tctccgataa ggtgctctcc aagaaagaag agatcgttac tgattccac 180  
gaagaggtga aggtgacaga tgagcttaag aagtccacaa aagaagagtc caagcagctc 240  
cttggaggtgc tcaagacaaa agaggaacac cagaaagaga tccagtacga gatcctccaa 300  
aagactatcc caactttcga gccaaaagag actatcctca ggaagcttga ggatatccag 360  
ccagagcttgc ttaagaagca gactaagctc ttcaggatct tcgagccaaa gcagctccca 420  
atctaccgtg ctaacggtga aagggaaactt aggaacaggt ggtactggaa gctcaagaag 480  
gatactctcc cagacggtga ttacgatgtg agagagtact tcctcaacct ctacgatcag 540  
gtgctcactg agatgccaga ttacctcctc ctcaaggata tggctgtgaa gaacaagaac 600  
tccagggatg ctggaaaggt ggtggattcc gagactgctt ccatctgtga tgctatcttc 660  
caggatgaag agactgaggg tgctgtgagg cgttcattt ctgagatgag gcagagggtt 720  
caggctgata ggaacgtggt gaactaccca tccatcctcc acccaatcga ttacgtttc 780

pctca2013050364-seq1.txt

aacgagtaact	tccttcagca	ccagcttg	gagccactca	acaacgat	at catttcaac	840				
tacatcccag	agaggattag	gaacgacgtt	aactacatcc	tcaacatgg	taggaac	900				
ccatccactg	ctcg	tttacat	caggccaaac	ctcc	tcagg	ataggctcaa	cctccacgat	960		
aacttcgagt	ccct	ctgg	taaaatca	acttcca	act	acatttcgc	tcgttccgt	1020		
gtgccagatc	tcaa	agaact	cgtgtccact	gagg	ctcaga	tcc	agaagat	gtcccaggat	1080	
ctccagctt	agg	ctc	act	atcc	act	tc	ctactgg	tatcaactcc	1140	
caggctgcta	acg	att	tgct	ca	gact	tc	tgct	cccca	gaggactat	1200
tccctcgatt	tcgt	gactac	taactat	atg	ccct	cat	cc	ccgaat	gtcttgact	1260
gtgg	tgccaa	acgat	atgtt	catcc	gtg	cc	tg	ccag	ctcg	1320
aacactatca	tct	accc	agg	ttc	ggaa	at	tg	ca	gtcc	1380
cagactccat	tcc	agat	cg	ag	cac	g	cc	aa	actgg	1440
cacttcgtga	aca	aca	acca	gtt	cagg	cag	g	tt	gat	1500
ctcaacgata	acat	ccgt	aa	cggt	ac	cg	tc	at	ggaa	1560
ctctccaggc	agc	agtt	ccc	aact	atgc	cct	atc	gat	ccat	1620
atc	ctcc	tcc	ca	ac	ag	tg	gg	ac	ggtt	1680
aactacgaga	ct	ct	cat	gg	tc	at	tc	act	tc	1740
actgagaagc	tcc	ag	ctc	ac	ttc	gt	gg	act	gg	1800
gtgatccat	cccc	ac	ag	act	ttcc	ac	tac	ta	act	1860
aactacaacg	agagg	atca	aa	cgat	gt	tg	ta	cagg	ctt	1920
ctctaccaa	aa	ga	agat	gaa	gg	ct	at	cg	tt	1980
gatgtgtcca	gggt	gcc	aga	tg	atc	agat	g	gg	atc	2040
ccagtgaga	tc	aga	agg	gt	cg	at	tc	tt	at	2100
gagagggctt	ccg	ata	ag	cg	tc	ttt	at	cc	gt	2160
gagagggatg	agat	gt	ac	gg	at	cg	ta	tt	ac	2220
atcaac	ttt	g	g	tt	cc	cg	gt	cc	c	2280
aacaacc	ag	tg	gc	tc	t	cc	at	tc	t	2340
tcc	catt	g	ta	at	tg	tc	act	gt	at	2400
gata	ct	ca	at	cc	tg	tc	act	g	aa	2460
gcta	act	ac	tg	cc	tt	cc	tt	cc	at	2520
ttcg	attt	cc	ta	act	cc	at	cc	aa	cc	2580
gat	tc	tc	cg	tt	cg	tg	tc	at	gt	2640
aacat	gag	ga	tt	at	ga	ac	gt	tt	at	2700

<210> 14  
<211> 2700  
<212> DNA

&lt;213&gt; Nicotiana tabacum

<400> 14						
ccatggctta	agcctgcgca	agcaaggta	cgaatggcat	tttccccacg	atccgcac	60
cgattggagt	tgttgtgct	atcctacgtt	ctcttctagc	tactcttcgt	cctaaggttg	120
ttcttaggtcg	agaggctatt	ccacgagagg	ttctttcttc	tctagcaatg	actaagggtg	180
cttctccact	tccactgtct	actcgaattc	ttcaggtgtt	ttcttctcag	gttcgtcgag	240
gaactccacg	agttctgttt	tctccttgc	gtctttctct	aggtcatgct	ctaggaggtt	300
ttctgatagg	gttgaagct	cgttttctc	tgataggagt	ccttcgaact	cctataggtc	360
ggtctcgaac	gattctcgt	ctgattcgag	aagtccctaga	agtcgggtt	cgtcgagggt	420
tagatggcac	gattgccact	ttcccttgc	tccttgc	ccatgac	cgagttctc	480
ctatgagagg	gtctgccact	aatgctacac	tctctcatga	aggagttgga	gatgctagtc	540
cacgagtgac	tctacggtct	aatggaggag	gagttcc	accgacac	cttgc	600
aggtccctac	gacctttcca	ccacctaagg	ctctgac	ggtagacact	acgatagaag	660
gtcctacttc	tctgactccc	acgacactcc	gcaaagtaac	gactctactc	cgtctccaa	720
gtccgactat	ccttgcacca	cttgc	aggttaggagg	tgggttagct	aatgc	780
ttgctcatga	aggaagtcgt	gtcga	agtaggac	ctcgg	gtataagttg	840
atgttagggtc	tctccta	atgc	tgttagg	agttgtac	atc	900
ggttaggtac	gagcaatgta	gtccgg	gaggagg	tatcc	ggaggtg	960
ttgaagctca	gggagacc	atgttagtga	tgaagg	tgt	agcagg	1020
cacgg	ctt	atgt	agg	agg	ggac	1080
gtccgac	gtctaa	atgt	gg	gg	gt	1140
agggagctaa	agcactgat	attgatatac	agggag	ttac	cgaga	1200
caccacg	tgctata	ca	gtt	ac	actg	1260
ttgtgatagt	agatgg	ttac	gtt	cc	tgac	1320
gtctgaggta	agg	tc	tt	cc	ttgt	1380
gtgaagcact	tg	tc	tt	cc	ttgt	1440
gagttgctat	tg	tc	tt	cc	ttgt	1500
gagaggtccg	tc	tc	tt	cc	ttgt	1560
ttgatgctct	aa	aa	tt	cc	ttgt	1620
tgactctcg	agg	gg	tt	cc	ttgt	1680
cactagg	ggg	gg	tt	cc	ttgt	1740
ttgatgtgc	tt	tt	tt	cc	ttgt	1800
gagatgg	tt	tt	tt	cc	ttgt	1860
gagatgg	tt	tt	tt	cc	ttgt	1920
gagatgg	tt	tt	tt	cc	ttgt	1980

pctca2013050364-seq1.txt

ctacacaggt	cccacggtct	actagtctac	atggcagaat	ccctatccga	atccgaggag	2040
ggtcacctct	agtcttccga	gctatagaag	ttggagtagg	aataacttgta	cctagtctag	2100
ctctccgaa	ggctattcta	gcgagtccca	caataatagc	aatggcact	atacgtggaa	2160
ctctccctac	tctacatgcc	tatgcacttg	taacgatcct	tgaaactccc	taaggtcgct	2220
tagtggAAC	ttctcgaata	cgcaaggcca	ctaatgcgag	tctagtgatt	gtacgaggag	2280
ttgttggTCG	gtcaccgaga	acaaccacga	gagggttaat	agtgactaag	gaggcactag	2340
agggagtaac	gattcaacct	acgatgacac	aagcgagtct	agcacttcga	gtcctttcac	2400
ctatgagagt	tcggtagga	gatgttctag	ttgaggctaa	ggttgctaaa	gatggagcac	2460
cgattgtgc	taacccacgg	ttgaaggtga	tgttccaca	tgttgcgtca	cggtgtcgct	2520
aagctaaagg	cattgaggta	cgtgtacgag	tgaagggtgg	agtgaaagtg	acacatgagg	2580
ctagaggagc	gaaagcacag	gcfactatga	cacctcggat	agttgcgaca	ccgaaagcta	2640
ttgtactcct	aatacttgct	cgaaactact	gagctcccta	ggagatctct	taagctcgag	2700

<210> 15  
 <211> 2388  
 <212> DNA  
 <213> Rotavirus

<400> 15	ggtaccgaat	tcggacgcgt	tcgttccatg	gcttccctca	tctaccgtca	gttgctca	60
	aactcctaca	ctgtggagct	ttccgatgag	atcaacacta	tcggttccga	gaagtcccag	120
	aacgtgacta	tcaacccagg	accattcgct	cagactaact	acgctccagt	gacttggtca	180
	cacggtaag	tgaacgattc	cactactatc	gagccagtgc	tcgatggacc	ataccagcca	240
	actaacttca	agccaccaaa	cgattactgg	attctcctca	acccaactaa	ccagcaggtg	300
	gtgcttggagg	gaactaacaa	gactgatatc	tgggtggcac	tccttcttgc	ggagccaaac	360
	gtgactaacc	agtccaggca	gtacactctc	ttcggagaga	ctaagcagat	cactgtggag	420
	aacaacacta	acaagtggaa	gttcttcgag	atgttcaggt	ccaacgtgaa	cgctgagttc	480
	cagcacaaga	ggactctcac	ttccgataca	aagctcgctg	gttttatgaa	gttctacaac	540
	tctgtgtgga	cttccacgg	tgaaactcca	cacgctacta	ctgattactc	ctccacttcc	600
	aaccttccg	aggtggagac	tgtgatccac	gtggagttct	acatcatccc	aaggcccac	660
	gagtctaagt	gctccgagta	catcaacact	ggactcccac	caatgcaaaa	cactaggaac	720
	atcgtgccag	tggcttgtc	ctctcggtcc	gtgacttacc	agagggctca	ggtgaacgag	780
	gatatcatca	tctccaagac	ttccctctgg	aaagagatgc	agtacaacag	ggatattatc	840
	atcaggttca	agttcaacaa	ctccatcggt	aagctcgag	gactcggata	caagtggagt	900
	gagatctcct	tcaaggctgc	taactaccag	tactcctacc	tcagggatgg	tgaacaggtg	960
	acagctcaca	ctacttgctc	cgtgaacggt	gttaacaact	tctcctacaa	cggtgttcc	1020
	ctcccaactg	atttctccgt	gtcccggtac	gaggtatca	aagagaactc	ctacgtttac	1080

pctca2013050364-seq1.txt

gtggattact	gggatgattc	ccaggcttc	aggaacatgg	tgtatgttag	atccctcgct	1140
gctaaccta	actccgtcaa	gtgctccgg	ggaaactaca	acttccagat	cccagtggaa	1200
gcttggccag	tgtatgtctgg	tggagctgt	tctctccact	tcgctgggt	tacactctcc	1260
actcagttca	ctgatttcgt	gtccctcaac	tccctcaggt	tcaggttctc	cctcactgt	1320
gaagagccac	cattctccat	cctcaggact	agggtgtccg	gactttacgg	actcccagct	1380
ttcaacccaa	acaacggaca	cgagtactac	gagatcgctg	gacgtttctc	ccttatctcc	1440
ctcgtgccat	ccaacgatga	ttaccagact	ccaattatga	actccgtgac	tgtgaggcag	1500
gatcttgaga	ggcagctcg	agatctcagg	gaagagttca	actccctctc	ccaagagatc	1560
gctatgactc	agctcatcga	tctcgctctc	ctcccactcg	atatgttctc	catgttctct	1620
ggtatcaagt	ccactatcga	tgtggctaag	tctatggta	ctaaggtgat	gaagaagttc	1680
aagaagtccg	gactcgctac	ttccatctcc	gagcttactg	gatctctctc	caacgctgct	1740
tcttctgtgt	ctaggtcctc	ctccatcagg	tccaaacatct	cctccatctc	agtgtggact	1800
gatgtgtccg	agcagatcgc	tggatcttcc	gattccgtgc	gtaacatctc	cactcagact	1860
tccgctatct	ccaagaggct	taggctcaga	gagatcacta	ctcagactga	ggaaatgaac	1920
ttcgatgata	tctccgctgc	tgtgctcaag	actaagatcg	ataggccac	tcacatctcc	1980
ccagatactc	tcccagatat	catcaactgag	tcctccgaga	agttcatccc	aaagcgtgct	2040
taccgtgttc	tcaaggatga	tgaggtgatg	gaagctgatg	tggatggaaa	gttcttcgct	2100
tacaaagtgg	gaactttcga	agaggtgcca	ttcgatgtgg	ataagttcgt	ggatctcg	2160
actgattccc	cagtgatctc	cgctatcatc	gatttcaaga	ctctcaagaa	cctcaacgat	2220
aactacggaa	tcacttaggtc	ccaggctctc	gatctcatcc	gttccgatcc	aagggtgctc	2280
agggatttca	tcaaccagaa	caacccaatc	atcaagaaca	ggatcgagca	gctcattctc	2340
cagtgccgtc	tttgcgtact	cgagggatcc	tctagagaat	tcgagctc		2388

<210> 16  
 <211> 2388  
 <212> DNA  
 <213> Rotavirus

<400> 16						
ccatggctta	agcctgcgca	agcaaggtac	cgaaggagt	agatggcagt	caacgagtga	60
ttgaggatgt	gacacctcga	aaggctactc	tagttgtat	agccaaaggct	cttcagggtc	120
ttgcactgat	agttgggtcc	tgtaaagcga	gtctgattga	tgcgaggta	ctgaaccagt	180
gtgccacttc	acttgctaag	gtgatgatag	ctcggtcacg	agctacctgg	tatggtcgt	240
tgattgaagt	tgcgtggttt	gctaattgacc	taagaggagt	tgggttgatt	ggtcgtccac	300
cacgaactcc	cttgattgtt	ctgactatag	acccaccgtg	aggaagaaca	cctcggtttg	360
cactgattgg	tcaggtccgt	catgtgagag	aagcctctct	gattcgtcta	gtgacacctc	420
ttgttgtat	tgttcaccc	caagaagctc	tacaagtcca	ggttgcactt	gctgactcaag	480
gtcgtgttct	cctgagagtg	aaggctatgt	ttcgagcgac	caaataactt	caagatgtt	540

pctca2013050364-seq1.txt

agacacacct	gaaagggtgcc	actttgaggt	gtgcgtatgt	gactaatgag	gaggtgaagg	600
ttggaaaggc	tccacctctg	acactaggtg	cacctaaga	tgttagtaggg	ttccagggtt	660
ctcagattca	cgaggctcat	gtagttgtga	cctgagggtg	gttacgtttt	gtgatccttg	720
tagcacggc	accgaaacag	gagagcaagg	caactgaatgg	tctcccgagt	ccacttgctc	780
ctatagtagt	agaggttctg	aaggagacc	tttctctacg	tcatgttgc	cctataatag	840
tagtccaagt	tcaagttgtt	gaggtagcac	ttcgagcctc	ctgagcctat	gttcacactca	900
ctctagagga	agttccgacg	attgatggtc	atgaggatgg	agtccctacc	acttgtccac	960
tgtcgagtgt	gatgaacgag	gcacttgcca	caattgtga	agaggatgtt	gccaccaagg	1020
gagggttgac	taaagaggca	cagggcaatg	ctccactagt	ttctctttag	gatgcaaatg	1080
cacctaattga	ccctactaag	ggtccgaaag	tccttgcattc	acatacaatc	tagggagcga	1140
cgattggagt	tgaggcactt	cacgaggcca	cctttgatgt	tgaaggctca	gggtcaccct	1200
cgaaccggc	actacagacc	acctcgacac	agagaggta	agcgaccaca	atgtgagagg	1260
tgagtcaagt	gactaaagca	cagggagttg	agggagttca	agtccaagag	ggagtgcac	1320
cttctcggtg	gtaagaggtt	ggagtcctga	tcccacaggc	ctgaaatgcc	tgagggtcga	1380
aagttgggtt	tgttgcctgt	gctcatgtt	ctctagcgac	ctgcaaagag	ggaatagagg	1440
gagcacggta	ggttgctact	aatggtctga	ggttaatact	tgaggcactg	acactccgtc	1500
ctagaactct	ccgtcgagcc	tctagagtcc	cttctcaagt	tgagggagag	ggttctctag	1560
cgatactgag	tcgagtagct	agagcgagag	gagggtgagc	tatacaagag	gtacaagaga	1620
ccatagttca	ggtgatagct	acaccgattc	agataccact	gattccacta	cttcttcaag	1680
ttcttcaggc	ctgagcgatg	aaggtagagg	ctcgaatgac	ctagagagag	gttgcacga	1740
agaagacaca	gatccaggag	gaggtagtcc	aggtttaga	ggaggttagag	tcacacctga	1800
ctacacaggc	tcgtctagcg	acctagaagg	ctaaggcacg	cattgttagag	gtgagttctga	1860
aggcgataga	ggttctccga	atccgagtct	ctctagtgat	gagtctgact	cccttacttg	1920
aagctactat	agaggcgacg	acacgagtcc	tgattcttagc	tatccaggtg	agtgtagagg	1980
ggtctatgag	agggtctata	gtagtgcactc	aggaggctct	tcaagttaggg	tttgcacga	2040
atggcacaag	agttcctact	actccactac	cttcgactac	acctacctt	caagaagcga	2100
atgtttcacc	cttgcggact	tctccacggt	aagctacacc	tattcaagca	cctagagcac	2160
tgactaaggg	gtcactagag	gcgatagtag	ctaaagttct	gagagttctt	ggagttgcta	2220
ttgatgcctt	agtgtatccag	ggtccgagag	ctagagtagg	caaggctagg	ttcccacgag	2280
tccctaaagt	agttggctt	gttgggttag	tagttctgt	cctagctcgt	cgagtaagag	2340
gtcacggcag	aaactactga	gctccctagg	agatctctta	agctcgag		2388

<210> 17  
 <211> 1254  
 <212> DNA  
 <213> Nicotiana tabacum

pctca2013050364-seq1.txt

<400> 17  
 ggtaccgaat tcggacgcgt tcgttccatg gatgtgctct actccctctc caagactctc 60  
 aaggatgcta gggataagat cgtggaggga actctctact ccaacgtttc cgatctcatc 120  
 cagcagttca accagatgat catcaactatg aacggaaacg agttccagac tggtsgaaatc 180  
 ggaaacctcc caatcagaa ctgaaacttc gatttggac tcctcggaac tactctcctc 240  
 aacctcgatg ctaactacgt ggagactgct aggaacacta tcgattactt cggtgatttc 300  
 gtggataatg tgtgcatttga tgagatggtt cgtgagtcgg agaggaacgg aattgctcca 360  
 cagtcgatt ccctcagaa gctctccggt atcaagttca agaggatcaa cttcgataaac 420  
 tcctccgagt acatcgagaa ctgaaacctc cagaacagaa ggcagaggac tggattcact 480  
 ttccacaaggc caaacatctt cccatactcc gtttccttca ctctcaacag gtcccagcca 540  
 gctcacgata acctcatggg aactatgtgg ctcaacgctg gttctgagat ccaggtggca 600  
 ggattcgatt actcctgcgc tatcaacgct ccagctaaca ctcagcagtt cgagcacatc 660  
 gttcagctca gaagggtgct cactactgct actatcactc tcctccaga tgctgagagg 720  
 ttctccttcc caagggtgat caactccgct gatggtgcta ctacttggtt cttcaaccca 780  
 gtgatcctca ggccaaacaa cgtggaggtg gagttccccc tcaacggaca gatcatcaac 840  
 acttaccagg ctcgttccgg aactatcgat gcttagaact tcgatacaat caggctctcc 900  
 ttccagctta tgaggccacc aaacatgact ccattcgatg ctgcactctt cccaaacgca 960  
 cagccattcg agcaccacgc tactgtggg ctcactctca agatcgagtc cgctgtgtgc 1020  
 gagtctgtgc tcgctgatgc ttccgagact atgctcgctt acgtgacttc tgtgaggcaa 1080  
 gagtacgctt tcccagtggg accagtgttt ccaccagggaa tgaactggac tgcgttcatc 1140  
 actaactact ccccatccag agaggataac ctccagaggg tggtcactgt ggcttccatc 1200  
 cgttccatgc tcgtgaagtg atgactcgag ggatccctta gagaattcga gctc 1254

<210> 18  
 <211> 1254  
 <212> DNA  
 <213> Nicotiana tabacum

<400> 18  
 ccatggctta agcctgcgc agcaaggtac ctacacgaga tgagggagag gttctgagag 60  
 ttcctacgt ccctatttta gcacccctt tgagagatga ggttgcaaaag gctagatgt 120  
 gtcgtcaagt tggtctacta gtagtatac ttgccttgc tcaaggcttg accaccctt 180  
 cctttggagg gttagtcctt gacccatgg ctaaaggctt aggagcctt atgagaggag 240  
 ttggagctac gattgatgca cctctgacga tccttgcgtt agctaattt gcaactaaag 300  
 cacctattac acacgtaccc actctaccaa gcactcaggg tctccttgc ttaacgaggt 360  
 gtcaggctaa gggagtcctt cgagaggcca tagttcaagt tctccttagtt gaagctattt 420  
 aggaggctca tggatctttt gacccatggag gtcttgcctt ccgtctcctt acctaagtga 480  
 aagggtttcg gttttagaa gggtatgagg cgaaggaagt gagagttgtc cagggtcggt 540

pctca2013050364-seq1.txt

cgagtgtat	tggagtaccc	ttgatacacc	gagttgcgac	caagactcta	ggtccaccgt	600
cctaagctaa	tgaggacgcg	atagttgcga	ggtcgattgt	gagtcgtcaa	gctcgtag	660
caagtcgagt	cttcccacga	gtgatgacga	tgatagttag	aggagggtct	acgactctcc	720
aagaggaagg	gttcccacta	gttgaggcga	ctaccacgt	gatgaaccat	gaagttgggt	780
cactaggagt	ccggttgtt	gcacccac	ctcaaggaag	agttgcctgt	ctagtagttg	840
tgaatggtcc	gagcaaagcc	ttgatagcac	cgatcctga	agctatgtta	gtccgagagg	900
aaggtcgaat	actccggtgg	tttgtactga	ggttaggcacc	gacgtgagaa	gggttgcgt	960
gtcggtaagc	tcgtggtgcg	atgacaccct	gagttagact	tctagctcag	gcgacacacg	1020
ctcagacacg	agcgactacg	aaggctctga	tacgagcgat	tgcactgaag	acactccgtt	1080
ctcatgcgt	agggtcaccc	tggcacaaa	ggtggcctt	acttgacctg	actagagtag	1140
tgattgatga	ggggtaggtc	tctcctattg	gaggctccc	acaagtgaca	ccgaaggtag	1200
gcaaggtagc	agcacttcac	tactgagctc	cctaggagat	ctcttaagct	cgag	1254

<210> 19  
 <211> 1041  
 <212> DNA  
 <213> Nicotiana tabacum

<400> 19	ggtaccgaat	tcggacgcgt	tcgttgcatt	tacggaatcg	agtacactac	tatcctcact	60
	ttcctcatct	ccatcggtct	cctcaactac	atcctcaagt	ccctcacttc	cgctatggat	120
	ttcctcatct	accgtttcct	cctcctcatc	gtgatcgctt	ccccattcgt	taagactcag	180
	aactacggta	tcaacccccc	aatcaactgga	tctatggata	ctgcttacgc	taactcctcc	240
	cagcaagaga	ctttcctcac	ttccacactc	tgcctctact	acccaactga	ggcatccaca	300
	cagatcgag	atacagagt	gaaggatact	ctctcccagc	tcttcctcac	taaggatgg	360
	ccaactgggtt	ccgtgtactt	caaagagtac	actgatatcg	cttccttctc	catcgatcca	420
	cagctctact	gcgattacaa	cgtggtgctt	atgaagtacg	attccactct	tgagcttgc	480
	atgtccgagc	ttgctgatct	catcctcaac	gagtggctct	gcaacccaa	ggatatcact	540
	ctctactact	accagcagac	tgtgaggct	aacaagtgg	tctctatggg	acagtcctgc	600
	actatcaaag	tgtgcccact	caacactcag	actctcgaa	tcggatgcat	cactactaac	660
	actgctactt	tcgaggaagt	ggctacttcc	gagaagctcg	tgatcactga	tgtggtggt	720
	ggtgttaacc	acaagctcga	tgtgactact	aacacatgca	caatcaggaa	ctgcaagaag	780
	ctcggaccaa	gggaaaacgt	ggctatcatc	caagtggag	gttccgatgt	gctcgatatc	840
	actgctgatc	caactactgc	tccacagact	gagaggatga	tgagggtgaa	ctggaagaag	900
	tggtggcagg	ttttctacac	tgtggtggt	tacatcaacc	agatcgatca	ggtgatgtcc	960
	aagaggtccc	gttctctcaa	ctccgctgct	ttctactacc	gtgtgtgatg	actcgaggga	1020
	tcctctagag	aattcgagct	c				1041

pctca2013050364-seq1.txt

<210>	20					
<211>	1041					
<212>	DNA					
<213>	Nicotiana tabacum					
<400>	20					
ccatggctta	agcctgcgca	agcaacgtac	atgccttagc	tcatgtgatg	ataggagtga	60
aaggagtaga	ggtagcacga	ggagttgatg	taggagttca	gggagtgaag	gcgataccta	120
aagtagtga	tggcaaagga	ggaggagtag	cactagcga	ggggtaaagca	attctgagtc	180
ttgatgccat	agttggaggg	ttagtgacct	agataccat	gacgaatgcg	attgaggagg	240
gtcgttctct	gaaaggagtg	aagggtgtag	acggagatga	tgggttgact	ccgtaggtgt	300
gtctagcctc	tatgtctcac	cttcctatga	gagagggtcg	agaaggagtg	attccctacc	360
ggttgaccaa	ggcacatgaa	gtttctcatg	tgactatagc	gaaggaagag	gtagctaggt	420
gtcgagatga	cgctaattgtt	gcaccacgaa	tacttcatgc	taaggtgaga	actcgaacta	480
tacaggctcg	aacgactaga	gttaggagttg	ctcaccgaga	cgttgggtta	cctatagtga	540
gagatgatga	tggtcgctcg	actactccga	ttgttccacct	agagatacc	tgtcaggacg	600
tgatagttc	acacgggtga	gttgtgagtc	tgagagccct	agcctacgta	gtgatgattg	660
tgacgatgaa	agctccttca	ccgatgaagg	ctcttcgagc	actagtact	acaccaccta	720
ccacaattgg	tgttcgagct	acactgatga	ttgtgtacgt	gttagtcctt	gacgttcttc	780
gagcctgggtt	ccctttgca	ccgatagtag	gttcaccctc	caaggctaca	cgagctatag	840
tgacgactag	gttgcgtacg	agggtctga	ctctcctact	actcccactt	gaccttcttc	900
accaccgtcc	aaaagatgtg	acaccaccta	atgttagttgg	tctagcaagt	ccactacagg	960
ttctccaggg	caagagagtt	gaggcgacga	aagatgatgg	cacacactac	tgagctccct	1020
aggagatctc	ttaagctcga	g				1041
<210>	21					
<211>	48					
<212>	DNA					
<213>	Artificial sequence					
<220>						
<223>	Primer IF-WA_VP2(opt).s1+3c					
<400>	21					
aaatttgcg	ggcccatggc	ataccggaag	agaggagcaa	agcgcgaa	48	
<210>	22					
<211>	50					
<212>	DNA					
<213>	Artificial sequence					
<220>						
<223>	Primer IF-WA_VP2(opt).s1-4r					
<400>	22					
actaaagaaa	ataggccttt	aaagctcggt	cattattcgc	atattgtcga	50	

pctca2013050364-seq1.txt

<210> 23

<211> 4903

<212> DNA

<213> Artificial sequence

<220>

<223> Construct 1191

<400> 23

tggcaggata tattgtggtg taaacaaatt gacgcttaga caacttaata acacattgcg	60
gacgtttta atgtactgaa ttaacgccga atcccgggct ggtatattta tatgttgtca	120
aataactcaa aaaccataaa agttaagtt agcaagtgtg tacattttta cttgaacaaa	180
aatattcacc tactactgtt ataaatcatt attaaacatt agagtaaaga aatatggatg	240
ataagaacaa gagtagtgat attttgacaa caattttgtt gcaacattt agaaaatttt	300
gttgttctct ctttcattt gtcaaaaaca atagagagag aaaaaggaag agggagaata	360
aaaacataat gtgagtgatga gagagaaagt tgtacaaaag ttgtaccaaa atagttgtac	420
aaatatcatt gaggaattt acaaaagcta cacaataaag ggttaattgc tgtaaataaa	480
taaggatgac gcatttagaga gatgtaccat tagagaattt ttggcaagtc attaaaaaga	540
aagaataaat tattttaaa attaaaagtt gagtcattt attaaacatg tgattattta	600
atgaattgat gaaagagttt gattaaagtt gtatttagtaa tttagaattt gtgtcaaattt	660
taatttgaca tttgatctt tcctatata tgcggccatag agtcagttaa ctcattttta	720
tatttcatac atcaaataag agaaataacg gtatattaat ccctccaaaa aaaaaaaacg	780
gtatatttac taaaaaatct aagccacgta ggaggataac agatccccg taggaggata	840
acatccaatc caaccaatca caacaatcct gatgagataa cccactttaa gcccacgcat	900
ctgtggcaca tctacattat ctaaatcaca cattctcca cacatctgag ccacacaaaa	960
accaatccac atctttatca cccattctat aaaaaatcac actttgtgag tctacacttt	1020
gattcccttc aaacacatac aaagagaaga gactaattaa ttaattaatc atcttgagag	1080
aaaatggaac gagctataca agggaaacgac gctagggAAC aagctaacag tgaacgttgg	1140
gatggaggat caggaggtac cacttctccc ttcaaacttc ctgacgaaag tccgagttgg	1200
actgagtggc ggctacataa cgatgagacg aattcgaatc aagataatcc cttgggtttc	1260
aaggaaagct ggggtttcgg gaaagttgtt ttaagagat atctcagata cgacaggacg	1320
gaagcttcac tgcacagagt cttggatct tggacggag attcggttaa ctatgcagca	1380
tctcgatttt tcggtttca ccagatcgga tgtacccata gtattcggtt tcgaggagtt	1440
agtatcaccg tttctggagg gtcgcgaact cttcagcatc tctgtgagat ggcaattcgg	1500
tctaagcaag aactgctaca gcttgccccca atcgaagtgg aaagtaatgt atcaagagga	1560
tgcctgaag gtactcaaac cttcgaaaaa gaaagcgagt aagttaaaat gcttctcgt	1620
ctcctattta taatatgtt tgttattgtt aattttgttc ttgtagaaga gcttaattaa	1680
tcgttgttgc tatgaaatac tatttgtatg agatgaactg gtgtatgtt attcattttac	1740
ataagtggag tcagaatcag aatgtttcct ccataactaa ctagacatga agacctgccc	1800

pctca2013050364-seq1.txt

pctca2013050364-seq1.txt

atctgtcttc	atcttccccc	caaagccaa	ggatgtgctc	accattactc	tgactcctaa	3900
ggtcacgtgt	gttgggttag	acatcagcaa	ggatgatccc	gaggtccagt	tcagctggtt	3960
tgttagatgtat	gtggagggtgc	acacagctca	gacgcaaccc	cgggaggagc	agttcaacag	4020
cactttccgc	tcagtcagtg	aacttcccat	catgcaccag	gactggctca	atggcaagga	4080
gcatcgctc	accatcacca	tcaccatcac	catcaccatt	aaaggcctat	tttcttagt	4140
ttgaatttac	tgttattcgg	tgtcatttc	tatgttggt	gagcggttt	ctgtgctcag	4200
agtgtgttta	ttttatgtaa	ttaatttct	tttgagctc	ctgttttagca	ggtcgtccct	4260
tcagcaagga	cacaaaaga	tttaatttt	attaaaaaaa	aaaaaaaaaa	agaccggaa	4320
ttcgatatac	agtttatcga	cctgcagatc	gttcaaacat	ttggcaataa	agtttcttaa	4380
gattgaatcc	tgttgcgggt	cttgcgatga	ttatcatata	atttctgttg	aattacgtta	4440
agcatgtaat	aattaacatg	taatgcatga	cgttatttat	gagatgggtt	tttatgatta	4500
gagtcccgca	attatacatt	taatacgcga	tagaaaacaa	aatatagcgc	gcaaactagg	4560
ataaaattatc	gcgcgcggtg	tcatctatgt	tactagatct	ctagagtctc	aagcttggcg	4620
cgcacacgtg	actagtggca	ctggccgtcg	ttttacaacg	tcgtgactgg	gaaaaccctg	4680
gcgttaccca	acttaatcgc	cttgcagcac	atccccctt	cgcagctgg	cgtaatagcg	4740
aagaggcccg	caccgatcgc	cctcccaac	agttgcgcag	cctgaatggc	gaatgctaga	4800
gcagcttgag	cttggatcag	attgtcggtt	ccgccttca	gtttaaacta	tcagtgttt	4860
acaggatata	ttggcgggta	aacctaagag	aaaagagcgt	tta		4903

<210> 24

<211> 2721

<212> DNA

<213> Artificial sequence

<220>

<223> Expression cassette number 1733

<400> 24

gtcaacatgg	tggagcacga	cacacttgc	tactccaaaa	atatacaaaga	tacagtctca	60
gaagacaaa	gggcaattga	gactttcaa	caaaggtaa	tatccggaaa	cctcctcgga	120
ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tgaaaagga	aggtggctcc	180
tacaaatgcc	atcattgcga	taaaggaaag	gccatcggt	aagatgcctc	tgccgacagt	240
ggtcccaaag	atggaccccc	accacgagg	agcatcggt	aaaaagaaga	cgttccaacc	300
acgtcttcaa	agcaagtgga	ttgatgtgat	aacatggtg	agcacgacac	acttgtctac	360
tccaaaaata	tcaaagatac	agtctcagaa	gaccaaagg	caattgagac	ttttcaacaa	420
aggtaatat	ccggaaacct	cctcgattc	cattgcccag	ctatctgtca	ctttattgtg	480
aagatagtgg	aaaaggaagg	tggctctac	aaatgccatc	attgcgataa	aggaaaggcc	540
atcggtgaag	atgcctctgc	cgacagtgg	cccaaagatg	gaccccccacc	cacgaggagc	600
atcggtggaaa	aagaagacgt	tccaaccacg	tcttcaaagc	aagtggattt	atgtgatatc	660

pctca2013050364-seq1.txt

tccactgacg	taagggatga	cgcacaatcc	cactatcctt	cgcaagaccc	ttcctctata	720
taaggaagtt	catttcattt	ggagaggtat	taaaatctta	ataggtttg	ataaaaagcga	780
acgtgggaa	acccgaacca	aaccttcttc	taaactctct	ctcatctctc	ttaaagcaaa	840
cttctctctt	gtctttcttg	cgtgagcgat	cttcaacggt	gtcagatcgt	gcttcggcac	900
cagtacaacg	ttttcttca	ctgaagcgaa	atcaaagatc	tctttgtgga	cacgtatgc	960
ggcgccatta	aataacgtgt	acttgccta	ttcttgcgg	tgtggtcttg	ggaaaagaaa	1020
gcttgctgga	ggctgctgtt	cagcccccata	cattacttgt	tacgattctg	ctgactttcg	1080
gcgggtgcaa	tatctctact	tctgcttgac	gaggtattgt	tgcctgtact	tctttttct	1140
tcttcttgct	gattggttct	ataagaaatc	tagtattttc	tttgaacacag	agttttcccg	1200
tggttttcga	acttggagaa	agattgttaa	gcttctgtat	attctgcccc	aatttgcgg	1260
gcccatgtac	ggcatcgagt	atacaacaat	ttaattttc	ctgatttcca	tcattctgtt	1320
aaactacatc	cttaagtccg	tgaccagaat	tatggattat	attatctatc	gtgcctcct	1380
catctacgtg	gcccttttg	ccctgaccag	ggcccagaac	tatggcctga	acttaccaat	1440
caccggttca	atggataccg	tttacgctaa	ttccactcaa	gagggatat	ttctgacaag	1500
taccctgtgc	ctgtatttac	caacagaagc	ctctaccag	atcaatgtat	gggagtggaa	1560
ggatagtctc	tcacagatgt	tcctaaccaa	gggctggccc	accggttccg	tctacttcaa	1620
ggaatactct	agtattgtcg	acttctcagt	tgaccccccag	ctttattgcg	actacaacct	1680
ggtacttatg	aaatacgacc	agaacctgga	gctggatatg	tccgagctgg	ctgacctgat	1740
cctcaatgag	tggctgtgca	acccatgga	catcacatta	tattactacc	agcagtcgg	1800
agaatccaac	aagtggatca	gtatggctc	aagttgcacc	gtgaagggtgt	gtcccttcaa	1860
cacccaaatg	ctgggcattt	gttgcagac	aactaatgtg	gattcgtttg	aaatggtagc	1920
cggaaaacgag	aagctggcta	tagtggacgt	agtcgatggg	attaaccaca	agatcaatct	1980
gactaccacc	acttgtacca	tcagaaactg	taaaaagctc	ggccccggg	agaacgtcgc	2040
cgtgatccag	gtggggggga	gcaatgtgct	cgacattact	gccgacccta	ccaccaatcc	2100
acagacggaa	cggatgtga	gagtcaactg	gaagaaatgg	tggcaggtct	tttataccat	2160
tgtggactac	attaaccaga	tttgcaagt	catgagtaaa	cgttccagat	ccctgaactc	2220
agcagccttc	tattatcgcg	tttagaggcc	tatTTTCTT	agtttgaatt	tactgttatt	2280
cggtgtgcat	ttctatgttt	ggtgagcggt	tttctgtgct	cagagtgtgt	ttatTTTATG	2340
taatttaatt	tctttgtgag	ctcctgttta	gcaggtcgtc	ccttcagcaa	ggacacaAAA	2400
agatttaat	tttattaaaa	aaaaaaaaaa	aaaagaccgg	gaattcgata	tcaagcttat	2460
cgacctgcag	atcggtcaaa	cattggcaa	taaagttct	taagattgaa	tcctgttgcc	2520
ggtcttgcga	tgattatcat	ataatttctg	ttgaattacg	ttaagcatgt	aataattaac	2580
atgtaatgca	tgacgttatt	tatgagatgg	gtttttatga	ttagagtccc	gcaattatac	2640
attaatacg	cgtatagaaaa	caaaatatacg	cgcgcact	aggataaatt	atcgcgccg	2700

pctca2013050364-seq1.txt

gtgtcatcta tgttactaga t

2721

<210> 25  
<211> 890  
<212> PRT  
<213> Rotavirus

<400> 25

Met Ala Tyr Arg Lys Arg Gly Ala Lys Arg Glu Asn Leu Pro Gln Gln  
1 5 10 15

Asn Glu Arg Leu Gln Glu Lys Glu Ile Glu Lys Asp Val Asp Val Thr  
20 25 30

Met Glu Asn Lys Asn Asn Arg Lys Gln Gln Leu Ser Asp Lys Val  
35 40 45

Leu Ser Gln Lys Glu Glu Ile Ile Thr Asp Ala Gln Asp Asp Ile Lys  
50 55 60

Ile Ala Gly Glu Ile Lys Lys Ser Ser Lys Glu Glu Ser Lys Gln Leu  
65 70 75 80

Leu Glu Ile Leu Lys Thr Lys Glu Asp His Gln Lys Glu Ile Gln Tyr  
85 90 95

Glu Ile Leu Gln Lys Thr Ile Pro Thr Phe Glu Ser Lys Glu Ser Ile  
100 105 110

Leu Lys Lys Leu Glu Asp Ile Arg Pro Glu Gln Ala Lys Lys Gln Met  
115 120 125

Lys Leu Phe Arg Ile Phe Glu Pro Lys Gln Leu Pro Ile Tyr Arg Ala  
130 135 140

Asn Gly Glu Lys Glu Leu Arg Asn Arg Trp Tyr Trp Lys Leu Lys Lys  
145 150 155 160

Asp Thr Leu Pro Asp Gly Asp Tyr Asp Val Arg Glu Tyr Phe Leu Asn  
165 170 175

Leu Tyr Asp Gln Ile Leu Ile Glu Met Pro Asp Tyr Leu Leu Leu Lys  
180 185 190

Asp Met Ala Val Glu Asn Lys Asn Ser Arg Asp Ala Gly Lys Val Val  
195 200 205

Asp Ser Glu Thr Ala Asn Ile Cys Asp Ala Ile Phe Gln Asp Glu Glu  
210 215 220

Thr Glu Gly Val Val Arg Arg Phe Ile Ala Asp Met Arg Gln Gln Val  
Page 23

225

230

235

240

Gln Ala Asp Arg Asn Ile Val Asn Tyr Pro Ser Ile Leu His Pro Ile  
 245 250 255

Asp His Ala Phe Asn Glu Tyr Phe Leu Asn His Gln Leu Val Glu Pro  
 260 265 270

Leu Asn Asn Glu Ile Ile Phe Asn Tyr Ile Pro Glu Arg Ile Arg Asn  
 275 280 285

Asp Val Asn Tyr Ile Leu Asn Met Asp Met Asn Leu Pro Ser Thr Ala  
 290 295 300

Arg Tyr Ile Arg Pro Asn Leu Leu Gln Asp Arg Leu Asn Leu His Asp  
 305 310 315 320

Asn Phe Glu Ser Leu Trp Asp Thr Ile Thr Thr Ser Asn Tyr Ile Leu  
 325 330 335

Ala Arg Ser Val Val Pro Asp Leu Lys Glu Lys Glu Leu Val Ser Thr  
 340 345 350

Glu Ala Gln Ile Gln Lys Met Ser Gln Asp Leu Gln Leu Glu Ala Leu  
 355 360 365

Thr Ile Gln Ser Glu Thr Gln Phe Leu Ala Gly Ile Asn Ser Gln Ala  
 370 375 380

Ala Asn Asp Cys Phe Lys Thr Leu Ile Ala Ala Met Leu Ser Gln Arg  
 385 390 395 400

Thr Met Ser Leu Asp Phe Val Thr Thr Asn Tyr Met Ser Leu Ile Ser  
 405 410 415

Gly Met Trp Leu Leu Thr Val Ile Pro Asn Asp Met Phe Leu Arg Glu  
 420 425 430

Ser Leu Val Ala Cys Glu Leu Ala Ile Ile Asn Thr Ile Val Tyr Pro  
 435 440 445

Ala Phe Gly Met Gln Arg Met His Tyr Arg Asn Gly Asp Pro Gln Thr  
 450 455 460

Pro Phe Gln Ile Ala Glu Gln Ile Gln Asn Phe Gln Val Ala Asn  
 465 470 475 480

Trp Leu His Phe Ile Asn Asn Arg Phe Arg Gln Val Val Ile Asp  
 485 490 495

Gly Val Leu Asn Gln Thr Leu Asn Asp Asn Ile Arg Asn Gly Gln Val  
 Page 24

pctca2013050364-seq1.txt  
500 505 510

Ile Asn Gln Leu Met Glu Ala Leu Met Gln Leu Ser Arg Gln Gln Phe  
515 520 525

Pro Thr Met Pro Val Asp Tyr Lys Arg Ser Ile Gln Arg Gly Ile Leu  
530 535 540

Leu Leu Ser Asn Arg Leu Gly Gln Leu Val Asp Leu Thr Arg Leu Val  
545 550 555 560

Ser Tyr Asn Tyr Glu Thr Leu Met Ala Cys Val Thr Met Asn Met Gln  
565 570 575

His Val Gln Thr Leu Thr Thr Glu Lys Leu Gln Leu Thr Ser Val Thr  
580 585 590

Ser Leu Cys Met Leu Ile Gly Asn Thr Thr Val Ile Pro Ser Pro Gln  
595 600 605

Thr Leu Phe His Tyr Tyr Asn Ile Asn Val Asn Phe His Ser Asn Tyr  
610 615 620

Asn Glu Arg Ile Asn Asp Ala Val Ala Ile Ile Thr Ala Ala Asn Arg  
625 630 635 640

Leu Asn Leu Tyr Gln Lys Lys Met Lys Ser Ile Val Glu Asp Phe Leu  
645 650 655

Lys Arg Leu Gln Ile Phe Asp Val Pro Arg Val Pro Asp Asp Gln Met  
660 665 670

Tyr Arg Leu Arg Asp Arg Leu Arg Leu Leu Pro Val Glu Arg Arg Arg  
675 680 685

Leu Asp Ile Phe Asn Leu Ile Leu Met Asn Met Glu Gln Ile Glu Arg  
690 695 700

Ala Ser Asp Lys Ile Ala Gln Gly Val Ile Ile Ala Tyr Arg Asp Met  
705 710 715 720

Gln Leu Glu Arg Asp Glu Met Tyr Gly Tyr Val Asn Ile Ala Arg Asn  
725 730 735

Leu Asp Gly Tyr Gln Gln Ile Asn Leu Glu Glu Leu Met Arg Thr Gly  
740 745 750

Asp Tyr Gly Gln Ile Thr Asn Met Leu Leu Asn Asn Gln Pro Val Ala  
755 760 765

Leu Val Gly Ala Leu Pro Phe Val Thr Asp Ser Ser Val Ile Ser Leu  
Page 25

770

775 pctca2013050364-seq1.txt  
780Ile Ala Lys Leu Asp Ala Thr Val Phe Ala Gln Ile Val Lys Leu Arg  
785 790 795 800Lys Val Asp Thr Leu Lys Pro Ile Leu Tyr Lys Ile Asn Ser Asp Ser  
805 810 815Asn Asp Phe Tyr Leu Val Ala Asn Tyr Asp Trp Ile Pro Thr Ser Thr  
820 825 830Thr Lys Val Tyr Lys Gln Val Pro Gln Pro Phe Asp Phe Arg Ala Ser  
835 840 845Met His Met Leu Thr Ser Asn Leu Thr Phe Thr Val Tyr Ser Asp Leu  
850 855 860Leu Ser Phe Val Ser Ala Asp Thr Val Glu Pro Ile Asn Ala Val Ala  
865 870 875 880Phe Asp Asn Met Arg Ile Met Asn Glu Leu  
885 890

&lt;210&gt; 26

&lt;211&gt; 6745

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Construct 193

&lt;400&gt; 26

tggcaggata	tattgtggtg	taaacaattt	gacgctttaga	caacttaata	acacattgcg	60
gacgtttta	atgtactgaa	ttaacgcccga	atcccgggct	ggtatattta	tatgttgtca	120
aataactcaa	aaaccataaa	agtttaagtt	agcaagtgtg	tacattttta	cttgaacaaa	180
aatattcacc	tactactgtt	ataaatcatt	attaaacatt	agagtaaaga	aatatggatg	240
ataagaacaa	gagtagtgat	attttgacaa	caatttgtt	gcaacatttg	agaaaatttt	300
gttggttctct	cttttcattt	gtcaaaaaca	atagagagag	aaaaaggaag	agggagaata	360
aaaacataat	gtgagtgat	gagagaaagt	tgtacaaaag	ttgtaccaaa	atagttgtac	420
aaatatcatt	gaggaattt	acaaaagcta	cacaataag	ggtaattgc	tgtaaataaa	480
taaggatgac	gcatttagaga	gatgtaccat	tagagaattt	ttggcaagtc	attaaaaaga	540
aagaataaat	tatttttaaa	attaaaagtt	gagtcattt	attaaacatg	tgattattta	600
atgaatttgat	gaaagagtt	gatcaaagt	gtatttagtaa	ttagaattt	gtgtcaaatt	660
taatttgaca	tttgatctt	tccttatat	tgccccatag	agtcaat	ctcattttta	720
tatttcatag	atcaaataag	agaaataacg	gtatattaat	ccctccaaaa	aaaaaaaacg	780
gtatatttac	taaaaaatct	aagccacgta	ggaggataac	aggatccccg	taggaggata	840

pctca2013050364-seq1.txt  
 acatccaatc caaccaatca caacaatcct gatgagataa cccactttaa gcccacgcat 900  
 ctgtggcaca tctacattat ctaaatcaca cattctcca cacatctgag ccacacaaaa 960  
 accaatccac atcttatca cccattctat aaaaaatcac actttgtgag tctacactt 1020  
 gattcccttc aaacacatac aaagagaaga gactaattaa ttaattaatc atcttgagag 1080  
 aaaatggaac gagctataca aggaaacgac gctagggAAC aagctaacag tgaacgTTGG 1140  
 gatggaggat caggaggtac cacttctccc ttcaaacttc ctgacgaaag tccgagTTGG 1200  
 actgagtggc ggctacataa cgatgagacg aattcgaatc aagataatcc cttggTTTC 1260  
 aaggaaagct ggggTTTCGG gaaagttgtA tttaagagat atctcagata cgacaggacg 1320  
 gaagcttcac tgcacagagt cttggatct tggacggag attcggttaa ctatgcagca 1380  
 tctcgatttt tcggTTTCGA ccagatcgga tgtacctata gtattcggtt tcgaggagtt 1440  
 agtatcaccg tttctggagg gtcgcgaact cttcagcattc tctgtgagat ggcaattcgg 1500  
 tctaagcaag aactgctaca gcttgccccca atcgaagtgg aaagtaatgt atcaagagga 1560  
 tgccctgaag gtactcaaac cttcgaaaaa gaaagcgagt aagttaaaat gcttctcgt 1620  
 ctcctattta taatatggtt ttttattgtt aattttgttc ttgtagaaga gcttaattaa 1680  
 tcgttggat tatgaaatac tatttgtatg agatgaactg gtgtaatgtt attcatttac 1740  
 ataagtggag tcagaatcag aatgtttcct ccataactaa ctagacatga agacctgccc 1800  
 cgtacaattt tcttataattt gaacaactaa aattgaacat ctttgccac aactttataa 1860  
 gtggtaata tagctcaa atatggtcaa gttcaataga ttaataatgg aaatatcagt 1920  
 tatcgaaattt cattaacaat caacttaacg ttatttaacta ctaattttat atcatcccct 1980  
 ttgataatg atagtacacc aatttaggaag gagcatgctc gcctaggaga ttgtcgTTTC 2040  
 ccgccttcag tttgcaagct gctctagccg ttttagccat acgcaaaccg cctctccccg 2100  
 cgcgttggga attactagcg cgtgtcgaga cgcgttggg tttgtactcc gaggggttgc 2160  
 ctcaactct atcttataac cggcgtggag gcatggaggc aggggtattt tggcatttt 2220  
 aatagatagt gaaaaatgac gtgaaattta cttaaagacg aagtcttgc gacaaggggg 2280  
 ggcccacgcc gaatttaata ttaccggcgt ggccccccct tattcgcaat gctttagcac 2340  
 gagcggtcca gatttaaagt agaaaatttc cggccacta gggttaaagg tgttcacact 2400  
 ataaaaagcat atacgatgtg atggtatttg gtcgacaagc ttgcattgccc gtcaacatgg 2460  
 tggagcacga cacacttgc tactccaaaa atatcaaaga tacagtctca gaagaccaaa 2520  
 gggcaattga gactttcaa caaaggtaa tatccggaaa cttccctcgga ttccattgcc 2580  
 cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc tacaaatgcc 2640  
 atcattgcga taaaggaaag gccatcggtt aagatgcctc tgccgacagt ggtcccaaag 2700  
 atggacccccc acccacgagg agcatcggtt aaaaagaaga cgttccaacc acgtttcaa 2760  
 agcaagtggaa ttgatgtgat aacatggtgg agcacgacac acttgcctac tccaaaaata 2820  
 tcaaagatac agtctcagaa gaccaaggaa caattgagac tttcaacaa agggtaatat 2880

pctca2013050364-seq1.txt	
ccggaaacct	2940
cctcgattc	
cattgcccag	
ctatctgtca	
ctttattgtg	
aagatagtgg	
aaaaggaagg	3000
tggctcctac	
aatgccatc	
attgcataa	
aggaaaggcc	
atcggtgaag	
atgcctctgc	3060
cgacagtggt	
cccaaagatg	
gaccccccacc	
cacgaggagc	
atcggtgaaa	
aagaagacgt	3120
tccaaccacg	
tcttcaaagc	
aagtggattg	
atgtgatatc	
tccactgacg	
taaggatga	3180
cgcacaatcc	
cactatcctt	
cgcaagaccc	
ttcctctata	
taaggaagtt	
catttcattt	3240
ggagaggtat	
taaaatctta	
atagggtttg	
ataaaagcga	
acgtggggaa	
acccgaacca	3300
aaccttcctc	
taaactctct	
ctcatctctc	
ttaaagcaaa	
cttctctctt	
gtctttcttg	3360
cgtgagcgat	
cttcaacgtt	
gtcagatcgt	
gcttcggcac	
cagtacaacg	
ttttcttca	3420
ctgaagcgaa	
atcaaagatc	
tcttgtgga	
cacgttagtgc	
ggcgccatta	
aataacgtgt	3480
acttgccta	
ttcttgcgg	
tgtggtcttg	
ggaaaagaaa	
gcttgctgga	
ggctgctgtt	3540
cagccccata	
cattacttgt	
tacgattctg	
ctgactttcg	
gcgggtgcaa	
tatctctact	3600
tctgcttgac	
gaggtattgt	
tgcctgtact	
tctttcttct	
tcttcttgct	
gattggttct	3660
ataagaaatc	
tagtattttc	
tttgaaacag	
agttttcccg	
tggtttcgaa	
acttggagaa	3720
agattgttaa	
gcttctgtat	
attctgccc	
aatttgcgg	
gcccgcggat	
ggcggaaaac	3780
gttgcgattt	
tcggcttatt	
gttttctctt	
cttgcgttgg	
ttccttctca	
gatcttcgcc	3840
tgcaggctcc	
tcagccaaaa	
cgacaccccc	
atctgtctat	
ccactggccc	
ctggatctgc	3900
tgcccaaact	
aactccatgg	
tgaccctggg	
atgcctggtc	
aagggttatt	
tccctgagcc	3960
agtgcacgt	
acctggaact	
ctggatccct	
gtccagcggt	
gtgcacaccc	
tcccagctgt	4020
cctgcagtct	
gacctctaca	
ctctgagcag	
ctcagtgact	
gtcccctcca	
gcacctggcc	4080
cagcgagacc	
gtcacctgca	
acgttgcaca	
cccggccagc	
agcaccaagg	
tggacaagaa	4140
aattgtgccc	
aggattgtg	
gttgcataagcc	
ttgcataatgt	
acagtcccaag	
aagtatcatc	4200
tgtcttcatc	
ttccccccaa	
agcccaagga	
tgtgctcacc	
attactctga	
ctcctaaggt	4260
cacgtgtgtt	
gtggtagaca	
tcagcaagga	
tgatcccgag	
gtccagttca	
gctggtttgt	4320
agatgtatgt	
gaggtgcaca	
cagctcagac	
gcaaccccg	
gaggagcagt	
tcaacagcac	4380
tttccgctca	
gtcagtgaac	
ttcccatcat	
gcaccaggac	
tggctcaatg	
gcaaggagcg	4440
atcgctcacc	
atcaccatca	
ccatcaccat	
caccattaaa	
ggcctatttt	
cttagtttg	4500
aatttactgt	
tattcggtgt	
gcatttctat	
gtttggtgag	
cggttttctg	
tgctcagagt	4560
gtgtttat	
tatgtat	
aatttcttg	
ttagctcctg	
tttagcaggt	
cgtcccttca	4620
gcaaggacac	
aaaaagattt	
taattttattt	
aaaaaaaaaa	
aaaaaaaaaga	
ccgggaattc	4680
gatataaagc	
ttatcgacct	
gcagatcggt	
caaacatttg	
gcaataaaatg	
ttcttaagat	4740
tgaatccgt	
tgccggctt	
gcgatgatta	
tcatataatt	
tctgttgaat	
tacgttaagc	4800
atgtataat	
taacatgtaa	
tgcacgtacgt	
tatttatgag	
atgggttttt	
atgatttagag	4860
tcccgcaatt	
atacatttaa	
tacgcgatag	
aaaacaaaat	
atagcgcgca	
aactaggata	4920
aattatcgcg	
cgcgggtgtca	
tctatgttac	
tagatctcta	
gagtctcaag	

pctca2013050364-seq1.txt

cttggcgcbc	cataaaatga	ttatTTTatg	aatatatttc	attgtgcaag	tagatagaaa	4980
ttacatatgt	tacataacac	acgaaataaa	caaaaaaaga	caatccaaaa	acaaacaccc	5040
caaaaaaaat	aatcactta	gataaactcg	tatgaggaga	ggcacgttca	gtgactcgac	5100
gattcccgag	caaaaaaagt	ctccccgtca	cacatatagt	gggtgacgca	attatctta	5160
aagtaatcct	tctgttact	tgtcattgtat	aacatccagt	cttcgtcagg	attgcaaaga	5220
attatagaag	ggatcccacc	ttttatTTtc	ttctttttc	catatTTagg	gttgacagt	5280
aaatcagact	ggcaacctat	taattgcttc	cacaatggga	cgaacttgaa	ggggatgtcg	5340
tcgatgatat	tataggtggc	gtgttcatcg	tagttggta	aatcgatggt	accgttccaa	5400
tagttgttc	gtccgagact	tctagcccag	gtggtcttc	cgtacgagt	tggtccgcag	5460
atgttagggc	tggggtgtcg	gattccatttc	cttccattgt	cctggtaaa	tcggccatcc	5520
attcaaggtc	agattgagct	tgttggtatg	agacaggatg	tatgtaagta	taagcgtcta	5580
tgcttacatg	gtatagatgg	gtttccctcc	aggagtgtag	atttcgtgg	cagcgaagat	5640
ctgattctgt	gaagggcgac	acatacggtt	caggttgtgg	aggaaataat	ttgttggctg	5700
aatattccag	ccattgaagt	tttggccc	attcatgagg	gaattcttcc	ttgatcatgt	5760
caagatattc	ctccttagac	gttgcagtct	ggataatagt	tctccatcgt	gcgtcagatt	5820
tgcgaggaga	gaccttatga	tctcgaaat	ctcctctgg	tttaatatct	ccgtcccttg	5880
atatgtaatc	aaggacttgt	tttagagtttc	tagctggctg	gatatttaggg	tgatttcctt	5940
caaaatcgaa	aaaagaagga	tccctaatac	aaggTTTTT	atcaagctgg	agaagagcat	6000
gatagtgggt	agtgcacatct	tgtgaagct	cagaagcaac	accaaggaag	aaaataagaa	6060
aagggtgtgag	tttctcccag	agaaactgga	ataaatcatc	tctttgagat	gagcacttgg	6120
gataggttaag	gaaaacatat	tttagattgga	gtctgaagtt	cttactagca	gaaggcatgt	6180
tgttgtgact	ccgagggggtt	gcctcaaact	ctatctata	accggcgtgg	aggcatggag	6240
gcaggggtat	tttggtcatt	ttaatagata	gtggaaaatg	acgtggaatt	tacttaaaga	6300
cgaagtcttt	gcfacacaaggg	ggggcccacg	ccgaatttaa	tattaccggc	gtggcccccc	6360
cttatcgca	gtgctttagc	acgagcggtc	cagattaaa	gtagaaaatt	tcccgcac	6420
tagggttaaa	ggtgttcaca	ctataaaagc	atatacgatg	tgtatggatt	tgactagtgg	6480
cactggccgt	cgttttacaa	cgtcgtact	gggaaaaccc	tggcgttacc	caacttaatc	6540
gccttgcagc	acatccccct	ttcgccagct	ggcgtaatag	cgaagaggcc	cgcaccgatc	6600
gcccttccca	acagttgcgc	agcctgaatg	gcgaatgcta	gagcagctt	agcttggatc	6660
agattgtcgt	ttcccgccctt	cagtttaaac	tatcagtgtt	tgacaggata	tattggcggg	6720
taaacctaag	agaaaagagc	gttta				6745

<210> 27  
 <211> 4413  
 <212> DNA  
 <213> Artificial sequence

pctca2013050364-seq1.txt

<220>

<223> Expression cassette number 1710

<400> 27

gtcaacatgg tggagcacga cacacttgtc tactccaaaa atatcaaaga tacagtctca	60
gaagacaaa gggcaattga gactttcaa caaaggtaa tatccggaaa ctcctcgga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tgaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcggt aagatgcctc tgccgacagt	240
ggtcccaaag atggaccccc acccacgagg agcatcggt aaaaagaaga cgttccaacc	300
acgtctcaa agcaagtgga ttgatgtat aacatggtg agcacgacac acttgtctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac tttcaacaa	420
aggtaatat ccggaaacct ctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctctac aaatgcctc attgcataa aggaaaggcc	540
atcggtgaag atgcctctgc cgacagtggt cccaaagatg gaccccccacc cacgaggagc	600
atcggtgaaa aagaagacgt tccaaccacg tcttcaaagc aagtggattt atgtgatatc	660
tccactgacg taagggatga cgacaaatcc cactatcctt cgcaagaccc ttccctata	720
taaggaagtt catttcattt ggagaggtat taaaatctt ataggtttt ataaaagcga	780
acgtgggaa acccgaacca aaccccttc taaactctct ctcatctctc ttaaagcaaa	840
cttctctttt gtctttctt cgtgagcgat cttcaacgtt gtcagatcgt gttcggcac	900
cagtacaacg ttttcttca ctgaagcgaa atcaaagatc tctttgttga cacgtatgc	960
ggcgccatta aataacgtgt acttgccta ttcttgcgg tgtggctttt ggaaaagaaa	1020
gcttgcttga ggctgctgtt cagccccata cattactgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgcg gaggtattgt tgccctgtact tctttttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agtttcccg	1200
tggttttcga acttggagaa agattgtttaa gcttctgtat attctgcccc aatttgcgg	1260
gcccatggca taccggaaaga gaggagcaaa gcgcggaaac ctgcccgaac agaacgagag	1320
actgcaagaa aaagagatag agaaagatgt cgacgtaca atggaaaaca agaataacaa	1380
taggaaacaa cagctgtccg acaaagttct gtcggagaag gaggaaatta tcactgacgc	1440
ccaggacgt attaaaattt ccggagaaat aaagaagagc tcgaaagaag aatctaaaca	1500
gctgctcgaa attctgaaaa caaaagaaga ccatcagaaa gagattcaat atgaaatttt	1560
gcaaaaaaca atacctacat ttgagtccaa agaaagtatc ctcaagaagc ttgaagacat	1620
aagaccggag caggcaaaaa aacagatgaa actcttcgc attttcgagc caaaacagct	1680
ccctatatat cgcccaatg gcgagaagga gctacgcaac cggtggtaact ggaagttgaa	1740
aaaagacacc ctgcccagatg gagattatga cgtccggag tatttcctca atctctatga	1800
tcagatccctc atcgaaatgc cgactatct gtcctcaag gacatggccg tggagaacaa	1860
aaatagcaga gacgcccggca aagttgtcga ctctgagact gccaatattt gtgtgccat	1920

pctca2013050364-seq1.txt		
cttccaggat	gaggagaccg	1980
ggtccaggct	gatcgtaaca	2040
attcaatgag	tatttctta	2100
caattacata	ccagagagga	2160
tctgccatct	acagccaggt	2220
cgataatttt	gagtccctgt	2280
cgtcgttccc	gatttgaagg	2340
gagccaggac	ctgcagctgg	2400
gattaacagt	caggctgcca	2460
aagaaccatg	tctttggact	2520
gctacttaca	gtgattccca	2580
ggcgatcatc	aacaccatcg	2640
tggcgaccct	cagacaccct	2700
gaactggctc	cattttatta	2760
gaatcagact	ctgaacgaca	2820
attgatgcaa	ctcagcagac	2880
ccaacggggc	attctgcttc	2940
ggtctcctat	aactacgaga	3000
aaccctgaca	actgagaagt	3060
taacacaacc	gtgattccgt	3120
tttccactcc	aattataatg	3180
taggctgaat	ctttatcaga	3240
ccagattttc	gacgtaccac	3300
tcggctctta	cccggtgaac	3360
ggagcagatc	gaacgcgctt	3420
tatgcagctg	ctgataagat	3480
ctaccagcaa	attaacttgg	3540
catgcttctc	aacaatcaac	3600
atccgtgatc	agtctaattcg	3660
cagggaaagtt	gacacactga	3720
ttaccttgtg	gccaactacg	3780
gccacaacca	ttcgacttta	3840
cgtctactct	gacctactgt	3900
cgcattcgcac	aatatgcgaa	3960
	taatgaacga	
	gctttaaagg	
	cctattttct	
	ttagttgaa	

		pctca2013050364-seq1.txt				
tttactgtta	ttcggtgtgc	atttctatgt	ttggtgagcg	gttttctgtg	ctcagagtgt	4020
gtttatTTTA	tgtaatttAA	tttCTTGTG	agctcctgtt	tagcaggtcg	tcccttcagc	4080
aaggacacAA	aaagatttTA	attttattAA	aaaaaaaAAA	aaaaaaAGAC	gggaattcga	4140
tatcaagCTT	atcgacCTGc	agatcgTTca	aacatttggc	aataaAGTT	cttaagatttG	4200
aatcCTGTTG	ccggTCTTGC	gatgattatC	atataatttC	tgttgaatttA	cgttaagcat	4260
gtaataatttA	acatgtAAatG	catgacgttA	tttatgagat	gggtttttat	gattagagtc	4320
ccgcaatttAT	acatttAAata	cgcgatAGAA	aacaaaatAT	agcgcgcaAA	ctaggataAA	4380
ttatcgCGCG	cggtgtcatC	tatgttactA	gat			4413
<210>	28					
<211>	49					
<212>	DNA					
<213>	Artificial sequence					
<220>						
<223>	Primer IF-WA_VP6(opt).s1+3c					
<400>	28					
aaatttgtcg	ggccatgga	ggtcctttat	agtctctcca	aaacgctga		49
<210>	29					
<211>	52					
<212>	DNA					
<213>	Artificial sequence					
<220>						
<223>	Primer IF-WA_VP6(opt).s1-4r					
<400>	29					
actaaagaaa	ataggcctct	acttgatcaa	catactccgg	atagaggcca	ca	52
<210>	30					
<211>	2934					
<212>	DNA					
<213>	Artificial sequence					
<220>						
<223>	Expression cassette number 1713					
<400>	30					
gtcaacatgg	tggagcacga	cacacttgc	tactccaaaa	atatcaaaga	tacagtctca	60
gaagaccaAA	gggcaattga	gactttcaa	caaagggtAA	tatccggAAA	cctcctcgga	120
ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tgaaaagga	aggtggctcc	180
tacaaatgcc	atcattgcga	taaaggaaag	gccatcgTT	aagatgcctc	tgccgacagt	240
ggtcccaaAG	atggaccccc	acccacgagg	agcatcgTgg	aaaaagaaga	cgttccaacc	300
acgtcttcaa	agcaagtggA	ttgatgtgat	aacatggTgg	agcacgacac	acttgcTtac	360
tccaaaaATA	tcaaagatac	agtctcagAA	gaccaaaggG	caattgagac	ttttcaacAA	420
aggtaataAT	ccggaaacct	cctcgattc	cattgcccAG	ctatctgtca	ctttattgtG	480
aagatagtgg	aaaaggaagg	tggccttac	aaatgccatc	attgcataAA	aggaaaggcc	540

pctca2013050364-seq1.txt	
atcggttgaag	600
atcggtggaaa	660
tccactgacg	720
taagggatga	
cgcacaatcc	
cactatcctt	
cgcaagaccc	
ttcctctata	
taaggaagtt	780
catttcattt	
ggagaggtat	
taaaatctta	
ataggttttg	
ataaaagcga	
acgtggggaa	840
acccgaacca	
aaccctcttc	
taaactctct	
ctcatctctc	
ttaaagcaaa	
cttctctctt	900
gtctttcttg	
cgtgagcgat	
cttcaacggt	
gtcagatcgt	
gcttcggcac	
cagtacaacg	960
ttttcttca	
ctgaagcgaa	
atcaaagatc	
tctttgtgga	
cacgtagtgc	
ggcgccatta	1020
aataacgtgt	
acttgtccta	
ttcttgcgg	
tgtggtcttg	
ggaaaagaaaa	
gcttgctgga	1080
ggctgctgtt	
cagcccccata	
cattacttgt	
tacgattctg	
ctgactttcg	
gcgggtgcaa	1140
tatctctact	
tctgcttgac	
gaggtattgt	
tgccctgtact	
tctttttct	
tcttcttgct	1200
gattggttct	
ataagaaatc	
tagtattttc	
tttgaaacag	
agttttcccg	
tggttttcga	1260
acttggagaa	
agattgttaa	
gcttctgtat	
attctgccc	
aatttgcgg	
gcccatggag	1320
gtccttata	
gtctctccaa	
aacgctgaag	
gacgcttaggg	
acaagatcgt	
ggagggtaca	1380
ctttatagca	
atgtcagcga	
cctaatacag	
cagtttaatc	
aatatgatcgt	
tacaatgaat	1440
gggaatgatt	
tccaaactgg	
cggattttgtt	
aatctgccc	
tgaggaactg	
gacattcgat	1500
ttcggcctgc	
tggcacgac	
tctccttaat	
ctcgatgcaa	
attatgtaga	
aaacgccaga	1560
acgattatcg	
agtactttat	
cgatttcatt	
gataacgttt	
gtatggatga	
gatggccgc	1620
gagtcacaac	
ggaacggagt	
tgctccacag	
tccgaggccc	
ttcggaaact	
cgccggcatt	1680
aagttcaagc	
gtattaattt	
cgacaactcc	
tccgaatata	
tagagaactg	
gaacttgcag	1740
aatcgtcgac	
agagaaccgg	
cttcgtgttc	
cataaaccta	
atatcttcc	
gtatagcgcc	1800
tcattcaccc	
tgaataggag	
tcagccatg	
cacgacaacc	
tcatgggtac	
aatgtggctg	1860
aatgcgggaa	
gtgaaataca	
ggtcgcgggg	
ttcgattact	
cctgtgccat	
taatgcaccc	1920
gcaaacatcc	
agcagttcga	
acatatcgt	
caactaagac	
gggctctcac	
gaccgcgaca	1980
attacactcc	
tgcccgcacgc	
cgagcgcctc	
tcctttcccc	
gcgtaatcaa	
ctcagctgat	2040
ggcgccacca	
cttgggtctt	
caaccctgtt	
atattgcgc	
ctaacaacgt	
agaggtggag	2100
tttctcttaa	
acggacagat	
catcaatacc	
taccaagcca	
ggttcggcac	
gattattgca	2160
agaaatttcg	
acgctatcag	
gctgcttttc	
caactgtatg	
ggccccccaa	
tatgactccc	2220
gctgtgaacg	
cttggttcc	
gcaggctcg	
cctttccagc	
accacgccac	
cgtcggttg	2280
actcttcgaa	
tagagagcgc	
ggtctcgaa	
tcagtgtgg	
cagacgccaa	
cgagacgctg	2340
ctggcaaacg	
ttaccgcccgt	
gcggcaagag	
tatgccatcc	
cagtagggcc	
tgtgtttcca	2400
cccgccatga	
actggactga	
actaattact	
aactatagcc	
catccagaga	
agacaacttg	2460
cagcgggtct	
tcactgtggc	
ctctatccgg	
agtatgttga	
tcaagtagag	
gcctattttc	2520
tttagtttga	
atttactgtt	
attcgggttg	
catttctatg	
tttgggtgagc	
ggttttctgt	2580
gctcagagtg	
tgtttatttt	
atgttaattt	
atttctttgt	
gagctccgt	

pctca2013050364-seq1.txt

tttagcaggc gtccttcag caaggacaca aaaagattt aattttatta aaaaaaaaaa 2640  
aaaaaaaaagac cggttattcg atatcaagct tatcgacctg cagatcggtc aaacatttgg 2700  
caataaagtt tcttaagatt gaatcctgtt gccggcttg cgatgattat catataattt 2760  
ctgttgaatt acgttaagca tgtaataatt aacatgtaat gcatgacgtt atttatgaga 2820  
tgggtttta tgatttaggt cccgcaatta tacatttaat acgcgataga aaacaaaata 2880  
tagcgcgcaa actaggataa attatcgatc gcggtgtcat ctatgttact agat 2934

<210> 31  
<211> 397  
<212> PRT  
<213> Rotavirus

<400> 31

Met Glu Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp  
1 5 10 15

Lys Ile Val Glu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu Ile Gln  
20 25 30

Gln Phe Asn Gln Met Ile Val Thr Met Asn Gly Asn Asp Phe Gln Thr  
35 40 45

Gly Gly Ile Gly Asn Leu Pro Val Arg Asn Trp Thr Phe Asp Phe Gly  
50 55 60

Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val Glu Asn  
65 70 75 80

Ala Arg Thr Ile Ile Glu Tyr Phe Ile Asp Phe Ile Asp Asn Val Cys  
85 90 95

Met Asp Glu Met Ala Arg Glu Ser Gln Arg Asn Gly Val Ala Pro Gln  
100 105 110

Ser Glu Ala Leu Arg Lys Leu Ala Gly Ile Lys Phe Lys Arg Ile Asn  
115 120 125

Phe Asp Asn Ser Ser Glu Tyr Ile Glu Asn Trp Asn Leu Gln Asn Arg  
130 135 140

Arg Gln Arg Thr Gly Phe Val Phe His Lys Pro Asn Ile Phe Pro Tyr  
145 150 155 160

Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Met His Asp Asn Leu  
165 170 175

Met Gly Thr Met Trp Leu Asn Ala Gly Ser Glu Ile Gln Val Ala Gly  
180 185 190

Phe Asp Tyr Ser Cys Ala Ile Asn Ala Pro Ala Asn Ile Gln Gln Phe  
 195 200 205

Glu His Ile Val Gln Leu Arg Arg Ala Leu Thr Thr Ala Thr Ile Thr  
 210 215 220

Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro Arg Val Ile Asn Ser  
 225 230 235 240

Ala Asp Gly Ala Thr Thr Trp Phe Phe Asn Pro Val Ile Leu Arg Pro  
 245 250 255

Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly Gln Ile Ile Asn Thr  
 260 265 270

Tyr Gln Ala Arg Phe Gly Thr Ile Ile Ala Arg Asn Phe Asp Ala Ile  
 275 280 285

Arg Leu Leu Phe Gln Leu Met Arg Pro Pro Asn Met Thr Pro Ala Val  
 290 295 300

Asn Ala Leu Phe Pro Gln Ala Gln Pro Phe Gln His His Ala Thr Val  
 305 310 315 320

Gly Leu Thr Leu Arg Ile Glu Ser Ala Val Cys Glu Ser Val Leu Ala  
 325 330 335

Asp Ala Asn Glu Thr Leu Leu Ala Asn Val Thr Ala Val Arg Gln Glu  
 340 345 350

Tyr Ala Ile Pro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr  
 355 360 365

Glu Leu Ile Thr Asn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg  
 370 375 380

Val Phe Thr Val Ala Ser Ile Arg Ser Met Leu Ile Lys  
 385 390 395

<210> 32  
 <211> 2934

<212> DNA  
 <213> Artificial sequence

<220>  
 <223> Expression cassette number 1714

<400> 32  
 gtcaacatgg tggagcacga cacacttgc tactccaaaa atatcaaaga tacagtctca 60  
 gaagacccaa gggcaattga gactttcaa caaagggtaa tatccggaaa ctcctcgga 120  
 ttccattgcc cagctatctg tcactttatt gtgaagatag tgaaaagga aggtggctcc 180  
 tacaaatgcc atcattgcga taaaggaaag gccatcggt aagatgcctc tgccgacagt 240

pctca2013050364-seq1.txt

ggtcccaaag atggacccccc acccacgagg agcatcgtagg aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtggaa ttgatgtgat aacatggtagg agcacgacac acttgtctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggaa caattgagac tttcaacaa	420
aggtaatat ccggaaacct cctcgattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctctac aaatgccatc attgcataa aggaaaggcc	540
atcggtgaag atgcctctgc cgacagtggt cccaaagatg gaccccccacc cacgaggagc	600
atcggtggaa aagaagacgt tccaaccacg tcttcaaagc aagtggattt atgtgatatc	660
tccactgacg taagggatga cgacacaatcc cactatcctt cgcaagaccc ttccctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta ataggttttg ataaaagcga	780
acgtggggaa acccgaacca aaccccttc taaactctct ctcatctctc tttaagcaaa	840
cttctctctt gtcttcttgc cgtagcgtat cttcaacgtt gtcagatcgt gcttcggcac	900
cagtacaacg ttttcttca ctgaagcgaa atcaaagatc tctttgtgga cacgtatgc	960
ggcgcattt aataacgtgt acttgccta ttcttgcgg tgtggcttttggaaaagaaa	1020
gcttgctgga ggctgctgtt cagcccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgccgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg	1200
tggttttcga acttggagaa agattgttaa gcttctgtat attctgcccata aatttgcgg	1260
gccccatggag gtccttata gtctctccaa aacgctgaag gacgcttaggg acaagatcgt	1320
ggagggtaca ctttatacgat atgtcagcga cctaatacag cagtttatac aatgatcgt	1380
tacaatgaat gggaaatgatt tccaaactgg cggattttgtt aatctgcccgttgaggaactg	1440
gacattcgat ttccggctgc tggcacgac tctccttaat ctcgatgcaa attatgtaga	1500
aaacgccaga acgattatcg agtactttat cgatttcatt gataacgttt gtatggatga	1560
gatggccgcg gagtcacaac ggaacggagt tgctccacag tccgaggccc ttccggaaact	1620
cgccggcatt aagttcaagc gtattaaattt cgacaactcc tccgaatata tagagaactg	1680
gaacttgcag aatcgatcgac agagaaccgg cttcgttttc cataaaaccta atatcttcc	1740
gtatagcgcc tcattcaccc tgaataggag tcagccatg cacgacaacc tcatgggtac	1800
aatgtggctg aatgcgggaa gtgaaataca ggtcgccggg ttgcattact cctgtgccat	1860
taatgcaccc gcaaacatcc agcagttcga acatatcgta caactaagac gggctctcac	1920
gaccgcgaca attacactcc tgccgcacgc cgagcgttc tccttcccc gcgtaatcaa	1980
ctcagctgat ggcgccacca cttgggttctt caaccctgtt atattgcgc ctaacaacgt	2040
agagggtggag tttctcttaa acggacagat catcaatacc taccaagcca ggttcggcac	2100
gattattgca agaaatttcg acgctatcag gctgcttcc caactgtatga ggccccccaa	2160
tatgactccc gctgtgaacg ctttgcgttcc gcaggctcag cctttccagc accacgccac	2220
cgtcggttg actcttcgaa tagagagcgc ggtctgcgaa tcagtgcgg cagacgccaa	2280

pctca2013050364-seq1.txt

cgagacgctg	ctggcaaacg	ttaccgcccgt	gcggcaagag	tatgccatcc	cagtagggcc	2340	
tgtgtttcca	cccgccatga	actggactga	actaattact	aactatagcc	catccagaga	2400	
agacaacttg	cagcgggtct	tcactgtggc	ctctatccgg	agtatgtga	tcaagtagag	2460	
gcctattttc	tttagtttga	atttactgtt	attcgggtgt	catttctatg	tttggtgagc	2520	
ggttttctgt	gctcagagt	tgtttatttt	atgttaattt	atttctttgt	gagctccctgt	2580	
ttagcaggc	gtcccttcag	caaggacaca	aaaagattt	aatttttatta	aaaaaaaaaa	2640	
aaaaaaaaagac	cggaaattcg	atatcaagct	tatcgacctg	cagatcggtc	aaacatttgg	2700	
caataaaagtt	tcttaagatt	gaatcctgtt	gccggcttg	cgatgattat	catataattt	2760	
ctgttgaatt	acgtaagca	tgttaataatt	aacatgtaat	gcatgacgtt	atttatgaga	2820	
tgggtttta	tgatttaggt	cccgcaatta	tacatttaat	acgcgataga	aaacaaaata	2880	
tagcgcgcaa	actaggataa	attatcgcc	gcgggtgtcat	ctatgttact	agat	2934	
<210>	33						
<211>	53						
<212>	DNA						
<213>	Artificial sequence						
<220>							
<223>	Primer IF-Rtx_VP4(opt).s1+3c						
<400>	33						
	aaatttgcg	ggcccatggc	tagcctgatc	taaaaaaaaaac	tcttgaccaa	ttc	
						53	
<210>	34						
<211>	55						
<212>	DNA						
<213>	Artificial sequence						
<220>							
<223>	Primer IF-Rtx_VP4(opt).s1-4r						
<400>	34						
	actaaagaaa	ataggccttc	agagtttaca	ttgcaggatt	aattgctcaa	tccta	
						55	
<210>	35						
<211>	4068						
<212>	DNA						
<213>	Artificial sequence						
<220>							
<223>	Expression cassette number 1731						
<400>	35						
	gtcaacatgg	tggagcacga	cacacttgc	tactccaaaa	atatcaaaga	tacagtctca	60
	gaagaccaaa	gggcaattga	gactttcaa	caaagggtaa	tatccggaaa	cctcctcgga	120
	ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tggaaaagga	aggtggctcc	180
	tacaaatgcc	atcattgcga	taaaggaaag	gccatcggt	aagatgcctc	tgccgacagt	240
	ggtcccaaag	atggaccccc	acccacgagg	agcatcggt	aaaaagaaga	cgttccaacc	300
	acgtcttcaa	agcaagtgga	ttgatgtat	aacatggtgg	agcacgacac	acttgtctac	360

pctca2013050364-seq1.txt

tccaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac tttcaacaa	420
aggtaatat ccggaaacct cctcgattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctcctac aaatgccatc attgcataa aggaaaggcc	540
atcggtgaag atgcctctgc cgacagtggt cccaaagatg gaccccccacc cacgaggagc	600
atcggtggaa aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660
tccactgacg taagggatga cgacaaatcc cactatcctt cgcaagaccc ttcctctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta ataggtttg ataaaagcga	780
acgtggggaa acccgaacca aaccccttc taaactctct ctcatctctc ttaaagcaaa	840
cttctctctt gtcttcctt cgtgagcgat cttcaacgtt gtcagatcgt gcttcggcac	900
cagtacaacg ttttcttca ctgaagcgaa atcaaagatc tctttgtgga cacgtatgc	960
ggcgcattt aataacgtgt acttgccta ttcttgcgg tgtggcttg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagcccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgccctgtact tctttcttct	1140
tcttcctgct gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg	1200
tggttttcga acttggagaa agattgttaa gcttctgtat attctgccc aatttgcgg	1260
gcccattggct agcctgatct acagacaact cttgaccaat tcatattctg tggatcttca	1320
tgacgaaatc gagcagattt ggtccgagaa gacccagaac gtgaccatca accctggacc	1380
ttttgcttag acccgctatg cccctgtgaa ttggatcac ggagaaatca acgacagtac	1440
gaccgtcgaa cccattctgg acggccata ccaacccacc accttcaccc cacctaatga	1500
ttattggatt ttaatcaact ccaacacaaa cggagtggtc tacgagtcca ctaataactc	1560
cgattttgg accgcccgtt tagccatcga gccacacgtc aatcctgtcg atcgccagta	1620
tatgatattc ggcgagtc aacagttaa cgtttccat gacagcaaca aatggaaagt	1680
tctggagatg tttcgctagct cctctcagaa cgaattctat aatagacgga cccttacctc	1740
cgatacacga ctcgtggta ttttaagta cggcggcagg gtgtggacat ttcacggta	1800
aacccctcga gcaaccactg actccagtag cactgcaaac ctgaacaata tatctattac	1860
catccacagc gaattctaca taatccaaag atctcaggaa agtaagtgtc acgaatataat	1920
caacaacgga ctccccccaa ttcaataac acggaacgtg gtgcctctcc cactcagttc	1980
tcggctatc cagtataaga gagcacaagt gaatgaggac attattgtgaa gcaagactag	2040
cctttggaaa gaaatgcagt acaacagaga cattatcatc cggttaagt ttggaaactc	2100
tatcgtaag atggcggcc tgggtacaa atggctcagaa atctcatata aagccgcca	2160
ctatcagtt aactacttga gagacggcga gcaggttaacc gcccacacaa catgctctgt	2220
caacggcgaa aataacttta gctacaacgg aggcttcctt cccaccgact tcggatcag	2280
ccggatgaa gtcataaggaaaattctta tgtgtacgtt gattactggg atgatagcaa	2340
agcgttccgc aacatggtgt atgttaggag cctggctgct aatctcaatt ctgtgaagtg	2400

pctca2013050364-seq1.txt

tactggtgga	tcatattatt	tctcaattcc	cgtggggct	tggccagtca	tgaatggcgg	2460
ggcagtctcc	ctccattttg	ctggcgtgac	gtttagcact	cagtttaccg	atttcgtgtc	2520
tctgaactcc	ctgaggttcc	ggttttccct	tactgtcgac	gagccccat	tcagcattct	2580
gcgtacaaga	actgtcaacc	tctacgggtt	acctgccg	aatccaaaca	acggcaatga	2640
atactatgaa	atttcggcc	gcttctctt	gataagtctg	gtaccaacta	atgacgacta	2700
tcagacaccc	atcatgaaca	gcgtgactgt	cagacaggac	ctggaaagac	aacttacaga	2760
tctgcggaa	gaattcaatt	ctctcagtca	ggagattgca	atggcccaat	tgatagatct	2820
tgcctactg	cctctcgata	tgtttagtat	gttctccggc	atcaaatcaa	ctatagatct	2880
gacaaagagc	atggctactt	ctgtgatgaa	gaagttcagg	aaatcaaaaac	ttgccacgag	2940
catatcagaa	atgacgaact	ctctgagtga	tgcagcatca	tcagcgtcac	gcaacgtttc	3000
cattcggtcg	aatctcagcg	ccatcagcaa	ctggacaaac	gtgtccaacg	acgtcagcaa	3060
cgtgaccaac	tccttgaacg	atatttctac	ccagacgtca	acgatcagta	agaaactccg	3120
cttggaaagaa	atgatcaccc	agactgaggg	aatgtcttc	gacgacattt	ccgcccgcgt	3180
gctaaaaacc	aaaatcgata	tgtctactca	gatcggcaag	aacactctgc	cggatatcgt	3240
aaccgaagcc	tccgaaaagt	ttatccctaa	gcfgcagctac	agaatattga	aagatgacga	3300
ggtcatggag	atcaacacag	aaggaaagtt	cttcgcttat	aagatcaaca	ccttgacga	3360
ggttccgttt	gacgtcaata	agtttgcaga	gctcgtgaca	gatagtccag	tgatttctgc	3420
catcattgac	tttaagactt	tgaagaacct	gaacgacaac	tatggaataa	cacggaccga	3480
agcgttgaac	ctcattaagt	ccaatccaa	tatgttg	gcgc aatttcatta	accagaacaa	3540
tccaatcata	agaaatagga	ttgagcaatt	aatcctgca	tgtaaactct	gaaggcctat	3600
tttctttagt	ttgaatttac	tgttattcgg	tgtgcatttc	tatgtttgg	gagcgggttt	3660
ctgtgctcag	agtgtgttta	tttatgtaa	tttaatttct	ttgtgagctc	ctgttttagca	3720
ggtcgtccct	tcagcaagga	cacaaaaaga	tttaatttt	ataaaaaaa	aaaaaaaaaa	3780
agaccggaa	ttcgatata	agcttacg	cctgcagatc	gttcaaacat	ttggcaataa	3840
agtttcttaa	gattgaatcc	tgttgcgg	cttgcgtat	ttatcatata	atttctgttg	3900
aattacgtta	agcatgtaat	aattaacatg	taatgc	cgttattt	gagatgggtt	3960
tttatgatta	gagtcccgca	attatacatt	taatacgc	tagaaaacaa	aatatagcgc	4020
gcaaactagg	ataaattatc	gcgcgcgt	tcatctatgt	tactagat		4068

<210> 36  
<211> 775  
<212> PRT  
<213> Rotavirus

<400> 36

Met Ala Ser Leu Ile Tyr Arg Gln Leu Leu Thr Asn Ser Tyr Ser Val  
1 5 10 15

pctca2013050364-seq1.txt

Asp Leu His Asp Glu Ile Glu Gln Ile Gly Ser Glu Lys Thr Gln Asn  
20 25 30

Val Thr Ile Asn Pro Gly Pro Phe Ala Gln Thr Arg Tyr Ala Pro Val  
35 40 45

Asn Trp Asp His Gly Glu Ile Asn Asp Ser Thr Thr Val Glu Pro Ile  
50 55 60

Leu Asp Gly Pro Tyr Gln Pro Thr Thr Phe Thr Pro Pro Asn Asp Tyr  
65 70 75 80

Trp Ile Leu Ile Asn Ser Asn Thr Asn Gly Val Val Tyr Glu Ser Thr  
85 90 95

Asn Asn Ser Asp Phe Trp Thr Ala Val Val Ala Ile Glu Pro His Val  
100 105 110

Asn Pro Val Asp Arg Gln Tyr Met Ile Phe Gly Glu Ser Lys Gln Phe  
115 120 125

Asn Val Ser Asn Asp Ser Asn Lys Trp Lys Phe Leu Glu Met Phe Arg  
130 135 140

Ser Ser Ser Gln Asn Glu Phe Tyr Asn Arg Arg Thr Leu Thr Ser Asp  
145 150 155 160

Thr Arg Leu Val Gly Ile Phe Lys Tyr Gly Gly Arg Val Trp Thr Phe  
165 170 175

His Gly Glu Thr Pro Arg Ala Thr Thr Asp Ser Ser Ser Thr Ala Asn  
180 185 190

Leu Asn Asn Ile Ser Ile Thr Ile His Ser Glu Phe Tyr Ile Ile Pro  
195 200 205

Arg Ser Gln Glu Ser Lys Cys Asn Glu Tyr Ile Asn Asn Gly Leu Pro  
210 215 220

Pro Ile Gln Asn Thr Arg Asn Val Val Pro Leu Pro Leu Ser Ser Arg  
225 230 235 240

Ser Ile Gln Tyr Lys Arg Ala Gln Val Asn Glu Asp Ile Ile Val Ser  
245 250 255

Lys Thr Ser Leu Trp Lys Glu Met Gln Tyr Asn Arg Asp Ile Ile Ile  
260 265 270

Arg Phe Lys Phe Gly Asn Ser Ile Val Lys Met Gly Gly Leu Gly Tyr  
275 280 285

pctca2013050364-seq1.txt

Lys Trp Ser Glu Ile Ser Tyr Lys Ala Ala Asn Tyr Gln Tyr Asn Tyr  
290 295 300

Leu Arg Asp Gly Glu Gln Val Thr Ala His Thr Thr Cys Ser Val Asn  
305 310 315 320

Gly Val Asn Asn Phe Ser Tyr Asn Gly Gly Phe Leu Pro Thr Asp Phe  
325 330 335

Gly Ile Ser Arg Tyr Glu Val Ile Lys Glu Asn Ser Tyr Val Tyr Val  
340 345 350

Asp Tyr Trp Asp Asp Ser Lys Ala Phe Arg Asn Met Val Tyr Val Arg  
355 360 365

Ser Leu Ala Ala Asn Leu Asn Ser Val Lys Cys Thr Gly Gly Ser Tyr  
370 375 380

Tyr Phe Ser Ile Pro Val Gly Ala Trp Pro Val Met Asn Gly Gly Ala  
385 390 395 400

Val Ser Leu His Phe Ala Gly Val Thr Leu Ser Thr Gln Phe Thr Asp  
405 410 415

Phe Val Ser Leu Asn Ser Leu Arg Phe Arg Phe Ser Leu Thr Val Asp  
420 425 430

Glu Pro Pro Phe Ser Ile Leu Arg Thr Arg Thr Val Asn Leu Tyr Gly  
435 440 445

Leu Pro Ala Ala Asn Pro Asn Asn Gly Asn Glu Tyr Tyr Glu Ile Ser  
450 455 460

Gly Arg Phe Ser Leu Ile Ser Leu Val Pro Thr Asn Asp Asp Tyr Gln  
465 470 475 480

Thr Pro Ile Met Asn Ser Val Thr Val Arg Gln Asp Leu Glu Arg Gln  
485 490 495

Leu Thr Asp Leu Arg Glu Glu Phe Asn Ser Leu Ser Gln Glu Ile Ala  
500 505 510

Met Ala Gln Leu Ile Asp Leu Ala Leu Leu Pro Leu Asp Met Phe Ser  
515 520 525

Met Phe Ser Gly Ile Lys Ser Thr Ile Asp Leu Thr Lys Ser Met Ala  
530 535 540

Thr Ser Val Met Lys Lys Phe Arg Lys Ser Lys Leu Ala Thr Ser Ile  
545 550 555 560

pctca2013050364-seq1.txt

Ser Glu Met Thr Asn Ser Leu Ser Asp Ala Ala Ser Ser Ala Ser Arg  
565 570 575

Asn Val Ser Ile Arg Ser Asn Leu Ser Ala Ile Ser Asn Trp Thr Asn  
580 585 590

Val Ser Asn Asp Val Ser Asn Val Thr Asn Ser Leu Asn Asp Ile Ser  
595 600 605

Thr Gln Thr Ser Thr Ile Ser Lys Lys Leu Arg Leu Lys Glu Met Ile  
610 615 620

Thr Gln Thr Glu Gly Met Ser Phe Asp Asp Ile Ser Ala Ala Val Leu  
625 630 635 640

Lys Thr Lys Ile Asp Met Ser Thr Gln Ile Gly Lys Asn Thr Leu Pro  
645 650 655

Asp Ile Val Thr Glu Ala Ser Glu Lys Phe Ile Pro Lys Arg Ser Tyr  
660 665 670

Arg Ile Leu Lys Asp Asp Glu Val Met Glu Ile Asn Thr Glu Gly Lys  
675 680 685

Phe Phe Ala Tyr Lys Ile Asn Thr Phe Asp Glu Val Pro Phe Asp Val  
690 695 700

Asn Lys Phe Ala Glu Leu Val Thr Asp Ser Pro Val Ile Ser Ala Ile  
705 710 715 720

Ile Asp Phe Lys Thr Leu Lys Asn Leu Asn Asp Asn Tyr Gly Ile Thr  
725 730 735

Arg Thr Glu Ala Leu Asn Leu Ile Lys Ser Asn Pro Asn Met Leu Arg  
740 745 750

Asn Phe Ile Asn Gln Asn Asn Pro Ile Ile Arg Asn Arg Ile Glu Gln  
755 760 765

Leu Ile Leu Gln Cys Lys Leu  
770 775

<210> 37

<211> 51

<212> DNA

<213> Artificial sequence

<220>

<223> Primer IF-Rtx\_VP7(opt).s1+3c

<400> 37

aaatttgtcg ggccatgta cggcatcgag tataacaaca ttttaatttt c

51

pctca2013050364-seq1.txt

<210> 38  
<211> 54  
<212> DNA  
<213> Artificial sequence  
  
<220>  
<223> Primer IF-Rtx\_VP7(opt).s1-4r  
  
<400> 38  
actaaagaaa ataggcctct aaacgcgata atagaaggct gctgagttca ggga 54  
  
<210> 39  
<211> 326  
<212> PRT  
<213> Rotavirus  
  
<400> 39  
  
Met Tyr Gly Ile Glu Tyr Thr Thr Ile Leu Ile Phe Leu Ile Ser Ile 1  
5 10 15  
  
Ile Leu Leu Asn Tyr Ile Leu Lys Ser Val Thr Arg Ile Met Asp Tyr 20 25 30  
  
Ile Ile Tyr Arg Ser Leu Leu Ile Tyr Val Ala Leu Phe Ala Leu Thr 35 40 45  
  
Arg Ala Gln Asn Tyr Gly Leu Asn Leu Pro Ile Thr Gly Ser Met Asp 50 55 60  
  
Thr Val Tyr Ala Asn Ser Thr Gln Glu Gly Ile Phe Leu Thr Ser Thr 65 70 75 80  
  
Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser Thr Gln Ile Asn Asp Gly 85 90 95  
  
Glu Trp Lys Asp Ser Leu Ser Gln Met Phe Leu Thr Lys Gly Trp Pro 100 105 110  
  
Thr Gly Ser Val Tyr Phe Lys Glu Tyr Ser Ser Ile Val Asp Phe Ser 115 120 125  
  
Val Asp Pro Gln Leu Tyr Cys Asp Tyr Asn Leu Val Leu Met Lys Tyr 130 135 140  
  
Asp Gln Asn Leu Glu Leu Asp Met Ser Glu Leu Ala Asp Leu Ile Leu 145 150 155 160  
  
Asn Glu Trp Leu Cys Asn Pro Met Asp Ile Thr Leu Tyr Tyr Tyr Gln 165 170 175  
  
Gln Ser Gly Glu Ser Asn Lys Trp Ile Ser Met Gly Ser Ser Cys Thr 180 185 190

Val Lys Val Cys Pro Leu Asn Thr Gln Met Leu Gly Ile Gly cys Gln  
 195 200 205

Thr Thr Asn Val Asp Ser Phe Glu Met Val Ala Glu Asn Glu Lys Leu  
 210 215 220

Ala Ile Val Asp Val Val Asp Gly Ile Asn His Lys Ile Asn Leu Thr  
 225 230 235 240

Thr Thr Thr Cys Thr Ile Arg Asn Cys Lys Lys Leu Gly Pro Arg Glu  
 245 250 255

Asn Val Ala Val Ile Gln Val Gly Gly Ser Asn Val Leu Asp Ile Thr  
 260 265 270

Ala Asp Pro Thr Thr Asn Pro Gln Thr Glu Arg Met Met Arg Val Asn  
 275 280 285

Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr Ile Val Asp Tyr Ile Asn  
 290 295 300

Gln Ile Val Gln Val Met Ser Lys Arg Ser Arg Ser Leu Asn Ser Ala  
 305 310 315 320

Ala Phe Tyr Tyr Arg Val  
 325

<210> 40

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<223> Primer IF-Rtx\_VP7(opt).s2+4c

<400> 40

tctcagatct tcgcccagaa ctatggctg aacttaccaa tcaccggttc aatggatacc

60

<210> 41

<211> 4897

<212> DNA

<213> Artificial sequence

<220>

<223> Construct 1192

<400> 41

tggcaggata tattgtggtg taaacaaatt gacgcttaga caacttaata acacattgcg

60

gacgtttta atgtactgaa ttaacgccga atcccggttct ggttatattta tatgttgtca

120

aataactcaa aaaccataaa agttaagtt agcaagtgtg tacattttta cttgaacaaa

180

aatattcacc tactactgtt ataaatcatt attaaacatt agagtaaaga aatatggatg

240

ataagaacaa gagtagtgat attttgacaa caatttgtt gcaacatttg agaaaatttt

300

gttggctct cttttcattt gtcaaaaaca atagagagag aaaaaggaag agggagaata

360

pctca2013050364-seq1.txt

aaaacataat	gtgagtatga	gagagaaagt	tgtacaaaag	ttgtaccaaa	atagttgtac	420
aaatatcatt	gaggaatttgc	acaaaagcta	cacaataag	ggtaattgc	tgtaaataaa	480
taaggatgac	gcattagaga	gatgtaccat	tagagaattt	ttggcaagtc	attaaaaaga	540
aagaataat	tatTTTaaa	ataaaaagtt	gagtcatttgc	attaaacatg	tgattatttgc	600
atgaattgat	gaaagagtttgc	gatTTTaaat	gtatttagtgc	tttagaatttgc	gtgtcaaatttgc	660
taatttgcata	tttgatcttgc	tcctatata	tgccccatag	agtcaatgc	ctcatTTTtttgc	720
tatTTTcatag	atcaaataag	agaaataacg	gtatattaaat	ccctccaaaaa	aaaaaaaacgc	780
gtatatttac	taaaaaatcttgc	aagccacgttgc	ggaggataac	aggatccccgc	taggaggata	840
acatccaatc	caaccaatca	caacaatccttgc	gatgagataa	cccaactttaa	gcccacgcatttgc	900
ctgtggcaca	tctacatttgc	ctaaatcaca	cattcttca	cacatctgag	ccacacaaaaatgc	960
accaatccac	atcttatca	cccattcttat	aaaaaatcacttgc	actttgtgag	tctacactttgc	1020
gattcccttc	aaacacatac	aaagagaaga	gactaattaa	ttaattaatc	atcttgagatgc	1080
aaaatggAAC	gagctataca	aggaaacgc	gctagggAAC	aagctaacag	tgaacgttgg	1140
gatggaggat	caggaggttgc	cacttctccc	ttcaaacttc	ctgacgaaag	tccgagttgg	1200
actgagtggc	ggctacataa	cgatgagacg	aattcgaatc	aagataatcc	ccttggtttc	1260
aaggaaagct	ggggTTTcg	gaaagttgttgc	tttaagagat	atctcagata	cgacaggacg	1320
gaagcttcac	tgcacagagt	ccttggatcttgc	tggacggag	attcggtttaa	ctatgcagca	1380
tctcgattt	tcggTTTcg	ccagatcg	tgtacccata	gtattcggtt	tcgaggagtttgc	1440
agtatcaccg	tttctggagg	gtcgcaact	cttcagcatc	tctgtgagat	ggcaattcgg	1500
tctaagcaag	aactgctaca	gcttgcccc	atcgaagtgg	aaagtaatgt	atcaagagga	1560
tgccctgaag	gtactcaaac	cttcgaaaaa	gaaagcgagt	aagttaaaat	gcttcttcgt	1620
ctcctatttgc	taatatggtt	tgtattgttgc	aattttgttc	ttgtagaaga	gcttaattaa	1680
tcgttgtgt	tatgaaatac	tatttgcatttgc	agatgaactg	gtgtatgttgc	attcattttac	1740
ataagtggag	tcagaatcag	aatgtttcc	ccataactaa	ctagacatg	agacctgccc	1800
cgtacaatttgc	tcttatatttgc	gaacaactaa	aattgaacat	ctttgccac	aactttataa	1860
gtggtaata	tagctcaa	atatggtcaa	gttcaataga	ttaataatgg	aaatatcagt	1920
tatcgaaatttgc	cattaacaat	caacttaacg	ttattaacta	ctaattttat	atcatccc	1980
ttgataatgc	atagtacacc	aatttaggaag	gagcatg	gcctaggaga	ttgtcg	2040
ccgccttcag	tttgcaagcttgc	gctctagcc	tgtagccat	acgcaaacc	cctctcccc	2100
cgcgttgg	attactagcg	cgtgtcgaca	agcttgc	ccggtaaca	tggtgagca	2160
cgacacacttgc	gtctactcca	aaaatatcaa	agatacagtc	tcagaagacc	aaaggcaat	2220
tgagacttttgc	caacaaagg	taatatccgg	aaacctcc	ggattccatt	gccca	2280
ctgtcactttgc	attgtgaaga	tagtgaaaa	ggaagg	ttc	tacaaat	2340
cgataaaggatgc	aaggccatcg	ttgaagatgc	ctctgccc	agtgg	ccacatttgc	2400

pctca2013050364-seq1.txt

cccacccacg	aggagcatcg	tggaaaaaga	agacgttcca	accacgtctt	caaagcaagt	2460
ggattgatgt	gataacatgg	tggagcacga	cacacttgc	tactccaaaa	atatcaaaga	2520
tacagtctca	gaagacccaaa	ggcaattga	gactttcaa	caaaggtaa	tatccggaaa	2580
cctcctcgga	ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tggaaaagga	2640
aggggctcc	tacaaatgcc	atcattgcga	taaagggaaag	gccatcggtt	aagatgcctc	2700
tgccgacagt	ggtcccaaag	atggacccccc	acccacgagg	agcatcggtt	aaaaagaaga	2760
cgttccaacc	acgtctcaa	agcaagtgg	ttgatgtgat	atctccactg	acgtaaggga	2820
tgacgcacaa	tcccactatc	cttcgcaaga	cccttcctct	atataaggaa	gttcatttca	2880
tttggagagg	tattaaaatc	ttaataggtt	ttgataaaag	cgaacgtggg	gaaacccgaa	2940
ccaaacccccc	ttctaaactc	tctctcatct	ctcttaaagc	aaacttctct	cttgcatttc	3000
ttgcgtgagc	gatcttcaac	gttgcagat	cgtgctcgg	caccagtaca	acgtttctt	3060
tcactgaagc	gaaatcaaag	atctttgt	ggacacgtag	tgcggcgcca	ttaaataaacf	3120
tgtacttgc	ctattctgt	cggtgtggc	ttggggaaaag	aaagcttgct	ggaggctgct	3180
gttcagccccc	atacattact	tgttacgatt	ctgctgactt	tcggcggttg	caatatctct	3240
acttctgctt	gacgaggtat	tgttgctgt	acttcttct	tcttcttctt	gctgattgg	3300
tctataagaa	atctagtatt	ttcttgaaa	cagagtttc	ccgtggttt	cgaacttgg	3360
gaaagattgt	taagcttctg	tatattctgc	ccaaatttgc	cggcccatg	gcgaaaaacg	3420
ttgcgatttt	cggcttattt	tttctcttc	ttgtgttggt	tccttctcag	atcttcgccc	3480
cggctcctca	gccaaaacga	caccccatc	tgtctatcca	ctggccctg	gatctgctgc	3540
ccaaactaac	tccatggta	ccctggatg	cctggtaag	ggctatttcc	ctgagccagt	3600
gacagtgacc	tggaactctg	gatccctgtc	cagcgggttg	cacaccttcc	cagctgtcct	3660
cgagcttgac	ctctacactc	ttagcagctc	agtgaactgc	ccctccagca	cctggccca	3720
cgagaccgtc	acctgcaacg	ttgcccaccc	ggccagcagc	accaagggtgg	acaagaaaat	3780
tgtgcccagg	gattgtggtt	gtaaggcttg	catatgtaca	gtcccaagaag	tatcatctgt	3840
cttcatcttc	cccccaaagc	ccaaggatgt	gctcaccatt	actctgactc	ctaaggtcac	3900
gtgtgttg	gtagacatca	gcaaggatga	tcccggatgc	cagttcagct	ggtttgtaga	3960
tgtatgtggag	gtgcacacag	ctcagacgca	accccgggag	gagcagttca	acagcacttt	4020
ccgctcagtc	agtgaacttc	ccatcatgca	ccaggactgg	ctcaatggca	aggagcgatc	4080
gctcaccatc	accatcacca	tcaccatcac	cattaaaggc	ctatttctt	tagttgaat	4140
ttactgttat	tcgggttgca	tttctatgtt	ttgtgagcgg	tttctgtgc	tcagagtgt	4200
tttattttat	gtaatttaat	ttctttgtga	gctcctgttt	agcaggtcgt	cccttcagca	4260
aggacacaaa	aagattttaa	tttattaaa	aaaaaaaaaa	aaaaagacccg	ggaattcgat	4320
atcaagctta	tcgacctgca	gatcgttcaa	acatttggca	ataaaagtttc	ttaagattga	4380
atcctgttgc	cggcttgcg	atgattatca	tataatttct	gttgaattac	gttaagcatg	4440

pctca2013050364-seq1.txt

taataattaa	catgtaatgc	atgacgttat	ttatgagatg	ggttttatg	attagagtcc	4500
cgcaattata	catttaatac	gcgatagaaa	acaaaatata	gcgcgcaaac	taggataat	4560
tatcgcgcc	ggtgtcatct	atgttactag	atctctagag	tctcaagctt	ggcgccca	4620
cgtgactagt	ggcactggcc	gtcgcccc	aacgtcgta	ctggaaaac	cctggcgta	4680
cccaacttaa	tcgcctgca	gcacatcccc	cttcgcccag	ctggcgtaat	agcgaagagg	4740
cccgccaccga	tcgccttcc	caacagttgc	gcagcctgaa	tggcgaatgc	tagacgact	4800
tgagcttggaa	tcagattgtc	gttcccgcc	ttcagttaa	actatcagtg	tttgacagga	4860
tatattggcg	ggtaaaccta	agagaaaaga	gcgttta			4897

<210> 42  
 <211> 2643  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Expression cassette number 1735

<400> 42	gtcaacatgg	tggagcacga	cacacttgc	tactccaaaa	atatcaaaga	tacagtctca	60
gaagacaaaa	gggcaattga	gactttcaa	caaaggtaa	tatccggaaa	cctcctcgga		120
ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tggaaaagga	aggtggctcc		180
tacaaaatgcc	atcattgcga	taaaggaaag	gccatcggt	aagatgcctc	tgccgacagt		240
ggtcccaaag	atggaccccc	acccacgagg	agcatcggt	aaaaagaaga	cgttccaacc		300
acgtcttcaa	agcaagtgga	ttgatgtgat	aacatggtg	agcacgacac	acttgcctac		360
tccaaaaata	tcaaagatac	agtctcagaa	gaccaaagg	caattgagac	ttttcaacaa		420
aggtaatat	ccggaaacct	cctcggattc	cattgcccag	ctatctgtca	ctttattgtg		480
aagatagtgg	aaaaggaagg	tggctctac	aatgccatc	attgcgataa	aggaaaggcc		540
atcgttgaag	atgcctctgc	cgacagtgg	cccaaagatg	gaccccccacc	cacgaggagc		600
atcgtggaaa	aagaagacgt	tccaaccacg	tcttcaaagc	aagtggattg	atgtgatatc		660
tccactgacg	taagggatga	cgcacaatcc	cactatcctt	cgcaagaccc	ttcctctata		720
taaggaagtt	catttcattt	ggagaggtat	taaaatctta	ataggtttg	ataaaaagcga		780
acgtggggaa	acccgaacca	aaccccttc	taaactctct	ctcatctctc	ttaaaagcaaa		840
cttctctctt	gtcttccttg	cgtgagcgat	cttcaacgtt	gtcagatcgt	gcttcggcac		900
cagtacaacg	ttttcttca	ctgaagcgaa	atcaaagatc	tctttgtgga	cacgtagtgc		960
ggcgccatta	aataacgtgt	acttgccta	ttcttgcgg	tgtggcttg	ggaaaaagaaa		1020
gcttgctgga	ggctgctgtt	cagcccccata	cattacttgt	tacgattctg	ctgactttcg		1080
gcgggtgcaa	tatctctact	tctgcttgac	gaggtattgt	tgcctgtact	tctttcttct		1140
tcttcttgct	gattggttct	ataagaaatc	tagtatttc	tttggaaacag	agttttcccg		1200
tggttttcga	acttggagaa	agattgttaa	gcttctgtat	attctgccc	aatttgcgg		1260

pctca2013050364-seq1.txt

gccccatggcg	aaaaacgttg	cgattttcg	cttattgttt	tctcttcttg	tgttggttcc	1320
ttctcagatc	ttcgcccaga	actatggcct	gaacttacca	atcaccgggtt	caatggatac	1380
cgtttacgct	aattccactc	aagagggat	atttctgaca	agtaccctgt	gcctgttatta	1440
tccaaacagaa	gcctctaccc	agatcaatga	tggggagtg	aaggatagtc	tctcacagat	1500
gttcctaacc	aagggctggc	ccaccggttc	cgtctacttc	aaggaatact	ctagtattgt	1560
cgacttctca	gttgacccccc	agctttattg	cgactacaac	ctggtaactt	tgaaatacga	1620
ccagaacctg	gagctggata	tgtccgagct	ggctgacctg	atcctcaatg	agtggctgt	1680
caaccccatg	gacatcacat	tatattacta	ccagcagtct	ggagaatcca	acaagtggat	1740
cagtagggc	tcaagttgca	ccgtgaaggt	gtgtcccttg	aacacccaaa	tgctgggcat	1800
tggttgtcag	acaactaatg	tggattcg	tgaaatggta	gccgaaaacg	agaagctggc	1860
tatagtggac	gtagtcgatg	ggattaacca	caagatcaat	ctgactacca	ccacttgtac	1920
catcagaaac	tgtaaaaagc	tcggccccc	ggagaacgtc	gccgtgatcc	aggtgggggg	1980
gagcaatgt	ctcgacatta	ctggc	taccaccaat	ccacagacgg	aacggatgat	2040
gagagtcaac	tggaagaaat	ggtggcaggt	cttttatacc	attgtggact	acattaacca	2100
gattgtgca	gtcatgagta	aacggtccag	atccctgaac	tcagcagcct	tctattatcg	2160
cgttagagg	cctatttct	ttagttgaa	tttactgtt	ttcggtgtgc	atttctatgt	2220
ttggtgagcg	gttttctgt	ctcagagtgt	gtttat	tgtat	tttcttgc	2280
agctcctgtt	tagcaggtcg	tcccttc	aaggacacaa	aaagat	ttaa	2340
aaaaaaa	aaaaaagacc	ggaaattcga	tatcaagctt	atcgac	ctgc	2400
aacatttggc	aataaagt	ttt	aaat	ttt	ttt	2460
atataatttc	tgttgaatta	cgtt	aaat	ttt	ttt	2520
tttatgagat	gggttttat	gat	tag	atg	atg	2580
aacaaaat	agcgcgcaaa	ctt	aggat	aaat	ttt	2640
gat						2643

<210> 43  
 <211> 300  
 <212> PRT  
 <213> Rotavirus

<400> 43

Met Ala Lys Asn Val Ala Ile Phe Gly Leu Leu Phe Ser Leu Leu Val  
 1 5 10 15

Leu Val Pro Ser Gln Ile Phe Ala Gln Asn Tyr Gly Leu Asn Leu Pro  
 20 25 30

Ile Thr Gly Ser Met Asp Thr Val Tyr Ala Asn Ser Thr Gln Glu Gly  
 35 40 45

pctca2013050364-seq1.txt

Ile Phe Leu Thr Ser Thr Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser  
50 55 60

Thr Gln Ile Asn Asp Gly Glu Trp Lys Asp Ser Leu Ser Gln Met Phe  
65 70 75 80

Leu Thr Lys Gly Trp Pro Thr Gly Ser Val Tyr Phe Lys Glu Tyr Ser  
85 90 95

Ser Ile Val Asp Phe Ser Val Asp Pro Gln Leu Tyr Cys Asp Tyr Asn  
100 105 110

Leu Val Leu Met Lys Tyr Asp Gln Asn Leu Glu Leu Asp Met Ser Glu  
115 120 125

Leu Ala Asp Leu Ile Leu Asn Glu Trp Leu Cys Asn Pro Met Asp Ile  
130 135 140

Thr Leu Tyr Tyr Tyr Gln Gln Ser Gly Glu Ser Asn Lys Trp Ile Ser  
145 150 155 160

Met Gly Ser Ser Cys Thr Val Lys Val Cys Pro Leu Asn Thr Gln Met  
165 170 175

Leu Gly Ile Gly Cys Gln Thr Thr Asn Val Asp Ser Phe Glu Met Val  
180 185 190

Ala Glu Asn Glu Lys Leu Ala Ile Val Asp Val Val Asp Gly Ile Asn  
195 200 205

His Lys Ile Asn Leu Thr Thr Thr Cys Thr Ile Arg Asn Cys Lys  
210 215 220

Lys Leu Gly Pro Arg Glu Asn Val Ala Val Ile Gln Val Gly Gly Ser  
225 230 235 240

Asn Val Leu Asp Ile Thr Ala Asp Pro Thr Thr Asn Pro Gln Thr Glu  
245 250 255

Arg Met Met Arg Val Asn Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr  
260 265 270

Ile Val Asp Tyr Ile Asn Gln Ile Val Gln Val Met Ser Lys Arg Ser  
275 280 285

Arg Ser Leu Asn Ser Ala Ala Phe Tyr Tyr Arg Val  
290 295 300

<210> 44  
<211> 4068  
<212> DNA

&lt;213&gt; Artificial sequence

<220>  
<223>

Expression cassette number 1730

<400> 44	
gtcaacatgg tggagcacga cacacttgc tactccaaaa atatcaaaga tacagtctca	60
gaagacaaa gggcaattga gactttcaa caaaggtaa tatccggaaa cctcctcgga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tgaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcggt aagatgcctc tgccgacagt	240
ggtcccaaag atggaccccc acccacgagg agcatcggt aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatggtg agcacgacac acttgtctac	360
tccaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac tttcaacaa	420
aggtaatat ccggaaacct cctcgattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctctac aaatgccatc attgcataa aggaaaggcc	540
atcggtgaag atgcctctgc cgacagtggt cccaaagatg gaccccccacc cacgaggagc	600
atcggtggaa aagaagacgt tccaaccacg tcttcaaagc aagtggattt atgtgatatc	660
tccactgacg taagggatga cgacataatcc cactatcctt cgcaagaccc ttcctctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta ataggttttg ataaaagcga	780
acgtgggaa acccgaacca aaccccttc taaactctct ctcatctctc ttaaagcaaa	840
cttctctctt gtcttcttg cgtgagcgat cttcaacgtt gtcagatcg gcttcggcac	900
cagtacaacg ttttcttca ctgaagcgaa atcaaagatc tctttgtgga cacgtatgc	960
ggcgccatta aataacgtgt acttgccta ttcttgcgg tgtggtcttgg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagcccccata cattactgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgccctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agtttcccg	1200
tggttttcga acttggagaa agattgttaa gcttctgtat attctgccc aatttgcgg	1260
gcccattggct agcctgatct acagacaact cttgaccaat tcatattctg tggatcttca	1320
tgacgaaatc gagcagattt ggtccgagaa gacccagaac gtgaccatca accctggacc	1380
ttttgcttag acccgctatg cccctgtgaa ttggatcac ggagaaatca acgacagtac	1440
gaccgtcgaa cccattctgg acggccata ccaacccacc accttcaccc cacctaatga	1500
ttattggatt ttaatcaact ccaacacaaa cggagtggtc tacgagtcca ctaataactc	1560
cgattttgg accgcccgtt tagccatcga gccacacgtc aatcctgtcg atcgccagta	1620
tatgatattc ggcgagtcca aacagttaa cgtttcaat gacagcaaca aatggaaatgg	1680
tctggagatg tttcgagct cctctcagaa cgaattctat aatagacgga cccttacctc	1740
cgatacacga ctcgtggta ttttaagta cggcggcagg gtgtggacat ttcacggta	1800

pctca2013050364-seq1.txt	
aaccctcg a	1860
gcaaccactg	
actccagtag	
caactgcaa	
ctgaacaata	
tatctattac	
catccacagc	1920
gaattctaca	
taatccaa	
atctcaggaa	
agtaagtgt	
acgaatata	
caacaacgga	1980
ctcccccaa	
ttcagaata	
acggaacgt	
gtgcctctcc	
caactcagg	
tcggctatc	2040
cagtataaga	
gagcacaagt	
gaatgaggac	
attattgtga	
gcaagactag	
cctttggaaa	2100
gaaatgcagt	
acaacagaga	
cattatcatc	
cggttaagt	
ttggaaactc	
tatcgtgaag	2160
atggcggcc	
tgggtacaa	
atggtcagaa	
atctcatata	
aagccgcaa	
ctatcagtat	2220
aactacttga	
gagacggcga	
gcaggttaacc	
gcccacacaa	
catgctctgt	
caacggcg	2280
tt aataacttta	
gctacaacgg	
aggcttc	
cccaccgact	
tcggtatcag	
ccggtatgaa	2340
gtcatcaagg	
aaaattctta	
tgtgtacgt	
gattactggg	
atgatagcaa	
agcgttccgc	2400
aacatggtgt	
atgttaggag	
cctggctgct	
aatctcaatt	
ctgtgaagtg	
tactggtgga	2460
tcatattatt	
tctcaattcc	
cgtggggct	
tggccagtca	
tgaatggcgg	
ggcagtc	2520
ctccattttg	
ctggcgtgac	
gttgagcact	
cagtttaccg	
atttcgtgtc	
tctgaactcc	2580
ctgaggttcc	
ggtttccct	
tactgtcgac	
gagccccat	
tcagcattct	
gcgtacaaga	2640
actgtcaacc	
tctacgggtt	
acctgccg	
aatccaaaca	
acggcaatga	
atactatgaa	2700
atttcgggc	
gcttctctt	
gataagtctg	
gtaccaacta	
atgacgacta	
tcagacaccc	2760
atcatgaaca	
gcgtgactgt	
cagacaggac	
ctggaaagac	
aacttacaga	
tctgcggaa	2820
gaattcaatt	
ctctcagtca	
ggagattgca	
atggcccaat	
tgatagatct	
tgcctactg	2880
cctctcgata	
tgttagtat	
gttctccgc	
atcaaata	
ctata	
gatct	
gacaaagagc	2940
atggctactt	
ctgtgtgaa	
gaagttcagg	
aaatcaaaac	
ttgccacgag	
catatcagaa	3000
atgacgaact	
ctctgagtga	
tgcagcatca	
tcagcgtcac	
gcaacgtt	
cattcggtcg	3060
aatctcagcg	
ccatcagcaa	
ctggacaaac	
gtgtccaa	
acgtcagcaa	
cgtgaccaac	3120
tccttgaac	
atatttctac	
ccagacgtca	
acgatcagta	
agaaactccg	
cttggaaagaa	3180
atgatcaccc	
agactgaggg	
aatgtcttc	
gacgacattt	
ccgcccgcgt	
gctaaaaacc	3240
aaaatcgata	
tgtctactca	
gatcggcaag	
aacactctgc	
cggatatcg	
aaccgaagcc	3300
tccgaaaagt	
ttatccctaa	
gcgcagctac	
agaatattga	
aagatgacga	
ggtcatggag	3360
atcaacacag	
aagggaaagt	
cttcgctt	
aat aagatcaaca	
ccttgcac	
ggttccgtt	3420
gacgtcaata	
agttgcaga	
gctcgtgaca	
gatagtccag	
tgatttctgc	
catcattgac	3480
tttaagactt	
tgaagaacct	
gaacgacaac	
tatggaataa	
cacggaccga	
agcgttgaac	3540
ctcatta	
gttccaa	
tatgtgc	
aatttcatta	
accagaacaa	
tccaatcata	3600
agaaatagga	
ttgagcaatt	
aatcctgca	
tgtaaaactct	
gaaggcctat	
tttcttagt	3660
ttgaatttac	
tgttattcgg	
tgtgcatttc	
tatgtttgg	
gagcggttt	
ctgtgtc	3720
agtggttta	
tttatgtaa	
tttaatttct	
ttgtgagctc	
ctgttttagca	
ggtcgtccct	3780
tcagcaagga	
cacaaaaga	
ttttaattt	
ataaaaaaa	
aaaaaaa	
agaccggaa	3840
ttcgatatca	
agcttacg	
cctgcagatc	
gttcaa	
acat	
ttggcaataa	

pctca2013050364-seq1.txt

agtttcttaa	gattgaatcc	tgtgcgggt	cttgcgtatga	ttatcatata	atttctgttg	3900
aattacgtta	agcatgtaat	aattaacatg	taatgcgtatga	cgttattttat	gagatgggtt	3960
tttatgatta	gagtcccgca	attatacatt	taatacgcga	tagaaaacaa	aatatacgac	4020
gcaaactagg	ataaattatc	gcgcgcgggt	tcatctatgt	tactagat		4068

<210> 45  
 <211> 2673  
 <212> DNA  
 <213> Rotavirus

<400> 45	atggcatacc	ggaagagagg	agcaaagcgc	gaaaacctgc	cgcaacagaa	cgagagactg	60
	caagaaaaag	agatagagaa	agatgtcgac	gtaacaatgg	aaaacaagaa	taacaatagg	120
	aaacaacagc	tgtccgacaa	agttctgtcc	cagaaggagg	aaattatcac	tgacgcccag	180
	gacgatatta	aaattgccgg	agaaataaaag	aagagctcga	aagaagaatc	taaacagctg	240
	ctcggaaattc	tgaaaacaaa	agaagaccat	cagaaagaga	ttcaaatatga	aattttgcaa	300
	aaaacaatac	ctacatttga	gtccaaagaa	agtatcctca	agaagcttga	agacataaga	360
	ccggagcagg	caaaaaaaca	gatgaaactc	tttcgcattt	tcgagccaaa	acagctccct	420
	atataatcgcg	ccaatggcga	gaaggagcta	cgcaaccgg	ggtactggaa	gttggaaaaaa	480
	gacaccctgc	cagatggaga	ttatgacgtc	cgggagttt	tcctcaatct	ctatgatcag	540
	atcctcatcg	aaatgccgga	ctatctgctc	ctcaaggaca	tggccgtgga	gaacaaaaat	600
	agcagagacg	ccggcaaagt	tgtcgactct	gagactgcca	atatttgtga	tgccatcttc	660
	caggatgagg	agaccgaggg	agtcgtccgt	agattcatcg	ctgatatgcg	gcaacaggtc	720
	caggctgatc	gtaacattgt	caattaccct	tccatccttc	accctattga	tcatgcattc	780
	aatgagtatt	ttcttaacca	ccagttggtg	gagccgctga	acaatgagat	aatcttcaat	840
	tacataccag	agaggataag	gaatgacgtg	aattacatcc	tgaacatgga	tatgaatctg	900
	ccatctacag	ccaggtatat	caggccaaac	ttgttgcagg	atagactgaa	tcttcacgat	960
	aattttgagt	ccctgtggga	taccatcaca	acatccaact	acattctggc	caggtccgtc	1020
	gttcccatt	tgaaggagaa	ggagctggc	tccaccgaag	cacagatcca	gaaaatgagc	1080
	caggacctgc	agctggaggc	cctcactatt	cagagcgaga	cacagtttt	agccggatt	1140
	aacagtcagg	ctgccaatga	ttgtttcaag	accctcatag	ccgccatgct	gtctcaaaga	1200
	accatgtctt	tggactttgt	gaccacgaac	tatatgagcc	taatctccgg	aatgtggcta	1260
	cttacagtga	ttcccaacga	tatgttcctc	cgggagtcac	tagtggcctg	tgagctggcg	1320
	atcatcaaca	ccatcgtgta	tccagcattc	ggaatgcaga	gaatgcatta	ccggaatggc	1380
	gaccctcaga	cacccttcca	gatgcagaa	cagcagatcc	agaatttcca	ggtggcgaac	1440
	tggctccatt	ttattaacaa	taacagattc	aggcaagttg	tgattgatgg	agttctgaat	1500
	cagactctga	acgacaatat	acgaaatgga	caggtcatca	accagctgat	ggaagcattg	1560
	atgcaactca	gcagacagca	gttccccacg	atgcctgtgg	attacaaacag	gagcatccaa	1620

pctca2013050364-seq1.txt

cggggcattc	tgtttctctc	caataggctg	gggcagcttgc	tcgacttaac	ccgactggtc	1680
tcctataact	acgagacgct	aatggcttgt	gtgaccatga	acatgcagca	cgtgaaacc	1740
ctgacaactg	agaagttgca	gctcacttct	gtgacttcgc	tttgtatgtt	aattgtaac	1800
acaaccgtga	ttccgtcccc	acagacactg	ttccactact	acaacatcaa	cgtgaatttc	1860
cactccaatt	ataatgagcg	gatcaacgc	gccgtcgcca	taattaccgc	agcaaatagg	1920
ctgaatctt	atcagaaaaa	aatgaagtcc	atagtggaa	actttctgaa	acggctccag	1980
attttcgacg	taccacgagt	gcctgacgac	caaagtaca	ggctgaggga	tcgccttcgg	2040
ctcttacccg	ttgaacggag	acggcttgac	atattcaact	tgatcctgat	gaatatggag	2100
cagatcgaac	gcgcttctga	taagattgct	caggggtta	tcatcgata	ccgagatatg	2160
cagctggaac	gchgacgagat	gtacggat	gttaatattg	cacggatct	tgatggctac	2220
cagcaaatta	acttggagga	actcatgcgc	accggtgatt	acggacaaat	tacgaacatg	2280
cttctcaaca	atcaaccgt	tgcccttgc	ggtgattgc	ccttcgttac	ggactcatcc	2340
tgatcagtc	taatcgccaa	gctcgacgca	accgtctcg	ctcagatagt	gaagctcagg	2400
aaagttgaca	cactgaagcc	catactgtac	aaaataaaact	cggattccaa	tgactttac	2460
cttggccca	actacgactg	gatccccaca	agtacaacta	aggtctacaa	acaggtgcca	2520
caaccattcg	acttttagagc	cagcatgcac	atgctgactt	ctaaccctac	gtttaccgtc	2580
tactctgacc	tactgtcatt	tgtttcagcg	gacacggtag	agcccattaa	cgcagtcgca	2640
ttcgacaata	tgcgataat	gaacgagctt	taa			2673

<210> 46  
 <211> 1194  
 <212> DNA  
 <213> Rotavirus

<400> 46	atggaggtcc	tttatagtct	ctccaaaacg	ctgaaggacg	ctagggacaa	gatcgtggag	60
	ggtacacttt	atagaatgt	cagcgaccta	atacagcagt	ttaatcaa	at gatcgttaca	120
	atgaatggga	atgatttcca	aactggcggt	attggtaatc	tgcccgtag	gaactggaca	180
	ttcgatttcg	gcctgctgg	cacgactctc	cttaatctcg	atgcaaatta	tgtagaaaac	240
	gccagaacga	ttatcgagta	ctttagcgat	ttcattgata	acgttgtat	ggatgagatg	300
	gcccgcagt	cacaacggaa	cgagttgct	ccacagtccg	aggcccttcg	gaaactcgcc	360
	ggcattaagt	tcaagcgtat	taatttcgac	aactccctcg	aatatata	gaactggaa	420
	ttgcagaatc	gtcgacagag	aaccggcttc	gtgtccata	aacctaata	ctttccgtat	480
	agcgcctcat	tcaccctgaa	taggagtcag	cccatgcacg	acaacctcat	gggtacaatg	540
	tggctgaatg	cggggagtga	aatacaggtc	gccgggttcg	attactcctg	tgccattaa	600
	gcacccgcaa	acatccagca	gttgaacat	atcgtcaac	taagacgggc	tctcacgacc	660
	gcgacaatta	cactcctgcc	cgacgcccag	cgcttccct	ttcccccgcgt	aatcaactca	720

pctca2013050364-seq1.txt	
gctgatggcg ccaccactt gttttcaac cctgttatat tgcgcctaa caacgttagag	780
gtggagttc tcttaaacgg acagatcatc aatacctacc aagccagggtt cggtcacgatt	840
attgcaagaa atttcgacgc tatcaggctg ctcttccaac tcatgaggcc ccccaatatg	900
actcccgctg tgaacgctt gttccgcag gctcagcctt tccagcacca cgccaccgtc	960
ggcttgactc ttcgaataga gagcgcggc tgcgaatcag tgctggcaga cgccaaacgag	1020
acgctgctgg caaacgttac cgccgtgcgg caagagtatg ccatcccagt agggcctgtg	1080
tttccacccg gcatgaactg gactgaacta attactaact atagcccatc cagagaagac	1140
aacttgcagc gggtcttac tttggcctct atccggagta ttttgatcaa gtag	1194

<210> 47  
 <211> 2328  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Optimized coding sequence of Rotavirus A VP4 from strain  
 RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]

<400> 47	
atggctagcc tcatctacag acaactctt accaattcat attctgttga tttcatgac	60
gaaatcgagc agattgggtc cgagaagacc cagaacgtga ccatcaaccc tggaccttt	120
gctcagaccc gctatgcccc tgtgaattgg gatcacggag aaatcaacga cagtacgacc	180
gtcgaaccca ttctggacgg gccataccaa cccaccaccc tcacccacc taatgattat	240
tggatttaa tcaactccaa cacaacgga gtggtctacg agtccactaa taactccgat	300
ttttggaccg ccgtttagc catcgagcca cacgtcaatc ctgtcgatcg ccagtatatg	360
atattcggcg agtccaaaca gtttaacgtt tccatgaca gcaacaaatg gaagttctg	420
gagatgttc gcagctcctc tcagaacgaa ttctataata gacggaccct tacctccgat	480
acacgactcg tgggtatccc taagtacggc ggcagggtgt ggacatttca cggtaaaacc	540
cctcgagcaa ccactgactc cagtagact gcaaacctga acaatataatc tattaccatc	600
cacagcgaat tctacataat cccaaatct cagggaaatgt agtgtaacgt atatatcaac	660
aacggactcc ccccaattca gaatacacgg aacgtggtgc ctctccact cagttctcg	720
tctatccagt ataagagagc acaagtgaat gaggacatta ttgtgagca gactgcctt	780
tggaaagaaa tgcagtacaa cagagacatt atcatccgt ttaagttgg gaactctatc	840
gtgaagatgg gcggcctgg gtacaaatgg tcagaaatct catataaagc cgccaaactat	900
cagtataact acttgagaga cggcgagcag gtaaccgccc acacaacatg ctctgtcaac	960
ggcgtaata actttagcta caacggaggc ttcccttcca ccgacttcgg tatcagccgg	1020
tatgaagtca tcaaggaaaa ttcttatgtg tacgttagatt actggatgtg tagcaaagcg	1080
ttccgcaaca tgggtatgt taggagcctg gctgctaatc tcaattctgt gaagtgtact	1140
ggtgatcat attatttctc aattccctgt ggggcttggc cagtcgtgaa tggcggggca	1200
gtctccctcc attttgcgtt cgtgacgttg agcactcagt ttaccgattt cgtgtctctg	1260

pctca2013050364-seq1.txt

aactccctga ggttccgggtt ttcccttact gtcgacgagc ccccattcag cattctgcgt	1320
acaagaactg tcaacctcta cgggttacct gccgcgaatc caaacaacgg caatgaatac	1380
tatgaaattt cgggcccgtt ctcttgcata agtctggtagt caactaatga cgactatcag	1440
acacccatca tgaacagcgt gactgtcaga caggacctgg aaagacaact tacagatctg	1500
cggagaata tcaattctct cagtcaggag attgcaatgg cccaattgat agatcttgcc	1560
ctactgcctc tcgatatgtt tagtatgttc tccggcatca aatcaactat agatctgaca	1620
aagagcatgg ctacttctgt gatgaagaag ttcagggaaat caaaacttgc cacgagcata	1680
tcagaaatga cgaactctct gagtgatgca gcatcatcag cgtcacgcaa cgtttccatt	1740
cggtcgaatc tcagcgccat cagcaactgg acaaacgtgt ccaacgacgt cagcaacgtg	1800
accaactcct tgaacgatata ttctacccag acgtcaacga tcagtaagaa actccgcttg	1860
aaagaaatga tcacccagac tgagggaaatg tctttcgacg acatttccgc cgccgtgcta	1920
aaaacccaaaa tcgatatgtc tactcagatc ggcaagaaca ctctgcccga tatcgtaacc	1980
gaagcctccg aaaagtttat ccctaagcgc agctacagaa tattgaaaga tgacgaggtc	2040
atggagatca acacagaagg gaagttcttc gcttataaga tcaacacaccc ttgacgaggtt	2100
ccgtttgcacg tcaataagtt tgcaagatc gtgacagata gtccagtgtat ttctgccatc	2160
attgacttta agactttgaa gaacctgaac gacaactatg gaataacacg gaccgaagcg	2220
ttgaacctca ttaagtccaa tcccaatatg ttgcgcatt tcattaacca gaacaatcca	2280
atcataagaa ataggatga gcaattaatc ctgcaatgt aactctga	2328

<210> 48  
 <211> 981  
 <212> DNA  
 <213> Rotavirus

<400> 48	
atgtacggca tcgagtatac aacaatttta attttcctga tttccatcat tctgttaaac	60
tacatcctta agtccgtgac cagaattatg gattatatta tctatcgtag cctcctcattc	120
tacgtggccc tttttgcctt gaccagggcc cagaactatg gcctgaactt accaatcacc	180
ggttcaatgg ataccgttta cgctaattcc actcaagagg ggatatttct gacaagtacc	240
ctgtgcctgt attatccaa agaaggctct acccagatca atgatggggta gtggaaggat	300
agtctctcac agatgttctt aaccaagggc tggcccaccc gttccgtcta cttcaaggaa	360
tactctagta ttgtcgactt ctcagttgac ccccagcttt attgcgacta caacctggta	420
cttatgaaat acgaccagaa cctggagctg gatatgtccg agctggctga cctgatcctc	480
aatgagtggc tgtgcaaccc catggacatc acattatatt actaccagca gtctggagaa	540
tccaacaagt ggatcagtat gggctcaagt tgcaccgtga aggtgtgtcc cttgaacacc	600
caaatgctgg gcattgggtt tcagacaact aatgtggatt cgtttgaat ggtagccgaa	660
aacgagaagc tggctatagt ggacgtagtc gatgggatta accacaagat caatctgact	720

pctca2013050364-seq1.txt

accaccactt	gtaccatcg	aaactgtaaa	aagctcgcc	cccgggagaa	cgtcgccgtg	780
atccaggtgg	gggggagcaa	tgtgctcgac	attactgccg	accctaccac	caatccacag	840
acggaacgga	tgatgagagt	caactggaag	aatggtggc	aggtcttttta	taccattgtg	900
gactacatta	accagattgt	gcaagtcatg	agtaaacggt	ccagatccct	gaactcagca	960
gccttctatt	atcgcttta	g				981
<210>	49					
<211>	903					
<212>	DNA					
<213>	Rotavirus					
<400>	49					
atggcgaaaa	acgttgcgat	tttcggctta	ttgtttctc	ttcttgtt	ggttccttct	60
cagatcttcg	cccagaacta	tggcctgaac	ttaccaatca	ccgggtcaat	ggataccgtt	120
tacgctaatt	ccactcaaga	ggggatattt	ctgacaagta	ccctgtgcct	gtattatcca	180
acagaagcct	ctacccagat	caatgatggg	gagtggaaagg	atagtctctc	acagatgttc	240
ctaaccagg	gctggcccac	cgttccgtc	tacttcaagg	aatactctag	tattgtcgac	300
ttctcagttg	accccccagct	ttattgcgac	tacaacctgg	tacttatgaa	atacgaccag	360
aacctggagc	tggatatgtc	cgagctggct	gacctgatcc	tcaatgagtg	gctgtgcaac	420
cccatggaca	tcacattata	ttactaccag	cagtctggag	aatccaacaa	gtggatcagt	480
atgggctcaa	gttgcaccgt	gaaggtgtgt	cccttgaaca	cccaaatgct	ggcattgggt	540
tgtcagacaa	ctaatgtgga	ttcgttgaa	atggtagccg	aaaacgagaa	gctggctata	600
gtggacgtag	tcgatggat	taaccacaag	atcaatctga	ctaccaccac	ttgttaccatc	660
agaaactgta	aaaagctcg	ccccgggag	aacgtcgccg	tgatccaggt	ggggggggagc	720
aatgtgctcg	acattactgc	cgaccctacc	accaatccac	agacggaacg	gatgatgaga	780
gtcaactgga	agaaatggtg	gcaggtcttt	tataccattg	tggactacat	taaccagatt	840
gtgcaagtca	ttagtaaacg	gtccagatcc	ctgaactcag	cagccttcta	ttatcgctt	900
tag						903
<210>	50					
<211>	2331					
<212>	DNA					
<213>	Rotavirus					
<400>	50					
atggcttcgc	tcatttata	acaattgctc	acgaattctt	atacagtaga	tttatccgat	60
gagatacaag	agattggatc	aactaaatca	caaaatgtca	caattaatcc	tggaccattt	120
gcgcaaacag	gttatgctcc	agtaactgg	ggacctggag	aaattaatga	ttctacgaca	180
gttgaaccat	tgctggatgg	gccttatcaa	ccaacgacat	tcaatccacc	agtgcattat	240
tggatgttac	tggctccaac	gacacctggc	gtaattttg	aaggtacaaa	taatacagat	300
agatggtag	ccacaatttt	aatcgagcca	aatgttcagt	ctgaaaatag	aacttacact	360

pctca2013050364-seq1.txt

atatttggta ttcaagaaca attaacggta tccaatactt cacaagacca gtggaaattt	420
attgatgtcg taaaaacaac tgcaaatgga agtataggac aatatggacc attactatcc	480
agtccgaaat tataatgcagt tatgaagcat aatgaaaaat tataatcata tgaaggacag	540
acacctaacg ctaggacagc acattattca acaacgaatt atgattctgt taatatgact	600
gcttttgtg acttttat aattcctaga tctgaagagt ctaaatgtac ggaatacatt	660
aataatggat taccaccaat acaaatact agaaatgtt taccattatc gttgactgct	720
agagatgtaa tacactatag agctcaagct aatgaagata ttgtgatatc caagacatca	780
ttgtggaaag aaatgcaata taatagagat ataactatta gatttaaatt tgcaaataca	840
attataaaat caggagggct gggatataag tggtcagaaa tatcatttaa gccagcgaat	900
tatcaataca catatactcg tcatggtaa gaagttaccg cacatactac ttgttcagtg	960
aatggcgtta atgacttcag tttatgga ggatattac caactgattt tggatct	1020
aaatttgaag taattaaaga gaattcatac gtctatatcg attactgggta tgattcacaa	1080
gcatttcgta acgtgggtga tgtccgatcg ttagcagcaa acttgaattt agttatgtgt	1140
actggaggca gctataattt tagtctacca gttggacaat ggcctgtttt aactggggga	1200
gcagttctt tacattcagc tggtaaca ctatctactc aatttacaga tttcgatca	1260
ttaaattcat taagatttag atttagacta gctgtcgaag aaccacactt taaactgact	1320
agaactagat tagatagatt gtatggctcg cctgctgcag atccaaataa tggtaaagaa	1380
tattatgaaa ttgctggacg attttcactt atatcattag tgccatcaaa tggatgactat	1440
cagactccta tagcaaactc agtactgtt cgacaagatt tagaaaggca gtttaggagaa	1500
ctaagagaag agtttaacgc tttgtctcaa gaaattgcaa tggcgtcagtt aatcgattt	1560
gcgcattctac cattagatat gttctcaatg tttctggca ttaaaagtac tattgatgct	1620
gc当地atcaa tggctactaa tggatgaaa aaattcaaaa agtcaggatt agcgaattca	1680
gtttcaacac tgacagattt tttatcagac gcagcatcat caatatcaag agttcatct	1740
atacgatcgat tggatcttc agcatcagca tggacggatg tatcaacaca aataactgat	1800
atatcgatcgat cagtaagttc agttcgaca caaacgtcaa ctatcgatg aagattgaga	1860
ctaaaggaaa tggcaacaca aactgagggt atgaattttt atgatatactc agcggctgtt	1920
ttgaagacta agatagataa atcgactcaa atatcaccaaa acacaatacc tgacattgtt	1980
actgaagcat cggaaaaattt cataccaaat agggcttacc gtgttataaa caacgtatgt	2040
gtgttgaag ctggaaattt tggaaaattt tttgcttata aagtggatac atttgaggaa	2100
ataccatttgcgtt atgtacaaaa attcgatcgac ttagttacag attctccagt aatatccgt	2160
ataattgatt taaaacact taaaatttgcgtt aacgataatt acggcattac taagcaacaa	2220
gcatttaatc ttttaagatc tgacccaa gtttacgtt aattcattaa tcaggacaat	2280
cctataatta gaaatagaat tgaacaactg attatgcaat gcagggtgtt a	2331

pctca2013050364-seq1.txt

<211> 2331

<212> DNA

<213> Artificial sequence

<220>

<223> Optimized coding sequence of Rotavirus A VP4 from strain RVA/Simian-1c/ZAF/SA11-H96/1958/G3P5B[2]

<400> 51		
atggcttcat tgatatatcg ccagttgctg actaatagct atactgtgga tttgtcagac	60	
gaaatccagg aaataggatc cacaagagt cagaacgtga ccataaacc cggaccgttc	120	
gcccagactg ggtatgcccc cgtaaaactgg ggccccggcg agattaacga cagcaccacc	180	
gtggagccac tgctggatgg accctaccaa cccactactt ttaatcctcc agtggactac	240	
tggatgttgt tggctccac gacacctggt gtaattgttag agggcaccaa caataccgat	300	
cgctggctgg cgacaatact gatagaaccc aacgtgcagt ccgagaacag aacctatacc	360	
attttggca tccaggaaca gctaaccgtg agcaatacga gccaggacca gtggaagttt	420	
atcgatgttag tgaaaactac gccaatgga tctatcgggc aatacgggccc gctgctgtcc	480	
tcacctaagc tctacgccgt gatgaaacat aatgagaaac tgtacactta cgagggccaa	540	
acccccaatg ccagaactgc ccactacagt acaaccaact atgactcggt gaacatgaca	600	
gcgttctgtg attttatat tattccaaga tcagaagaat ccaagtgtac tgagtacatc	660	
aacaatggac ttccacccat ccagaacact cgaaatgtcg tcccactgtc tctaactgct	720	
cgggatgtga tccactatcg cgcccaagct aatgaggata tagtcatttc aaagacgagc	780	
ttatggaagg aaatgcagta taacagagac atcacaatca ggttcaagtt cgccaaact	840	
attattaagt ccggggact ggggtacaaa tggagtgaga tcagtttaa gcccgttaac	900	
tatcagtaca cctatactcg cgacggcgaa gaggttaaccg cccacacaac ttgctcggtt	960	
aatggcgtga acgattttag cttcaacggg ggctacctgc ctactgattt cgtggtgagc	1020	
aagttgaag tcatcaagga aaattcctac gtgtatattt actactggga tgatagccag	1080	
gccttcgaa atgttgtta tggtagatca ctggccgcaa accttaattt agtcatgtgc	1140	
acaggagggtt cttacaattt tagtcttccc gtcggcagt gcccagtgtc cacagggggc	1200	
gctgtgagct tgcattccgc cggagtcacc ttgagttactc agttcacaga ctttgtgtct	1260	
ctgaatagcc taaggttcag gtttagactt gcagtagaaag agcctcactt taagctcact	1320	
cgtacgaggc tggatcggt gtacggcctg ccggccgctg atcccaataa cggcaaggaa	1380	
tattacgaga tagccggag atttcgctg atcagttctgg tgccgtcaaa cgatgattac	1440	
cagacccaa ttgccaacag tgtcactgtc aggcaagatc tggagagaca acttggcgag	1500	
ctgagagagg agttcaacgc cctgtctcaa gagatcgcaa tgtctcagct cattgacctg	1560	
gccctgttac ccctcgacat gttctcaatg ttctccggca taaaatccac tatcgacgt	1620	
gcaaagtcca tggccacaaa tgtgatgaag aagtttaaga agagcggct ggcaaatacg	1680	
gtgtctacgc tgaccgatag tttgtcggat gccgcccaggcc catttagccg tggatccagc	1740	
attaggtcca ttggctcttc cgccctgtctg tggactgacg tgagtacaca gataactgac	1800	

pctca2013050364-seq1.txt

atttcctctt	ctgtctccag	tgtgagcaca	caaactcca	cgatatcaag	acgactgagg	1860
ctcaaagaga	tggcaacgca	aacggaaggt	atgaatttg	atgacatcag	cgccgcagtt	1920
ttgaagacaa	agatcgataa	aagcactcaa	attagcccc	atacgatccc	tgacattgtg	1980
actgaggcat	ctgaaaagtt	cattcccaac	cgtgcttatac	gggtcattaa	caatgatgat	2040
gtcttcgagg	ccggcatcga	tggcaagttt	tttgcttata	aagtggatac	cttcgaggag	2100
attccttcg	atgtacagaa	gttgctgac	ctcgtaacgg	atagccagt	gataagcgcc	2160
attatagact	tcaaaacatt	gaaaatttg	aacgataatt	atggattac	caaggcagcag	2220
gcttttaact	tgttaagatc	tgaccctcgc	gtgctcagag	agtttattaa	ccaggacaac	2280
cccatcatca	gaaacaggat	cgagcagctg	attatgcagt	gtcgctgt	a	2331

<210> 52  
 <211> 981  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Coding sequence of Rotavirus A VP7 from strain  
 RVA/Simian-1c/ZAF/SA11-H96/1958/G3P5B[2]

<400> 52	atgtatggta	ttgaatatac	cacagttcta	acctttctga	tatcgattat	tctactaaat	60
	tacatactta	aatcattaac	tagaataatg	gactttataa	ttttagatt	tctttttata	120
	attgtgatat	tgtcaccatt	tctcagagca	caaaattatg	gtattaatct	tccaatcaca	180
	ggctccatgg	acactgcata	cgctaattca	acgcaagaag	aaacattcct	cacttctaca	240
	ctttgcctat	attatccgac	tgaggctgcg	actgaaataa	acgataattc	atggaaagac	300
	acactgtcac	aactatttct	tacgaaaggg	tggccaactg	gatccgtata	ttttaaagaa	360
	tatactaaca	ttgcatcgtt	ttctgttgat	ccgcagttgt	attgtgatta	taacgtagta	420
	ctaatgaaat	atgacgcac	gttgcattt	gatatgtcag	aacttgcgga	tctaataat	480
	aacgaatgg	tgtgtatcc	aatggatatt	actctgtatt	attatcagca	aactgacgaa	540
	gcgaataaat	ggatatcaat	gggctcatca	tgtacaatta	aagtatgtcc	acttaataca	600
	caaactcttg	gaattggatg	cttgacaact	gatgctacaa	cttttgaaga	agttgcgaca	660
	gctgaaaagt	tggtaattac	tgacgtggtt	gatggcgtta	atcataagct	ggatgtcaca	720
	acagcaacgt	gtactattag	aaactgtaag	aaattggac	caagagaaaa	cgtagccgtt	780
	atacaagttg	gtggttctga	catcctcgat	ataactgctg	atccaactac	tgcaccacag	840
	acagaacgga	tgatgcgaat	taactggaaa	aaatggtggc	aagttttta	tactgttagta	900
	gactatgtag	atcagataat	acaagttatg	tccaaaagat	caagatcact	aaattcagca	960
	gcattttatt	acagagtgt	g				981

<210> 53  
 <211> 981  
 <212> DNA

pctca2013050364-seq1.txt

<213> Rotavirus

<400> 53		
atgtacggaa tcgagttatac caccgttctg acatttctta ttagtattat cctcttgaac	60	
tatattctga agtcacttac ccggataatg gattttatta tatatagggtt tctgttcatc	120	
attgttaattc tgagcccttt cctgagggcc cagaattacg gcataaacct accaattcacc	180	
ggttctatgg ataccgctta tgcttaactct acacaagagg agacattcct cacatcaacc	240	
ctatgcctgt actatccgac tgaagcagcc acagagataa acgataactc ttggaaagat	300	
acattgagcc agctttcct gactaaggga tggccaccg gatcggtcta cttaaggag	360	
tacacaaaca tcgcaagttt cagcgtggat cccagctgt attgtgatta taacgttgc	420	
ctgatgaaat acgacgcaac cctccagctt gacatgagcg agttggcaga cctaattcctc	480	
aatgagtggc tgtgttaaccc aatggatata acactgtact attatcagca gaccgatgaa	540	
gcaaacaat ggatttcaat gggaaagcagc tgtaccatca aagtttgc	600	
caaactctcg gcatagggtg tctgaccaca gacgctacta cctttgaaga agttgcgacc	660	
gcggaaaagc tggttatcac agatgtggta gatggcgta accacaaatt ggacgtaacc	720	
acagcaacat gcacaattag gaactgcaag aagctaggac ccagggaaaaa cgtagccg	780	
atccaagtgg gcggcagtga catcctagac atcaccgcag acccaacaac agcaccacaa	840	
accgagagga tcatgcgcac taatttggaaag aaatggtggc aggtgttttta cactgtcg	900	
gactatgtgg accagatcat tcaggtgatg agcaagcgg a gtcgctcatt gaatagtgc	960	
gccttttatt acagagtcta a	981	

<210> 54

<211> 981

<212> DNA

<213> Artificial sequence

<400> 54		
atgtacggca tcgagttatac aacaatttta attttcctga tttccatcat tctgttaaac	60	
tacatcctta agtccgtgac cagaattatg gattatatta tctatcgtag cctcctcattc	120	
tacgtggccc tttttgcctt gaccagggcc cagaactatg gcctgaactt accaattcacc	180	
ggttcaatgg ataccgttta cgctaattcc actcaagagg ggatatttct gacaagtacc	240	
ctgtgcctgt attatccaac agaaggctct acccagatca atgatgggaa gtggaaaggat	300	
agtctctcac agatgttcctt aaccaagggc tggccaccg gttccgtcta cttcaaggaa	360	
tactctagta ttgtcgactt ctcagttgac cccagcttt attgcgacta caacctggta	420	
cttataat acgaccagaa cctggagctg gatatgtccg agctggctga cctgatcctc	480	
aatgagtggc tgtgtcaaccc catggacatc acattatatt actaccagca gtctggagaa	540	
tccaaacaagt ggatcgttat gggctcaagt tgcaccgtga aggtgtgtcc cttgaacacc	600	
caaattgtgg gcattgggtt tcagacaact aatgtggatt cgtttgaat ggtagccgaa	660	
aacgagaagc tggctatagt ggacgtagtc gatgggatta accacaagat caatctgact	720	

pctca2013050364-seq1.txt

accaccactt	gtaccatcg	aaactgtaaa	aagctcgcc	cccgggagaa	cgtcgccgtg	780					
atccaggtgg	gggggagcaa	tgtgctcgac	attactgccg	accctaccac	aatccacag	840					
acggaacgga	tgatgagagt	caactggaag	aatggtggc	aggtctttt	taccattgtg	900					
gactacatta	accagattgt	gcaagtcatg	agtaaacggt	ccagatccct	gaactcagca	960					
gccttctatt	atcgcttta	g				981					
<210> 55											
<211> 50											
<212> DNA											
<213> Artificial sequence											
<220>											
<223> Primer IF-TrSP+Rtx_VP7(opt).s1+3c											
<400> 55											
aaatttgcg						ggcccatgga	ttatattatc	tatcgtagcc	tcctcatct	50	
<210> 56											
<211> 54											
<212> DNA											
<213> Artificial sequence											
<220>											
<223> Primer IF-Rtx_VP7(opt).s1-4r											
<400> 56											
actaaagaaa						ataggcctct	aaacgcgata	atagaaggct	gctgagttca	ggga	54
<210> 57											
<211> 981											
<212> DNA											
<213> Artificial sequence											
<220>											
<223> Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]											
<400> 57											
atgtacggca						tcgagtatac	aacaatttta	atttcctga	tttccatcat	tctgttaaac	60
tacatcctta						agtccgtgac	cagaattatg	gattatatta	tctatcgtag	cctcctcatc	120
tacgtggccc						ttttgcctt	gaccagggcc	cagaactatg	gcctgaactt	accaatcacc	180
ggttcaatgg						ataccgttta	cgctaattcc	actcaagagg	ggatatttct	gacaagtacc	240
ctgtgcctgt						attatccaac	agaagcctct	acccagatca	atgatgggga	gtggaaggat	300
agtctctcac						agatgttcct	aaccaagggc	tggcccacgg	gttccgtcta	cttcaaggaa	360
tactctagta						ttgtcgactt	ctcagttgac	ccccagcttt	attgcgacta	caacctggta	420
cttatgaaat						acgaccagaa	cctggagctg	gatatgtccg	agctggctga	cctgatcctc	480
aatgagtggc						tgtgcaaccc	catggacatc	acattatatt	actaccagca	gtctggagaa	540
tccaacaagt						ggatcagttat	gggctcaagt	tgcaccgtga	aggtgtgtcc	cttgaacacc	600
caaatgctgg						gcattggttt	tcagacaact	aatgtggatt	cgtttgaat	ggttagccgaa	660
aacgagaagc						tggctatagt	ggacgtagtc	gatgggatta	accacaagat	caatctgact	720

pctca2013050364-seq1.txt

accaccactt	gtaccatcg	aaactgtaaa	aagctcgcc	cccgaggaa	cgtcgccgtg	780
atccaggtgg	gggggagcaa	tgtgctcgac	attactgccg	accctaccac	aatccacag	840
acggaacgga	tgatgagagt	caactggaag	aatggtggc	aggtcttta	taccattgtg	900
gactacatta	accagattgt	gcaagtcatg	agtaaacggt	ccagatccct	gaactcagca	960
gccttctatt	atcgcttta	g				981

<210> 58  
<211> 2634  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Expression cassette number 1734

<400> 58	gtcaacatgg	tggagcacga	cacacttgc	tactccaaaa	atatcaaaga	tacagtctca	60
	gaagacccaaa	gggcaattga	gactttcaa	caaaggtaa	tatccggaaa	cctcctcgga	120
	ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tgaaaagga	aggtggctcc	180
	tacaaatgcc	atcattgcga	taaaggaaag	gccatcggt	aagatgcctc	tgccgacagt	240
	ggtcccaaag	atggaccccc	acccacgagg	agcatcggt	aaaaagaaga	cgttccaacc	300
	acgtttcaa	agcaagtgga	ttgatgtgat	aacatggtgg	agcacgacac	acttgtctac	360
	tccaaaaata	tcaaagatac	agtctcagaa	gaccaaaggg	caattgagac	tttcaacaa	420
	aggtaatat	ccggaaacct	cctcgattc	cattgcccag	ctatctgtca	ctttattgtg	480
	aagatagtgg	aaaaggaagg	tggctctac	aatgccatc	attgcgataa	aggaaaggcc	540
	atcgttgaag	atgcctctgc	cgacagtgg	cccaaagatg	gaccccccacc	cacgaggagc	600
	atcgtggaaa	aagaagacgt	tccaaccacg	tcttcaaagc	aagtggattg	atgtgatatc	660
	tccactgacg	taagggatga	cgcacaatcc	cactatcctt	cgcacgaccc	ttcctctata	720
	taaggaagtt	catttcattt	ggagaggtat	taaaatctta	atagttttt	ataaaagcga	780
	acgtgggaa	acccgaacca	aaccccttc	taaactctct	ctcatctctc	ttaaagcaaa	840
	cttctctctt	gtctttctt	cgtgagcgat	cttcaacgtt	gtcagatcgt	gcttcggcac	900
	cagtacaacg	ttttcttca	ctgaagcgaa	atcaaagatc	tctttgtgga	cacgtatgc	960
	ggcgccatta	aataacgtgt	acttgccta	ttcttgcgg	tgtggcttt	ggaaaagaaa	1020
	gcttgctgga	ggctgctgtt	cagccccata	cattactgt	tacgattctg	ctgactttcg	1080
	gcgggtgcaa	tatctctact	tctgcttgc	gaggtattgt	tgcctgtact	tctttcttct	1140
	tcttcttgct	gattggttct	ataagaaatc	tagtatttc	tttgaacacag	agtttccccg	1200
	tggttttcga	acttggagaa	agattgttaa	gcttctgtat	attctgccc	aatttgcgg	1260
	gcccatggat	tatattatct	atcgtagcct	cctcatctac	gtggcccttt	ttgcctgac	1320
	cagggccca	aactatggcc	tgaacttacc	aatcaccggt	tcaatggata	cgtttacgc	1380
	taattccact	caagagggga	tatttctgac	aagtaccctg	tgcctgtatt	atccaacaga	1440

pctca2013050364-seq1.txt

agcctctacc cagatcaatg atggggagtg gaaggatagt ctctcacaga tggccataac	1500
caaggcctgg cccaccggtt ccgtctactt caaggaatac tctagtattt tcgacttctc	1560
agttgacccc cagcttattt gcgactacaa cctggactt atgaaatacg accagaacct	1620
ggagctggat atgtccgagc tggctgaccc gatcctcaat gagtggctgt gcaacccat	1680
ggacatcaca ttatattact accagcagtc tggagaatcc aacaagtggg tcagttatggg	1740
ctcaagttgc accgtgaagg tggccctt gaacacccaa atgctggca ttgggtgtca	1800
gacaactaat gtggattcgt ttgaaatggg agccgaaaac gagaagctgg ctatagtgaa	1860
cgtagtcgt gggattaacc acaagatcaa tctgactacc accacttgta ccatcagaaa	1920
ctgtaaaaag ctcggccccc gggagaacgt cgccgtgatc caggtggggg ggagcaatgt	1980
gctcgacatt actgcccacc ctaccaccaa tccacagacg gaacggatga tgagagtcaa	2040
ctggaagaaa tggggcagg tctttatac cattgtggac tacattaacc agatttgca	2100
agtcatgagt aaacggtcca gatccctgaa ctcagcagcc ttctattatc gcgtttagag	2160
gcctattttc tttagtttga atttactgtt attcgggtgtg catttctatg tttggtgagc	2220
ggttttctgt gctcagagtg tgtttatttt atgtaatttta atttctttgt gagctcctgt	2280
ttagcaggcgtc gtcccttcag caaggacaca aaaagattt aattttattt aaaaaaaaaaa	2340
aaaaaaaaagac cggaaattcg atatcaagct tatcgacctg cagatcggttc aaacatttgg	2400
caataaaagtt tcttaagatt gaatcctgtt gccggcttg cgatgattat catataattt	2460
ctgttgaatt acgttaagca tgtaataatt aacatgtaat gcatgacgtt atttatgaga	2520
tgggtttta tgatttaggt cccgcaatta tacatttaat acgcataga aaacaaaata	2580
tagcgcgaa actaggataa attatcgccgc gcgggtgtcat ctatgttact agat	2634

<210> 59  
 <211> 297  
 <212> PRT  
 <213> Rotavirus

<400> 59

Met Asp Tyr Ile Ile Tyr Arg Ser Leu Leu Ile Tyr Val Ala Leu Phe  
 1 5 10 15

Ala Leu Thr Arg Ala Gln Asn Tyr Gly Leu Asn Leu Pro Ile Thr Gly  
 20 25 30

Ser Met Asp Thr Val Tyr Ala Asn Ser Thr Gln Glu Gly Ile Phe Leu  
 35 40 45

Thr Ser Thr Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser Thr Gln Ile  
 50 55 60

Asn Asp Gly Glu Trp Lys Asp Ser Leu Ser Gln Met Phe Leu Thr Lys  
 65 70 75 80

pctca2013050364-seq1.txt

Gly Trp Pro Thr Gly Ser Val Tyr Phe Lys Glu Tyr Ser Ser Ile Val  
85 90 95

Asp Phe Ser Val Asp Pro Gln Leu Tyr Cys Asp Tyr Asn Leu Val Leu  
100 105 110

Met Lys Tyr Asp Gln Asn Leu Glu Leu Asp Met Ser Glu Leu Ala Asp  
115 120 125

Leu Ile Leu Asn Glu Trp Leu Cys Asn Pro Met Asp Ile Thr Leu Tyr  
130 135 140

Tyr Tyr Gln Gln Ser Gly Glu Ser Asn Lys Trp Ile Ser Met Gly Ser  
145 150 155 160

Ser Cys Thr Val Lys Val Cys Pro Leu Asn Thr Gln Met Leu Gly Ile  
165 170 175

Gly Cys Gln Thr Thr Asn Val Asp Ser Phe Glu Met Val Ala Glu Asn  
180 185 190

Glu Lys Leu Ala Ile Val Asp Val Val Asp Gly Ile Asn His Lys Ile  
195 200 205

Asn Leu Thr Thr Thr Cys Thr Ile Arg Asn Cys Lys Lys Leu Gly  
210 215 220

Pro Arg Glu Asn Val Ala Val Ile Gln Val Gly Gly Ser Asn Val Leu  
225 230 235 240

Asp Ile Thr Ala Asp Pro Thr Thr Asn Pro Gln Thr Glu Arg Met Met  
245 250 255

Arg Val Asn Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr Ile Val Asp  
260 265 270

Tyr Ile Asn Gln Ile Val Gln Val Met Ser Lys Arg Ser Arg Ser Leu  
275 280 285

Asn Ser Ala Ala Phe Tyr Tyr Arg Val  
290 295